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Heat shock protein 90 (Hsp90) is a conserved molecular chaperone in eukaryotes, 
essential for protein folding and activation (Taipale et al., 2010). With its dominance in 
sustaining growth, the Plasmodium falciparum Hsp90 (PfHsp90) has emerged as a promising 
molecular target for malaria inhibition. Specifically, it has been observed that Hsp90-specific 
inhibitors are capable of killing the malaria parasite by arresting the development of P. 
falciparum at the human blood stage (Banumathy et al., 2003). However, little is known 
about the biological activity of PfHsp90. Yet, in considering PfHsp90 as an anti-malarial drug 
target, elucidation of its functionality and physiological roles in the malaria parasite is 
necessary, to support the basis of exploiting PfHsp90. Hence, this project was undertaken to 
initiate investigations on the existence, activity, interaction partners and regulation of 
PfHsp90 in P. falciparum. 
Firstly, PfHsp90 was shown to possess a functional ATPase activity. GST pull-down 
assays further revealed PfHsp90’s interaction with two putative co-chaperones, Pfp23 and 
PfAha1, respectively. The two co-chaperones exerted contrasting regulatory effects on 
PfHsp90 whereby Pfp23 inhibited while PfAha1 stimulated the ATPase activity of PfHsp90. 
Using homology predictions and site-directed mutagenesis, the residues K91, H93, W94, K96 
in Pfp23 and N108 in PfAha1 were identified and shown to be crucial for PfHsp90 interaction. 
In addition, the pull-down assays showed that the binding of Pfp23 and PfAha1 to PfHsp90 
were mutually exclusive. This was also supported by bio-computational analysis of the 
modeled PfHsp90-Pfp23-PfAha1 complex which revealed overlapping binding sites of Pfp23 
and PfAha1 on PfHsp90. The binding characteristics of Pfp23 and PfAha1 have unique 
influences on the ATPase activity of PfHsp90, thus highlighting their potential in vivo 
regulatory roles on the function of PfHsp90 in P. falciparum.  
After demonstrating PfHsp90’s functionality and regulation by Pfp23 and PfAha1, 
protein-protein interaction assays were employed to identify potential client proteins of 
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PfHsp90. Screening PfHsp90 against a prepared P. falciparum cDNA library by split-ubiquitin 
assays identified PF13_0165, a conserved Plasmodium protein with unknown function, to be 
a potential client protein of PfHsp90. Sequence analysis revealed the presence of a RNA 
recognition motif in PF13_0165. Coupled with the knowledge that Hsp90s in human and 
yeast can chaperone clients involved in RNA processing (Boulon et al., 2008; Chen et al., 
2007; Zhao et al., 2008), the identified PF13_0165 may plausibly be involved in similar 
processes in P. falciparum. In separate studies, PfHsp90 was shown to interact with falcipain 
2B, a cysteine protease implicated in the degradation of hemoglobin in P. falciparum. This 
observed interaction would support the previously proposed involvement of PfHsp90 in the 
malaria parasite’s indispensible hemoglobin degradation pathway (Pavithra et al., 2007).  
Interestingly, while examining PfHsp90’s interaction with another potential client 
protein PfMap2, a P. falciparum MAP kinase, PfMap2 was unexpectedly found to increase 
the level of threonine phosphorylation in PfHsp90. This observed enhancement of threonine 
phosphorylation may potentially influence PfHsp90’s chaperone function similar to a report 
on the regulatory effect of phosphorylation on yeast Hsp90 (Mollapour et al., 2011b).  
Taken together, this project has provided evidence on the presence of a functional 
Hsp90 in P. falciparum and its regulation by the plasmodial co-chaperones Pfp23 and PfAha1. 
The interaction studies have further opened leads for future studies on PfHsp90’s 
involvement in RNA processing and hemoglobin degradation pathways. As such, uncovering 
other important biological processes regulated by PfHsp90 in P. falciparum would thereby, 
contribute to understanding how Hsp90-specific inhibitors could bring about cellular 
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1.1 Hsp90 is an essential molecular chaperone in eukaryotes 
Heat shock protein 90 (Hsp90) is a vital molecular chaperone in eukaryotes that has 
been implicated in the folding and activation of many proteins essential for signal 
transduction and developmental regulation (Pearl and Prodromou, 2000). Hsp90 operates 
together with a cohort of co-chaperones (e.g. p23, Aha1, Hop) that assist and regulate the 
association between Hsp90 and its client proteins in a multi-stage chaperone cycle (Taipale 
et al., 2010). The current understanding of the chaperone cycle involves: (1) the recruitment 
of newly synthesized or misfolded client protein by Hsp40 and Hsp70, (2) the transfer of 
partially folded client protein to Hsp90 through Hop, and (3) the final activation of client 
protein by Hsp90, achieved via a tightly regulated ATPase cycle. The ATPase activity of 
Hsp90 is known to be further modulated by certain co-chaperones (e.g. p23, Aha1), where 
their timely associations presumably orchestrate Hsp90’s structural transitions and 
accelerate the client protein activation process. Thus, rather than acting at an early stage of 
protein folding, Hsp90 is thought to bind these clients when they are already substantially 
folded to induce further structural changes, through which they attain their full functional 
activity (Jakob et al., 1995). The list of Hsp90 client proteins is constantly expanding and they 
include the transcription factor p53, steroid receptors and kinases such as Raf-1, Src, MEK, 
Cdk4 and CK2. As many of these client proteins have involvement in growth and 
developmental pathways in the cell, inhibition of Hsp90 would inevitably result in 
detrimental cellular effects. This is evident in genetic studies conducted in Saccharomyces 
cerevisiae (Borkovich et al., 1989), Drosophila melanogaster (van der Straten et al., 1997) 
and Caenorhabditis elegans (Birnby et al., 2000) where Hsp90 gene deletion invariably 
resulted in a lethal phenotype. As a corollary to its essentiality for cellular development and 
survival, Hsp90s in infectious pathogens (i.e. parasites and fungi) have been considered as 
potential targets for therapeutic interventions (Neckers and Tatu, 2008). 
 
Chapter 1: Introduction 
3 
 
1.2 Plasmodium falciparum Hsp90 is a promising molecular target for malaria therapy 
Plasmodium falciparum is the causative agent of cerebral malaria and it remains one 
of the most deadly human pathogens, causing more than half a million deaths annually 
(WHO World Malaria Report 2011). Treatment of P. falciparum infection is increasingly 
difficult due to the rapid emergence of Plasmodium strains that are resistant to conventional 
anti-malarial drugs (WHO Global Report on Anti-Malarial Efficacy and Drug Resistance: 2000-
2010). Furthermore, a completely effective malaria vaccine is not yet available commercially, 
although several candidates are currently under clinical trials. Recent clinical trial results on 
the most advanced malaria vaccine candidate, RTS,S/AS01 manufactured by GlaxoSmithKline 
Biologicals, revealed that the vaccine could only offer limited protection (approximately 50% 
efficacy) against malaria (Bejon et al., 2008). Hence, in the absence of an effective malaria 
vaccine, the continual chase for a chemotherapeutic approach to treat malaria on a broader 
perspective is an obvious necessity. The current circumstances highlight an urgent need to 
identify new drugs and targets for effective malaria inhibition. In this context, P. falciparum 
Hsp90 (PfHsp90) has emerged as one of the promising targets and over the recent years, 
there has been an increasing interest in its biology in the malaria parasite.  
The recognition of PfHsp90 as a promising drug target for malaria inhibition arose 
from inhibitor studies on in vitro P. falciparum blood cultures. Such P. falciparum cultures 
treated with Hsp90 inhibitors were found to be arrested in their intra-erythrocytic 
development, particularly in the progression from ring to trophozoite stage (Banumathy et 
al., 2003). Similar experiments conducted in another independent study reported that the 
exposure of P. falciparum to Hsp90 inhibitors resulted in parasitic death (Kumar et al., 2003). 
Collectively, these observations indicated that PfHsp90 is an essential protein in the malaria 
parasite and may consequently, be a potential anti-malarial drug target. Furthermore, small 
molecules that can specifically inhibit Hsp90 (e.g. radicicol, geldanamycin) are already 
available (Roe et al., 1999) and thus demonstrates the feasibility of targeting PfHsp90 for 
Chapter 1: Introduction 
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malaria inhibition. In addition, a recent study has also shown that selective inhibition of 
PfHsp90 can be achieved without compromising on the function of human Hsp90s (Shahinas 
et al., 2010). Taken together, the current literature information endorses PfHsp90 as a drug 
target for malaria therapy. Nevertheless, despite recognizing the therapeutic potential of 
inhibiting PfHsp90, surprisingly very little is known on the activity and biological roles of this 
molecular chaperone in P. falciparum. Therefore, the mechanistic aspect on how the 
inhibition of Hsp90 could lead to the collapse in the cellular activities of the malaria parasite 
remains unknown.   
 
1.3 The functionality, regulation and biological roles of Hsp90 in P. falciparum remain 
elusive 
While Hsp90 and its co-chaperones in human and yeast have been extensively 
studied, the functionality and biological roles of the homologues in P. falciparum remain 
elusive (Table 1.1). The paucity in the literature knowledge of PfHsp90 is likely to be a 
reflection of the technical difficulty in conducting experiments on P. falciparum. The unusual 
adenine and thymine (A-T) rich genomic content imposes substantial impediments in the 
heterologous expression of the plasmodial genes for biochemical characterization (Gardner 
et al., 2002). Furthermore, genetic manipulation and transfection of P. falciparum continue 
to be of a great challenge.  
Bio-computational analysis revealed that P. falciparum encodes four Hsp90 genes; 
one cytosolic Hsp90 (PfHsp90; PF07_0029), one putative endoplasmic reticulum paralog 
(PfGrp94; PFL1070c), and two putative mitochondrial paralogs (PfTRAP1; PF11_0188, 
PF14_0417) (Pavithra et al., 2007). The parasiticidal effect of Hsp90-specific inhibitor on P. 
falciparum is likely to be due to the inhibition of the cytosolic PfHsp90. This was thought to 
be the case as the cytosolic Hsp90 from various eukaryotic organisms has been shown to be 
essential for survival (Birnby et al., 2000; Borkovich et al., 1989; van der Straten et al., 1997), 
Chapter 1: Introduction 
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while Grp94 (Randow and Seed, 2001) and TRAP1 (Kang et al., 2007; Leav et al., 2010) were 
demonstrated to be dispensable in mammalian cells. Hence, most investigations had 
focused on studying the structure, function and biological roles of the cytosolic Hsp90. 
Thus far, PfHsp90 has only been shown to associate with a limited number of 
chaperone (i.e. PfHsp70), co-chaperones (i.e. PfCyp19, PfPP5 and PfFKBP35) and client 
proteins (i.e. calcineurin and α-tubulin) through co-immunoprecipitation experiments 
(Banumathy et al., 2003; Kumar et al., 2005a; Kumar et al., 2005b). Although genome-wide 
yeast two-hybrid assays revealed several other interaction partners, many of them are 
putative or hypothetical proteins and their interactions with PfHsp90 have not been verified 
through pull-down or co-immunoprecipitation experiments (LaCount et al., 2005). More 
importantly, the functional significance of PfHsp90’s association with these proteins, 
whether for regulation, activation and/or stability, remains unclear. In addition, it is 
surprising that co-immunoprecipitation and yeast two-hybrid analyses have not been able to 
provide evidence for the interaction of PfHsp90 with homologues of co-chaperones (e.g. p23, 
Aha1, Hop) that are known to be essential in regulating the chaperone function of Hsp90 in 
human and yeast. As many of these putative plasmodial co-chaperones share low sequence 
identities with the human and yeast homologues, this has inexorably raised questions on 
whether Hsp90’s interaction and regulation by the co-chaperones are conserved in P. 
falciparum. Therefore, apart from being known to be an essential protein in P. falciparum, 
PfHsp90’s functionality, regulation and biological roles in the malaria parasite have remained 
largely unexplored.  
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1.4 Objectives of the project 
As with any drug target identified, it is essential to determine the mechanistic aspect 
of inhibition that leads to the desired outcome for designing effective therapeutic strategies. 
In the case of PfHsp90, its potential development as an anti-malarial drug target would 
necessitate investigations on its functionality, regulation and biological roles in P. falciparum. 
This would provide an understanding on the basis of its inhibition that would eventually 
result in the death of the malaria parasite and also uncover plausible mechanisms of 
resistance that may arise due to changes in its function and regulation. Hence, three general 
aims have been drawn for the project (Figure 1.1): 
 
Aim 1.  Biochemical characterization of PfHsp90 to endorse the functionality of the 
molecular chaperone 
The chaperone activity of Hsp90 is known to require the binding and hydrolysis of ATP in the 
ATPase cycle (Panaretou et al., 1998; Prodromou et al., 2000). However, so far there is no 
evidence demonstrating the functionality of PfHsp90’s ATPase activity. Thus, the project 
begins with the biochemical characterization of PfHsp90 to investigate whether it possesses 
a functional ATPase activity. PfHsp90 will be heterologously expressed and purified to obtain 
recombinant PfHsp90 protein for ATPase activity assay. As plasmodial genes are generally 
known to be difficult to be expressed in heterologous hosts (e.g. Escherichia coli) due to the 
high A-T nucleotide content, and the purification of lowly expressed proteins tends to result 
in high levels of contaminating proteins, it is foreseeable that substantial optimization would 
have to be carried out for the expression and purification of PfHsp90. Currently, there is no 
report on the expression and purification of recombinant PfHsp90 in the literature. The 
procurement of a functional PfHsp90 recombinant protein would also pave the way for 
subsequent studies on its regulation by the putative co-chaperones identified.    
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Aim 2.  Investigation on the regulation of PfHsp90 to examine the roles of co-chaperones 
in modulating the activity of the molecular chaperone 
Co-chaperones are known regulators of Hsp90’s chaperone activity (Zuehlke and Johnson, 
2009). Recent studies have also demonstrated that the binding of certain co-chaperones can 
influence Hsp90’s affinity for the inhibitors and hence the sensitivity of cells to the biological 
effects of the inhibitors (Forafonov et al., 2008; Holmes et al., 2008). Considering the 
importance of co-chaperone in Hsp90’s function, PfHsp90 will be investigated for its 
interaction with the putative co-chaperones identified from the P. falciparum genome. The 
effects of the co-chaperone association on the ATPase activity of PfHsp90 will also be 
evaluated to reveal regulatory roles of the co-chaperones on PfHsp90. Hence, the putative 
PfHsp90 co-chaperones will also be heterologously expressed and purified to near 
homogeneity and their interaction with PfHsp90 will be evaluated using GST pull-down 
assays. Site-directed mutagenesis will also be employed to probe important residues and 
molecular surfaces that are essential for their interaction. 
 
Aim 3.  Identification of the interaction partners of PfHsp90 to reveal potential client 
proteins of PfHsp90 and the biological pathways that it may regulate in P. falciparum 
One of the approaches to investigate the cellular function of a protein is to identify its 
interaction partners. Currently, little is known on the biological roles of PfHsp90 in P. 
falciparum and it is hoped that by mapping out its protein interaction network, its cellular 
function would begin to emerge i.e. the biological pathways with its involvement either for 
activation, regulation or stability. Split-ubiquitin assays will be carried out to screen for 
PfHsp90 interaction partners from a prepared P. falciparum cDNA library. In addition, GST 
pull-down assays will be performed to investigate plasmodial proteins that may potentially 
interact with PfHsp90, as predicted from literature and bio-computational analyses. These 
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interaction assays allow the identification of potential PfHsp90 client proteins and would 
also reveal chaperones and co-chaperones that associate with PfHps90 in P. falciparum.  
  


































Figure 1.1: Summary of knowledge gaps in PfHsp90 research and the proposed aims of 
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2.1 Malaria: An Old and Formidable Foe 
The relationship between Man and Malaria is one that is of a complex and dynamic 
nature that began since time immemorial. Anthropology studies and genetic evidence 
suggest that the malaria parasite could be as old as 150 million years and has evolved to 
infect human approximately 5 to 10 million years ago; at about the same time the ancestral 
lineages of human diverged from chimpanzee (Escalante and Ayala, 1994, 1995). Malaria is 
believed to have originated in Africa and to have spread to India and South East Asia in the 
recent 10,000 years (Carter and Mendis, 2002). Historically, malaria is considered to be one 
of the most devastating diseases in ancient human civilizations, as it claimed countless lives 
and plausibly causing the fall of many great dynasties and empires e.g. Roman empire 
(Gibbon, 2000). The word Malaria has its origin in Ancient Rome where “mal aria” refers to 
“bad air”. For a long period in history, malaria was thought to be caused by foul vapours, 
first described by Hippocrates in B.C. 400 and continued to be subscribed by many 
philosophers and scientists till the late 18th century (Cunha and Cunha, 2008). The 
conception arose from observational cues on the surge of malarial fevers during hot 
summers that often correlated with the intensity of foul stench from stagnant swamps. 
While the danger and fallacy of equating correlation with causation are widely recognized in 
the scientific community today, their distinction is less perceptible in the earlier days, limited 
by blunt experimental tools and before the inception of molecular biology. In 1880, while 
observing a blood smear from a patient who had died of malaria, Charles Louis Alphonse 
Laveran discovered the protozoan malaria parasite residing in the red blood cells (Nye, 2002). 
After centuries of deaths inflicted by malaria, for the first time in history, Man has finally 
caught a glimpse of the bona fide causative agent of malaria which has eluded many great 
minds of the past. Since then, with the identification of the malaria parasite, progress in the 
understanding of the etiology, pathogenesis and inhibition of malaria have greatly 
accelerated. Nevertheless, despite these advances in knowledge, treatment of malaria 




continues to be of a great challenge today as the parasite proved to be highly adept and 
dynamic in overcoming most anti-malarial efforts deployed by man against it. The literature 
review will provide an overview of the current status of malaria, knowledge, strategies and 
progress that have been made over the past decades to fight the disease as we continue to 
seek an edge on our formidable foe in this old battle.  
 
2.2 Current Global Status of Malaria 
Malaria is one of the most devastating infectious diseases in the world today. It is 
estimated that there are 250 million cases of malaria infection every year resulting in more 
than half a million deaths annually (WHO World Malaria Report 2011). Currently, half the 
world’s population is at risk of malaria infection and 106 countries are considered to be 
malaria-endemic by World Health Organization (WHO) (Figure 2.1). Most of the affected 
populations are from the world’s poorest region (e.g. Sub-Saharan Africa), where living 
conditions are impoverished, healthcare services are inadequate and knowledge of the 
disease is limited. Among the malaria victims, children below the age of 5 are the most 
susceptible group as they constitute 85% of the fatalities. This translates to an astounding 
realization that malaria claims the life of a child every 45 seconds (Sachs and Malaney, 2002). 
The persistently high morbidity and mortality rates in the underdeveloped countries place 
serious social and economic burdens on the host country and the world. Malaria further 
marginalizes the welfare of the underprivileged populations, undermines the survival and 
education of children, debilitates the productive workforce of the population, hampers 
economic development, drains the countries resources and its presence poses a constant 
threat of resurgence in countries that have been freed from the disease. Economists 
believed that the current malaria situation imposes a ‘growth penalty’ of up to 1.3% of the 
national income of African countries annually, equivalent to approximately US$ 12 billion 
(Roll-Back-Malaria-Partnership, 2008).    




According to the World Malaria Reports published by WHO, the number of malaria 
cases has decreased approximately 7.3% over the past decade, from 233 million in Year 2000 
to 216 million in Year 2010 (Figure 2.1). Similarly, the number of deaths due to malaria has 
reduced approximately 32.5% from 985,000 in 2000 to 655,000 in 2010. Nevertheless, 
despite a concerted global effort to alleviate the disease burden over the last decade, the 
number of malaria infection and fatality remains astronomical to date. The Millennium 
Development Goals set by WHO in Year 2000 to achieve “zero malaria death” by 2015  
(United-Nations, 2005) would appear to be increasingly challenging, if not impossible, with 
the rapid emergence of malaria parasites that are resistant to current anti-malarial drugs. 
The global effort to eliminate malaria is further dampened by the lack of enthusiasm from 
profit-driven pharmaceutical companies to develop new drugs against malaria (which is 
considered to be a poor man’s disease). Fortunately, contributions from developed nations 
in The Global Fund to Fight AIDS, Tuberculosis and Malaria, and public charities such as the 
Wellcome Trust and the Bill and Melinda Gates Foundation have provided the much 
needed financial resources to support the global initiatives against malaria (Table 2.1).  
To handle the current malaria situations in underdeveloped countries, WHO focused 
on vector controls to protect people against malaria-infected mosquitoes (WHO World 
Malaria Report 2011) as they are the most rapid and effective means. The strategies include:  
(1) reducing vector density through the use of indoor insecticide and (2) preventing human-
vector contact by providing long-lasting insecticide-treated mosquito nets. Nevertheless, to 
eliminate malaria in the endemic countries, it is clear that the development of new malarial 
therapeutics in the form of vaccines and drugs are necessary for malaria prophylaxis and 
treatment. The high mortality rates and emergence of resistance to current anti-malarial 
drugs have steered the malarial research climate towards the identification of novel anti-
malarial targets and drugs, and the development of an effective vaccine, in the hope to 
eventually and totally eradicate malaria from the world.   
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Figure 2.1: Global Malaria Status and Demographic. A. According to the WHO World Malaria Report 
2011, a total of 106 countries are considered to be malaria-endemic. The prevalence of malaria 
transmission in these countries continues to put approximately half the world’s population at 
risk of malaria infection. B. In Year 2010, a total of 94 million probable/confirmed malaria 
cases (grey line) and 152,982 deaths (red bar) were reported to WHO. The reported malaria 
cases and mortality are likely to be an underestimate of the actual numbers, as WHO 
published the suspected figures to be approximately 216 million malaria cases with 655,000 
deaths. The number of malaria cases and fatality prior to 2000 (pink bars) is significantly lower 
on record as only several countries participated in reporting to WHO. The graph was plotted 
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Table 2.1 Global Malaria Initiatives and Resources 




 2.3 Etiology and Pathogenesis of Malaria 
Malaria is caused by the parasitic Apicomplexan protozoa of the genus Plasmodium 
which was first discovered by Charles Louis Alphonse Laveran in 1880 (Nye, 2002). Currently, 
more that 200 Plasmodium species have been identified, of which five are known to infect 
humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium 
ovale and Plasmodium knowlesi (Cox-Singh and Singh, 2008). Among the five species, P. 
falciparum causes the most severe disease in the form of cerebral malaria. Malaria 
infections by P. falciparum and P. vivax are the most prevalent as they account for most of 
the reported cases annually. 
The Plasmodium parasite assumes a complex life-cycle that alternates between a 
female Anopheles mosquito vector and a human host (Figure 2.2). So far, Anopheles 
gambiae is the most well-studied mosquito species as it serves as a transmission vector for 
the lethal P. falciparum (Holt et al., 2002). The P. falciparum infection cycle in human 
consists of 3 main stages: (1) the pre-erythrocytic stage that initiates the infection, (2) the 
asexual erythrocytic stage that causes the clinical disease and (3) the gametocyte stage that 
produces sexual forms of the parasite for infecting new mosquitoes. The P. falciparum 
infection begins with a bite from an infected female Anopheles mosquito that inoculates P. 
falciparum sporozoites under the host skin. The sporozoites enter the bloodstream and 
migrate to the liver cells, where they invade the hepatocytes and initiate the pre-
erythrocytic stage infection (Amino et al., 2006a; Amino et al., 2006b). This process occurs 
rapidly, usually within 30 minutes after the initial mosquito bite (Prudencio et al., 2006). 
Over the next 14 days, each sporozoite develops and multiplies within the infected 
hepatocytes into thousands of merozoites asymptomatically, without inducing clinical 
disease on the host. The clinical symptoms of malaria appear only on the onset of the 
asexual erythrocytic stage of infection. This occurs when the infected hepatocytes burst and 
release tens of thousands of merozoites into the bloodstream which will then target the 




erythrocytes. Each merozoite invades an erythrocyte and multiplies up to 20-fold as it 
develops through the ring, trophozoite and schizont stage over the next 48 hours (Simpson 
et al., 2002). The infected erythrocyte would subsequently burst and release new 
merozoites from the schizonts to establish a new round of erythrocyte infection. The cycle of 
erythrocytic invasion, replication, erythrocytic rupture and release of infectious merozoites 
occurs once every two days. The repeated bursting of infected erythrocytes often coincides 
with the clinical manifestation of the cyclical fever which is a hallmark of malaria infection. 
During the erythrocytic stage, a subset of the asexual P. falciparum parasites 
converts to gametocyte, the sexual form, through a series of development that is still not 
well-understood. The gametocytes are able to infect new female Anopheles mosquito that 
bite the infected host during feeding. The P. falciparum gametocytes are transmitted to the 
mosquito gut where they undergo fertilization and subsequently migrate to the hemolymph 
and develop into oocysts that contain thousands of sporozoites. Upon bursting of the 
oocysts, the released sporozoites invade the salivary glands and migrate to the salivary duct. 
When the infected mosquito takes a new blood meal, the sporozoites are again injected into 
the human host, initiating and perpetuating the cycle of P. falciparum infection.  
The knowledge and improved understanding on the life-cycle and pathogenesis of 
the Plasmodium parasite have been essential in the development of effective strategies for 
intervening malaria transmission and clinical disease. Much effort and resources have been 
invested in developing new anti-malarial drugs and vaccines that target various stages of the 
parasite’s developmental cycle for prophylaxis and treatment of malaria. 
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Figure 2.2: The Life-Cycle of Malaria Parasite. P. falciparum has a complex life cycle that alternates 
between mosquito and human. The mosquito serves as a vector for transmission and the 
human as a centre for replication. The human phase begins with a bite from an infected 
Anopheles mosquito that injects P. falciparum sporozoites into the skin. The inoculated 
sporozoites target rapidly to the liver and invade hepatocytes to initiate an infection. Within a 
period of two weeks, each sporozoite would develop into thousands of infectious merozoites 
in the hepatocytes. This process is asymptomatic. The clinical symptoms only manifest when 
the merozoites exit the hepatocytes and begin to invade red blood cells in the erythrocytic 
cycle. Each merozoite would develop into the ring, trophozoite and schizont stage to generate 
more merozoites in a replicative manner. Some of them would develop into gametocytes 
which will be taken up by mosquitoes during feeding to perpetuate the cycle of transmission, 
infection and replication.     
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2.4 Malaria Vaccines: The “Magic Bullets” for Eradication of Malaria? 
Vaccine has been highly regarded as the “magic bullet” against the disease malaria 
(Chilengi and Gitaka, 2010). The documented success of vaccines in bringing some of the 
world’s most infectious diseases under control e.g. small pox (eradicated), polio (eliminated 
in several regions of the world), diphtheria, tetanus, yellow fever, whooping cough and 
measles (De Jesus, 2007; Plotkin, 1999), have stimulated great interest and motivation in the 
development of a vaccine for malaria to alleviate the current disease burden. Much 
optimism on the possibility of producing a malaria vaccine stems from the observation that 
malaria immunity can be acquired through natural infection (Baird et al., 1991; Gupta et al., 
1999). Some individuals living in malaria-endemic area, who are exposed to thousands of 
infected mosquito bites every year, are known to develop clinical immunity to the life-
threatening disease. The immunity provides protection against clinical disease that 
manifests during the blood stage development, but does not per se confer sterile protection 
against malaria infection; as these individuals reportedly experience occasional episodes of 
malarial fever (Marsh and Kinyanjui, 2006). The precise mechanism leading to the observed 
clinical immunity as opposed to a sterile immunity remains elusive and is largely due to poor 
understanding on the human immune system’s interaction with the malaria parasite. Hence, 
the development of malaria vaccine that can provide sterile immunity is an enormous 
challenge and any success is likely to require knowledge and critical deliberation on: (1) the 
immunological aspect of the human-parasite interaction, (2) the extensive antigenic 
variation intrinsic to P. falciparum proteins and (3) the complexity of the life-cycle of the 
malaria parasite.  
One of the most successful demonstrations on the possibility of inducing sterile 
immunity against malaria was the experimental immunization study performed using 
sporozoites of P. falciparum (Roestenberg et al., 2009). Volunteers were inoculated with 
sporozoites through the bites of P. falciparum infected mosquitoes once a month for three 




months, during which they were prescribed with chloroquine prophylaxis. Chloroquine is 
known to kill the malaria parasite at the erythrocytic stages but not at the pre-erythrocytic 
stage. Hence, the presence of chloroquine would presumably arrest the malaria parasite 
development at the pre-erythrocytic liver stage, directing the host immune response to that 
particular stage where the malaria parasite initiates an infection. Following a month without 
chloroquine prophylaxis, the volunteers were subsequently challenged with P. falciparum 
infected mosquitoes. All the volunteers who were previously exposed to P. falciparum 
infected mosquitoes were protected from infection, whereas those who were exposed to 
uninfected mosquitoes developed clinical disease. The results clearly showed that it is 
possible to induce sterile immunity in humans against malaria. Nevertheless, the huge 
logistical challenge in the mosquito bite immunization method would hinder their 
implementation for vaccination purposes.        
The current vaccines in the development pipelines target 3 main stages of P. 
falciparum development (Table 2.2); the pre-erythrocytic stage to protect against infection; 
the asexual erythrocytic stage to inhibit clinical disease development; the sexual 
gametocyte stage to block disease transmission.  
The RTS,S/AS01 produced by GlaxoSmithKline Biologicals is the most advanced 
malaria vaccine at present and it targets the pre-erythrocytic stage of the malaria parasite 
(Casares et al., 2010). Pre-erythrocytic stage vaccines are designed to prime the human 
immune response against mosquito-injected sporozoites that initiate the liver-stage 
infection. Although pre-erythrocytic stage immunity was not observed naturally among 
individuals living in malaria-endemic region, it was shown to be possible through 
experiments using irradiated sporozoites (Nussenzweig et al., 1967). Subsequent studies 
demonstrated that similar immunity could be generated using a protein found on the 
surface of the sporozoites as an antigen: the circumsporozoite protein (CSP) (Nussenzweig 
and Nussenzweig, 1986). The RTS,S/AS01 vaccine is the fusion of the CSP protein with the 




Hepatitis B surface antigen formulated in adjuvant AS01. RTS,S/AS01 has been tested in 
Phase 2 trials and was observed to confer protection against malaria infection, in 
approximately 35% of the adults, and clinical malaria in approximately 30% to 50% of the 
children and infants immunized (Abdulla et al., 2008; Alonso et al., 2005; Alonso et al., 2004; 
Bejon et al., 2008; Bojang et al., 2001; Sacarlal et al., 2009). However, the protection is 
short-lived and could only achieve approximately 50% efficacy in the trial populations. 
Nevertheless, the partial immunity conferred is estimated to be able to protect millions 
against the disease each year considering the high morbidity inflicted by malaria where 
approximately 250 million cases are reported annually. Currently, RTS,S/AS01 is under Phase 
3 evaluations in 11 trial sites in seven sub-Saharan African countries i.e. Burkina Faso, Gabon, 
Ghana, Kenya, Malawi, Mozambique and Tanzania (Agnandji et al., 2011). 
Although vaccine holds the potential of eradicating malaria from the world, it is clear 
that the efficacies of current malaria vaccines are far from ideal. Malaria immunologists 
recognized that to develop an efficacious vaccine, it is necessary to bridge the existing 
knowledge gap in the interaction between the human immune system and the Plasmodium 
parasite. Hence, without an effective malaria vaccine in sight, the current circumstances 
have consequently underscored the importance of the anti-malarial chemotherapeutic 
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Table 2.2 Malaria Vaccines in the Development Pipeline 
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Table 2.3 General Comparison of Malaria Vaccines and Anti-Malarial Drugs  
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Challenges in malaria vaccine 
development:  
 
1. The complexity of Plasmodium 
parasites life cycle 
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2. Extensive antigenic variation in 
Plasmodium proteins  
Antigenic variation can rapidly render 
vaccine against a particular epitope 
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3. Immunology of human-
Plasmodium interaction 
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Challenges on the use of anti-
malarial drugs: 
 
1. Emergence of Plasmodium 
strains that are resistant to 
conventional anti-malarial drugs 
Resistance have rendered 
conventional anti-malarial drugs 
chloroquine and sulfadoxine-
pyrimethamine ineffective in most 
parts of Africa and South East Asia 
(Figure 2.3, Table 2.5) 
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2.5 Anti-Malarial Drugs: The Chemotherapeutic Approach Facing Resistance  
Anti-malarial drugs are traditionally used for the treatment of malaria. As the clinical 
symptoms of malaria only begin to manifest during the erythrocytic/blood stage of infection, 
many of the compounds discovered earlier for malaria treatment mainly target the parasite 
at this developmental phase (Schlitzer, 2007). Some of these anti-malarial compounds were 
found to have long half-lives (i.e. the time required for half of the drug to be eliminated from 
the body) and were subsequently exploited for short-term malaria prophylaxis.  
The most commonly used anti-malarial drugs are the aryl amino alcohols (e.g. 
quinine), quinolines (e.g. chloroquine), anti-folates (e.g. sulfadoxine-pyrimethamine) and 
peroxides (e.g. artemisinin and derivatives) (Table 2.4). Quinine is a natural compound found 
in the bark of cinchona tree and it is one of the oldest anti-malarial agents documented 
(Meshnick, 1997). Quinine has been used for the treatment of malarial fevers since the early 
17th century and is still in use at present. However, the adverse side effects of the drug have 
limited its use only in severe malaria cases (Taylor, 2004). The shortage of quinine and 
increasing malaria infections in the early 1900s have led to the development of semi-
synthetic anti-malarial drugs. Many of these drugs (e.g. chloroquine, sulfadoxine, 
pyrimethamine, atovaquone, proguanil) were synthesized during World War II as malaria 
was a major disease among the troops, claiming more lives than those that were lost in the 
battlefield (Greenwood, 1995). Since then, chloroquine was used extensively throughout the 
1950s to 1960s for the treatment of malaria as it was safe, affordable and more effective 
than quinine (Schlitzer, 2007). However, the unregulated distribution of chloroquine in 
malaria-endemic region as a generic medicine for fever, without prior diagnosis for malaria 
infection, has led to the emergence of chloroquine-resistant Plasmodium strains (Wellems 
and Plowe, 2001). When chloroquine was substituted with anti-folates such as sulfadoxine-
pyrimethamine, similar resistance began to emerge rendering these once potent anti-
malarial drugs ineffective against the Plasmodium parasite (Hastings et al., 2004; Schlitzer, 




2007; Yuvaniyama et al., 2003). Hence, chloroquine and sulfadoxine-pyrimethamine 
treatment are no longer effective in most parts of Africa and South East Asia today (Figure 
2.3; Table 2.5). 
At present, artemisinin is the first-line medicine for treatment of clinical malaria and 
also, the last line of defence against resistant Plasmodium strains. Artemisinin was isolated 
in the 1970s from the Chinese herb Artemisia annua which has been used for almost 2000 
years by the Chinese to treat malarial fever (Miller and Su, 2011). So far, artemisinin is the 
most potent anti-malarial agent discovered to date, more effective and less toxic than the 
quinolines and anti-folates. However, due to its low solubility in water and oil, derivatives of 
artemisinin e.g. artemeter, artesunate have been developed and used for malaria treatment 
(Schlitzer, 2007). In view of the potential resistance that may arise against artemisinin 
derivatives, WHO has recommended the artemisinin-based combination therapy (ACT) 
strategy where artemisinin derivatives are to be prescribed with another class of anti-
malarial agent for treatment of clinical malaria e.g. artemether-lumefantrine (Coartem and 
Riamet), artesunate-mefloquine (Artequin) and artesunate-sulfadoxine-pyrimethamine 
(Artescope) (WHO Guidelines for the Treatment of Malaria, 2010). Nevertheless, despite a 
global conscientious effort to regulate the prescription of artemisinin-based drugs, the 
effectiveness of the drugs have been observed to decline in certain parts of South East Asia 
with reports citing the emergence of artemisinin-resistant Plasmodium strains at the 
Cambodia-Thailand border (Alker et al., 2007; Denis et al., 2006).      
The development of anti-malarial resistance in Plasmodium strains is thought to be a 
two-step process (WHO Global Report on Anti-Malarial Efficacy and Drug Resistance: 2000-
2010; Table 2.4). In the initial phase, random and spontaneous genetic events result in the 
generation of mutant Plasmodium strains that possess survival advantage in the presence of 
the anti-malarial drugs. These events are rare and are generally perceived to occur 
independently of the drugs. In the later phase, the application of anti-malarial drugs leads to 




the selection of these mutant strains, which will begin to multiply and eventually result in a 
population of Plasmodium parasites that is resistant to the drugs. Hence, the 
chemotherapeutic approach for disease treatment cycles perpetually through the process of 
drug discovery, application for treatment, emergence of resistance, loss of effectiveness and 
replacement by new drugs. With the emergence of artemisinin-resistant Plasmodium strains, 
the current situation thus highlights an urgent need to identify new drug targets and anti-
malarial agents to combat malaria.        
 
  




Anti-Malarial Drug Molecular Target of the Drug References 




Exact plasmodicidal mechanism remains unclear.  
However, aryl amino alcohols may share similar 
mechanism of inhibition to 4-aminoquinolines as 
quinine and mefloquine have been shown to 
competitively inhibit the accumulation of chloroquine, 
indicating a common locus of action. Quinine is 
generally used for treatment of severe malaria. 
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Chloroquine targets the parasite’s digestive vacuole 
where hemoglobin is degraded. Chloroquine 
complexes with ferriprotoporphyrin IX (FPIX), the 
oxidized iron from degraded hemoglobin, and prevents 
its polymerization to hemozoin. The accumulation of 
FPIX is toxic, although the precise mechanism on how 
it causes parasitic death is unclear.  
 
 
(Bray et al., 2006; Foley 
and Tilley, 1997; Schlitzer, 
2007) Amodiaquine  
















Sulfadoxine inhibits dihydropteroate synthase (DHPS) 
whereas proguanil and pyrimethamine inhibit 
dihydrofolate reductase (DHFR). DHPS and DHFR are 
both involved in the biosynthesis of folate, an essential 




(Muller and Hyde, 2010; 









Binds cytochrome bc1 complex and arrests electron 
transport in mitochondria, leading to parasitic death.  
 
 






Binds gyrase and disrupt gyrase-controlled 
supercoiling of DNA. 
 
(Hawkey, 2003) 
Rifampicin Inhibits RNA polymerase. (Gardner et al., 1991) 
Tetracycline Binds 16S RNA of 30S ribosomal subunit and inhibits 




(Derivative of tetracycline) 
Clindamycin Binds amino-acyl and peptidyl binding site of 50S 
ribosomal subunit and inhibits protein synthesis. 
(Schlitzer, 2007) 
Azithromycin  Binds to MLSB site of 50S ribosomal subunit and 
inhibits protein synthesis. 






Exact plasmodicidal mechanism remains unclear.  
May bind PfATP6, an ATP-dependent SERCA-type Ca2+ 
pump, at endoplasmic reticulum. 
Generally used as artemisinin-based combination 
therapy for treatment of uncomplicated malaria.  
 
 
(Eckstein-Ludwig et al., 
2003) Artesunate, artemether, 
arteether, artelinic acid 
(Derivatives of artemisinin)  
Table 2.4 Classes of Anti-Malarial Drugs and their Molecular Targets 



































Introduction of Anti-Malarial Drugs 
Emergence of Resistance to Drugs 
Doxycyclin Proguanil 
1930 1940 1950 1960 1970 1980 1990 2000 2010 
Figure 2.3: Timeline for Anti-Malarial Drugs Introduction and Emergence of Resistance. 
Treatment of malaria is increasingly difficult despite a collection of anti-malarial drugs 
that is available. This is due to the rapid emergence of malaria parasites that are 
resistant to the drugs and thus rendering them ineffective for treatment. The current 
situation highlights the continual need for new anti-malarial drugs. The references are 
listed in Table 2.5. 




Table 2.5 Emergence of Resistance to Anti-Malarial Drugs  
Anti-Malarial Drug 












(Peters, 1987, 1990) 
 
Increased copy number of gene encoding 
PfMDR1 has been associated with 
resistance to quinine, mefloquine and 
halofantrine (Duraisingh and Cowman, 2005). 
However, the exact mechanism of 
resistance remains unclear.  
Mefloquine 1977 1982 
(Boudreau et al., 1982) 
Halofantrine 1988 1990 











Polymorphism in PfCRT (K76T) has been 
shown to be the main determinant for 
chloroquine resistance (Lakshmanan et al., 
2005). Polymorphisms in PfMDR1 have also 
been implicated in modulating the degree 
of chloroquine resistance, although the 
exact mechanism remains unclear.  
 
Amodiaquine 1955 1975 
(Hall et al., 1975) 
Cross resistance between amodiaquine 
and chloroquine has been reported with 
mutations in PfCRT and PfMDR1 
associated with the observed resistance 
(Schlitzer, 2007). However, the exact 












Mechanism remains unknown. 








(Peters, 1987, 1990) 
 
Polymorphisms in dihydropteroate 
synthase (S436A, A437G, K540E, A581G, 
A613S) can confer resistance against 
sulfadoxine (Triglia et al., 1997). 
 
Proguanil  1948 
 
1949  
(Peters, 1987, 1990) 
Polymorphism in dihydrofolate reductase 
(S108N) can confer resistance against 
proguanil and pyrimethamine (Yuvaniyama et 
al., 2003).  
Pyrimethamine 1950 1953 








(Looareesuwan et al., 
1996) 
 
Polymorphisms in cytochrome bc1 (L271V, 
K272R, I258M, F267I, Y268S/C) are 
associated with atovaquone resistance 
(Srivastava et al., 1999). 
 








(Alker et al., 2007; 
Denis et al., 2006) 
 
Polymorphisms in PfATP6 and PfMDR1 
have been associated with resistance to 
artemisinin and its derivatives (Jambou et al., 
2005). However, the exact mechanism of 
resistance remains unclear.  
 
  




2.6 Anti-Malarial Drug Targets: Targeting the Plasmodium falciparum Heat Shock Protein 
90 
The emergence of Plasmodium parasites that are increasingly resistant to 
conventional anti-malarial drugs has underscored the importance of identifying new targets 
and drugs to curb the current malaria situation. Research in the biology of the P. falciparum 
has led to the identification of potential drug-targets based on their essentiality in 
maintaining the cellular functions of the malaria parasite (Table 2.6). The prominent targets 
include the cysteine proteases (i.e. plasmepsins and falcipains) that are involved in 
hemoglobin degradation (Banerjee et al., 2002; Pandey et al., 2005; Sijwali and Rosenthal, 
2004), the kinases (i.e. cyclin-dependent kinases) that are essential for cell-cycle regulation 
(Dorin-Semblat et al., 2007; Keenan et al., 2005), and enzymes crucial for metabolic 
pathways in the apicoplast (Surolia et al., 2004), a unique aplicomplexan organelle which is 
absent in humans. Recent studies have also revealed the possibility of targeting the 
molecular chaperones for malaria inhibition (Neckers and Tatu, 2008). In P. falciparum, the 
molecular chaperone heat shock protein 90 (Hsp90) is of particular interest as an anti-
malarial drug target. Chapter 3 will provide an overview on the current understanding of 
Hsp90’s structure, function and biology. This is followed by Chapter 4 which will discuss the 
research work conducted on the Hsp90 from P. falciparum thus far.  
  

















Transporters are essential for 
nutrients uptake and 
expulsion of waste in the 
parasite 




Electron transport chain is the 
core component for 
respiration 
Ubiquinone (Ellis et al., 1994; 
Painter et al., 2007) 
Fatty acid  
biosynthesis 
(Apicoplast) 
Fatty acids are crucial 









Hydrolysis of hemoglobin by 
plasmodial proteases provides 




(Banerjee et al., 2002; 





Degradation of hemoglobin 
results in toxic heme that has 
to be converted to non-toxic 
hemozoin 
Histidine-rich protein 2 (Huy et al., 2003) 
Shikimate  
biosynthesis  
Shikimate pathway is involved 
in the production of 
chorismate, which can be 
metabolized into aromatic 
amino acids, folate, 
ubiquinone, vitamin K and 
enterochelin 





Farnesyltransferase (Nallan et al., 2005) 
Redox system Plasmodial redox system is 
essential to counteract 
reactive oxygen species 
produced by themselves, 





Thioredoxin  reductase 





Nucleotides are precursors of 
DNA and RNA biosynthesis. 
They are essential for 
replication and proliferation 





(Keough et al., 1998; 
Yuthavong et al., 
2005) 
Cell cycle progression Essential regulators of cell 
growth and differentiation 
Cyclin-dependent 
protein kinases; Pfmrk 
(Geyer et al., 2005) 
Protein folding Cellular proteins require 
chaperones for folding to 
their biologically active state 
Heat shock proteins; 
Hsp70, Hsp90 
(Neckers and Tatu, 
2008) 
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3.1 Molecular Chaperones: Proteins That Help Other Proteins 
Protein constitutes the fundamental force of life. Genetic information inscribed on 
DNA is translated into proteins of complex and dynamic structures which drive essentially all 
biochemical processes in the cell. Protein depends on their tertiary conformation for activity 
and the loss of structural configuration often entails cellular dysregulation (Balch et al., 
2008). A close scrutiny of the cellular lifetime of a protein reveals how vulnerable the 
macromolecule is to structural perturbations: (1) The cytoplasm of the cell is densely packed 
with proteins (~300 mg/mL) and the crowded cellular milieu poses a constant threat to 
protein stability (Ellis, 2007). Nascent polypeptides and proteins with exposed hydrophobic 
surfaces are highly susceptible to aggregation, a phenomenon that can expand and disrupt 
otherwise stable proteins (Ben-Zvi and Goloubinoff, 2002; Zou et al., 2008). (2) Exposure to 
stress stimuli, both endogenous (e.g. oxidative stress, inflammation, fever) and/or 
exogenous (e.g. heat shock, heavy metals, drugs, infections) can also destabilize protein 
structures leading to protein misfolding and aggregation (Dobson, 2003; Jahn and Radford, 
2005). Consequently, aberrant proteins would impose significant burden on the organism 
and the implications are evident in pathological disorders due to protein-misfolding such as 
Parkinson’s and Alzheimer’s diseases (Cohen and Kelly, 2003).  
Most living systems have evolved with a specialized set of proteins that are 
dedicated in folding and maintaining the structural integrity of cellular proteins. This 
repertoire of proteins is collectively known as the molecular chaperones. Molecular 
chaperones are widely known to: (1) assist newly synthesized proteins to fold into their 
active conformations (Hartl and Hayer-Hartl, 2009), (2) prevent cellular protein aggregation 
in the absence/presence of stress stimuli by binding reversibly to exposed hydrophobic 
surfaces (Doyle et al., 2007), (3) aid in the assemblies and disassemblies of macro-complexes 
(Ellis, 2007), and (4) guide misfolded proteins for degradation (McClellan et al., 2005). Taken 
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together, the molecular chaperones ensure protein homeostasis is achieved to support 
cellular growth and development. 
Many molecular chaperones were initially discovered as proteins that were 
upregulated during heat stress. Hence, they were termed as the heat shock proteins (Hsp) 
(Burdon, 1986). Traditionally, Hsp were differentiated based on their approximate molecular 
weight e.g. a 90 kDa molecular chaperone would be referred to as Hsp90. However, with the 
advancement of protein and structural biology, the molecular chaperones are now defined 
based on their protein domain which provides a better reflection of their biological activity. 
Hence, a newly discovered Hsp90 protein family member may no longer necessarily be a 90 
kDa protein. In fact, members of Hsp90 protein family include the yeast Hsp82 and Hsc82, 
Drosophila melanogaster Hsp83, mouse Hsp84 and the human Hsp90α and Hsp90β. 
Currently, the major families of heat shock proteins known to date are the Hsp10, Hsp40, 
Hsp60, Hsp70, Hsp90 and Hsp100 (Table 3.1).  
In prokaryotes, protein folding is carried out by Hsp60 (GroEL) and Hsp10 (GroES) 
(Saibil et al., 2001). It is well-established that GroEL forms a double-ringed tetradecamer 
complex with an isolated central cavity dedicated for the protein folding activity (Harris et al., 
1994; Llorca et al., 1994). GroES facilitates the chaperone activity of GroEL by promoting 
substrate entry and discharge from the folding cavity (Langer et al., 1992; Saibil, 1996). On 
the other hand, protein folding in eukaryotes is performed primarily by the Hsp40, Hsp70 
and Hsp90 (Taipale et al., 2010). With the support of a cohort of accessory proteins termed 
as co-chaperones, Hsp40, Hsp70 and Hsp90 would collaborate to form large dynamic multi-
chaperone complexes that fold proteins into their biologically active states. The protein 
folding process is an elaborate and ordered sequence of events, known as the Hsp90 
chaperone cycle.  
Hsp40 and Hsp70 are thought to act at the early stage of the chaperone cycle to 
recruit and initiate folding of the nascent polypeptide (Cintron and Toft, 2006). Conversely, 
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Hsp90 is only involved at the late stage of the process. Hsp90 is believed to act on substrates 
that are already in their near-native conformation and its function is to provide the final 
‘tweak’ that would configure them into their biological active states (Jakob et al., 1995). It is 
important to note that Hsp90 does not chaperone all substrates recruited by Hsp40 and 
Hsp70. Instead, it chaperones only a subset of these substrates, many of which are 
metastable signal transduction proteins. These substrates are termed as Hsp90’s client 
proteins and they include kinases and transcription factors that are involved in important 
biological pathways in the cell (Taipale et al., 2010). Incidentally, many of these client 
proteins are also implicated in disease development, particularly cancer (Trepel et al., 2010). 
This has thrown Hsp90 into the limelight of research and there is currently an intense 
interest in its biology in human diseases and its potential exploitation as a therapeutic target. 
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Table 3.1 Major Families of Heat Shock Protein  
1 Endoplasmic reticulum paralog 











Hsp10 GroES Hsp10 A cofactor of GroEL that 
assists protein folding in 
prokaryotes 
 
(Saibil et al., 
2001) 
Hsp40 DnaJ Hsp40 Recruits polypeptides for 
folding 
Acts as a cofactor of 
Hsp70 for protein folding 
in eukaryotes 
 
(Mayer et al., 
1999) 
Hsp60 GroEL Hsp60 Main protein folding 
machinery in prokaryotes 
 
(Saibil et al., 
2001) 







Major protein folding 




(Mayer et al., 
1999) 









Important in folding and 
maintenance of a subset 
of metastable proteins in 
their active 
conformations e.g. 

















(Hoskins et al., 
2001) 
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3.2 Heat Shock Protein 90: An Essential Protein in Eukaryotes 
Hsp90 is an essential molecular chaperone in eukaryotes. Hsp90 is crucial for the 
folding and activation of many key proteins required for signal transduction and cellular 
development. The list of Hsp90 client proteins is ever-expanding and they include 
transcription factor p53, steroid hormone receptors and kinases such as Raf, v-Src, MEK, 
Cdk4 and CK2 involved in cell cycle control. Thus, Hsp90 has been recognized as a central 
‘hub’ protein whose function is crucial for the regulation of a multitude of biological 
pathways essential for the cellular growth and differentiation (Taipale et al., 2010).  
Given the extensive list of client proteins that Hsp90 is required to chaperone, it is 
not surprising that Hsp90 is one of the most abundant proteins in the cytoplasm, 
constituting approximately 1-2% of the total cellular protein (Borkovich et al., 1989). Hsp90 
has been shown to be essential in eukaryotes through gene deletion studies in 
Saccharomyces cerevisiae (Borkovich et al., 1989), Drosophila melanogaster (van der Straten 
et al., 1997) and Caenorhabditis elegans (Birnby et al., 2000). Complete homozygous 
deletions of Hsp90s in these organisms have all resulted in a lethal phenotype, whereas 
heterozygous deletions invariably led to the development of unusual phenotypes in the test 
populations. These varied phenotypes observed when Hsp90 level was reduced has led to 
the proposal that Hsp90 may function as a capacitor of phenotypic variation (Queitsch et al., 
2002; Rutherford and Lindquist, 1998). Hsp90 is postulated to mask the effects of genetic 
variations at the protein level by chaperoning the mutant protein to assume the wild-type’s 
structure and function. This would buffer against the effects of deleterious mutations and 
preserve the normal functioning of the cell. The cell and organism would hence assume and 
maintain a wild-type phenotype despite variations in their genetic content. However, when 
the function of Hsp90 is compromised, the effects of these cryptic mutations would be 
revealed (i.e. altered functions, loss of functions, crippled biological pathways) and 
manifested in the forms of phenotypic variations (Sangster et al., 2008). Thus, in view of the 
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importance of Hsp90 in protein folding and maintenance of structural integrity, the 
molecular chaperone has been considered to be one of the most important proteins in 
eukaryotes and its dysregulation can have serious implications on human health.  
 
3.3 Heat Shock Protein 90: Structure and Function 
The Hsp90 is a homodimeric protein that is conserved from bacteria to eukaryotes, 
and only known to be absent in the archea. Hsp90 belongs to the GHKL protein superfamily, 
characterized by a unique Bergerat-fold ATPase domain that is distinct from the ATPase 
domain common to actin, Hsp70 and most kinases (Bergerat et al., 1997). Members of this 
superfamily include DNA-mismatch-repair enzyme MutL, DNA topoisomerase II and histidine 
kinases (Pearl and Prodromou, 2006). Although a highly conserved protein, Hsp90s from 
bacteria (HtpG) and eukaryotes are known to exhibit slight structural differences. Structural 
variations are also observed between Hsp90 paralogs from various eukaryotic organelles i.e. 
cytosol (Hsp90), mitochondria (TRAP1) and endoplasmic reticulum (Grp94) (Table 3.2). 
Nevertheless, all of these Hsp90 homologues and paralogs possess a basic three-domain 
organization; an N-terminal domain, middle domain and C-terminal domain (Figure 3.1).  
N-terminal domain: the ATP binding site. The N-terminal domain is made up of a 
two-layer α/β sandwich structure (CATH Code: 3.30.565.10) that houses the binding site of 
ATP in Hsp90. Analyses of the human and yeast Hsp90s N-terminal domain crystal structures 
revealed a deep nucleotide binding pocket, lined with α-helices at the sides and anti-parallel 
β-sheets at the base (Prodromou et al., 1997b; Stebbins et al., 1997). The Bergerat-fold ATP 
binding pocket is unique among the ATP-hydrolyzing proteins because the ATP would need 
to assume a kink conformation to bind at the pocket (Prodromou et al., 1997a). The unusual 
conformational requirement reflects the unique architecture of the pocket. For this reason, 
only several classes of natural compound (i.e. geldanamycin, radicicol) have been identified 
thus far to bind Hsp90 at the ATP-binding pocket and they have since been exploited for 
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drug development (Roe et al., 1999; Whitesell and Cook, 1996). Apart from nucleotide 
binding, the N-terminal domain is also the known binding site for the co-chaperone p23 (Ali 
et al., 2006). In addition, the first few amino acid residues at the N-terminus have been 
implicated in mediating transient N-terminal dimerization of the Hsp90 homodimer upon 
ATP binding (Richter et al., 2006).   
Middle domain: the proposed client protein binding site. The middle domain of 
Hsp90 is relatively larger than the N- and C-terminal domains and is composed of a large and 
small αβα domain connected by a series of short α-helices. The larger αβα domain was 
found to be highly similar to that of the GHKL proteins, MutL and DNA gyrase B, at the 
corresponding regions (Meyer et al., 2003). Mutagenesis studies on MutL and DNA gyrase B 
revealed certain amino acid residues in this region to be crucial for protein-protein 
interaction (Tingey and Maxwell, 1996). When mapped onto the yeast Hsp82, a conserved 
hydrophobic patch around residue W300 and an unusual amphipathic structure formed by a 
stretch of protruding amino acids, from residues 327 to 340, were identified (Fujita et al., 
2002; Meyer et al., 2003). This region has since been proposed as the binding site for 
Hsp90’s client proteins. In addition, the middle domain of Hsp90 also contains an important 
amino acid residue that is crucial for ATP hydrolysis. The residue, R380 in yeast Hsp82, has 
been proposed as a catalytic residue that would interact and polarize the γ-phosphate of 
ATP bound at the N-terminal domain to promote hydrolysis of the nucleotide. Mutation at 
this residue has been shown to abolish ATP hydrolysis and cripple Hsp90’s cellular activities 
(Meyer et al., 2003). Nevertheless, results from a recent study have indicated that the 
residue R380 is essential for stabilizing the closed conformation of Hsp90 required for ATP 
hydrolysis, instead of assuming the catalytic role proposed previously (Cunningham et al., 
2012). Apart from that, the middle domain is also the known binding site for the co-
chaperone Aha1 (Meyer et al., 2004b).   
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C-terminal domain: the dimerization site. The C-terminal domain of Hsp90 
comprises of a mixture of α/β structures that contains the dimerization site. The 
dimerization site is crucial as Hsp90 functions as a homodimer to carry out its chaperone 
activity (Minami et al., 1994). In addition, the eukaryotic Hsp90s possess a highly conserved 
MEEVD motif at the C-terminus. The motif is recognized by tetratricopeptide repeat (TPR) 
domain-containing co-chaperones and their interactions are essential in facilitating Hsp90 in 
its chaperoning activity (Chen et al., 1998; Young et al., 1998). 
Crystallographic studies on Hsp90 have certainly provided detailed structures of the 
individual domains of Hsp90. However, due to the large protein size and the inherent 
flexibility of the Hsp90 protein, crystallization of the full-length Hsp90 has been extremely 
difficult. So far, only one full-length eukaryotic Hsp90 protein, that of yeast Hsp82 (Ali et al., 
2006), has been successfully crystallized out of the more than 200 Hsp90 crystal structures 
published (Table 3.3). Therefore, although crystal structures have provided detailed 
knowledge on the respective domains of Hsp90, the lack of full-length structures has 









Eukaryotic Hsp90 Family Members 
Heat shock protein 90 
TNF receptor- 




(Perdew and Whitelaw, 1991) 
Mitochondria 
(Felts et al., 2000) 
Endoplasmic reticulum 



















Absent in prokaryotes 
Hsp90 proteins in various organisms (Protein; ID): 
H. sapiens: 
(Chen et al., 2005) 
3 copies 
















Not present Not present 
P. falciparum: 
(Pavithra et al., 2007) 
1 copy 
(PfHsp90; PF07_0029) 




1 putative copy 
(PfGrp94; PFL1070c) 
Cellular function and essentiality: 
Cellular essentiality Essential for survival 
 e.g. gene knock-out studies in S. 
cerevisiae, D. melanogaster & C. 
elegans (Birnby et al., 2000; 
Borkovich et al., 1989; Cutforth 
and Rubin, 1994) 
Essential for tumour cell 
survival; Not essential for 
normal cell viability 
 shown using human cell lines 
(Kang et al., 2007; Leav et al., 
2010) 
Essential for embryogenic 
development; Not essential 
for mammalian cells viability  
 shown in gene knock-out studies 
in mice & using  mouse/human 
cell lines (Randow and Seed, 
2001; Wanderling et al., 2007) 
 
Cellular functions Folds and activates proteins  
 i.e. kinases, transcription factors 
etc. (Taipale et al., 2010) 
Protects mitochondria 
against reactive oxygen 
species-induced DNA 
damage (Hua et al., 2007) 
 
Chaperones membrane and 
secretory proteins 
 i.e. Toll-like receptors, integrins 
(Eletto et al., 2010) 
 
Protein structure and function: 
General protein 
structure  
(Sreedhar et al., 2004) 
 
N-terminal domain; charged 
linker; middle and C-
terminal domains; MEEVD 
motif 
Similar to cytosolic Hsp90 
except that it lacks the 
charged linker and MEEVD 
motif 
 
Similar to cytosolic Hsp90 






(Panaretou et al., 1998; Taipale et 
al., 2010) 
Yes  
(Felts et al., 2000) 
Yes 
(Frey et al., 2007) 
Regulation by co-
chaperones 
Yes (e.g. p23, Aha1, Hop) 
(Taipale et al., 2010) 
No  
(Felts et al., 2000) 
No  




In vitro: Yes 
In vivo: Yes 
(e.g. yeast, human cell lines) 
 
(Panaretou et al., 1998; Taipale et 
al., 2010) 
In vitro: Yes 
In vivo: No 
(i.e. human cell lines; inhibitors 
unable to penetrate mitochondrial 
membrane) 
 
(Felts et al., 2000; Kang et al., 2007) 
 
In vitro: Yes 
In vivo: Yes 
(i.e. using  mouse/human cell lines) 
 
(Chu et al., 2006; Schulte et al., 
1999; Vogen et al., 2002) 
Table 3.2 Comparison of Eukaryotic Hsp90 Paralogs 





























Homologues of Hsp90 
Paralogs of Hsp90 
 ATP-binding pocket 
 Inhibitor binding site  
(e.g. geldanamycin) 
 p23 binding site 
 Dimerize transiently  
when ATP is bound 
 Dimerization site 
 Contains the conserved 
MEEVD motif 
 Binding site of Hop and 
other TPR-co-chaperones 
 Proposed client protein 
binding site 
 Contains catalytic residue 
for ATP hydrolysis 
 Aha1 binding site 








 Rich in charged 
amino acids 
 Deletion in yeast 
Hsp82 is lethal  
 Implicated in p23 
and Aha1 binding 
Basic Structural Organization of Hsp90 
N M C 
N M C 
N M C 
MEEVD N M C 
MEEVD N M C 
Figure 3.1: The Protein Structure of Hsp90. A. The Hsp90 has a three-domain organization: a 
nucleotide binding N-terminal domain, a middle domain that was proposed to be the 
client protein binding site and a C-terminal domain for homodimerization. In addition, 
the N-terminal and the middle domains are connected by a flexible linker that is rich in 
charged amino acid residues. B. The eukaryotic Hsp90 and the prokaryotic homologue, 
HtpG, exhibit substantial structural differences e.g. the prokaryotic HtpG lacks the 
MEEVD motif essential for the binding of TPR-co-chaperones. The eukaryotes also 
possess organelle-specific Hsp90; the mitochondria paralog TRAP1 and the endoplasmic 
reticulum paralog Grp94. Similar to the prokaryotic HtpG, the eukaryotic TRAP1 and 
Grp94 lack the MEEVD motif at the C-terminus that is crucial for the binding of TPR-co-
chaperones. Therefore, they are unlikely to be regulated by this group of co-chaperones. 
A. 
B. 
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Yeast Hsp82 Full-length SbaI/p23 2CG9 3.10 (Ali et al., 2006) 
Yeast Hsp82 N-terminal  
(Tetragonal form) 
- 1AH6 1.80 (Prodromou et al., 
1997b) 
Yeast Hsp82 N-terminal  
(Orthorhombic form) 
- 1AH8 2.10 (Prodromou et al., 
1997b) 
Yeast Hsp82 N-terminal  
(Delta24, N210 mutant) 
- 2AKP 1.94 (Richter et al., 2006) 
Yeast Hsp82 N-terminal ATP 1AM1 2.00 (Prodromou et al., 
1997a) 
Yeast Hsp82 N-terminal ADP 1AMW 1.85 (Prodromou et al., 
1997a) 
Yeast Hsp82 N-terminal p50/Cdc37 1US7 2.30 (Roe et al., 2004) 
Yeast Hsp82 N-terminal  Geldanamycin 1A4H 2.50 (Prodromou et al., 
1997a) 
Yeast Hsp82 N-terminal Radicicol 1BGQ 2.50 (Roe et al., 1999) 
Yeast Hsp82 N-terminal Mg2+, ADP 1BYQ 1.50 (Obermann et al., 
1998) 
Yeast Hsp82 N-terminal Hsp90 inhibitors 1ZW9, 1ZWH 1.65-1.90 (Immormino et al., 
2009) 
Yeast Hsp82 N-terminal Hsp90 inhibitors 2BRC, 2BRE 1.60-2.00 (Cheung et al., 2005) 




2.20 (Proisy et al., 2006) 
Yeast Hsp82 N-terminal HSP90 Inhibitor  2FXS 2.00 (Immormino et al., 
2009) 
Yeast Hsp82 N-terminal Hsp90 inhibitors: 
Macbecin analogues 
2VW5, 2VWC 1.90-2.40 (Martin et al., 2008) 




1.85-2.20 (Day et al., 2011) 
Yeast Hsp82 N-terminal 
(L34I, I35V mutant) 
- 2WEP 2.00 (Prodromou et al., 
2009) 
Yeast Hsp82 N-terminal 
(L34I, I35V mutant) 
Geldanamycin 2WEQ 2.20 (Prodromou et al., 
2009) 
Yeast Hsp82 N-terminal 
(L34I, I35V mutant) 
Radicicol 2WER 1.60 (Prodromou et al., 
2009) 
Yeast Hsp82 N-terminal 
(K98A, S99A mutant) 
- 3C0E 1.90 (
2Immormino et al., 
2008) 
Yeast Hsp82 N-terminal 
(K98A, S99A mutant) 
Geldanamycin 3C11 1.60 (
2Immormino et al., 
2008) 
Yeast Hsp82 N-terminal 
(E88G,N92L mutant) 
Geldanamycin 2YGA, 2YGE 1.96-2.37 (Millson et al., 2011) 
Yeast Hsp82 N-terminal 
(L89V, L93I, V136M 
mutant) 
Geldanamycin 2YGF 2.00 (Millson et al., 2011) 
Yeast Hsp82 Middle domain - 1HK7 2.50 (Meyer et al., 2003) 
Yeast Hsp82 Middle domain AhaI 1USU, 1USV 2.15-2.70 (Meyer et al., 2003) 
Table 3.3 Summary of Hsp90 Crystal Structures Published To Date1 




1Data curated from Protein Data Bank  
2To be published 
  




Human Hsp90α N-terminal 
(Open-conformation) 
- 1YER 1.65 (Stebbins et al., 1997) 
Human Hsp90α N-terminal 
(Closed-conformation) 
- 1YES 2.20 (Stebbins et al., 1997) 
Human Hsp90α N-terminal  
(Docking model) 
Cdc37 2K5B - (Sreeramulu et al., 
2009) 
Human Hsp90α N-terminal Geldanamycin 1YET 1.90 (Stebbins et al., 1997) 
Human Hsp90α N-terminal 17-DMAG 1OSF 1.75 (Jez et al., 2003) 







1.40-2.20 (Wright et al., 2004) 
Human Hsp90α N-terminal Hsp90 inhibitor 1YC3 2.12 (Kreusch et al., 2005) 
Human Hsp90α N-terminal Hsp90 inhibitors 2BT0, 2BSM 1.90-2.05 (Dymock et al., 2005) 
Human Hsp90α N-terminal Hsp90 inhibitors 2BYI, 2BYH 1.60-1.90 (Brough et al., 2005) 
Human Hsp90α N-terminal Hsp90 inhibitors 2BZ5, 2CCS, 
2CCT, 2CCU, 
2CDD 
1.79-2.70 (Barril et al., 2005) 
Human Hsp90α N-terminal Hsp90 inhibitors 2FWY, 2FWZ, 
2H55 
2.00-2.10 (Immormino et al., 
2006) 
Human Hsp90α N-terminal Hsp90 inhibitor 2JJC 1.95 (Congreve et al., 2008) 
Human Hsp90α N-terminal Hsp90 inhibitors  2QFO, 2QF6, 
2QG0, 2QG2 
1.68-3.10 (Huth et al., 2007) 





1.90-2.50 (Sharp et al., 2007) 
Human Hsp90α N-terminal Hsp90 inhibitors 3BMY, 3BM9 1.60 (Gopalsamy et al., 
2008) 
Human Hsp90α N-terminal Hsp90 inhibitor 3D0B 1.74 (Barta et al., 2008) 
Human Hsp90α N-terminal Hsp90 inhibitors 3EKO, 3EKR 1.55-2.00 (Kung et al., 2008) 
Human Hsp90α N-terminal Hsp90 inhibitors 3FT5, 3FT8 1.90-2.00 (Barker et al., 2009) 
Human Hsp90α N-terminal Hsp90 inhibitor 3HEK 1.95 (Cho-Schultz et al., 
2009) 
Human Hsp90α N-terminal Hsp90 inhibitor 3HHU 1.59 (Feldman et al., 2009) 
Human Hsp90α N-terminal Hsp90 inhibitors 3K97, 3K98, 
3K99 
1.95 (Kung et al., 2010) 
Human Hsp90α MEEVD peptide Hop 1ELR 1.90 (Scheufler et al., 2000) 
Human Hsp90α MEEVD peptide FKBP52 1QZ2 3.00 (Wu et al., 2004) 
Human Hsp90β N-terminal Hsp90 inhibitor 1UYM 2.45 (Wright et al., 2004) 
Leishmania major 
Hsp90 (LMJF33.0312) 
N-terminal Hsp90 inhibitors 3Q5J, 3Q5K, 
3Q5L 
2.10-2.65 (




C-terminal - 3HJC 2.50 (






N-terminal ADP 3K60 2.30 (Corbett and Berger, 
2010) 
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3.4 Heat Shock Protein 90: An ATP-driven Molecular Chaperone 
The chaperone activity of Hsp90 is driven by the binding and hydrolysis of ATP at its 
N-terminal domain. Hsp90 utilizes the energy from ATP to induce structural changes that 
would promote its interaction with the client proteins and assist in their functional 
maturation (Grenert et al., 1999). Generally, Hsp90 operates as a homodimer that traverses 
between a nucleotide-free ‘open’ conformation and an ATP-bound ‘closed’ conformation for 
protein chaperoning (Ali et al., 2006; Bracher and Hartl, 2006; Pearl et al., 2008; Shiau et al., 
2006) (Figure 3.2). In the absence of ATP, the Hsp90 homodimer assumes an ‘open’ V-
shaped structure that is dimerized at the C-terminal domain. When ATP is bound, Hsp90 
undergoes conformational changes resulting in a ‘closed’ structure with the N-terminal 
domains transiently dimerized. The two Hsp90 molecules that are dimerized at the N- and C-
terminal domains wrap around each other in a left-handed helical twist and this 
configuration has been postulated to be essential for folding the client proteins into their 
active conformations (Ali et al., 2006). Upon the hydrolysis of ATP, the interaction between 
the N-terminal domains is released and the Hsp90 homodimer reverts to the ‘open’ 
conformation. With the conformations of Hsp90 tightly coupled to its nucleotide-binding 
status, the abilities to bind and hydrolyse ATP are thus the crucial factors that dictate the 
functionality of Hsp90. This is well-supported by mutagenesis experiments on yeast Hsp82, 
where substitutions on Hsp82 residues involved in ATP binding (D79N) and hydrolysis (E33A) 
abolished Hsp90 function and resulted in non-viable yeast strains (Panaretou et al., 1998).  
Hsp90 is well-known to have an inherently slow ATP hydrolysis rate. The yeast Hsp82 
hydrolyses one molecule of ATP per minute (Obermann et al., 1998; Panaretou et al., 1998; 
Prodromou et al., 2000; Richter et al., 2002), whereas the human Hsp90 requires 
approximately 20 minutes (McLaughlin et al., 2002; McLaughlin et al., 2006). One of the 
postulations for the slow ATPase rate is that it would allow delicate control of Hsp90’s 
activity. The hypothesis springs from the observation that Hsp90 operates in concert with a 
Chapter 3: Literature Review Part II            Hsp90’s Structure, Function and Biology 
48 
 
cohort of co-chaperones that can stimulate or inhibit its ATPase activity through their 
interactions. Therefore, depending on cellular needs, the intrinsically slow ATPase rate can 
be enhanced or further inhibited to regulate the level of Hsp90’s activity. Furthermore, 
Hsp90 chaperones an extensive spectrum of client proteins and they are likely to require 
different degree of assistance from Hsp90. Thus, having an ATPase activity that can be 
regulated and tailored to the needs of the client proteins would certainly provide the 
dynamism required of Hsp90.  
 
  







AMPPNP bound  
(PDB: 2CG9) 
Evidence from Hsp90/HtpG crystallographic studies: 
Figure 3.2: The ATPase Cycle of Hsp90. The chaperone activity of Hsp90 is impelled by the 
binding and hydrolysis of ATP at the N-terminal domain. Hsp90 functions as a 
homodimer and in the absence of nucleotide, it assumes an ‘open’ V-shaped 
conformation. This conformation is proposed to be receptive for the loading of 
client protein that is to be folded and/or activated. Upon the binding of ATP, 
the Hsp90 homodimer dimerizes transiently at the N-terminal domain to form a 
left-handed twisted ‘closed’ conformation. This structural configuration is 
believed to be crucial for Hsp90 to activate its client protein. Following the 
hydrolysis of ATP, Hsp90 reverts back to the ‘open’ conformation. AMPPNP: a 
non-hydrolysable analogue of ATP. Note: Currently a full-length eukaryotic Hsp90 crystal 
structure in ‘open’ conformation is not available. Hence the full-length prokaryotic E. coli 
HtpG in ‘open’ conformation is shown instead. The ‘open’ E. coli HtpG and ‘closed’ yeast 













ATP ATP   
Hsp90 ATPase Cycle 
Hsp90 Hsp90 
Open  
E. coli HtpG  
(PDB: 21OQ) 
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3.5 The Co-chaperones: Regulators of Hsp90’s Biological Function 
The Hsp90 performs protein chaperoning functions in vivo with the assistance of a 
group of accessories proteins, termed co-chaperones. Co-chaperones interact and guide 
Hsp90 through the chaperone cycle to facilitate client protein activation. Currently, more 
than 20 co-chaperones have been identified in the eukaryotic cells (Li et al., 2011; 
Wandinger et al., 2008; Zuehlke and Johnson, 2009) (Table 3.4). However, many of their 
biological functions remain largely unclear. Thus far, the several co-chaperones that have 
been extensively studied are known to: (1) regulate the structural conformations of Hsp90 
by inhibiting or stimulating the ATPase activity of the chaperone, (2) recruit specific classes 
of client proteins to Hsp90 for activation, and (3) bridge the interaction between Hsp90 and 
other chaperones (i.e. Hsp70) during the protein chaperone cycle. 
Regulation of Hsp90’s conformation. The tight coupling of Hsp90’s ATPase activity 
to its conformational state has provided the co-chaperones an avenue to modulate the 
function of Hsp90 by regulating its capacity to bind and hydrolyse ATP. Interaction studies on 
human and yeast Hsp90s revealed four co-chaperones i.e. Hop/Sti1, p50/Cdc37, p23/Sba1 
and Aha1 that can influence the conformation of Hsp90 upon binding. For this reason, these 
four proteins are the few most extensively studied co-chaperones. The co-chaperones 
Hop/Sti1 and p50/Cdc37 are found in the early complexes of Hsp90 and their respective 
association inhibits ATP hydrolysis, presumably to facilitate the loading of client protein onto 
the chaperone (Prodromou et al., 1999; Richter et al., 2003; Siligardi et al., 2002). The co-
chaperone p23/Sba1 interacts at the later stage when Hsp90 is in the ATP-bound 
conformation. The binding of p23 has been shown to slow the ATPase activity of Hsp90 
(McLaughlin et al., 2006; Richter et al., 2004). This was proposed to prolong Hsp90’s 
interaction with the client protein which would promote their functional maturation. In the 
case of Aha1, the co-chaperone also binds to Hsp90 in the ATP-bound conformation but its 
interaction accelerates the hydrolysis of ATP, leading to the release of the activated client 
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protein (Lotz et al., 2003; Panaretou et al., 2002). While it remains unclear mechanistically 
how structural changes in Hsp90 configure client proteins to their active conformations, it is 
evident that the participation of these co-chaperones (i.e. p23/Sba1 and Aha1) would 
significantly accelerate the process.  
Recruitment of client proteins. Certain co-chaperones have been found to bind to a 
specific class of Hsp90 client proteins and present them to the chaperone for activation. The 
best understood example is p50/Cdc37. The co-chaperone p50/Cdc37 interacts with a wide-
range of Hsp90-dependent protein kinases and acts as a scaffold that brings the client 
proteins to the proximity of Hsp90 (Dey et al., 1996; MacLean and Picard, 2003). Crystal 
structures and protein truncation studies revealed that this is achieved through using its N-
terminal domain to interact with the kinases and C-terminal domain to bind Hsp90 
(Grammatikakis et al., 1999; Roe et al., 2004; Shao et al., 2001).  
Adaptor between Hsp90 and Hsp70. The co-chaperone Hop/Sti1 is known to be an 
essential adaptor that bridges the interaction between Hsp70 and Hsp90 during the protein 
chaperone cycle (Chen and Smith, 1998; Richter et al., 2004). Hop belongs to the largest 
class of Hsp90 co-chaperones that are defined by their tetratricopeptide repeat (TPR) 
domains. The TPR domain binds to the EEVD and MEEVD motifs found at the C-terminus of 
Hsp70 and Hsp90 respectively (D'Andrea and Regan, 2003). However, it should be noted that 
not all TPR-domain-containing proteins interact with Hsp70 and Hsp90. In the case of Hop, 
the co-chaperone possesses three TPR domains, the most N-terminal one interacts with 
Hsp70, the central one binds exclusively to Hsp90 and the most C-terminal one is not known 
to associate with any chaperone (Brinker et al., 2002). Hence, using the N-terminal and 
central TPR domains, Hop binds to Hsp70 and Hsp90 concurrently and brings them to 
proximity. This is proposed to be essential in facilitating the transfer of partially folded client 
proteins from Hsp70 to Hsp90 during the protein chaperone cycle. 
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p23 Sba1 Slows Hsp90’s ATPase activity 
Binds to the N-terminal domain of Hsp90 in 
closed conformation 
Promotes functional maturation of steroid 
receptors 
(McLaughlin et al., 
2006; Richter et al., 
2004) 
Aha1 Aha1, Hch1 Enhances Hsp90’s ATPase activity 
Binds to the middle domain of Hsp90 
Promotes the activation and release of 
client proteins from Hsp90 
(Lotz et al., 2003; 
Panaretou et al., 
2002) 
p50 Cdc37 Inhibits Hsp90’s ATPase activity 
Binds to the middle domain of Hsp90 
Recruits Hsp90-dependent kinases to Hsp90 
(Siligardi et al., 
2002) 
Sse1 Sse1 Interacts with early Hsp90 complex, with 
Hsp70 and Sti1 
Involved in the degradation of misfolded 
client proteins 
(Liu et al., 1999) 
 
TPR-domain co-chaperones (more than 20 known to date) 
 
Hop Sti1 Sti1 inhibits Hsp82’s ATPase activity in yeast 
Human Hop does not exhibit inhibitory 
effect on Hsp90 
Binds the EEVD motifs in Hsp70 and Hsp90 
Serves as an adaptor to bridge Hsp70 and 
Hsp90 for client protein transfer 
(Richter et al., 




- Large immunophilins 
Interacts with Hsp90 to promote the 
maturation of steroid hormone receptors 
(Riggs et al., 2003) 
Cyp40 Cpr6, Cpr7 Large immunophilins 
Interacts with Hsp90 to promote the 
maturation of steroid hormone receptors 
(Mayr et al., 2000) 
CHIP - A ubiquitin ligase 




PP5 Ppt1 A protein phosphatase 
Dephosphoryalates Hsp90 to promote client 
protein maturation 
(Wandinger et al., 
2006) 
Unc45 She4 Involved in the assembly of myosin fibres (Liu et al., 2008) 
TTC4 Cns1 An essential gene in yeast 
A homologue of Hop 
Interacts with Hsp90 but function is 
unknown 
(Crevel et al., 2008) 
Tom70 Tom70 Involved in protein export in mitochondria (Young et al., 2003) 
Sgt1 Sgt1 Promotes Hsp90 dimerization and 
interaction with Skp1 
(Liu et al., 2004) 
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3.6 The Client Proteins: Proteins that Depend on Hsp90 for Activation 
Hsp90 clients are proteins that require the assistance of the molecular chaperone to 
achieve their biologically active states. Given that Hsp90 is highly promiscuous as it interacts 
with an extraordinary number of cellular proteins, identification of the bona fide client 
proteins is a challenging task. Genome-wide studies in yeast have identified 1232 individual 
proteins that interacted with the yeast Hsp82, either through genetic or protein-protein 
interaction analyses (Breitkreutz et al., 2008). This constitutes approximately 20% of the 
total number of unique proteins in yeast and highlights the complexity of Hsp90 interaction 
network. Some of these proteins are known co-chaperones and client proteins, while others 
are proteins that interact but do not seem to require Hsp90 for their functional activation. 
Furthermore, with increasing recognition on the dynamicity of Hsp90’s function, it is 
becoming clear that delineating clients from non-clients is increasingly difficult as Hsp90’s 
clientele can change significantly in response to environmental cues i.e. chemical insult, 
temperature, pH changes and other stress factors (McClellan et al., 2007). Hence, the client 
protein profiles of Hsp90 may vary depending on the experimental setup, conditions and 
techniques used. Current standards for establishing a protein as a client of Hsp90 would thus 
require two lines of evidence: (1) the protein must interact with Hsp90 and (2) the inhibition 
of Hsp90 would result in reduced client protein activity (Taipale et al., 2010).  
The list of client proteins that Hsp90 chaperones is extensive and many of them are 
involved in pathways essential for cellular development (Figure 3.3). As Hsp90 is known only 
to act at the late stage of the chaperone cycle, its involvement in protein folding has been 
viewed to be a crucial step in tweaking the client proteins into their biologically active states. 
This process is delicate and it reflects the physical properties of the client proteins where 
most of them are metastable proteins that require Hsp90 for stability and functionality. The 
three main classes of client proteins that Hsp90 chaperones are the nuclear steroid 
receptors (e.g. glucocorticoid receptor, progesterone receptor), kinases (e.g. cyclin-
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dependent kinase 4, ERBB2) and transcription factors (e.g. arylhydrocarbon receptor, p53) 
(Pearl et al., 2008; Richter and Buchner, 2001; Taipale et al., 2010; Young et al., 2001). Other 
important client proteins that have been identified include telomerase reverse transcriptase 
(Holt et al., 1999), calcineurin (Singh et al., 2009), myosin (Du et al., 2008) and endothelial 
nitric oxide synthase (Garcia-Cardena et al., 1998). Interestingly, Hsp90 has also been found 
to chaperone mutant and oncoproteins (i.e. v-Src, p53) and has thus been implicated in 
cancer development (Taipale et al., 2010). The rapidly growing list of Hsp90 clientele is 
industriously maintained and updated by the Picard’s laboratory 
(www.picard.ch/downloads). Many of the client proteins that Hsp90 chaperones are part of 
the intricate biochemical pathways that are involved in signal transduction and gene 
regulation. As some of these client proteins function upstream of the pathways, their 
respective inhibition can cause significant pleiotropic effects on proteins that function 
downstream, leading to a breakdown in the biological activity mediated by the pathway. 
Further regression of the pathway’s initiator would eventually point to Hsp90. For this 
reason, Hsp90 has been viewed as an extremely potent drug target whose inhibition is 
capable of triggering simultaneous arrestment in a multitude of biochemical pathways that 
inevitably entails cellular death.  
 
  












Figure 3.3: Client Proteins of Hsp90. Hsp90 is involved in the folding and activation of numerous 
cellular proteins, many of which have important biological roles. The client proteins 
include kinases, nuclear receptors and transcription factors that are crucial for signal 
transduction and gene regulation.  Due to the diverse client protein network, Hsp90 has 
been viewed as a crucial ‘hub’ protein that serves as a nodal point for integrating and 
coordinating signals essential for cellular growth and development.                                        
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3.7 The Hsp90 Chaperone Cycle: Intricate Mechanism of Protein Folding and Activation 
Current model on protein folding posits that Hsp90 cooperates with a cohort of 
chaperones and co-chaperones to form multi-complexes machinery to carry out its 
chaperone activity (Pearl et al., 2008; Taipale et al., 2010). The model is mainly built upon 
results from in vitro co-immunoprecipitation and pull-down experiments that identified their 
protein partners and subsequent in vitro chaperone assay using recombinant proteins for 
verification of their collaboration. It is important to recognize that many of these protein-
protein interaction assays, between Hsp90 and other chaperones/co-chaperones were 
performed in the absence of a bona fide client protein. This was plausibly due to several 
reasons: (1) There is a lack of information on the structures of the client proteins before and 
after activation by Hsp90. This poses a problem in finding suitable partially folded client 
proteins to be used in the chaperone assay. Furthermore, to investigate the chaperone 
activity of Hsp90, the client protein has to demonstrate detectable changes in activity prior 
to and after its interaction with Hsp90. Hence, the availability of suitable client protein 
substrate and assays remains a large challenge. (2) The inclusion of client proteins would add 
an additional layer of complexity to the problem under investigation. Therefore, initial 
studies on Hsp90 chaperone activity have adopted a step-wise approach by identifying the 
interaction partners first in the absence of the client proteins. 
The difficulty in crystallizing full-length Hsp90, and much less in complex with co-
chaperones/client proteins, invariably limits the physical evidence of Hsp90’s interaction to 
simpler domain-complexes structures. This is far from the multi-complex chaperone 
machinery proposed in the current model, as supported by pull-down experiments. 
Therefore, although extensively researched, current literature information on Hsp90 
involvement in the chaperone cycle remains fragmented due to the dynamic protein folding 
process that is difficult to capture and assemble.  
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The current model on the chaperone cycle of Hsp90 is based on the studies of 
steroid hormone receptors (SHR; Figure 3.4) (Owens-Grillo et al., 1996; Pratt and Dittmar, 
1998). SHR is one of the rare substrates suitable for studying Hsp90 chaperone function for 
two reasons: (1) SHR has two conformational states that are assayable; an inactive state that 
does not bind hormone ligand and an active state that binds hormone ligand at high affinity 
(Dittmar et al., 1996; Kosano et al., 1998). Hsp90 chaperone activity is required for the 
transition from the inactive to the active state (Bresnick et al., 1989; Hutchison et al., 1992). 
(2) SHR in the activated state is inherently unstable in the absence of bound hormone. 
Hsp90 interaction provides stability and is important to maintain the SHR in the active 
ligand-binding state. Therefore, much of the knowledge gathered for the current Hsp90 
chaperone cycle is obtained through deconvoluting the activation process of SHR.  
Newly synthesized SHR nascent polypeptides are first recognized and bound to 
Hsp40 through their exposed hydrophobic surfaces (Hernandez et al., 2002). Upon binding, 
Hsp40 would recruit Hsp70 to carry out protein folding on the nascent polypeptide. The 
chaperone activity of Hsp70 requires ATP and it has been shown that Hsp40 binding 
promotes ATP hydrolysis in Hsp70 leading to its interaction with the client protein (Laufen et 
al., 1999; Russell et al., 1999). Hsp70 folds the nascent SHR substantially but not completely. 
For SHR to achieve its active ligand-binding conformation, it would require activation by 
Hsp90 chaperone function (Bresnick et al., 1989; Hutchison et al., 1992). It is speculated that 
Hsp70 prepares SHR for subsequent activation by chaperoning it to a conformation that can 
be recognized by Hsp90. Following that, the partially folded SHR would be transferred from 
Hsp70 to Hsp90. This process is mediated by the co-chaperone Hop. Hop contains three TPR 
domains of which two are utilized to simultaneously bind the EEVD and MEEVD motifs 
present at the C-terminus of Hsp70 and Hsp90 respectively (D'Andrea and Regan, 2003). 
Thus, Hop is viewed as an adaptor that bridges the interaction between Hsp70 and Hsp90 to 
facilitate the transfer of client protein (Chen and Smith, 1998). It is noteworthy that 
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currently, the mechanism of how the client protein transits from Hsp70 to Hsp90 is unclear. 
As in vitro experiments indicated that Hop inhibits the ATPase of Hsp90 (Prodromou et al., 
1999; Richter et al., 2003), it is likely that Hsp90 with Hop bound assumes the ‘open’ V-
shaped conformation. Upon successful transfer of the partially folded SHR to Hsp90, the 
Hsp70-Hop complex would dissociate to allow progression of Hsp90 to a ‘closed’ 
conformation. This occurs with the binding of ATP to Hsp90 that ensues dimerization of the 
N-terminal domains of the Hsp90 homodimer (Prodromou et al., 2000). This ‘closed’ 
conformation is recognized by the co-chaperone p23 and leads to its binding at the N-
terminal domain (Johnson and Toft, 1995; Sullivan et al., 1997; Sullivan et al., 2002). In vitro 
experiments indicated that p23 only binds to Hsp90 in the ATP-bound state and its 
interaction slows Hsp90’s ATP hydrolysis (McLaughlin et al., 2006). This led to the proposal 
that p23’s role is to trap Hsp90 in the ‘closed’ conformation and prolong its interaction with 
the SHR. It is believed that this ‘closed’ conformation is the stage where Hsp90 configures 
the client protein to the functionally active state.  The importance of the co-chaperone is 
endorsed by in vitro chaperone reconstitution assay results where the activation of SHR is 
shown to require a minimum of 5 proteins, namely, Hsp40, Hsp70, Hop, Hsp90 and p23 
(Kosano et al., 1998). The eventual hydrolysis of ATP bound in Hsp90 would cause the 
dissociation of the N-terminal domains and p23 to dislodge. Thereafter, Hsp90 would revert 
back to the nucleotide free or ADP-bound ‘open’ conformation and the activated SHR would 
be released.  
The current model does provide a basic impression of the Hsp90 chaperone cycle, 
based on SHR studies, but is by no means applicable to all types of Hsp90 client proteins. 
Neither is it comprehensive considering that Hsp90 has more than 20 known co-chaperones 
and only two are described in the model. Indeed studies on Hsp90-dependent kinases have 
revealed variation in the chaperone scheme (Caplan et al., 2007). The kinase clients were 
found to be recruited by the co-chaperone Cdc37 that provides direct access to Hsp90, 
Chapter 3: Literature Review Part II            Hsp90’s Structure, Function and Biology 
59 
 
instead of going through the Hsp40, Hsp70 and Hop route. In addition, the co-chaperone 
Aha1 has been proposed to bind to Hsp90 at a certain point while it is in the ‘closed’ 
conformation as its interaction has been shown to stimulate ATP hydrolysis and promote 
client protein activation (Lotz et al., 2003; Meyer et al., 2003). In vitro experiments showed 
that the binding of Aha1 and p23 to Hsp90 to be mutually exclusive, although the order of 
their interaction could not be established (Harst et al., 2005). Therefore, despite increasing 
interest and effort invested on Hsp90 research, we are still far from achieving a full 
understanding on the mechanistic aspect of the Hsp90 chaperone activity. This is largely due 
to the complexity of Hsp90 clientele and the difficulty in capturing the dynamic motion of 
Hsp90 at work. Much of the knowledge gaps reside in the dynamic processes (i.e. how client 
proteins are moved from Hsp70 to Hsp90; how structural changes in Hsp90 result in 
conformational changes in client proteins), the order of interaction between co-chaperones 
and Hsp90, and the combination of chaperones/co-chaperones required by different classes 
of client proteins. 
  





Figure 3.4: The Chaperone Cycle of Hsp90. Hsp90 functions in concert with a cohort of chaperones and 
co-chaperones to fold and activate its client proteins. The chaperone cycle begins with the 
binding of co-chaperone Hop to Hsp90 in the ‘open’ conformation. Hop would then recruit 
the Hsp40-Hsp70-client protein complex and facilitate the transfer of the partially folded 
client protein to Hsp90. Subsequent binding of ATP induces dimerization at the N-terminal 
domain of Hsp90 resulting in the ‘closed’ conformation. The co-chaperone p23 would bind to 
the N-terminal domain of Hsp90 and stabilize the ‘closed’ conformation to prolong the 
interaction between Hsp90 and the client protein. The role of immunophilin co-chaperones 
(Cyp40) is not well-understood but their binding to Hsp90 has been shown to promote the 
activation of steroid hormone receptors. Upon the hydrolysis of ATP, Hsp90 reverts back to 
the ‘open’ conformation and the activated client protein is released.  
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3.8 Hsp90 in Scope: An Emerging Therapeutic Target against Human Diseases 
Disease: Cancer 
Rationale: Many mutant and oncoproteins involved in malignant transformation are 
dependent on Hsp90 for their activities. 
Hsp90 has been implicated in cancer development and malignant progression as it is 
known to chaperone a substantial pool of mutant and overexpressed oncoproteins (Trepel 
et al., 2010). These oncoproteins include kinases such as Bcr-Abl, ErbB2, EGFR, PKB/Akt, C-
Raf, transcription factor p53, androgen receptors and telomerase (Figure 3.5). Indeed many 
of these oncoproteins are structurally unstable and easily misfolded. Thus, oncoproteins are 
highly dependent and ‘addicted’ to Hsp90 for stability and activity, as well as evasion from 
protein degradation pathways (Whitesell and Lindquist, 2005). Since Hsp90 contributes 
substantially in maintaining the functionality of these oncoproteins, it presents itself 
naturally as an obvious target for cancer inhibition. However, knowing that Hsp90 is also an 
essential protein in normal healthy cells, targeting the chaperone for cancer treatment has 
raised concerns on potential off-target toxicity. Nevertheless, clinical studies have shown 
that cancer cells tend to be more susceptible to Hsp90 inhibitors as compared to normal 
cells (Biamonte et al., 2006; Kamal et al., 2003). The observed selectivity of the Hsp90 
inhibitors for the cancer cells could be due to several reasons: (1) As mentioned, oncogenic 
and mutant proteins are more dependent on Hsp90 for their stability and activity as 
compared to the normal client proteins (Grbovic et al., 2006; Weinstein and Joe, 2006). The 
increased reliance on Hsp90 would translate to a more significant disruption of cellular 
activities or even survival, when Hsp90’s activity is compromised. Therefore, for the same 
concentration of Hsp90 inhibitors used, the cancer cell would be more sensitive to the 
inhibitory effects as compared to the normal cells. (2) Due to the oncogenic processes, the 
internal cellular environment of cancer cells are highly stressed e.g. hypoxia, acidosis and 
nutrient deprivation (Whitesell et al., 2003). Therefore, there is a great dependence on 
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chaperones to manage these stresses and ensure the survival of the cancer cells. This would 
render the cancer cells more susceptible to disruption by Hsp90 inhibitors. Currently, more 
than 10 Hsp90 inhibitors have entered clinical trials for evaluation on their use to treat 
various cancers (Table 3.5). 
  






Figure 3.5: Hsp90’s Involvement in the Establishment of Cancer Hallmarks. Hsp90 
chaperones a diverse array of client proteins and they include many mutated 
kinases and oncoproteins that are involved in cancer development and 
progression. Many of these oncoproteins are key mediator of cancer hallmarks 
such as evasion of apoptosis, metastasis, tissue invasion and limitless replicative 
potential (Neckers, 2007). Considering the significant roles of Hsp90 in 
oncogenesis, Hsp90 has been considered as an attractive anti-cancer drug target. 
The figure is adapted from Neckers, 2007.   
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Table 3.5 List of Hsp90 Inhibitors in Clinical Trial for Treatment of Cancers 





Benzoquinone, hydroquinone and phenol ansamycins  
 
Geldanamycin Available 
Bind to Hsp90 N-
terminal ATP-binding 
pocket. Inhibit 
ATPase activity of 
Hsp90. 
- - 
17-AAG Available Phase 2 & 3 BMS Kosan 
17-DMAG Available - BMS Kosan 
IPI-504 Available Phase 2 Infinity 





Bind to Hsp90 N-
terminal ATP-binding 
pocket. Inhibit 
ATPase activity of 
Hsp90. 
- - 
Pochozime Available - - 
NVP-AUY922 Available Phase 1 & 2 Novartis 
AT-13387 Available   
STA-9090 Not disclosed Phase 1 & 2 Synta 
 
Purine, imidazo pyridine, thieno pyrmidine and novel chemotypes  
 
BIIB021 Available Mimic conformation 
of ATP when bound 
to Hsp90. Inhibit 
ATPase activity of 
Hsp90. 
Phase 2 Biogen Idec 
CUDC-305 Available - Novartis 
NVP-BEP800 Available - Novartis 




ABI-010 Not disclosed  
 





Phase 1 Abraxis 
Bioscience 
KW-2478 Not disclosed Phase 1 Kyowa Hakko 
Kirin 
MPC-3100 Not disclosed Phase 1 Myriad 
Pharmaceuticals 
XL888 Not disclosed Phase 1 Exelixis 
Hsp990 Not disclosed Phase 1 Novartis 
BIIB028 Not disclosed Phase 1 Biogen Idec 
AT13387 Not disclosed Phase 1 Astex 
Therapeutics 
1 The status of the clinical trials was updated to May 2012 (ClinicalTrials.gov)  
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Disease: Protozoan diseases e.g. malaria, leishmaniasis, Chagas’ disease  
Rationale: Hsp90 is a ‘hub’ protein and its inhibition allows simultaneous disruption of a 
multitude of important biochemical pathways in the pathogen. 
The roles of heat shock proteins in the pathogenesis of protozoan diseases are 
beginning to be appreciated with increasing understanding on the life-cycle of the 
pathogens. Human protozoan parasites often encounter drastic changes in their cellular 
environment during their entry to human host (Neckers and Tatu, 2008). The shift in 
environment is stressful and they come in the form of elevated temperature, oxidative 
stress, nutrient deprivation and host induced inflammation. Hence, to establish an infection, 
the parasites would need to adapt and overcome these unfavourable conditions. One of the 
common strategies used by the parasite is to upregulate their heat shock proteins to 
manage these stresses. The increased expression of heat shock proteins such as Hsp90 at 
the initial stage of infection is well-documented in clinical studies (Goulhen et al., 2003; 
Kamiya et al., 1998). The role of Hsp90 is also known to extend beyond the initial infection 
phase. In Plasmodium falciparum, Leishmania donovani and Trypanosoma cruzi, Hsp90 has 
been shown to be essential for growth and survival. In the case of T. cruzi, Hsp90 is crucial 
for the developmental progression from the blood form trypomastigotes to epimastigotes 
(Graefe et al., 2002). As for L. donovani, the conversion from the insect form promastigote 
to the pathogenic mammalian form amastigote requires the presence of Hsp90 (Wiesgigl 
and Clos, 2001). Inhibition of L. donovani Hsp90 using specific inhibitor would abrogate the 
conversion process and arrest the growth at the promastigote stage. Similarly, inhibition of 
Hsp90 in P. falciparum has been shown to cause developmental arrest and parasitic death 
(Banumathy et al., 2003; Kumar et al., 2003). P. falciparum exposed to Hsp90 inhibitors 
demonstrated abrogated developmental progression in the intra-erythrocytic stages, in 
particular from the ring to trophozoite stage. Collectively, these findings highlight the 
importance of Hsp90 in these parasitic protozoa. While the precise roles of Hsp90 remain 
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unclear, it is generally assumed that Hsp90s in these parasites are likely to hold similar 
positions described in eukaryotic cells, where they function as a ‘hub’ protein that is 
involved in an extensive spectrum of important biological pathways. Hence, there is now an 
immense interest in exploring the inhibition of Hsp90 for the treatment of these protozoan 
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4.1 Molecular chaperones in Plasmodium falciparum 
If the primary role of heat shock proteins is to protect the organism against the 
detrimental effects of heat stress, it is likely that the malaria parasite has evolved to possess 
one of the most robust sets of these proteins. The malaria parasite has a complex life-cycle 
that exposes it to frequent episodes of heat shock (Acharya et al., 2007). These occur during 
two major events in its life-cycle: (1) Initiation of infection. Infected poikilothermic mosquito 
would transmit the sporozoites into the homoeothermic human host to initiate an infection. 
During this process, the sporozoites would inexorably experience a drastic change in 
environmental temperature, from ambient (~24˚C) to approximately 37˚C, which is a heat 
shock of more than 10˚C. (2) Initiation and progression of clinical disease. Febrile episode is 
the hallmark of clinical malaria. The accompanied fever (~42˚C) that occurs when infected 
erythrocytes burst to release merozoites during cycles of erythrocytic invasion, invariably 
subjects the parasite to a periodic exposure of heat shock. Since heat stress is an intrinsic 
part of its life-cycle, it would not be surprising that the malaria parasite is highly adept at 
managing these unfavourable exposures. Indeed, analysis of P. falciparum database 
revealed that as much as 2% of the genome encodes for chaperones that are expressed at 
various stages of its life-cycle (Acharya et al., 2007). 
Apart from the protective role against heat shock, the molecular chaperones have 
also been shown to be essential for the growth and development of the malaria parasite. A 
study on febrile episodes observed in clinical malaria revealed that recurring events of fever 
help to promote the development of P. falciparum in the erythrocyte (Pavithra et al., 2004). 
Further investigation implicated the molecular chaperone PfHsp90 to be essential for the 
observed growth promotion. The PfHsp90 was demonstrated to be vital for the intra-
erythrocytic development of P. falciparum through inhibition studies (Banumathy et al., 
2003). Treatment of in vitro P. falciparum culture with geldanamycin, an Hsp90-specific 
inhibitor, arrested the developmental progression of the parasite from the ring to 
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trophozoite stage. In another independent study, similar treatment was observed to cause 
parasitic death in P. falciparum cultures (Kumar et al., 2003). Collectively, these studies 
indicated that PfHsp90 is an essential protein in P. falciparum and it is likely to be involved in 
crucial biological pathways governing the survival of the parasite. 
 
4.2 PfHsp90 and its associated proteins in P. falciparum  
The genome of P. falciparum encodes a single copy cytosolic Hsp90 on chromosome 
7 (PF07_0029) (Kumar et al., 2007). The PfHsp90 protein is composed of 745 amino acid 
residues with a pI of 4.94 and a molecular weight of approximately 86 kDa. Sequence 
comparison revealed that PfHsp90 shares approximately 57% amino acid sequence identity 
and 74% sequence similarity with the yeast Hsp82. In addition, the amino acid residues 
known to be essential in yeast Hsp82 for ATP binding and hydrolysis were found to be 
conserved in PfHsp90, indicating that PfHsp90 is likely to possess a functional ATPase 
domain.   
Genomic analysis also revealed 16 Hsp90 co-chaperone genes although most are 
annotated as putative proteins with unverified association with PfHsp90. The identified co-
chaperones include nine cyclophilins, two FKBPs, Hop, p23 and Aha1. Conversely, P. 
falciparum seems to lack certain co-chaperones that are known to have important functions 
in human and yeast. For example, the co-chaperone Cdc37 that is involved in recruiting 
kinases client proteins to Hsp90 is absent in P. falciparum genome. Thus far, only PfCyp19, 
PfPP5 and PfFKBP35 have been demonstrated to interact with PfHsp90 through co-
immunoprecipitation studies (Dobson et al., 2001; Kumar et al., 2005a; Kumar et al., 2005b). 
Surprisingly, the co-chaperones Hop, p23 and Aha1 that have been extensively studied in 
yeast and known for their important roles in regulating Hsp90’s chaperone function were 
not found in those PfHsp90 complexes. Their low sequence identities with the 
corresponding homologues in human and yeast further raised questions on their 
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authenticity as PfHsp90 co-chaperones in P. falciparum, and on a wider perspective, 
whether the well-studied functional and regulatory aspects of Hsp90 are conserved in the 
malaria parasite. To establish their roles as co-chaperones, it is imperative to characterize 
these putative proteins to ascertain their functionality and influence on the activity of 
PfHsp90. 
So far, apart from co-chaperones, other proteins that have been shown to interact 
with PfHsp90 through co-immunoprecipitation are calcineurin and α-tubulin (Banumathy et 
al., 2003; Kumar et al., 2005b) (Table 4.1). Although the genome-wide yeast two-hybrid 
study has identified a list of plasmodial proteins that may associate with PfHsp90 i.e. PelOta 
protein homologue (putative), Cg4, QF122 antigen, N-acetylglucosamine transferase, 
nucleosome assembly protein, endoplasmin homolog precursor, eukaryotic translation 
initiation factor 2b, subunit 2 (putative) and several hypothetical proteins with unknown 
functions (LaCount et al., 2005), the lack of sequence information on the plasmids and 
primers used hindered analysis on whether the gene fragments encoding these proteins 
were expressed in the correct frame when they were detected for their interaction with 
PfHsp90. Furthermore, whether these interacting proteins depend on PfHsp90 for 
functionality and hence are PfHsp90’s client proteins, remains to be investigated. 
Nevertheless, it is clear that the current knowledge on the client proteins of PfHsp90 is 
lacking and thereby, little is known on the biological roles of PfHsp90 in the malaria parasite.  
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(Heat shock protein 70) 
PF08_0054 Co-immunoprecipitation 
using anti-Hsp90 and anti-
Hsp70 antibodies  
Banumathy et al., 
2003 
α-tubulin Not reported Co-immunoprecipitation 
using anti-PfHsp90 antibody 
Pavithra et al., 2004 
PfPP5 
(Ser/Thr phosphatase 5) 
PF13_0294 Co-immunoprecipitation 
using anti-PfHsp90 antibody 
Pavithra et al., 2004 
Calcineurin  
(Protein phosphatase 2B) 
PF08_0129 Co-immunoprecipitation 
using anti-PfHsp90 antibody 
Affinity pull-down using 
recombinant His6 tagged-
calcineurin 






Kumar et al., 2005a 
PfCyp19 
(Immunophilin) 
PFC0975c Co-immunoprecipitation Kumar et al., 2005b 
Endoplasmin homolog 
precursor (putative) 
PFL1070c Yeast 2-hybrid LaCount et al., 2005 
N-acetylglucosamine 
transferase 
PFF0915w Yeast 2-hybrid LaCount et al., 2005 
Nucleosome assembly 
protein 
PFI0930c Yeast 2-hybrid LaCount et al., 2005 
Eukaryotic translation 
initiation factor 2b, 
subunit 2 (putative) 
PFL2430c Yeast 2-hybrid LaCount et al., 2005 
PelOta protein 
homologue (putative) 
MAL7P1.118 Yeast 2-hybrid LaCount et al., 2005 
Cg4 protein PF07_0033 Yeast 2-hybrid LaCount et al., 2005 
QF122 antigen PF10_0115 Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PF07_0086 Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PF10_0171 Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PF10_0242 Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PF14_0032 Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PF14_0700 Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PF14_0708 Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PFI1610c Yeast 2-hybrid LaCount et al., 2005 
Hypothetical protein PFL0130c Yeast 2-hybrid LaCount et al., 2005 
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4.3 P. falciparum Hsp90 as a drug target 
PfHsp90 was recognized as a promising molecular target for malaria therapy as it 
was found to possess two important qualities required for being a good drug target: cellular 
essentiality and “druggability” (achievable specific and selective inhibition). Cellular 
essentiality: PfHsp90 was shown to be essential for the survival of the malaria parasite as its 
inhibition resulted in developmental arrest and parasitic death (Banumathy et al., 2003; 
Kumar et al., 2003). This may indicate PfHsp90’s involvement in crucial biological pathways 
in P. falciparum and thereafter its inhibition is an attractive avenue to abrogate the cellular 
activities of the parasite. Specific inhibition: With any good protein target identified, there is 
a corresponding challenge in finding small molecules that can inactivate the target for 
therapeutic purposes. In the case of Hsp90, natural compounds (e.g. geldanamycin, radicicol) 
that specifically inhibit the function of Hsp90 (through binding to its unique ATP-binding 
pocket) have been identified (Stebbins et al., 1997). These natural compounds are valuable 
scaffolds which can be exploited to engineer small molecules that are highly specific against 
PfHsp90. Selective inhibition:  As Hsp90 is highly conserved in the eukaryotes, targeting a 
pathogen’s Hsp90 for disease treatment inevitably raises concerns on potential undesirable 
effects that may affect the human Hsp90 homologues. However, a recent screen for 
PfHsp90-specific inhibitors has identified compounds that can selectively inhibit the activity 
of PfHsp90, without affecting the human Hsp90 (Shahinas et al., 2010). Specifically, 
recombinant proteins of the ATP binding domain of PfHsp90 and the human Hsp90 were 
respectively screened against 4000 compounds. Three compounds [i.e. (±)-2-amino-3-
phosphonopropionic acid (Pubchem ID 44291306), harmine (Pubchem ID 5280953) and 
acrisorcin (Pubchem ID 24144)] were found to significantly inhibit PfHsp90 but not the 
human Hsp90. These three compounds were subsequently shown to inhibit P. falciparum 
with an IC50 at nanomolar range in cell-based anti-malarial assay. Collectively, these 
observations endorsed PfHsp90 as a promising drug target for malaria inhibition.   
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4.4 Knowledge gaps in PfHsp90 
Despite recognizing the importance of PfHsp90 for the development and survival of 
the malaria parasite, the current knowledge on PfHsp90 is limited. The three major areas 
where knowledge gaps are evident are (Figure 1.1): 
  
1. Functionality of PfHsp90. Prior to this study, there is no report on the biochemical 
characterization of PfHsp90. Although primary sequence analysis revealed a potentially 
functional ATPase domain, the ATPase activity of PfHsp90 has yet to be demonstrated. 
Considering that ATPase activity is the major driving force for the human and yeast 
Hsp90’s chaperone function, it is thus essential to establish whether PfHsp90 possesses 
a functional ATPase activity. This is especially crucial since the proposed anti-malarial 
strategy assumed the inhibition of P. falciparum is achieved via the abrogation of 
PfHsp90’s ATPase activity. 
 
2. Regulation of PfHsp90. The chaperone function of Hsp90 is driven by it ATPase activity, 
which in turn is influenced by the binding of certain co-chaperones (i.e. p23, Aha1). 
Although putative homologues of the co-chaperones have been identified in P. 
falciparum genome, their functionality, interaction and regulation of PfHsp90 have not 
been examined. The ambiguity of their roles as PfHsp90 co-chaperone in P. falciparum 
is further compounded by their low amino acid sequence identities to the 
corresponding human and yeast co-chaperones. Considering that co-chaperone 
interaction has also been implicated in influencing Hsp90’s affinity for the inhibitors, 
ascertaining the bona fide Hsp90 co-chaperones in P. falciparum is imperative in the 
context of targeting PfHsp90 for anti-malarial purposes.   
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3. Biological roles of PfHsp90. Biological roles of proteins are often inferred from the 
profile of their interaction partners. In the case of PfHsp90, the number of proteins that 
is known to interact with it is currently limited. Analysis of the biological functions of 
these interacting-proteins could not shed light on how the inhibition of PfHsp90 could 
have led to the observed breakdown in the cellular development of P. falciparum. 
Therefore, to gain insights to the important biological pathways governed by PfHsp90, 
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The recent recognition of PfHsp90 as a promising anti-malarial drug target has 
stimulated great interest in the biochemistry and biology of this protein in the malaria 
parasite. PfHsp90 has been shown to be essential in the malaria parasite through inhibitor 
studies (Banumathy et al., 2003). Treatment of in vitro P. falciparum cultures with 
geldanamycin (an Hsp90 specific-inhibitor) was observed to cause developmental arrest and 
parasitic death at the intra-erythrocytic stage. The effect of geldanamycin was further 
elucidated to be specific to its interaction with PfHsp90 where immobilized geldanamycin 
successfully pulled down native PfHsp90 from the cell lysate of P. falciparum (Kumar et al., 
2003). Collectively, these studies highlighted the biological importance of PfHsp90 in P. 
falciparum and underscored the plausibility of targeting PfHsp90 for malaria inhibition.   
Currently, although it is clear that PfHsp90 is an essential protein in P. falciparum, its 
functionality and biological roles in the malaria parasite remain largely unknown and 
unexplored. How the inhibition of PfHsp90 leads to the collapse in the cellular activities of P. 
falciparum and inexorably its death are still elusive. While it is convenient to assume that 
PfHsp90 would function as a molecular chaperone similar to that of the human and yeast 
Hsp90s that have been well-studied, the lack of sequence conservation in the putative 
plasmodial co-chaperones would caution against such direct extrapolation. On the contrary, 
the unverified activity and function of PfHsp90 and its putative co-chaperones have cast 
doubts on whether a similar Hsp90 protein folding/activation chaperone system observed in 
human and yeast is conserved and present in P. falciparum. Nevertheless, the observation of 
PfHsp90’s inhibition leading to parasitic death provides an indication that if PfHsp90 is to 
assume the role of a molecular chaperone in P. falciparum, it is likely to fold/activate 
proteins which are involved in biochemical pathways crucial to the survival of the malaria 
parasite. These client proteins of PfHsp90 with important cellular functions could in turn be 
valuable drug targets on their own. On a broader perspective, considering that 
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approximately 50% of the P. falciparum genome has been annotated to code for 
hypothetical proteins with unknown function (Aurrecoechea et al., 2009), PfHsp90 could 
potentially serve as an useful nodal point that provides access to identifying some of these 
proteins with essential functions in P. falciparum. To this end, it is hence important and 
necessary to characterize PfHsp90 with regards to its functionality and interaction partners.  
The paucity in PfHsp90 literature could possibly be attributed to the widely known 
difficulty in producing plasmodial recombinant proteins for biochemical studies and protein 
interaction analysis. Approximately 80% of the P. falciparum genome is made up of A-T 
nucleotides (Gardner et al., 2002) and this poses significant challenges for protein expression 
in heterologous host, due to the usage of rare codons in plasmodial genes (Sibley et al., 
1997). Nevertheless, in view of the importance PfHsp90, it is necessary to procure PfHsp90 
recombinant proteins for characterization studies. Therefore, this project began with the 
attempt to clone and optimize the expression and purification of PfHsp90 recombinant 
proteins for in vitro characterization of its functionality. The availability of PfHsp90 
recombinant proteins would also pave the way for subsequent studies on its interaction and 
regulation by co-chaperones as well as the identification of its potential client proteins.  
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5.2 Materials and Methods    
5.2.1 Culturing of P. falciparum for mRNA extraction 
The P. falciparum 3D7 strain was obtained from the Malaria Research and Reference 
Reagent Resource Centre (MR4) and was cultured according to the instructions given. Briefly, 
the P. falciparum 3D7 parasite was cultured in vitro using treated human red blood cells and 
RPMI-1640 medium containing 10% human serum, 25 mM HEPES, 0.2% NaHCO3 (w/v), 2 
mM L-glutamine, 20 mM glucose and 0.005 ug/ml hypoxanthine and 2.5 ug/ml gentamicin. 
The human red blood cells were washed thrice with the RPMI-1640 medium (without human 
serum) before use to remove leukocytes and anti-coagulants. Subsequently, the human red 
blood cells were diluted to 5% hematocrit with the RPMI-1640 medium and infected red 
blood cells were added to it to constitute approximately 1% parasitemia. The culture was 
then aerated with a gas mixture of 5% CO2, 5% O2, 90% N2 and incubated at 37˚C with the 
culture medium changed every 24 hrs. The growth and parasitemia of the parasite were 
evaluated during medium replacement by Giemsa (Sigma) staining. 
For mRNA extraction purposes, the asynchronous intra-erythrocytic parasite culture 
was allowed to grow to approximately 20% parasitemia before harvesting. The total RNA of 
P. falciparum was subsequently extracted using RNeasy Mini kit (Qiagen) according to the 
manufacturer’s protocol. Following that, mRNA was purified from the total RNA using the 
Oligotex mini kit (Qiagen) as per manufacturer’s instruction (Figure 5.1).       
 
5.2.2 Cloning of PfHsp90 for recombinant protein production 
To clone PfHsp90 (PlasmoDB ID: PF07_0029), the gene sequence was retrieved from 
PlasmoDB and gene-specific primers were designed for reverse transcription and 
polymerase chain reaction (RT-PCR). The forward and reverse primers used were 5’ 
ATCATTggatccATGTCAACGGAAACATTCGC 3’ and 5’ CTGGATctcgagGTCAACTTCTTCCA-
TTTTAGAATCGG 3’ (restriction enzyme sites are in lowercase) respectively. The PfHsp90 was 
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reverse transcribed using the reverse primer and SuperScript® II kit (Invitrogen) according to 
the manufacturer’s protocol. Following that, PfHsp90 was amplified from the first strand 
cDNA using the following PCR cycling parameters: (1) 95˚C for 1 min, (2) 95˚C for 30 sec, (3) 
45˚C for 30 sec, (4) 68˚C for 7 min, (5) 35 cycles of step 2 to 4 and (6) 72˚C for 10 min. Low 
temperatures were used for primer annealing and extension because the gene is rich in A-T 
nucleotides.  
Upon successful amplification, the PfHsp90 gene was subsequently separated by 
agarose gel electrophoresis using 0.8% (w/v) agarose gel and the band that corresponded to 
its expected size was excised and purified using the MinEluteTM Gel Extraction Kit (Qiagen). 
Subsequently, the purified PfHsp90 was double-digested with restriction enzymes BamH1 
and Xho1 and ligated into the pET24a (Novagen) expression vector that has been treated 
with the same set of restriction enzymes. The recombinant pET24a was then transformed 
into Escherichia coli BL21 (DE3) cells with and without the RIG or RIL plasmids (Baca and Hol, 
2000). The plasmids of the recombinant clones were extracted using Wizard® Plus SV 
Minipreps DNA Purification System (Promega) and sequencing was carried out using the ABI 
PRISMTM BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer) and 
analyzed using ABI PRISM 3100 DNA sequencer to identify recombinant clones that carried 
PfHsp90. The forward and reverse sequencing primers used were 5’ 



































Figure 5.1 Schematic illustration of the procedures for cloning PfHsp90 into the pET24a 
expression vector 
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5.2.3 Expression and purification of PfHsp90 recombinant protein 
Bacterial culture carrying the recombinant pET24a-PfHsp90 plasmid was grown in 
100 ml Luria Bertani broth with 50 ug/ml kanamycin (Sigma) for protein expression. For 
bacterial clones containing an additional RIG or RIL plasmid, the culture was further 
supplemented with 40 ug/ml of chloramphenicol (Sigma) for plasmid maintenance. The 
culture was grown at 37°C with agitation at 250 rpm until an OD600 of 0.8 was reached. 
Protein expression was induced by the addition of 1 mM isopropyl-β-D-1-
thiogalactopyranoside (IPTG; Sigma) followed by incubation at 16°C with shaking at 250 rpm 
for 16 hr.  
Following induction, the culture was harvested by centrifugation at 6000 rpm (3944 
x g) for 5 min at 4°C. The supernatant was discarded and the pelleted cells were 
resuspended in cold 50 mM Tris-HCl, pH7.5 buffer. The cells were lysed via sonication with a 
1/8 inch probe at an intensity of 10 um for eight cycles with 10 sec pulse and 10 sec rest in 
each cycle. Cell lysate was subsequently centrifuged at 12000 rpm (13362 x g) for 20 min and 
the soluble protein fraction which contained the PfHsp90 recombinant protein was 
subjected to purification. 
The PfHsp90 recombinant protein which was expressed with a C-terminal His6-tag 
was purified by Ni2+ affinity chromatography using nickel-nitrilotriacetic acid (Ni-NTA) beads 
(Qiagen). For each purification, an aliquot of 1 ml of the soluble protein fraction was 
incubated with 50 ul of Ni-NTA beads for 15 min at 4°C. Unbound proteins were removed by 
washing thrice with 250 ul of 50 mM Tris-HCl, pH7.5, 20 mM imidazole buffer. The PfHsp90 
recombinant protein was eluted in 50 ul of 50 mM Tris-HCl, pH7.5, 300 mM imidazole buffer.  
To remove co-purified contaminating proteins, the Ni2+ affinity purified PfHsp90 
fraction was further purified by gel filtration chromatography on a Superdex 200 column (GE 
Healthcare). The recombinant protein was separated at a flow-rate of 0.5 ml/min in buffer 
containing 50 mM Tris-HCl, pH7.5. The eluted samples were analyzed by SDS-PAGE to 
Chapter 5: Characterization of PfHsp90             Materials and Methods 
82 
 
determine the fractions that contained the PfHsp90 recombinant protein. These fractions 
were pooled and concentrated using Amicon Ultra-4 Centrifugal Filter Units with appropriate 
molecular weight cut-off and stored at 4°C for the subsequent ATPase assay. The 
concentration of the purified PfHsp90 recombinant protein was determined by Bradford 
assay (Biorad) using bovine serum albumin (Sigma) as a standard. Expression and 
purification of the PfHsp90 were upscaled proportionately when necessary to obtain 
sufficient amount of recombinant protein for subsequent assays (Figure 5.2).   
 
5.2.4 Measurement of the ATPase activity of PfHsp90 
The ATPase activity of PfHsp90 was measured using the pyruvate kinase/lactate 
dehydrogenase-coupled assay (Ali et al., 1993; Panaretou et al., 1998). The assay was carried 
out in a 200 ul reaction containing 2 uM PfHsp90 incubated in 100 mM Tris-HCl pH7.5, 6 mM 
MgCl2, 20 mM KCl, 0.8 mM ATP, 2 mM phosphoenolpyruvate, 0.2 mM NADH, 50 ug/ml 
lactate dehydrogenase and 0.2 mg/ml pyruvate kinase at 37°C. The decrease in NADH level, 
which is in direct stoichiometry to the amount of ATP hydrolysed, was determined 
spectrophotometrically at 340 nm. The authenticity of PfHsp90 ATPase activity was verified 
by its sensitivity to inhibition by radicicol (200 uM), a specific Hsp90 ATPase inhibitor. The 
ATPase activity reported was expressed as micromole of ATP hydrolysed per micromole of 
PfHsp90 in one minute at 37°C.       
 
5.2.5 Bio-computational analyses of PfHsp90 
Protein sequence alignment was performed using the CLUSTAL W Multiple 
Alignment Program (Thompson et al., 1994) and the percentage similarity and identity were 
determined by MatGAT 2.02 (Campanella et al., 2003). Tertiary structure of PfHsp90 was 
modelled by the SWISS-MODEL program using the “First Approach Mode” (Schwede et al., 
2003). The Hsp82-Sba1 crystal structure complex (PDB accession number: 2CG9) was used as 
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a template for protein modelling. The modelled protein structures were subsequently 
visualized using the Swiss-PdbViewer (SPdbV) program (Guex and Peitsch, 1997).  
 
5.2.6 Reproducibility of experiments 
The ATPase assay was repeated thrice in independent experiments with duplicates to ensure 
reproducibility of the results.  
  


























Figure 5.2 Schematic illustration of the methodology employed for the expression and purification of 
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5.3.1 Bio-computational analyses of P. falciparum Hsp90 
The availability of the full genome data of P. falciparum in PlasmoDB has provided 
convenient access to gene sequences for bio-computational analysis (Aurrecoechea et al., 
2009; Gardner et al., 2002). Genomic analysis revealed four Hsp90 protein family genes in P. 
falciparum (Table 5.1); a cytosolic copy (PfHsp90; PF07_0029), two putative mitochondrial 
paralogs (PfTRAP1; PF11_0188 and PF14_0417) and a putative endoplasmic reticulum 
paralog (PfGrp94; PFL1070c). So far, only the cytosolic PfHsp90 has been reported in the 
literature and information on PfTRAP1 and PfGrp94 in P. falciparum is not available.  
Multiple sequence alignment revealed PfHsp90 to be highly similar to that of the 
human and yeast Hsp90s. PfHsp90 shares approximately 80% amino acid sequence 
similarities to that of human Hsp90α and Hsp90β, and 76.9% amino acid sequence similarity 
to the yeast Hsp82 (Table 5.2). As Hsp90 is known to assume a modular structure (consisting 
of an N-terminal domain, middle domain and C-terminal domain), PfHsp90 was also 
compared with the respective domains of yeast Hsp82. Among the three domains analyzed, 
the N-terminal domains of PfHsp90 and yeast Hsp82 displayed the highest amino acid 
sequence similarity (Table 5.3). As the N-terminal domain is known to be the site for ATP 
binding and hydrolysis that drive the chaperone function of Hsp90 (Ali et al., 1993; 
Panaretou et al., 1998; Pearl and Prodromou, 2006), it is thus not surprising that this 
important domain is highly conserved in PfHsp90 (Table 5.4). Further comparison with the 
amino acid residues known to have important functions in yeast Hsp82 revealed that the 
residues involved in ATP binding and hydrolysis (Prodromou et al., 1997a), geldanamycin and 
radicicol binding (Roe et al., 1999; Stebbins et al., 1997), C-terminal dimerization (Ali et al., 
2006) and TPR co-chaperones interaction (Chen and Smith, 1998)  are almost all identically 
conserved in PfHsp90 (Figure 5.3). Nevertheless, it was observed that PfHsp90 possesses an 
unusually long linker that connects the N-terminal domain to the middle domain. The 
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PfHsp90 linker is highly acidic, containing 16 glutamate/aspartate residues, and is 
significantly longer than that of yeast Hsp82 by 33 amino acid residues. While the linker in 
yeast Hsp82 has been implicated in co-chaperone interaction (Hainzl et al., 2009; Tsutsumi 
et al., 2012), it is difficult to postulate whether the longer acidic linker in PfHsp90 would 
have similar influence.  
As the crystal structure of PfHsp90 was not available, bio-computational modeling 
was carried out. A modelled tertiary structure of PfHsp90 was predicted using the yeast 
Hsp82-Sba1 crystal structure (PDB accession number: 2CG9) as a template. The modelled 
PfHsp90 was observed to have a similar three-domain structure with an unusually long linker 
connecting the N-terminal and the middle domain (Figure 5.4). Comparison of the modelled 
structure with the PfHsp90’s N-terminal domain crystal structure that was recently resolved 
(PDB accession number: 3K60) (Corbett and Berger, 2010) revealed close resemblance 
between the predicted and the actual structure. The two structures were superimposed and 
structurally aligned with a root mean square value of 0.8 Å. Hence, in the absence of a full-
length PfHsp90 crystal structure, the predicted tertiary structure would be a useful model 









Table 5.1 Paralogs of Hsp90 in P. falciparum 
 
Hsp90 paralogs Localization Protein length 

































Table 5.2 Percentage Amino Acid Sequence Similarity and Identity among Hsp90s of Various Organisms 
 
Percentage of primary sequence identity (highlighted in dark grey) 
Percentage of primary sequence similarity (highlighted in light grey) 
Human Hsp90α (NP_005339.2); Human Hsp90β (NP_031381.2); Human TRAP1 (NP_057376.1); 

























 85.8 27.6 44 61.6 35.8 63.6 26.9 29.4 35.1 
Human 
Hsp90β 
93.7  27.3 43.6 61.7 37 64.4 25.2 29.5 36.2 
Human 
TRAP1 
53.4 53.5  28.5 28.5 31.7 25.6 27.6 25.9 26.1 
Human 
Grp94 
63.1 62.6 49.6  42.8 31.7 41.4 25.2 32.5 28.3 
Yeast 
Hsp82 
78 79.1 54.9 60.3  36.3 59.7 24.6 29.3 35.1 
E. coli 
HtpG 
57.7 58 54.7 49.2 58.5  35.4 24 25.9 29.2 
PF07_0029 
(PfHsp90) 
80 79.7 50.1 62.4 76.9 56.4  27.7 28.6 35.1 
PF11_0188  
(PfTRAP1) 
48 45.7 47.3 48.9 46.7 42 48.9  25.6 27.3 
PF14_0417  
(PfTRAP1) 
49.8 49.3 44.6 53.9 49.9 42.7 48.7 50  31.7 
PFL1070c  
(PfGrp94) 
58.6 57.6 48.7 63.7 55.7 49.6 56.8 49.4 53.1  
Chapter 5: Characterization of PfHsp90               Results 
88 
 
Table 5.3 Percentage Amino Acid Sequence Similarity and Identity among Hsp90 Domains 
 
 
Percentage of primary sequence identity (highlighted in dark grey) 














Role the residue2 
E47 E42 E33 E33 Hydrolysis of ATP 
D93 D88 D79 D79 
Found at the base of pocket. 
Forms H-bond with  adenine N6 
of ATP 
G97 G92 G83 G83 
H-bond via water molecule with 
N6 of ATP 
K112 K107 K98 R98 Binds β-phosphate of ADP/ATP 
F138 F133 F124 F124 Binds α-phosphate of ADP/ATP 
T184 T179 T171 T171 
H-bond via water molecule with 
N6 of ATP 
R400 R392 R380 R419 Binds γ-phosphate of ATP 
1Corresponding residues identified by primary sequence alignment with yeast Hsp82 sequence 






































 19.4 19.7 69.1 17 17.4 
M-domain 
(255-540) 
36.5  16.4 14 61.9 17.5 
C-domain 
(540-709) 
















83.6 33.3 33.6  13.9 17.2 
M-domain 
(295-580) 
36.4 81.8 31.1 33.9  16.2 
C-domain 
(581-745) 
35.9 33.7 73.5 31.4 28.3  
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Human-Hsp90α      MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIR 60 
Human-Hsp90β      MPEEVHHG-----EEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNASDALDKIR 55 
Yeast-Hsp82       --------------MASETFEFQAEITQLMSLIINTVYSNKEIFLRELISNASDALDKIR 46 
PF07_0029         --------------MSTETFAFNADIRQLMSLIINTFYSNKEIFLRELISNASDALDKIR 46 
                                   *** *:*:* *********.**************:******** 
 
Human-Hsp90α      YETLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFME 120 
Human-Hsp90β      YESLTDPSKLDSGKELKIDIIPNPQERTLTLVDTGIGMTKADLINNLGTIAKSGTKAFME 115 
Yeast-Hsp82       YKSLSDPKQLETEPDLFIRITPKPEQKVLEIRDSGIGMTKAELINNLGTIAKSGTKAFME 106 
PF07_0029         YESITDTQKLSAEPEFFIRIIPDKTNNTLTIEDSGIGMTKNDLINNLGTIARSGTKAFME 106 
                  *::::*..:*.:  :: * : *.  :..* : *:****** :*********:******** 
 
Human-Hsp90α      ALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTG-EP 179 
Human-Hsp90β      ALQAGADISMIGQFGVGFYSAYLVAEKVVVITKHNDDEQYAWESSAGGSFTVRADHG-EP 174 
Yeast-Hsp82       ALSAGADVSMIGQFGVGFYSLFLVADRVQVISKSNDDEQYIWESNAGGSFTVTLDEVNER 166 
PF07_0029         AIQASGDISMIGQFGVGFYSAYLVADHVVVISKNNDDEQYVWESAAGGSFTVTKDETNEK 166 
                  *:.*..*:************ :***::* **:* *:**** *** *******  *   *  
 
Human-Hsp90α      MGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEE-- 237 
Human-Hsp90β      IGRGTKVILHLKEDQTEYLEERRVKEVVKKHSQFIGYPITLYLEKEREKEISDDEAEE-- 232 
Yeast-Hsp82       IGRGTILRLFLKDDQLEYLEEKRIKEVIKRHSEFVAYPIQLVVTKEVEKEVPIPEEEK-- 224 
PF07_0029         LGRGTKIILHLKEDQLEYLEEKRIKDLVKKHSEFISFPIKLYCERQNEKEITASEEEEGE 226 
                  :**** : *.**:** *****:*:*:::*:**:*:.:** *   :: :**:.  * *:   
 
Human-Hsp90α      -----------------KEDKEEEKEKEEKESEDK-------------PEIEDVGSDEEE 267 
Human-Hsp90β      -----------------EKG---EKEEEDKDDEEK-------------PKIEDVGSDEED 259 
Yeast-Hsp82       ------------------KDEEKKDEEKKDEDDKK-------------PKLEEVDEEEE- 252 
PF07_0029         GEGEREGEEEEEKKKKTGEDKNADESKEENEDEEKKEDNEEDDNKTDHPKVEDVTEELEN 286 
                                    :.   ...     .:.*             *::*:* .: *  
 
Human-Hsp90α      EKKDGDKKKKKKIKEKYIDQEELNKTKPIWTRNPDDITNEEYGEFYKSLTNDWEDHLAVK 327 
Human-Hsp90β      DSGKDKKKKTKKIKEKYIDQEELNKTKPIWTRNPDDITQEEYGEFYKSLTNDWEDHLAVK 319 
Yeast-Hsp82       -----KKPKTKKVKEEVQEIEELNKTKPLWTRNPSDITQEEYNAFYKSISNDWEDPLYVK 307 
PF07_0029         AEKKKKEKRKKKIHTVEHEWEELNKQKPLWMRKPEEVTNEEYASFYKSLTNDWEDHLAVK 346 
                       .: :.**::    : ***** **:* *:*.::*:***  ****::***** * ** 
 
Human-Hsp90α      HFSVEGQLEFRALLFVPRRAPFDLFENRKKKNNIKLYVRRVFIMDNCEELIPEYLNFIRG 387 
Human-Hsp90β      HFSVEGQLEFRALLFIPRRAPFDLFENKKKKNNIKLYVRRVFIMDSCDELIPEYLNFIRG 379 
Yeast-Hsp82       HFSVEGQLEFRAILFIPKRAPFDLFESKKKKNNIKLYVRRVFITDEAEDLIPEWLSFVKG 367 
PF07_0029         HFSVEGQLEFKALLFIPKRAPFDMFENRKKRNNIKLYVRRVFIMDDCEEIIPEWLNFVKG 406 
                  **********:*:**:*:*****:**.:**:************ *..:::***:*.*::* 
 
Human-Hsp90α      VVDSEDLPLNISREMLQQSKILKVIRKNLVKKCLELFTELAEDKENYKKFYEQFSKNIKL 447 
Human-Hsp90β      VVDSEDLPLNISREMLQQSKILKVIRKNIVKKCLELFSELAEDKENYKKFYEAFSKNLKL 439 
Yeast-Hsp82       VVDSEDLPLNLSREMLQQNKIMKVIRKNIVKKLIEAFNEIAEDSEQFEKFYSAFSKNIKL 427 
PF07_0029         VVDSEDLPLNISRESLQQNKILKVIKKNLIKKCLDMFSELAENKENYKKFYEQFSKNLKL 466 
                  **********:*** ***.**:***:**::** :: *.*:**:.*::.***. *:**:** 
 
Human-Hsp90α      GIHEDSQNRKKLSELLRYYTSASGDEMVSLKDYCTRMKENQKHIYYITGETKDQVANSAF 507 
Human-Hsp90β      GIHEDSTNRRRLSELLRYHTSQSGDEMTSLSEYVSRMKETQKSIYYITGESKEQVANSAF 499 
Yeast-Hsp82       GVHEDTQNRAALAKLLRYNSTKSVDELTSLTDYVTRMPEHQKNIYYITGESLKAVEKSPF 487 
PF07_0029         GIHEDNANRTKITELLRFQTSKSGDEMIGLKEYVDRMKENQKDIYYITGESINAVSNSPF 526 
                  *:***. **  :::***: :: * **: .*.:*  ** * ** *******: . * :*.* 
 
Human-Hsp90α      VERLRKHGLEVIYMIEPIDEYCVQQLKEFEGKTLVSVTKEGLELPEDEEEKKKQEEKKTK 567 
Human-Hsp90β      VERVRKRGFEVVYMTEPIDEYCVQQLKEFDGKSLVSVTKEGLELPEDEEEKKKMEESKAK 559 
Yeast-Hsp82       LDALKAKNFEVLFLTDPIDEYAFTQLKEFEGKTLVDITKD-FELEETDEEKAEREKEIKE 546 
PF07_0029         LEALTKKGFEVIYMVDPIDEYAVQQLKDFDGKKLKCCTKEGLDIDDSEEAKKDFETLKAE 586 
                  :: :  :.:**::: :*****.. ***:*:**.*   **: ::: : :* * . *    : 
 
Human-Hsp90α      FENLCKIMKDILEKKVEKVVVSNRLVTSPCCIVTSTYGWTANMERIMKAQALRDNSTMGY 627 
Human-Hsp90β      FENLCKLMKEILDKKVEKVTISNRLVSSPCCIVTSTYGWTANMERIMKAQALRDNSTMGY 619 
Yeast-Hsp82       YEPLTKALKEILGDQVEKVVVSYKLLDAPAAIRTGQFGWSANMERIMKAQALRDSSMSSY 606 
PF07_0029         YEGLCKVIKDVLHEKVEKVVVGQRITDSPCVLVTSEFGWSANMERIMKAQALRDNSMTSY 646 
                  :* * * :*::* .:****.:. ::  :*. : *. :**:**************.*  .* 
 
Human-Hsp90α      MAAKKHLEINPDHSIIETLRQKAEAD-KNDKSVKDLVILLYETALLSSGFSLEDPQTHAN 686 
Human-Hsp90β      MMAKKHLEINPDHPIVETLRQKAEAD-KNDKAVKDLVVLLFETALLSSGFSLEDPQTHSN 678 
Yeast-Hsp82       MSSKKTFEISPKSPIIKELKKRVDEGGAQDKTVKDLTKLLYETALLTSGFSLDEPTSFAS 666 
PF07_0029         MLSKKIMEINARHPIISALKQKADAD-KSDKTVKDLIWLLFDTSLLTSGFALEEPTTFSK 705 
                  * :** :**..  .*:. *:::.: .  .**:****  **::*:**:***:*::* :.:. 
 
Human-Hsp90α      RIYRMIKLGLGIDEDDPTADDTSAAVTEEMPPLEG--DDDTSRMEEVD 732 
Human-Hsp90β      RIYRMIKLGLGIDEDEVAAEEPNAAVPDEIPPLEG--DEDASRMEEVD 724 
Yeast-Hsp82       RINRLISLGLNIDEDEETETAPEAS---TAAPVEE--VPADTEMEEVD 709 
PF07_0029         RIHRMIKLGLSIDEEENND--------IDLPPLEETVDATDSKMEEVD 745 
                  ** *:*.***.***::              .*:*       :.***** 
 
Figure 5.3 Multiple sequence alignment of PfHsp90 with human and yeast Hsp90s 
The primary sequence of PfHsp90 (PF07_0029) was aligned with that of human Hsp90α, 
Hsp90β and yeast Hsp82. The residues important for ATP binding and hydrolysis, 
geldanamycin binding, radicicol binding, C-terminal dimerization and TPR co-chaperone 
interaction are highly conserved in PfHsp90. In addition, PfHsp90 was observed to have an 
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Figure 5.4 Analysis of PfHsp90 tertiary structures 
A. PfHsp90 was modelled against the yeast Hsp82-Sba1 crystal structure (PDB accession 
number: 2CG9). The modelled PfHsp90 was shown to possess the classical three-domain 
structure; an N-terminal nucleotide binding domain, a middle domain proposed to be the 
client protein binding site and a C-terminal dimerization domain. B. The N-terminal domain 
of PfHsp90 has been resolved with an ADP bound (PDB accession number: 3K60). 
Superimposition of the resolved PfHsp90 crystal structure with that of the modelled PfHsp90 
revealed a root mean square value of 0.8 Å. This indicated that the modelled PfHsp90 is 
highly similar to the resolved N-terminal domain structure of PfHsp90. AMP-PNP: a non-
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5.3.2 PfHsp90 is solubly expressed as a recombinant protein 
Cloning of PfHsp90 was carried using mRNA extracted from P. falciparum mixed 
intra-erythrocytic stage in vitro cultures. Using appropriate primers, PfHsp90 was reverse 
transcribed and PCR-amplified from the prepared mRNA of P. falciparum (Figure 5.5). The 
amplified PfHsp90 was subsequently cloned into the pET24a expression vector and the gene 
sequence was verified by DNA sequencing. The pET24a encodes a His6-tag sequence that 
would be attached to the C-terminus of PfHsp90 for purification purposes. Following that, 
the recombinant pET24a vector carrying PfHsp90 was transformed into E. coli BL21 (DE3).   
SDS-PAGE analysis showed that PfHsp90 was solubly expressed as a recombinant 
protein of approximately 88 kDa in size (Figure 5.5). To purify the recombinant PfHsp90, the 
cell lysate containing PfHsp90 was subjected to Ni2+ affinity chromatography. The Ni2+ in the 
Ni-NTA beads is known to bind His6-tag found at the C-terminus of PfHsp90 with high affinity. 
Analysis of the purified fraction revealed the presence of a substantial amount of 
contaminating proteins that were co-purified with PfHsp90. Similar contamination is known 
to be common in the purification of human and yeast Hsp90s and they include many 
proteins with ATPase activity. The presence of contaminating ATPase protein is a major 
problem in the study of Hsp90’s ATPase activity which is inherently low and difficult to 
detect. Hence to minimize potential problems posed by contaminating ATPases, the Ni2+ 
affinity purified PfHsp90 fraction was subjected to further purification by gel filtration. The 
SDS-PAGE result showed that most of the contaminating co-purified proteins could be 
removed after separation by gel filtration, and a relatively clean fraction of PfHsp90 was 
obtained.  
In the attempt to improve the expression of PfHsp90, four expression parameters 
were analyzed: (1) The inclusion of the RIG or RIL plasmid into the E. coli BL21 clone carrying 
PfHsp90. The RIG and RIL plasmids encode tRNAs that recognize rare codons present in the 
A-T rich plasmodial genes and their inclusions have been reported to improve the expression 
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of certain plasmodial proteins in E. coli (Baca and Hol, 2000). (2) The concentration of IPTG 
to be used for induction of protein expression, (3) induction temperature and (4) induction 
time. SDS-PAGE analysis revealed that the expression of PfHsp90 could be improved with the 
inclusion of the RIG plasmid and by using 1 mM IPTG for induction at 16˚C for 16 hr (Figure 
5.6). Hence, this set of expression parameters was adopted in the production of PfHsp90 
recombinant protein for subsequent experimental assays. However, despite using the 
optimized expression parameters, the yield of purified PfHsp90 recombinant protein 
remained relatively low. Following two modules of purification, only approximately 0.5 mg 
of purified PfHsp90 recombinant protein was obtained per liter of bacterial culture.   
 
5.3.3 Recombinant PfHsp90 possesses a functional ATPase activity 
As the chaperone function of Hsp90 is known to be governed by its ATPase activity 
that effect conformational changes required for protein folding, ATPase assay was carried 
out to test the functionality of the recombinant PfHsp90. Using a sensitive enzyme-coupled 
assay, PfHsp90 was shown to have an ATPase activity of 0.504±0.044 
umolATP/min/umolPfHsp90 at 37°C. The activity measured was sensitive to inhibition by 
radicicol, a specific Hsp90 ATPase inhibitor, and thus, ensured that the activity detected was 
not attributed to other co-purified ATPase contaminants.  
  











































Figure 5.5 Cloning and expression of PfHsp90 recombinant protein 
A. PfHsp90 was amplified from the mRNA of P. falciparum by RT-PCR and subsequently 
cloned into the expression vector pET24a. B. PfHsp90 was expressed from the pET24a vector 
as a recombinant protein with a C-terminal His6-tag and subjected to Ni
2+ affinity 
chromatography and gel filtration separation. SDS-PAGE analysis showed that the PfHsp90 
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Figure 5.6 Optimization of PfHsp90 recombinant protein expression analyzed by SDS-PAGE  
The expression of PfHsp90 was optimized to improve the yield of the recombinant protein. 
The expression level of PfHsp90 was compared using the total Ni2+ affinity purified PfHsp90 
recombinant protein obtained from 100 mL of bacterial cultures. The expression parameters 
were tested by varying the standard conditions of E. coli BL21 culture (OD600 of 0.8) induced 
with 0.1 mM IPTG at 24˚C for 9 hours, accordingly. Based on the SDS-PAGE analysis, the use 
of E. coli BL21 carrying the RIG plasmid and 1 mM IPTG induction at 16˚C for 16 hours could 
improve the expression of PfHsp90 recombinant protein. All the protein bands shown 
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One of the most fundamental requirements in any effort to characterize a protein is 
the ability to procure large quantity of its recombinant protein for in vitro experimental 
investigation. Prior to this study, there has been no report on the expression of PfHsp90 
recombinant protein. The difficulty in obtaining PfHsp90 recombinant protein could have 
hindered experimental investigation and probably account for the lack of knowledge on its 
structure and function in the malaria parasite. Generally, production of Hsp90 recombinant 
protein is known to require considerable effort due to its large protein size that often results 
in low expression and the need for multi-step purification procedures to remove co-purified 
contaminants. In the case of the malarial Hsp90, the difficulty may be further amplified by 
the usage of unusual codons, due to the high A-T nucleotides content in P. falciparum genes, 
which are rare and thus not easily recognizable by the heterologous host during protein 
translation (Gardner et al., 2002; Sibley et al., 1997). Nevertheless, the requirement of 
recombinant protein for in vitro protein characterization is obvious and necessary. Therefore, 
production of PfHsp90 recombinant protein was undertaken in the initial part of this project 
in the effort to characterize the activity of PfHsp90.   
Bio-computational analyses carried out prior to experimental investigation revealed 
that PfHsp90 shares high amino acid sequence similarities with the human and yeast Hsp90s. 
Amino acid residues in yeast Hsp82 that are known to be essential for the binding and 
hydrolysis of ATP, formation of homodimer and interaction with co-chaperones with TPR 
motifs are almost identically conserved in PfHsp90. This indicated that the PfHsp90 encoded 
by P. falciparum is likely to be functional and possibly operates in a manner similar to that of 
the yeast Hsp82, with respect to its dimerization and interaction with TPR co-chaperones. In 
addition, the amino acid residues in yeast Hsp82 that are known to bind its inhibitors, 
geldanamycin and radicicol, are also almost identically conserved in PfHsp90. While the 
interaction between PfHsp90 and geldanamycin has been shown and ascertained in previous 
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studies (Kumar et al., 2003), the role of radicicol as an inhibitor of PfHsp90 has yet to be 
demonstrated experimentally.  
Expression of PfHsp90 recombinant protein was carried out using pET24a expression 
vector and E. coli BL21 (DE3) as a heterologous expression host. PfHsp90 was successfully 
expressed as a recombinant protein with a C-terminal His6-tag and the fusion protein is 
predicted to be approximately 88 kDa. Subsequent attempts to purify the recombinant 
PfHsp90 by Ni2+ affinity chromatography resulted in many contaminating proteins that were 
co-purified with PfHsp90. Nevertheless, upon further separation by gel filtration, most of the 
co-purified contaminants were removed. The use of two purification modules coupled with 
the low expression level of PfHsp90 in E. coli invariably resulted in a low yield of purified 
PfHsp90 recombinant protein.  For each liter of bacterial culture, only approximately 0.5 mg 
of purified PfHsp90 recombinant protein could be obtained. Hence, the process was up-
scaled and 5 to 10 liters of bacterial cultures were routinely prepared per batch of analysis.  
The functionality of the recombinant PfHsp90 was investigated via the ATPase assay 
and was shown to have an ATPase activity of 0.504±0.044 umolATP/min/umolPfHsp90 at 37°C. 
The activity observed is approximately ten times more than the human Hsp90 ATPase 
activity (0.034-0.089 umolATP/min/umolHsp90) (McLaughlin et al., 2002; McLaughlin et al., 
2006), but comparable to that reported for yeast Hsp82 (0.40-1.05 umolATP/min/umolHsp82) 
(Obermann et al., 1998; Panaretou et al., 1998; Prodromou et al., 2000; Richter et al., 2002). 
The PfHsp90’s ATPase activity measured (Chua et al., 2010) is also consistent with that 
subsequently reported by Pallavi et al., 2010. In addition, the ATPase activity of PfHsp90 was 
demonstrated to be abrogated by radicicol, validating it as an inhibitor of PfHsp90 as alluded 
by the sequence analysis results mentioned earlier. 
In summary, this Chapter showed that P. falciparum encodes a functional PfHsp90 
with ATPase activity. This is also the first report on the heterologous expression of PfHsp90 
recombinant protein. The methodology employed for the expression and purification of 
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PfHsp90 recombinant protein would serve as a useful platform for subsequent procurement 
of the recombinant proteins of its putative co-chaperones. With the availability of 
recombinant proteins, PfHsp90 was subsequently investigated for its interaction and 













Characterization of the co-chaperone Pfp23:  
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Co-chaperones are essential regulators of Hsp90’s chaperone function (Taipale et al., 
2010). It is known that Hsp90 chaperones its client proteins by undergoing a series of 
conformational changes driven by the binding and hydrolysis of ATP at its N-terminal domain 
(Panaretou et al., 1998; Pearl and Prodromou, 2006). By modulating the nucleotide 
exchanges in Hsp90, certain co-chaperones have been demonstrated to assist and promote 
the chaperone activity of Hsp90.  
The co-chaperone, p23, is a small protein that binds Hsp90 in the presence of ATP 
(Panaretou et al., 2002). Their interaction usually occurs at the late stage of the chaperone 
cycle when Hsp90 is in the ATP-bound conformation with its client protein (Freeman et al., 
2000). The binding of p23 reduces the rate of ATP hydrolysis and traps the Hsp90 in the ATP-
bound conformation (McLaughlin et al., 2006). This was proposed to prolong the interaction 
between Hsp90 and its client proteins that would accelerate their functional maturation. 
The contribution of p23 for the activation of Hsp90 client proteins have been demonstrated 
in vitro using reconstituted Hsp90 chaperone system (Morishima et al., 2003). The 
incorporation of p23 was shown to significantly increase the competence of mature 
progesterone and glucocorticoid receptors in binding steroid hormones, as such attesting to 
p23’s importance in driving the Hsp90 functional repertoire (Dittmar et al., 1997; Kosano et 
al., 1998).    
In the crystal structure complex of Hsp82 and Sba1, homologues of Hsp90 and p23 
in yeast, respectively, the two proteins were shown to interact through their N-terminal 
domains (Ali et al., 2006). Hsp82 was crystallized in the ATP-bound conformation and 
possessed a closed ‘lid’ segment positioned over the ATP-binding pocket, which would 
otherwise remain open in the absence of ATP. In the case of Sba1, the N-terminal domain 
was found to bind over the ATP-binding pocket of Hsp82, with the closed ‘lid’ forming one of 
the interaction interfaces. The requirement for this ATP-induced closed ‘lid’ conformation in 




Hsp82 to interact with Sba1 is circumstantially supported by experiments showing the 
preferential binding of p23 to ATP-bound Hsp90 (Fang et al., 1998; Johnson and Toft, 1995).  
Apart from regulating Hsp90 chaperone functions, p23 is also capable of binding 
partially folded proteins and suppressing protein aggregation in vitro (Bose et al., 1996; 
Freeman et al., 1996). This has led to the suggestion that p23 may itself function as a 
chaperone, independent of Hsp90. When the C-terminal tail of p23 was truncated, its 
chaperone activity was abolished, suggesting that the acidic amino acid-rich tail may be 
instrumental for its function (Weikl et al., 1999). This intrinsic chaperone activity of p23 has 
been demonstrated to be essential for the recycling of steroid receptors and telomerase 
(Freeman and Yamamoto, 2002; Toogun et al., 2007).  
In P. falciparum, a putative homologue of p23 (Pfp23) has been reported (Wiser, 
2003). Pfp23 was initially identified as a 36 kDa major phosphoprotein associated with the 
kinase activity of an unknown protein in P. falciparum (Wiser, 1995). Subsequent 
procurement of its protein sequence revealed its homology to the co-chaperone p23. 
However, investigation of its role as a co-chaperone of PfHsp90 has been unsuccessful so far. 
Co-immunoprecipitation experiments performed using either antibodies specific to Pfp23 or 
PfHsp90 did not detect complexes containing both the proteins (Banumathy et al., 2003; 
Wiser, 2003). Similarly, P. falciparum genome-wide yeast two-hybrid analysis was unable to 
provide evidence for their association (LaCount et al., 2005). The general lack of empirical 
evidence on PfHsp90’s interaction with co-chaperones has invariably raised questions on the 
conservation of the role of co-chaperones in P. falciparum and how PfHsp90 is regulated in 
the malaria parasite. Hence, to study the regulation of PfHsp90, the putative Pfp23 was 
probed for its interaction with PfHsp90. The interaction study was designed to use 
recombinant proteins and GST pull-down assays in view of the lack of success in previous co-
immunoprecipitation and yeast two-hybrid methodologies.  
  




6.2 Materials and Methods  
6.2.1 Cloning of Pfp23 and PfHsp90 for recombinant proteins production 
The DNA sequence of Pfp23 (PlasmoDB ID: PF14_0510) was retrieved from 
PlasmoDB and appropriate primers were designed for cloning the gene (Table 6.1). Using 
gene-specific primers, Pfp23 was cloned from the mRNA of P. falciparum 3D7 by RT-PCR in a 
process similar to that described for PfHsp90 (Chapter 5, Section 5.2.2). The PCR-amplified 
Pfp23 gene was subsequently separated by agarose gel electrophoresis using 0.8% (w/v) 
agarose gel and the band that corresponded to its expected size was excised and purified 
using the MinEluteTM Gel Extraction Kit (Qiagen). The purified Pfp23 gene fragment was then 
ligated into pCR-BluntII-TOPO vector using the Zero BluntTM TOPOTM PCR Cloning Kit 
(Invitrogen). The plasmids of the recombinant clones were extracted using Wizard® Plus SV 
Minipreps DNA Purification System from Promega. Full sequencing was carried out using the 
ABI PRISMTM BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit from Perkin Elmer 
and analyzed using ABI PRISM 3100 DNA sequencer to identify recombinant clones that 
contained the Pfp23 gene.  
Subsequently, the recombinant clone that contained Pfp23 was double-digested 
with restriction enzymes BamH1 and Sal1. Pfp23 was subcloned into the expression vector 
pET24a (Novagen) and transformed into E. coli BL21 (DE3) cells with a RIG plasmid for 
recombinant protein expression. DNA sequencing was performed to authenticate the 
recombinant clones carrying the Pfp23 gene. 
 In the case of PfHsp90, the gene was PCR-amplified from the pET24a recombinant 
vector carrying PfHsp90 using appropriate primers (Table 6.1). The PCR-amplified product 
was purified, double-digested with restriction enzymes BamH1 and Xho1 and ligated into the 
pGK vector (Loke et al., 2000) that has been treated with similar restriction enzymes. The 
pGK expression vector allowed the expression of recombinant PfHsp90 with an N-terminal 
GST-tag and a C-terminal His6-tag. The C-terminal His6-tag would facilitate the purification of 




PfHsp90 as described earlier (Chapter 5, Section 5.2.3) whereas the N-terminal GST-tag 
would be used for pull-down assay.   
 
6.2.2 Construction of Pfp23-truncated and single mutants  
The recombinant pET24a plasmid that contained Pfp23 was used as a template for 
the construction of Pfp23-truncated mutants. Pfp23-truncated mutants T1, T2, T3, T4 and T5 
were PCR-amplified using appropriate forward primers and a common reverse primer used 
for Pfp23 wild-type (Pfp23-WT) previously. On the other hand, amplifications of Pfp23-
truncated mutants, Pfp23-(135-275) and Pfp23-(220-275), were carried out using 
appropriate reverse primers designed and a common forward primer from Pfp23-WT (Table 
6.1). Similar cloning procedures described earlier were adopted for the subsequent steps. 
QuikChangeTM Site-directed Mutagenesis Kit from Stratagene was used for the 
construction of Pfp23 single mutants. Primers were designed to introduce the desired 
mutations using PCR strategy described previously (Loke and Sim, 2001). The PCR cycling 
parameters used were: (1) 95˚C for 1 min, (2) 95˚C for 30 sec, (3) 48˚C-55˚C for 30 sec, (4) 
72˚C for 14 min, (5) 28 cycles of step 2 to 4 and (6) 72˚C for 5 min. The amplified plasmids 
were subsequently transformed into E. coli BL21 (DE3) cells with a RIG plasmid, and the 
bacterial clones carrying the desired Pfp23 mutant plasmids were identified by DNA 
sequencing.  
 
6.2.3 Expression and purification of Pfp23 and PfHsp90 recombinant proteins 
The expression and purification of Pfp23 and PfHsp90 (from pGK expression vector) 
recombinant proteins were carried out using the same protocol as described in Chapter 5, 
Section 5.2.3.  The procedures are summarized in Figure 6.1.  
 
 




6.2.4 Citrate synthase aggregation assay 
The intrinsic Hsp90-independent chaperone activity of Pfp23 was assayed based on 
the aggregation of citrate synthase using a slightly modified protocol. Porcine citrate 
synthase (Sigma) was dialyzed with 40 mM HEPES, pH7.5 buffer, overnight and concentrated 
to an 8.5 uM stock solution. Aggregation was induced by the incubation of citrate synthase 
(0.15 uM) in 40 mM HEPES, pH7.5 buffer, at 45°C. The assays were performed in the 
presence or absence of five-fold excess (0.75 uM) of Pfp23-WT and Pfp23-(220-275). The 
extent of aggregation was measured by the increase in absorbance due to light scattering 
and monitored at 334 nm using the Tecan Safire spectrophotometer. The absorbance was 
recorded every 2.5 min for 20 min.   
 
6.2.5 In vitro interaction assay between Pfp23 and PfHsp90  
The in vitro interaction of Pfp23 and PfHsp90 was investigated using GST pull-down 
assay. Ni2+ affinity purified dual-tagged PfHsp90 fusion protein expressed from the pGK 
vector was used as bait. For each experiment, 2 ug of PfHsp90 fusion protein was incubated 
with 50 ul of glutathione sepharose beads (GE Healthcare) at 4°C for 15 min. Following that, 
the beads were washed thrice with 50 mM Tris-HCl, pH7.5 buffer, to remove unbound 
proteins. Subsequently, the beads were reconstituted in 500 ul of binding buffer (50 mM 
Tris-HCl, pH7.5, 10 mM KCl, 2 mM dithiothreitol, 0.01% (v/v) Triton X-100). The binding 
assays were carried out in the presence of 5 mM MgCl2, 5 mM ATP and 10 ug of Pfp23, 
unless stated otherwise. Samples were incubated at 30°C for 30 min for PfHsp90-Pfp23 
complex formation. Thereafter, the samples were washed thrice with 500 ul of binding 
buffer prior to elution in 150 ul of reduced glutathione buffer. 50 ul of the eluted sample 
was analyzed by SDS-PAGE. Gel image analyses and densitometric measurements were 
performed using Bio-Rad Molecular Imager Gel Doc XR system equipped with the Quantity 
One® Software.   




6.2.6 Measurement of the ATPase activity of PfHsp90 in the presence of Pfp23 
To determine the effect of Pfp23 interaction on PfHsp90 ATPase activity, Pfp23 was 
added to the ATPase assay reactions as described previously (Chapter 5, Section 5.2.4) in 
increasing concentrations (2 to 30 uM). In addition, Pfp23 single mutants with differential 
binding capacity to PfHsp90 were also tested for their influence on PfHsp90 ATPase activity. 
The Pfp23 single mutants were added in ten-fold molar excess (20 uM) and their effects on 
the ATPase activity of PfHsp90 were compared to that of Pfp23-WT. All measurements were 
made using the Tecan Safire spectrophotometer. The ATPase activity reported was 
expressed as micromole of ATP hydrolysed per micromole of PfHsp90 in one minute at 37°C.       
 
6.2.7 Bio-computational analyses of Pfp23 and PfHsp90  
Pfp23 was analyzed using the same bio-computational tools employed for examining 
PfHsp90 (Chapter 5, Section 5.2.5). Similarly, Pfp23 was modelled against the yeast Hsp82-
Sba1 crystal structure complex (PDB accession number: 2CG9). The modelled Pfp23 and 
PfHsp90 were subsequently superimposed against the Hsp82-Sba1 crystal structure to 
obtain a predicted PfHsp90-Pfp23 complex. 
  




Table 6.1 Primers Designed for Pfp23 Cloning and Mutants Construction 
1Restriction enzyme sites are in lowercase; F represents forward primer; R represents reverse 
primer 
2Codon changes in Pfp23 are in bold and underlined 
 
  










T1 (25-275) F: ggatccATGATAGAAAATGTAAAGATTGACC 
T2 (50-275) F: ggatccATGATAGAAAATGTAAAGATTGACC 
T3 (75-275) F: ggatccATGATAATAAAAAAAGAACAAGAAAGATGG 
T4 (100-275) F: ggatccATGAACTCCTGGGTAGATACCGATG 
T5 (125-275) F: ggatccATGGGAGGTATGCCAGATATGAGTC 
Pfp23-(135-275) R: gtcgacAAATTGACTCATATCTGGCATACC 
Pfp23-(220-275) R: gtcgacATTCATATTATTCATATTAGGC 











































































Figure 6.1 Schematic illustration of the methodology employed for investigating the interaction 














2. Removal of unbound 





































1. 1st purification module:  
Ni2+ affinity chromatography 
3. Elution with 300 mM imidazole 
4. 2nd purification module: 






















6. Removal of unbound 
PfHsp90 by washing 
 
5. Immobilization of PfHsp90 on 
glutathione sepharose beads 7. Addition of Pfp23 in 
excess 
 
8. Removal of unbound 
Pfp23 by washing 
 
9. Elution of PfHsp90-Pfp23 
complex with reduced 
glutathione 
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6.3 Results  
6.3.1 Bio-computational analyses of the putative Pfp23 
P. falciparum genome encodes a putative p23 homologue (PF14_0510) of 275 amino 
acid residues. The Pfp23 was observed to possess the characteristic “Hsp20-like chaperone 
superfamily” domain (residues 2-106) and a C-terminal tail rich in acidic residues. The 
“Hsp20-like chaperone superfamily” domain which is also present in the yeast Sba1 is known 
to be important for Hsp82 interaction. Sequence homology analyses indicated that Pfp23 
exhibited only 19.6% and 23.6% sequence identities to the human p23 and yeast Sba1, 
respectively (Table 6.2). In addition, the putative Pfp23 (275 residues) has a longer protein 
sequence than the human p23 (160 residues) and yeast Sba1 (216 residues). Multiple 
sequence alignment further revealed the difference in protein length of Pfp23 lies in the 
presence of the unique tandem repeats, GNMGGLx7 (between amino acid residues 135 to 
176), and a longer C-terminal tail (Figure 6.2). Similar glycine-rich tandem repeats were also 
found in p23 of other Plasmodium species, namely Plasmodium chabaudi, Plasmodium 
berghei, Plasmodium yoelii and P. knowlesi. In comparison, the human p23 only possessed a 
GGD sequence, whereas the yeast Sba1 has two repeats of GGAGGA and a single GGAGGM 
sequence. So far, the significance of these glycine-rich sequences has yet to be reported and 
as such its functionality remains unknown. 
  




















 24.3 19.6 17.6 17.8 
Yeast Sba1 
(NP_012805.1) 
39.8  23.6 24.6 23.8 
P. falciparum 
(PF14_0510) 
33.8 43.6  72.3 70.4 
P. vivax 
(PVX_117795) 
34.6 44.4 82.5  93.2 
P. knowlesi 
(PKH_125280) 
35 46 82.2 97  
Percentage of primary sequence identity (highlighted in dark grey) 
Percentage of primary sequence similarity (highlighted in light grey) 




Yeast Sba1      MSDKVINPQVAWAQRSSTTDPERNYVLITVSIADCDAPELTIKPSYIELKAQSKPHVGDE 60 
Human p23       ----MQPASAKWYDR-------RDYVFIEFCVEDSKDVNVNFEKSKLTFSCLG----GSD 45 
Pfp23        ---MPLYPIVLWAQK-------KECLYLTIELQDIENVKIDLKEDKLYF-------YGTK 43 
                  . . * ::       :: : : . : * .  :: :: . : :        * . 
 
Yeast Sba1      NVHHYQLHIDLYKEIIPEKTMHKVANGQHYFLKLYKKDLESEYWPRLTKEKVKYPYIKTD 120 
Human p23       NFKHLN-EIDLFHCIDPNDSKHKRTD--RSILCCLRKGESGQSWPRLTKERAKLNWLSVD 102 
Pfp23        DKNEYEFTLNFLKPINVEESKYSTQR--NIKFKIIKK--EQERWKTLNND-GKKHWVKCD 98 
                   : :. :  ::: : *  :.: :.     .  :   :*  . : *  *.::  *  ::. * 
 
Yeast Sba1      FDKWVDEDEQDEV---------------------------------------------EA 135 
Human p23       FNNWKDWEDDSDE---------------------------------------------DM 117 
Pfp23        WNSWVDTDEEDKANDYDDMGMNSFGGMGGMPDMSQFGNMGGLGNMGGLGNMGGLGNMGGL 158 
                  ::.* * :::..                                                 
 
Yeast Sba1      EGNDAAQGMDFSQMMGGAGGAGGAGGMDFSQMMGG-------AGGAGSPDMAQLQQLLAQ 188 
Human p23       SNFDR-----FSEMMN---NMGGDEDVDLPEVDG-------------------------- 143 
Pfp23        GNMGGLGNMGGLGNMGGLGNMGGMGDLDFSKLGNMGGDMPNFAGLGGMDQFKNMPNMNNM 218 
                    . .          *.   . **  .:*:.:: .                           
 
Yeast Sba1      SGGNLDMGDFKENDEEDEEEEIEPEVKA----------------------------- 216 
Human p23       ----------ADDDSQDSDDEKMPDLE------------------------------ 160 
Pfp23        NDDDSSSYGDDTSDEEDDDDEEDEDVEVDNKTLDSDKLKDEENKIPDAAVEVQEPVA 275 
                               .*.:*.::*   :::                               
 
 
Figure 6.2 Protein sequence alignment of p23 and related sequences 
Protein sequences of human p23 (NP_006592.3) and yeast Sba1 (NP_012805.1) were 
obtained from GenBank whereas that of Pfp23 (PF14_0510) was retrieved from PlasmoDB. P. 
falciparum genome encodes a longer putative p23 homologue which shares only 19.6% and 
23.6% amino acid sequence identities to the human p23 and yeast Sba1, respectively. The 
glycine-rich GNMGGLx7 sequence repeats in Pfp23 were bold and underlined. * indicates 
identical amino acid residues in all the sequences; : indicates conserved amino acid 
substitutions; . indicates semi-conserved amino acid substitutions  
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6.3.2 Cloning, expression and purification of Pfp23 and PfHsp90 
To clone the putative Pfp23, RT-PCR was carried out using appropriate primers and 
mRNA from P. falciparum 3D7 (Chapter 6, Section 6.2.1). The amplified Pfp23 gene was 
inserted into the pET24a expression vector (Figure 6.3). Subsequently, DNA sequencing was 
performed to verify the authenticity of the gene. The recombinant plasmid was transformed 
into E. coli BL21 (DE3) harbouring the RIG plasmid.  
PfHsp90 was subcloned from the recombinant pET24a vector (Chapter 5, Section 
5.2.2) to another expression vector, pGK. The pGK vector allows the expression of a 
recombinant PfHsp90 with dual tags: a C-terminal His6-tag for protein purification purposes 
and an N-terminal GST-tag for GST pull-down assay that is to be carried out subsequently to 
investigate the interaction between PfHsp90 and the putative Pfp23. To carry out the 
subcloning, PfHsp90 was PCR-amplified from the recombinant pET24a plasmid using 
appropriate primers, purified, restriction digested and ligated into the pGK expression vector. 
The strategy employed is similar to that described for the cloning of PfHsp90 into the pET24a 
expression vector (Chapter 5, Section 5.2.2).     
Subsequently, Pfp23 and PfHsp90 were solubly expressed as recombinant proteins. 
Both the Pfp23 and PfHsp90 recombinant proteins were subjected to Ni2+ affinity 
chromatography and gel filtration separation. The recombinant Pfp23 was predicted to be 
approximately 36 kDa whereas the recombinant PfHsp90 expressed from the pGK vector 
was approximately 114 kDa as shown in the SDS-PAGE analyses (Figure 6.4).  
 
  















































Figure 6.3 Cloning of Pfp23 and PfHsp90 into expression vectors 
Pfp23 was PCR-amplified from the mRNA of P. falciparum and cloned into the pET24a 
expression vector. PfHsp90 was amplified from the pET24a recombinant vector carrying 





1. PCR-amplified Pfp23 
2. Restriction digested pCR-BluntII-TOPO-
Pfp23 recombinant plasmid 
3. Restriction digested pET24a-Pfp23 
recombinant plasmid 
4. Representation of pET24a-Pfp23 site-
directed mutagenesis PCR product 
5. PCR-amplified PfHsp90 
6. Restriction digested pET24a-PfHsp90 
recombinant plasmid 
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Figure 6.4 SDS-PAGE analyses of purified Pfp23 and PfHsp90 recombinant proteins 
A. Pfp23 was expressed from the pET24a vector as a recombinant protein with a C-terminal 
His6-tag. The Pfp23 recombinant protein was purified by Ni
2+ affinity chromatography 
followed by gel filtration separation. The Pfp23 recombinant protein was predicted to be 
approximately 36 kDa as shown in the SDS-PAGE analysis. B. PfHsp90 was expressed from 
the pGK vector as a recombinant protein with an N-terminal GST-tag and a C-terminal His6-
tag. The PfHsp90 recombinant protein was purified by Ni2+ affinity chromatography followed 
by gel filtration separation and subsequently tested for its ability to be purified through GST 
for subsequent GST pull-down assay. The recombinant PfHsp90 is predicted to be 














1. Protein marker (Biorad) 
2. Pfp23 after Ni2+ affinity chromatography 
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2. PfHsp90 after Ni2+ affinity 
chromatography purification 
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6.3.3 The recombinant Pfp23 possesses chaperone activity 
Prior to this study, the functionality of the putative Pfp23 has not been 
demonstrated. As the human p23 has been reported to possess anti-aggregation activity 
(Buchner et al., 1998), Pfp23 was examined for its intrinsic chaperone activity in preventing 
the aggregation of citrate synthase. Pfp23 was added to citrate synthase in a 5:1 molar ratio 
and incubated at 45°C. Aggregation of citrate synthase was detected by the increase in 
absorbance at 334 nm over a 20 min interaction time. 
In the absence of Pfp23, citrate synthase aggregated spontaneously at 45°C (Figure 
6.5). The addition of Pfp23 suppressed the aggregation of citrate synthase, as reflected by 
the decrease in absorbance reading. Similar anti-aggregation activity observed in human p23 
was abolished when its acidic C-terminal tail was truncated by 30 amino acid residues. To 
investigate whether the C-terminal tail of Pfp23 also contributes to anti-aggregation activity, 
a mutant clone of Pfp23 that lacks the C-terminal acidic residues was constructed. Deletion 
of the C-terminal tail in Pfp23-(220-275) resulted in a total loss of the anti-aggregation 
activity observed in Pfp23-WT, implying the requirement of the C-terminal tail for its full 
chaperone activity. No self-aggregation of Pfp23-WT and Pfp23-(220-275) was observed at 
45°C in the control experiments performed without citrate synthase.  
 
  



















Figure 6.5 The Pfp23 recombinant protein exhibited intrinsic chaperone activity 
The intrinsic chaperone activity of Pfp23 was determined by citrate synthase aggregation 
assay. Spontaneous aggregation of citrate synthase was monitored continuously over 20 min 
at 45°C by the increase in absorbance at 334 nm. Addition of Pfp23-WT suppressed the 
aggregation of citrate synthase. The anti-aggregation activity was abolished when Pfp23-WT 
was substituted with Pfp23-(220-275), which has a truncated C-terminal tail. Results shown 
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6.3.4 Pfp23 interaction with PfHsp90 is dependent on MgCl2 and ATP 
The role of Pfp23 as a co-chaperone of PfHsp90 in P. falciparum remained debatable 
as previous attempts to identify their interaction via co-immunoprecipitation techniques 
were unsuccessful. As such, their interaction was probed in this study using recombinant 
proteins and GST pull-down assays. Purified Pfp23 recombinant protein (10 ug) was added to 
PfHsp90 (2 ug) immobilized on glutathione sepharose beads and incubated either in the 
presence or absence of 5 mM MgCl2, 5 mM ADP and 5 mM ATP. Under the different 
conditions tested, the binding of Pfp23 to PfHsp90 was only observed in the presence of 
MgCl2 and ATP (Figure 6.6). Recombinant GST protein without PfHsp90 was used as a control 
to ensure that the recombinant tag did not contribute to the interaction observed. Pfp23 
binding was absent in the control experiments performed under similar conditions (Figure 
6.6).  
 
6.3.5 Pfp23 interaction with PfHsp90 is stable at high salt concentration 
 To investigate whether the interaction between Pfp23 and PfHsp90 is dependent on 
polar-polar and ion-pair interaction, the binding assay was carried out in the presence of 
increasing concentrations of KCl (10 mM to 500 mM). High salt concentration is known to 
disrupt polar-polar and ion-pair interaction by ‘insulating’ the charges on the protein 
through the salt ions, and hence preventing effective interaction between the two proteins. 
Pfp23-PfHsp90 association was observed to be stable at high salt concentration as their 
interaction can be observed at 500 mM KCl (Figure 6.7). The results indicated that the 
interaction between Pfp23 and PfHsp90 is unlikely to be dependent on charged or polar 
amino acid residues.   
  



































Figure 6.6 SDS-PAGE analyses of Pfp23 interaction with PfHsp90  
A. The interaction between Pfp23 and PfHsp90 was tested in the presence or absence of 5 
mM MgCl2, 5 mM ADP and 5 mM ATP as indicated. Pfp23 was bound to PfHsp90 only in the 
presence of MgCl2 and ATP. B. As a control, Pfp23 was tested for interaction with GST in a 
similar experimental set up. No interaction was observed between Pfp23 and GST in all the 
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Figure 6.7 SDS-PAGE analysis of Pfp23-PfHsp90 interaction in increasing salt concentration  
Pfp23-PfHsp90 binding assay was carried out in the presence of 5 mM MgCl2, 5 mM ATP and 
with increasing concentrations of KCl (10 mM to 500 mM). SDS-PAGE analysis revealed that 
the interaction between Pfp23 and PfHsp90 is stable in the presence of high salt 
concentration. Pfp23 was shown to be able to interact with PfHsp90 even in the presence of 
500 mM KCl, although lower amount of interaction was detected when compared to that 
with 10 mM KCl. The results indicated that the association between Pfp23 and PfHsp90 is 
unlikely to be due to polar-polar and ion-pair interaction.  Result shown is representative of 
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6.3.6 Sequential N-terminal truncation of Pfp23 affects interaction with PfHsp90 
As Pfp23 shares low amino acid sequence identities to the human p23 and yeast 
Sba1, its interaction with PfHsp90 may potentially differ from that of their homologues. 
Hence, the interaction between Pfp23 and PfHsp90 was further analyzed. Pfp23 was 
sequentially truncated by 25 amino acid residues from the N-terminal end to identify regions 
that are essential for binding PfHsp90 (Figure 6.8).  
A total of five Pfp23-truncated mutants (T1 to T5) were constructed, cloned, 
expressed and purified under similar conditions described for Pfp23-WT. All the truncated 
mutants were solubly expressed in E. coli BL21 (DE3). Pfp23-truncated mutants T1, T2 and T3 
retained their binding to PfHsp90, whereas further truncations in T4 and T5 abolished 
interaction with PfHsp90 (Figure 6.8). The results indicated that certain amino acid residues 
located between the 75th to 100th positions in Pfp23 are crucial for binding PfHsp90. To 
identify these amino acid residues, the corresponding region in yeast Sba1 was determined 
by primary sequence alignment and examined for the presence of Hsp82-interacting 
residues. Inspection of the region using the yeast Hsp82-Sba1 crystal structure complex 
revealed an interface in Sba1 (K113, Y114, P115, Y116, I117 and K118) which interacts with 
the closed ‘lid’ segment of Hsp82 (Figure 6.9). This interface corresponded to the amino acid 
residues K91, K92, H93, W94, V95 and K96 in Pfp23 and was observed to be in proximity to 
PfHsp90 in the modelled complex (Figure 6.9). Hence, these residues may potentially be 
essential for PfHsp90 interaction, such that when deleted (in Pfp23-truncated mutants T4), 






























Figure 6.8 Interaction between Pfp23-WT and truncated mutants with PfHsp90  
A. Schematic representation of the Pfp23-truncated mutants constructed in this study. A 25 
amino acids serial truncation was performed from the N-terminal end of Pfp23 (T1 to T5) to 
identify the region which is essential for binding PfHsp90. Pfp23-(220-275) was constructed 
to investigate the intrinsic chaperone activity of Pfp23. On the other hand, Pfp23-(135-275) 
was generated to determine whether the GNMGGLx7 sequence repeats are essential for 
PfHsp90 interaction. B. Purified Pfp23-WT and the respective truncated mutants were 
incubated with PfHsp90 in the presence of 5 mM MgCl2 and 5 mM ATP. Truncated mutants 
T4 and T5 were unable to bind PfHsp90, as shown in the SDS-PAGE analysis. Result shown is 
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Figure 6.9 Analyses of the modelled structures of Pfp23 and PfHsp90 
A. PfHsp90 and Pfp23 were modelled against the yeast Hsp82-Sba1 crystal structure 
complex (PDB accession number: 2CG9). The modelled Pfp23 shares similar structural 
features to Sba1 and possesses an extended loop (highlighted in grey) that is projected 
towards the closed ‘lid’ segment of PfHsp90. Only the N-terminal domains of PfHsp90 and 
Hsp82 were shown in the graphical presentation. B. Amino acid residues K91, K92, H93, W94, 
V95 and K96, located at the extended loop of Pfp23, were observed to be in proximity to the 
closed ‘lid’ segment of PfHsp90. Pfp23 residue H93 was observed to be in close contact with 
the hydrophobic residues F104 and I114 in PfHsp90 (top right). Similarly, the residue W94 in 
Pfp23 is directed towards residues I108 and M105 in PfHsp90 (bottom right). AMP-PNP: a 
non-hydrolysable analogue of ATP   
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6.3.7 Residues K91, H93, W94 and K96 in Pfp23 are essential for PfHsp90 interaction 
To investigate the importance of the amino acid residues K91, K92, H93, W94, V95 
and K96 in Pfp23 for PfHsp90 interaction, single mutants were generated. Firstly, Pfp23 
residues K91, K92 and K96 were each mutated to an alanine to examine the importance of 
the lysine side-chains for binding PfHsp90. As for residues H93 and W94, mutation to a polar 
serine residue was proposed to disrupt any hydrophobic interaction formed between Pfp23 
and PfHsp90. Similarly, the hydrophobic amino acid residue, V95, was mutated to a polar 
asparagine residue as a previous study showed that substitution at the corresponding 
position in Sba1 (I117N) abolished interaction with Hsp82 (Oxelmark et al., 2003). All the 
Pfp23 mutant proteins were solubly expressed, purified and tested for PfHsp90 interaction 
under similar binding conditions described for Pfp23-WT. Pfp23 mutants K91A, H93S, W94S 
and K96A displayed significant reduction in their binding to PfHsp90, retaining less than 25% 
of Pfp23-WT’s binding (Figure 6.10). This highlighted the importance of the residues K91, 
H93, W94 and K96 for interaction with PfHsp90. On the other hand, Pfp23 mutants K92A 
and V95N retained more than 85% of Pfp23-WT’s binding to PfHsp90, indicating that K92 
and V95 amino acid residues are not essential for PfHsp90 interaction.  
 
6.3.8 The GNMGGLx7 sequence repeats in Pfp23 are not essential for PfHsp90 interaction 
The protein sequence of Pfp23 contains the GNMGGLx7 sequence repeats which 
have yet to be functionally characterized. To determine if the sequence repeats are 
important for PfHsp90 interaction, two additional truncated mutants, Pfp23-(220-275) and 
Pfp23-(135-275), were constructed. The Pfp23-(220-275) mutant contained the 
GNMGGLx7 sequence repeats but lacked the C-terminal tail while Pfp23-(135-275) had 
both the sequence repeats and the C-terminal tail deleted (Figure 6.11). SDS-PAGE analysis 
showed that Pfp23-(220-275) retained interaction with PfHsp90. Similarly, further removal 
of the GNMGGLx7 sequence repeats in Pfp23-(135-275) did not affect the mutant’s 
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competency in binding PfHsp90. Hence, the results indicated that the GNMGGLx7 sequence 
repeats are not essential for PfHsp90 interaction. 

























Figure 6.10 Effects of Pfp23 mutations on PfHsp90 interaction 
A. Pfp23-WT and mutants were incubated with PfHsp90 in the presence of 5 mM MgCl2 and 
5 mM ATP. The complexes formed were analyzed by SDS-PAGE. B. The binding of Pfp23 
mutants to PfHsp90 was analyzed by densitometry. The percentage of PfHsp90 bound was 
calculated with respect to the PfHsp90 control (i) whereas Pfp23 mutants binding to PfHsp90 
was determined with respect to Pfp23-WT (ii). Statistical analysis was carried out using the 
Student’s t-test (* indicates p<0.05). Pfp23 single mutants K91A, H93S, W94S and K96A 
displayed significantly reduced binding to PfHsp90 whereas single mutants K92A and V95N 
retained comparable binding as Pfp23-WT to PfHsp90. Results shown are representative of 



























K91A K92A H93S W94S V95N K96A 
PfHsp90 
Pfp23 
(i)  (ii) 




































* * * 
* 
















Figure 6.11 SDS-PAGE analyses of Pfp23-(220-275) and Pfp23-(135-275) interactions 
with PfHsp90  
To investigate the importance of the GNMGGLx7 sequence repeats in Pfp23 for PfHsp90 
interaction, Pfp23-(135-275) was constructed. Using Pfp23-(220-275) mutant, the C-
terminal tail of Pfp23 was shown to be dispensable for PfHsp90 interaction. Further deletion 
of the GNMGGLx7 sequence repeats in Pfp23-(135-275) did not affect its binding to 
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6.3.9 Pfp23 inhibits the ATPase activity of PfHsp90 
The binding and hydrolysis of ATP are known to induce conformational changes in 
Hsp90, essential for the chaperoning of its client proteins. To determine whether the binding 
of Pfp23 affects the hydrolysis of ATP in PfHsp90, and henceforth, the regulation of its 
chaperone function, ATPase assay was carried out. The effect of Pfp23 interaction on 
PfHsp90 ATPase activity was investigated by the addition of Pfp23 in increasing 
concentrations to the Hsp90 ATPase assay reactions (Figure 6.12). Introduction of an 
equimolar concentration of Pfp23 had negligible effect on the ATPase activity of PfHsp90. 
However, when added in ten-fold molar excess, Pfp23 reduced the ATPase activity of 
PfHsp90 to approximately 20% of its original activity.  
To further verify whether the ATPase inhibitory effect was due to the interaction of 
Pfp23 with PfHsp90, Pfp23 single mutants with differential PfHsp90 binding levels were used. 
As expected, Pfp23 single mutants (K91A, H93S, W94S and K96A) which displayed drastically 
reduced PfHsp90 binding, had little inhibitory effect on the ATPase activity of PfHsp90 
(Figure 6.12). PfHsp90 retained approximately 90% of its ATPase activity in the presence of 
Pfp23 single mutants K91A, H93S and W94S, respectively. Nevertheless, Pfp23 single mutant 
K96A was able to suppress the ATPase activity of PfHsp90 to approximately 65% of its 
original activity. On the contrary, Pfp23 single mutants (K92A and V95N) that have similar 
binding capacity to PfHsp90 as Pfp23-WT, significantly inhibited the ATPase activity of 
PfHsp90 to approximately 35% of its original activity. The results clearly demonstrated the 
inhibitory effect that Pfp23 binding has on the ATPase activity of PfHsp90, and this may have 
significance in the regulation of PfHsp90 chaperone function in vivo.      
























Figure 6.12 Effects of Pfp23-WT and mutants on PfHsp90 ATPase activity 
A. Pfp23 was added in increasing concentrations to the ATPase assay reactions containing a 
fixed amount of PfHsp90 (2 uM). The ATPase activity of PfHsp90 was inhibited by Pfp23 in a 
concentration-dependent manner. At ten-fold molar excess, Pfp23 inhibited the ATPase 
activity of PfHsp90 to approximately 20% of its original activity. B. Pfp23 single mutants 
were tested for their ability to inhibit the ATPase activity of PfHsp90. Pfp23 single mutants 
known to have reduced binding to PfHsp90 (K91A, H93S, W94S and K96A) displayed 
negligible inhibitory effect on its ATPase activity. On the other hand, Pfp23 single mutants 
(K92A and V95N) that exhibited comparable binding to PfHsp90 as Pfp23-WT, inhibited 
PfHsp90 ATPase activity to approximately 35% of its original activity. Statistical analysis was 
carried out using the Student’s t-test (* indicates p<0.05). Pfp23-WT and mutants were 
added in ten-fold molar excess to PfHsp90 in all the assay reactions. Results shown are 
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6.4 Discussion  
Studies on co-chaperones are gaining increasing attention as they are known to 
regulate the chaperone function of the indispensable eukaryotic protein Hsp90 (Taipale et 
al., 2010). Recent studies have also revealed that the binding of certain co-chaperones to 
Hsp90 can alter the sensitivity of cells to Hsp90-specific inhibitors (Forafonov et al., 2008; 
Holmes et al., 2008; Piper et al., 2003), with potential implications on the use of the 
inhibitors as anti-cancer or anti-infective drugs. Given the important involvement of co-
chaperones in Hsp90’s activity, it is thus necessary to study their interaction in any effort to 
characterize the function and regulation of an Hsp90.  
In P. falciparum, PfHsp90 has thus far been demonstrated to form complexes with 
PfHsp70, PfPP5, PfFKBP35, PfCyp19, calcineurin and α-tubulin (Banumathy et al., 2003; 
Dobson et al., 2001; Kumar et al., 2005a; Kumar et al., 2005b). It is surprising that 
homologues of co-chaperones (e.g. p23, Aha1), that are known to be essential in regulating 
the chaperone function of Hsp90 in human and yeast, were not detected in those PfHsp90 
complexes isolated. Inevitably, this has raised doubts on the functional conservation of 
these putative co-chaperones in P. falciparum. As the interaction between p23 and Hsp90 is 
essential for client protein activation (McLaughlin et al., 2006; Richter et al., 2004), and 
recently shown to influence the sensitivity of yeast to Hsp90-specfic inhibitors (Forafonov et 
al., 2008), the interaction status of their homologues in P. falciparum may have implications 
on the modus operandi of PfHsp90 and its affinity for the drugs. Hence, the putative co-
chaperone Pfp23 was investigated for its interaction and regulation of PfHsp90.  
The purified Pfp23 recombinant protein was shown to possess intrinsic chaperone 
activity by virtue of its ability to suppress the aggregation of citrate synthase at 45°C. 
However, removal of the C-terminal tail of Pfp23 resulted in the loss of this anti-aggregation 
activity and attested to the need to have a full-fledged Pfp23 protein to elicit the chaperone 
activity. Pfp23 was subsequently probed for its interaction with PfHsp90 to assess its 
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potential role as a co-chaperone in P. falciparum. Using GST-pull down assays, Pfp23 was 
observed to bind PfHsp90 in the presence of MgCl2 and ATP. The conditions conducive for 
binding were similar to that of the human and yeast homologues, where Mg2+ ion is essential 
as a cofactor for ATP binding in Hsp90. Truncation experiments indicated that the unique 
GNMGGLx7 sequence repeats in Pfp23 are dispensable for PfHsp90 interaction. Instead, 
when coupled to computational analyses, the results from the truncation study suggested 
that the 91st to 96th amino acid residues in Pfp23 may form an essential interface for binding 
PfHsp90. This interface (consisting of amino acid residues K91, K92, H93, W94, V95 and K96) 
is located at an extended loop of Pfp23 and was observed to be in proximity to the closed 
‘lid’ segment of PfHsp90 (Figure 6.7). Site-directed mutagenesis experiments affirmed the 
importance of residues K91, H93, W94 and K96 for PfHsp90 interaction. Their respective 
single amino acid substitutions, K91A, H93S, W94S and K96A resulted in drastically reduced 
binding to PfHsp90. Conversely, Pfp23 mutants with K92A or V95N substitution displayed 
comparable PfHsp90 binding levels as Pfp23-WT. The effects of these mutations were 
analyzed by computationally modelled structures to further comprehend the molecular 
forces that are involved in their interaction.   
With the aid of modelled tertiary structures, the side-chains of K91, H93, W94 and 
K96 in Pfp23 were observed to be projected towards the closed ‘lid’ segment of PfHsp90 
(Figure 6.7). Under the in vitro binding conditions used (at pH7.5), the side-chain of the 
histidine residue (H93) would be uncharged, suggesting that the main force of interaction to 
be hydrophobic in nature. This was supported by the observation where its side-chain is 
located close to the hydrophobic residues, F104 and I114, of PfHsp90 (Figure 6.7). Similar 
hydrophobic interaction would be expected of Pfp23 residue W94, which was visualized to 
be in proximity to I108 and the aliphatic side chain of M105 in PfHsp90. Conceivably, 
substitutions of H93 and W94 to a polar serine residue, respectively, would disrupt the 
hydrophobic interaction and diminish binding to PfHsp90, as observed in this study.  
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Apart from that, in silico analyses of Pfp23 residues, K91 and K96, did not reveal any 
electrostatic interaction between the charged group in the lysine side-chains with PfHsp90 
residues. This is consistent with the observation where the interaction between Pfp23 and 
PfHsp90 was stable at high salt concentrations of up to 500 mM KCl (Figure 6.5), suggesting 
that electrostatic force plays a minor role in their interaction. Instead, results from the 
mutation study suggested that the long aliphatic side-chains of the lysine residues may be 
important in contributing to the hydrophobic interaction between Pfp23 residues, H93 and 
W94, with PfHsp90. Substitution to an alanine with a much shorter side-chain would greatly 
diminish the hydrophobicity and proximity required for binding PfHsp90 and these may 
account for the lack of PfHsp90 interaction as observed. 
On the contrary, the Pfp23 mutant K92A retained similar PfHsp90 binding capacity 
as that of the Pfp23-WT. This implies that the residue K92 is not essential for PfHsp90 
interaction. Likewise, replacing V95 with an asparagine resulted in a mutant that retained 
comparable binding to PfHsp90 as the Pfp23-WT. This result is surprising as the 
corresponding mutation in yeast Sba1 (I117N) had rendered it defective in binding Hsp82 
(Oxelmark et al., 2003). However, using the modelled structures, the side chain of V95 was 
observed to be projected away from PfHsp90. In view of this, Pfp23 mutant V95N ability to 
retain its binding to PfHsp90 is likely to be attributed to the lack of interaction between the 
amino acid residue V95 and PfHsp90.  
The results of the truncation study have also highlighted that a large segment of 
Pfp23’s N-terminal domain (1st to 74th amino acid residues) can be deleted without affecting 
its interaction with PfHsp90. This segment corresponds to the region in Sba1 (1st to 93rd 
amino acid residues) where three other Hsp82-interacting interfaces (amino acid residues 
13-16, 31-37, 85-91) were found. It is difficult to postulate whether the deletion of these 
interfaces in Sba1 (similar to that of Pfp23-truncated mutants T4) would affect Hsp82 
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interaction, as only a few amino acid residues located at these interfaces were conserved at 
the corresponding positions in Pfp23.  
Probing into the significance of Pfp23 binding on PfHsp90 function, results from the 
ATPase assays revealed that Pfp23 is capable of suppressing the hydrolysis of ATP by 
PfHsp90. The ATPase inhibitory effect of Pfp23 is positively correlated with its binding 
capacity to PfHsp90. Pfp23 single mutants (K91A, H93S, W94S and K96A) that were defective 
in binding PfHsp90 were unable to inhibit PfHsp90 ATPase activity as effectively as Pfp23-WT. 
The observation is consistent with that reported for the human and yeast homologues, and 
it was suggested that the binding of p23 traps Hsp90 in the ATP-bound state and prolongs its 
interaction with the client proteins (McLaughlin et al., 2006). Nevertheless, it is noteworthy 
that the ATPase inhibitory effect was only observed when Pfp23 was added in large molar 
excess. While this may indicate limitations of the in vitro environment for stable binding of 
Pfp23 to PfHsp90, it may also highlight the transient interaction between the two proteins. 
Coupled with semi-quantitative mass spectrometry data which suggested that Pfp23 is 
present at a low physiological concentration in P. falciparum (Florens et al., 2002; Prieto et 
al., 2008), these observations could explain why previous studies were unsuccessful in 
identifying PfHsp90-Pfp23 complex through co-immunoprecipitation techniques (Banumathy 
et al., 2003; Wiser, 2003). 
Taken together, this part of the study has demonstrated that P. falciparum encodes 
a functional Pfp23 co-chaperone with potential regulatory effect on the chaperone activity 
of PfHsp90 in vivo, through modulation of the ATPase activity of the chaperone. In addition, 
the GST pull-down methodology adopted was shown to be feasible and useful for the study 
of PfHsp90’s interaction partners. As such, this approach can be exploited to investigate 
other putative co-chaperones’ interaction that may not have been detected in previous 
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In the previous Chapter, PfHsp90 was investigated for its interaction with the co-
chaperone Pfp23. Pfp23 was shown to interact with PfHsp90 and in the process inhibited the 
ATPase activity of the chaperone (Chua et al., 2010). The ATPase inhibitory effect of 
p23/Sba1 has been postulated to be important in prolonging the interaction between Hsp90 
and the client protein to facilitate the latter’s activation. Several other co-chaperones in 
human and yeast, such as Hop/Sti1 and p50/Cdc37, have also been demonstrated to inhibit 
the ATPase activity of Hsp90 to facilitate the protein folding activity of Hsp90 in the 
chaperone cycle (Prodromou et al., 1999; Siligardi et al., 2002; Song and Masison, 2005). 
While the ATPase inhibitory effect exerted by co-chaperones on Hsp90 is commonly 
observed, the reverse is relatively rare. So far, only two co-chaperones have been shown to 
be capable of activating the ATPase activity of Hsp90 (Panaretou et al., 2002). One of them is 
Aha1 (Activator of Hsp90 ATPase), a co-chaperone that associates with Hsp90 at the late 
stage of the chaperone cycle.  
Aha1 was initially discovered as a homologue of S. cerevisiae Hch1, a suppressor of 
growth defect observed in temperature sensitive yeast strain carrying mutant Hsp82 with 
E381K substitution (Nathan et al., 1999; Panaretou et al., 2002). Yeast Aha1, a 350-residue 
protein, has an N-terminal domain that shares 36.5% amino acid identity with Hch1, a 
smaller protein of 153 residues. Aha1 was suspected to function as a co-chaperone of Hsp82 
as it exhibited similar transcription and expression profiles to that of other known yeast co-
chaperones (Sti1 and Cpr6) and chaperone (Hsp70) under induced stress conditions. This 
was subsequently verified experimentally where Aha1 was demonstrated to interact with 
Hsp82 and activate its ATPase activity (Panaretou et al., 2002).  
Gene deletion studies in yeast indicated that both Aha1 and Hch1 are non-essential 
for viability, although temperature sensitive phenotypes were observed in the single and 
double deletion strains constructed i.e. Δaha1, Δhch1 and Δaha1-Δhch1 (Lotz et al., 2003; 
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Panaretou et al., 2002). Nevertheless, the deletion of Aha1 significantly impaired the 
activation of glucocorticoid receptor and v-Src kinase in yeast, suggesting that the presence 
of the co-chaperone is essential for functional maturation of these Hsp82 client proteins 
(Lotz et al., 2003; Meyer et al., 2003). Similar observation was made in an siRNA study 
conducted on mammalian cell culture where downregulation of Aha1 led to drastically 
reduced level of activated glucocorticoid receptors (Harst et al., 2005). Together with the 
observed role in activating Hsp90’s ATPase activity, Aha1 has been proposed as a positive 
regulator of Hsp90’s chaperone function, whose association with Hsp90 is important in 
driving certain client proteins towards their activated states.      
Crystallographic and truncation studies have mapped the interaction site of Aha1 to 
the middle domain of Hsp90 (Meyer et al., 2004a). In the crystal structure of yeast Hsp82’s 
middle domain complexed with the N-terminal domain of Aha1, a subtle structural 
rearrangement was observed at a loop of Hsp82 that contains the residue R380. This 
conformational change allows the residue R380 to contact the ATP bound at the N-terminal 
domain of Hsp82, leading to enhanced ATP hydrolysis. In a recent study, the interaction 
between Aha1 and Hsp90 was further investigated by NMR using full-length proteins 
(Retzlaff et al., 2010). Surprisingly, the previously uncharacterized C-terminal domain of 
Aha1 was found to bind to the N-terminal domain of Hsp90. The contact made by the C-
terminal domain of Aha1 was proposed to be essential in promoting a ‘closed’ Hsp90 
conformation state that is competent in hydrolyzing ATP. This was supported by the 
observation that a full-length Aha1 is required for maximal activation of Hsp90’s ATPase 
activity (Panaretou et al., 2002; Retzlaff et al., 2010). In addition, in vitro interaction 
experiments have also demonstrated the binding of Aha1 to Hsp90 to be competitive with 
that of co-chaperones Hop/Sti1 and p50/Cdc37 that bind Hsp90 at the early stages of the 
chaperone cycle, as well as p23/Sba1 that interacts at the late stage of the cycle (Harst et al., 
2005).  
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In P. falciparum, a putative Aha1 (PfAha1; PlasmoDB accession number: PFC0270w) 
that shares approximately 20% amino acid sequence identity with that of the yeast 
homologue has been described in a computational study (Kumar et al., 2007). As the 
putative PfAha1 has not been characterized prior to this study, its role as a co-chaperone of 
PfHsp90 remains unclear. Similar to Pfp23, previous co-immunoprecipitation and genome-
wide yeast two-hybrid studies were unable to provide evidence on the interaction between 
PfHsp90 and the putative PfAha1. In view of the importance of Aha1 in the yeast and human 
Hsp90 chaperone systems for client protein activation, the putative PfAha1 was investigated 
for its interaction and regulation of PfHsp90 using the methodology established earlier for 
examining PfHsp90-Pfp23 association. 
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7.2 Materials and Methods  
7.2.1 Cloning of PfAha1 for recombinant protein production 
PfAha1 (PlasmoDB ID: PFC0270w) was reverse transcribed and amplified from the 
mRNA of P. falciparum 3D7 using appropriate forward and reverse primers (Table 7.1) in a 
process similar to that described for PfHsp90 (Chapter 5, Section 5.2.2). The PCR-amplified 
DNA product was similarly separated by agarose gel electrophoresis and purified using 
MinEluteTM Gel Extraction Kit (Qiagen). The purified PfAha1 gene was subsequently double-
digested with restriction enzymes BamHI and XhoI, and ligated into the expression vector 
pET24a which has been treated with the same set of restriction enzymes. The ligated 
recombinant plasmid was transformed into E. coli BL21 (DE3) cells with a RIG plasmid for 
recombinant protein expression. DNA sequencing was performed to authenticate the 
recombinant clone that carried PfAha1.  
 
7.2.2 Construction of PfAha1 single, double and quadruple mutants 
Similar to the strategy employed for the construction of Pfp23 mutants, 
QuikChangeTM Site-directed Mutagenesis Kit from Stratagene was used for the construction 
of PfAha1 single mutants, using the recombinant pET24a plasmid that carried PfAha1 as a 
template. Appropriate primers were designed (Table 7.1) and the desired mutations were 
introduced using the following PCR cycling parameters: (1) 95˚C for 1 min, (2) 95˚C for 30 sec, 
(3) 48˚C-55˚C for 30 sec, (4) 72˚C for 14 min, (5) 28 cycles of step 2 to 4 and (6) 72˚C for 5 
min. The amplified plasmids were subsequently transformed into E. coli BL21 (DE3) cells with 
a RIG plasmid, and the bacterial clones carrying the desired PfAha1 mutant plasmids were 
identified by DNA sequencing. PfAha1 double and triple mutants were respectively 
constructed from verified PfAha1-containing plasmids with single and double mutations, 
using the appropriate mutagenic primers.   
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7.2.3 Expression and purification of PfHsp90, Pfp23 and PfAha1 recombinant proteins 
The expression and purification of PfHsp90 and Pfp23 recombinant proteins have 
been described (Chapter 6, Section 6.2.3). The expression conditions and purification 
strategy used for Pfp23 were employed for obtaining purified PfAha1 recombinant proteins 
(Figure 7.1).  
 
7.2.4 In vitro interaction assay between PfHsp90 and PfAha1 
GST pull-down assay was employed to investigate the interaction between PfHsp90 
and PfAha1. The purified dual-tagged PfHsp90 fusion protein (with an N-terminal GST-tag 
and a C-terminal His6-tag) expressed from the pGK vector was used as bait to capture 
interacting PfAha1 recombinant protein. In each 500-ul reaction, 2 ug PfHsp90 fusion protein 
was incubated with 50 ul of glutathione sepharose beads (GE Healthcare) at 4°C for 15 min. 
Following that, the beads were washed thrice with 50 mM Tris-HCl, pH 7.5 buffer, to remove 
unbound proteins. Subsequently, the beads were reconstituted in 500 ul of binding buffer 
(50 mM Tris-HCl, pH7.5, 25 mM KCl, 2 mM dithiothreitol, 0.01% (v/v) Triton X-100). The 
binding assay was carried out in the presence or absence of 5 mM MgCl2, 5 mM ADP and 5 
mM ATP, with an excess of 41 ug of PfAha1 (2 uM). Samples were incubated at 30°C for 30 
min to allow any formation of PfHsp90-PfAha1 complex. In the case of competitive binding 
assays between PfAha1 and Pfp23, this was followed by the addition of 0.1 uM to 4 uM 
Pfp23 and incubated for an additional 30 min at 30°C. Thereafter, the samples were washed 
thrice with 500 ul of binding buffer prior to elution in 150 ul of reduced glutathione buffer. 
50 ul of the eluted sample was analyzed by SDS-PAGE. Gel image analyses and densitometric 
measurements were performed using Bio-Rad Molecular Imager Gel Doc XR system 
equipped with the Quantity One® Software. 
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7.2.5 Measurement of the ATPase activity of PfHsp90 in the presence of PfAha1 
The ATPase activity of PfHsp90 was measured using the pyruvate kinase/lactate 
dehydrogenase-coupled assay as described previously with some modifications. As the 
interaction between PfHsp90 and PfAha1 is salt-sensitive, a low KCl concentration was used 
to promote their interaction. Briefly, the assay was carried out in a 200-ul reaction 
containing 2 uM PfHsp90, 25 mM Tris-HCl pH7.5, 4 mM KCl, 1.2 mM MgCl2, 0.8 mM ATP, 2 
mM phosphoenolpyruvate, 0.2 mM NADH, 50 ug/ml lactate dehydrogenase and 0.2 mg/ml 
pyruvate kinase. To determine the effect of PfAha1 binding on the ATPase activity of 
PfHsp90, PfAha1 was added in increasing concentrations (0.1 uM to 2 uM) to the assay 
reaction containing a fixed concentration of PfHsp90 (2 uM). Radicicol was used at a final 
concentration of 200 uM to specifically inhibit the ATPase activity of PfHsp90 for accurate 
determination of its ATP turnover rate. The ATPase activity reported was expressed as 
micromole of ATP hydrolysed per micromole of PfHsp90 in one minute at 37°C.       
 
7.2.6 Bio-computational analyses of PfHsp90 interaction with PfAha1  
PfAha1 was analyzed using the same bio-computational tools employed for 
examining PfHsp90 (Chapter 5, Section 5.2.5). A modelled PfHsp90-PfAha1 complex was 
constructed using the crystal structure of PfAha1 (PDB accession number: 3N72) and the 
modelled PfHsp90 tertiary structure (Chapter 5, Section 5.2.5). The PfAha1 crystal structure 
and the modelled PfHsp90 were superimposed against the yeast Hsp82-Aha1 crystal 
structure complex (PDB accession number: 1USV) to obtain a predicted PfHsp90-PfAha1 
complex.  
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Table 7.1 Primers Designed for PfAha1 Cloning and Mutants Construction 
1Restriction enzyme sites are in lowercase; F represents forward primer; R represents reverse 
primer 
2 Codon changes in PfAha1 are in bold and underlined 
 
  
Gene constructs Primer sequence1 (5’ to 3’) 
PfAha1 (PFC0270w) 







































































































Figure 7.1 Schematic illustration of the methodology employed for investigating the interaction 
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1. 1st purification module: 
Ni2+ affinity chromatography 
3. Elution with 300 mM imidazole 
4. 2nd purification module: 







6. Removal of unbound 
PfHsp90 by washing 
 
5. Immobilization of PfHsp90 on 
glutathione sepharose beads 7. Addition of PfAha1 in 
excess 
 
8. Removal of unbound 
PfAha1 by washing 
 
9. Elution of PfHsp90-
PfAha1 complex with 
reduced glutathione 
 

























7.3 Results  
7.3.1 P. falciparum genome encodes two putative Aha1 
Homology search revealed two putative copies of Aha1 in the genome of P. 
falciparum, namely PFC0270w and PFC0360w. PFC0270w encodes a 349 amino acid protein 
that shares approximately 20% amino acid identity with the human and yeast Aha1 (Table 
7.2). On the other hand, PFC0360w is relatively shorter with 140 amino acid residues and 
displayed only 13.9% and 12% amino acid identities with the human and yeast Aha1 
respectively. The proteins of both putative homologues of Aha1 were detected in the intra-
erythrocytic stages of P. falciparum (Le Roch et al., 2003). Multiple sequence analysis further 
revealed that the shorter PFC0360w is aligned to the C-terminal portion of the human and 
yeast Aha1 (Figure 7.2) with no homologous N-terminal domain. As the N-terminal domain 
of Aha1 has been shown to be important for interaction and inducing structural 
rearrangement in Hsp90 to promote ATP hydrolysis (Meyer et al., 2003; Meyer et al., 2004b), 
the lack of a homologous N-terminal domain in PFC0360w has prompted the study to focus 
on the characterization of PFC0270w, the longer putative copy of Aha1 in P. falciparum 
(PfAha1 refers to PFC0270w hereafter). Moreover, the crystal structure of the N-terminal 
domain of PFC0270w (PDB accession number: 3N72; deposited in 2010, yet to be published) 
was recently resolved, and thus warrants investigation on its functionality as a co-chaperone 
of PfHsp90.   
 
7.3.2 Expression and purification of recombinant PfAha1 and PfHsp90 
To investigate whether the putative PfAha1 is a co-chaperone of PfHsp90, PfAha1 
was cloned and expressed as a recombinant protein for interaction study with PfHsp90 
(Figure 7.3A). The cloning, expression and purification of dual-tagged PfHsp90 recombinant 
protein for interaction study has already been described previously (Chapter 6, Sections 
6.2.1 and 6.2.3). PfAha1 was expressed and purified as a recombinant fusion protein with a 




C-terminal His6-tag of approximately 44 kDa whereas PfHsp90 as a 114 kDa dual-tagged 
fusion protein with an N-terminal GST-tag and a C-terminal His6-tag (Chua et al., 2010) 
(Figure 7.3B).  
 
  






















(NP_036243.1)  25.1 20 13.9 18.6 20.3 
Yeast Aha1 
(NP_010500.1) 48.6  20.1 12 21.3 21.9 
P. falciparum 
(PFC0270w) 42.1 44.9  14.9 56.1 61.9 
P. falciparum 
(PFC0360w) 23.1 22.3 21.5  11.2 12.1 
P. vivax 
(PVX_119435) 40.8 40.8 73.2 18.5  81 
P. knowlesi 
(PKH_083370) 42.5 43.4 78.3 20.3 86.6  
Percentage of primary sequence identity (highlighted in dark grey) 
Percentage of primary sequence similarity (highlighted in light grey) 
The primary sequences of Aha1 from P. malariae and P. ovale are not available 
  







Human-Aha1      MAKWGEGDPRWIVEERADATNVNNWHWTERDASNWSTDKLKTLFLAVQVQNEEGK--CEV 58 
Yeast-Aha1      ----------------MVVNNPNNWHWVDKNCIGWAKEYFKQKLVGVEAGSVKDKKYAKI 44 
PFC0270w        --------------MSGSVWNSNSWHWEERNYNKWAESYIKYNLSNLKIEKEDLTIYFDN 46 
                                  . * *.*** :::   *: . :*  :  ::  . . .   .  
 
Human-Aha1      TEVSKLDGEASINNRKGKLIFFYEWSVKLNWTGTSKS----GVQYKGHVEIPNLS-DENS 113 
Yeast-Aha1      KSVSSIEGDCEVNQRKGKVISLFDLKITVLIEGHVDSKDGSALPFEGSINVPEVA-FDSE 103 
PFC0270w        LQVS---GNACVSIRKGKQINSFEYIIKFEWLYSKKKE--GKDYFGGSVEIPDFSTFSLE 101 
                 .**   *:. :. **** *  ::  :..      ..       : * :::*:.:  . . 
 
Human-Aha1      VDEVEISVSLAKDEPD--TNLVALMKEEGVKLLREAMGIYISTLKTEFTQGMILPTMNGE 171 
Yeast-Aha1      ASSYQFDISIFKETSEL-SEAKPLIRSELLPKLRQIFQQFGKDLLATHGNDIQVPESQVK 162 
PFC0270w        ENDYAINIERTDESENLRFIYDSILKKEGKEKIKECLKNFQEDLLKHDKNESNKELKIKE 161 
                 ..  :.:.  .:  :      .:::.*    ::: :  : . *     :         : 
 
Human-Aha1      SVDPVGQPALKTEERKAKPAPSKTQARPVG----------VKIP------TCKITLKETF 215 
Yeast-Aha1      SNYTRGNQKSSFTEIKDSASKPKKNALPSSTSTSAPVSSTNKVPQNGSGNSTSIYLEPTF 222 
PFC0270w        EEKIKLENIKTCNEKKTEEENKSNQNINNNINDEKKEGSVWNINNYHWEEKCLTKWAIEE 221 
                .     :   .  * * .    ..:    .           ::       .          
 
Human-Aha1      LTSPEELYRVFTTQELVQAFTHAPATLEAD----RGGKFHMVDGNVSGEFTDLVPEKHIV 271 
Yeast-Aha1      NVPSSELYETFLDKQRILAWTRSAQFFNSGPKLETKEKFELFGGNVISELVSCEKDKKLV 282 
PFC0270w        LQNIFNKSIIELSNNIFLEFFSCDVEGEASSSLRKKKKILMYDLKITSEWKAYQKNKNQQ 281 
                     :       :: .  :  .    ::.       *: : . :: .*      :*:   
 
Human-Aha1      MKWRFKSWPEGHFATITLTFIDKN--GETELCMEGRGIPAPEEERTRQGWQRYYFEGIKQ 329 
Yeast-Aha1      FHWKLKDWSAPFNSTIEMTFHESQEFHETKLQVKWTGIPVGEEDRVRANFEEYYVRSIKL 342 
PFC0270w        IEIESKGHVS-INDILSDFSSDDNTKYSYYFIFDNKTDEYNQINDVIKLEGPNKINQIID 340 
                :. . *.        :     :.:   .  : ..       : : .        .. *   
 
Human-Aha1      TFGYGARLF 338 
Yeast-Aha1      TFGFGAVL- 350 
PFC0270w        DFILKMREK 349 
                 *        
B. 
 
Human-Aha1      MAKWGEGDPRWIVEERADATNVNNWHWTERDASNWSTDKLKTLFLAVQVQNEEGK--CEV 58 
Yeast-Aha1      ----------------MVVNNPNNWHWVDKNCIGWAKEYFKQKLVGVEAGSVKDKKYAKI 44 
PFC0360w        ------------------------------------------------------------ 
                                                                             
 
Human-Aha1      TEVSKLDGEASINNRKGKLIFFYEWSVKLNWTG----TSKSGVQYKGHVEIPNLSDENSV 114 
Yeast-Aha1      KSVSSIEGDCEVNQRKGKVISLFDLKITVLIEGHVDSKDGSALPFEGSINVPEVAFDSEA 104 
PFC0360w        ------------------------------------------------------------ 
                                                                             
 
Human-Aha1      DEVEISVSLAKDEPDT-NLVALMKEEGVKLLREAMGIYISTLKTEFTQGMILPTMNGESV 173 
Yeast-Aha1      SSYQFDISIFKETSELSEAKPLIRSELLPKLRQIFQQFGKDLLATHGNDIQVPESQVKSN 164 
PFC0360w        ------------------------------------------------------------ 
                                                                             
 
Human-Aha1      DPVGQPALKTEERKAKPAPSKTQARPVGVKIPT----------------CKITLKETFLT 217 
Yeast-Aha1      YTRGNQKSSFTEIKDSASKPKKNALPSSTSTSAPVSSTNKVPQNGSGNSTSIYLEPTFNV 224 
PFC0360w        -------------------------------------------------MSFEITEEYYV 11 
                                                                  .: :   : . 
 
Human-Aha1      SPEELYRVFTTQELVQAFTH----APATLEADRGGKFHMVDGNVSGEFTDLVPEKHIVMK 273 
Yeast-Aha1      PSSELYETFLDKQRILAWTRSAQFFNSGPKLETKEKFELFGGNVISELVSCEKDKKLVFH 284 
PFC0360w        PPEVLFNAFTDAYTLTRLSRG---SLAEVDLKVGGKFSLFSGSILGEFTEITKPHKIVEK 68 
                ... *:..*     :   ::      :  . .   ** :..*.: .*:..    :::* : 
 
Human-Aha1      WRFKSWPEGHFATITLTFIDKNG--ETELCMEGRGIPAPEE-------ERTRQGWQRYYF 324 
Yeast-Aha1      WKLKDWSAPFNSTIEMTFHESQEFHETKLQVKWTGIPVGEE-------DRVRANFEEYYV 337 
PFC0360w        WKFRDWNECDYSTVTVEFISVKEN-HTKLKLTHNNIPASNKYNEGGVLERCKNGWTQNFL 127 
                *:::.*     :*: : * . :   .*:* :   .**. ::       :* : .: . :. 
 
Human-Aha1      EGIKQTFGYGARLF 338 
Yeast-Aha1      RSIKLTFGFGAVL- 350 
PFC0360w        HNIEVILGYPKKK- 140 
                ..*:  :*:      
 
  Figure 7.2 Protein sequence alignment of human, yeast and putative P. falciparum Aha1  
P. falciparum genome encodes two putative Aha1, PFC0270w and PFC0360w. When aligned 
with the human Aha1 (NP_036243.1) and yeast Aha1 (NP_010500.1), (A) PFC0270w 
displayed high homology to the N-terminal domain whereas the shorter homologue (B) 
PFC0360w mapped to the C-terminal domain.  * indicates identical amino acid residues in all 
the sequences; : indicates conserved amino acid substitutions; . indicates semi-conserved 
amino acid substitutions  
 


















































Figure 7.3 Cloning and expression of PfAha1 recombinant protein 
A. PfAha1 was amplified from the mRNA of P. falciparum by RT-PCR and subsequently 
cloned into the expression vector pET24a. B. The PfAha1 recombinant protein was shown to 










1. Protein marker (Biorad) 
2. PfAha1 after Ni2+ affinity chromatography 








1. PCR-amplified PfAha1 
2. Restriction digested pET24a-PfAha1 
recombinant vector 
3. Representation of pET24a-PfAha1 site-
directed mutagenesis PCR product 
 





























7.3.3 PfAha1 interaction with PfHsp90 is dependent on MgCl2 and ATP 
The interaction between PfAha1 and PfHsp90 was probed using GST pull-down assay 
where 2 ug of PfHsp90 was immobilized on glutathione sepharose beads and used to pull-
down PfAha1 that was added in an excess of 41 ug. PfHsp90’s association with the putative 
PfAha1 was tested in various conditions, either in the presence or absence of 5 mM MgCl2, 5 
mM ADP and 5 mM ATP. Under the different conditions tested, the interaction between 
PfHsp90 and PfAha1 was only observed in the presence of MgCl2 and ATP (Figure 7.4). No 
interaction was detected between PfAha1 and GST in the controls performed under similar 
experimental conditions.    
 
7.3.4 PfAha1 and PfHsp90 interaction is disrupted under high salt condition 
Previous study on yeast indicated that the interaction between Aha1 and Hsp82 was 
sensitive to high salt concentration (Panaretou et al., 2002). To test whether the binding of 
PfAha1 to PfHsp90 is also affected by high salt content, their association was investigated 
using buffers with increasing salt concentrations i.e. 10 mM, 25 mM, 50 mM, 75 mM, 100 
mM, 125 mM and 150 mM KCl. At a low concentration of KCl (i.e. 10 mM), PfAha1 was 
bound to PfHsp90 as expected. However, in the presence of increasing concentrations of KCl 
(25 mM to 100 mM KCl), the association between PfAha1 and PfHsp90 was progressively 
reduced (Figure 7.5). At 150 mM KCl, the interaction between PfAha1 and PfHsp90 was 
almost completely disrupted. The observed results indicated that the association between 
PfAha1 and PfHsp90 may be dependent on ion-pair and/or polar-polar interaction mediated 
by charged and/or polar amino acid residues in the two proteins.     
 
  











































Figure 7.4 SDS-PAGE analyses of the interaction between PfAha1 and PfHsp90  
A. GST pull-down assay was employed to investigate the interaction between PfAha1 and 
PfHsp90. In each 500-ul reaction, 2 ug PfHsp90 was immobilized on 50-ul glutathione 
sepharose beads and used to pull-down PfAha1 that was added in an excess of 41 ug. The 
assay was performed either in the presence or absence of 5 mM MgCl2, 5 mM ADP and 5 
mM ATP. The interaction between PfAha1 and PfHsp90 was only observed in the presence 
of MgCl2 and ATP. B. As a control, PfAha1 was tested for interaction with GST in a similar 
experimental set up. No interaction was observed between PfAha1 and GST in all the 
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Figure 7.5 Interaction between PfAha1 and PfHsp90 is sensitive to disruption by high salt 
concentration 
A. To investigate whether the association between PfAha1 and PfHsp90 is dependent on 
polar-polar and ion-pair interaction, the PfAha1-PfHsp90 binding assay was carried out in 
the presence of 5 mM MgCl2, 5 mM ATP and with increasing concentrations of KCl (10 mM 
to 150 mM). SDS-PAGE analysis revealed a gradual reduction in the level of PfAha1 bound to 
PfHsp90 when KCl was introduced in increasing concentrations. B. The effect of KCl on 
PfAha1 binding to PfHsp90 was analyzed by densitometry. The percentage of PfHsp90 bound 
was calculated with respect to the sample with PfHsp90 only; PfAha1 with respect to the 
PfAha1 bound to PfHsp90 at 10 mM KCl. At 150 mM KCl, the interaction between PfAha1 
and PfHsp90 is significantly disrupted. Statistical analysis was carried out using the Student’s 












































































PfHsp90 + PfAha1 + KCl (increasing concentrations) 
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7.3.5 Mutational effects of residues E15, R58, E67, D94 and K127 in PfAha1 on PfHsp90 
interaction  
The crystal structure of yeast Aha1 complexed with Hsp82 (PDB accession number: 
1USV) revealed two interacting interfaces involving polar amino acid residues in Aha1 that 
are important for binding Hsp82 i.e. (1) residues D53, D68, E97, D101 (interact with residues 
K387, K390, K394, K398 in Hsp82) and (2) residues E122, D110 and R128 (interact with 
residues K469, K514, E515 in Hsp82). Of these residues, three were found to be conserved in 
PfAha1 by sequence alignment, namely, E67 (D68 in yeast Aha1), D94 (E97 in yeast Aha1) 
and K127 (R128 in yeast Aha1) (Figure 7.2). In addition, analyses of the modelled complex of 
PfHsp90-PfAha1 structure revealed two additional charged residues in PfAha1, E15 and R58, 
that could potentially interact with PfHsp90. Hence, to investigate whether these conserved 
charged amino acid residues in PfAha1 are essential in forming ion-pair interaction with 
PfHsp90, site-directed mutagenesis was carried out where alanine substitutions were 
introduced to replace the highlighted residues. The PfAha1 single mutants E15A, R58A, E67A, 
D94A and K127A were solubly expressed, purified and their respective ability to interact 
with PfHsp90 was tested and compared to that of PfAha1 wild-type (PfAha1-WT).      
Results from the GST pull-down assay showed that these PfAha1 single mutants had 
comparable PfHsp90 binding capacity as PfAha1-WT (Figure 7.6A), indicating that single 
amino acid mutation at these residues did not affect PfAha1’s interaction with PfHsp90. To 
further evaluate the effect of these substitutions, the mutations were combined and the 
resulting PfAha1 mutants were respectively tested for their ability to interact with PfHsp90. 
Similar to that of the single mutants, PfAha1 double (E15A/R58A and E67A/D94A) and 
quadruple (E15A/R58A/E67A/D94A) mutants were able to bind PfHsp90 at levels 
comparable to that of PfAha1-WT. Likewise, substituting these single, double and quadruple 
PfAha1 mutants to an amino acid residue with oppositely charged side chain (i.e. E15K, R58D, 
E67K, D94K, K127D, E15K/R58D, E67K/D94K and E15K/R58D/E67K/D94K) did not 




significantly affect PfAha1’s interaction with PfHsp90 (Figure 7.6B). Hence, the results 
indicated that residues E15, R58, E67, D94 and K127 in PfAha1 are not important for 
interaction with PfHsp90.  
 
7.3.6 Amino acid residue N108 in PfAha1 is essential for PfHsp90 interaction 
As the proposed conserved charged residues in PfAha1 were found to be non-
essential for PfHsp90 interaction, other residues that were observed in the modelled 
PfHsp90-PfAha1 complex to be potentially involved in binding PfHsp90 were investigated i.e. 
E91, F98, N108, E110, R111 and R119 (Figure 7.7). As residues in proximity may potentially 
form interfaces that are important for interaction, these residues were mutated singly and 
subsequently combined into double, triple or quadruple PfAha1 mutants to investigate their 
involvement in PfHsp90 interaction. Seven additional Aha1 mutants were constructed; 3 
single mutants (E91A, F98A and N108A), a double mutant (E91A/N108A), 2 triple mutants 
(E67A/D94A/F98A and E110A/R111A/R119A) and a quadruple mutant 
(E110A/R111A/R119A/K127A). These PfAha1 mutant proteins were solubly expressed, 
purified and their respective ability to interact with PfHsp90 was tested and compared to 
that of PfAha1-WT. SDS-PAGE analysis of the pulled down complexes revealed that PfAha1 
single mutant N108A had significantly diminished binding to PfHsp90, retaining only 
approximately 20% of PfAha1-WT binding (Figure 7.8). When further combined with the 
E91A mutation, the resulting PfAha1 double mutant E91A/N108A displayed almost no 
observable binding to PfHsp90. Hence, the results indicated that the residue N108 in PfAha1 
is essential for interaction with PfHsp90. On the other hand, alanine substitutions at residues 
F98, E110, R111 and R119 in PfAha1 had negligible effects on PfHsp90 interaction, 
suggesting that these residues are not important for binding PfHsp90.  
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Figure 7.6 Amino acid substitutions at residues E15, R58, E67, D94 and K127 in PfAha1 did 
not affect interaction with PfHsp90  
A. Amino acid residues in PfAha1 that were postulated to be important for forming ion-pair 
interaction with PfHsp90 were mutated to investigate their importance for PfHsp90 
interaction. SDS-PAGE analysis revealed that the respective PfAha1 single mutants (i.e. E15A, 
R58A, E67A, D94A and K127A) possessed comparable PfHsp90 binding capacity to that of 
PfAha1-WT. Combination of these substitutions in PfAha1 double (E15A/R58A and 
E67A/D94A) and quadruple (E15A/R58A/E67A/D94A) mutants also did not compromise their 
binding to PfHsp90. This indicated that the residues E15, R58, E67, D94 and K127 are not 
essential for forming interaction with PfHsp90. B. Densitometric analysis of the PfAha1-WT 
and mutants bound to PfHsp90. The percentage of PfHsp90 and PfAha1 bound were 
calculated with respect to the sample with PfAha1-WT. C. SDS-PAGE analysis revealed that 
substitution of the PfAha1 single, double and quadruple mutants to amino acid residues with 
oppositely charged side chains also did not affect their respective interaction with PfHsp90. 
D. Densitometric analysis of the PfAha1-WT and mutants bound to PfHsp90 revealed that 
the PfAha1 mutants had comparable binding capacity to PfHsp90 as PfAha1-WT. Statistical 
analysis was carried out using the Student’s t-test (* indicates p<0.05). Results shown are 
representative of three independent experiments. 
  




































































Figure 7.7 Analysis of PfAha1 and PfHsp90 tertiary structures  
A. The tertiary structures of PfHsp90 (modelled) and PfAha1 (PDB accession number: 3N72) 
were superimposed against the yeast Hsp82-Aha1 complex (PDB accession number: 1USV). 
Residues in PfAha1 that were investigated for their importance in PfHsp90 interaction by 
site-directed mutagenesis were highlighted. PfAha1’s residue N108 was observed to be in 
proximity with residues N472 and T476 in PfHsp90, presumably forming polar-polar 
interaction. B. Using the yeast Hsp82-Aha1 (PDB accession number: 1USV) and Hsp82-Sba1 
(PDB accession number: 2CG9) crystal structures, the PfHsp90-PfAha1-Pfp23 complex was 
modelled and constructed. PfAha1 and Pfp23 were observed to have overlapping PfHsp90-
interaction interfaces (boxed), supporting the experimentally observed binding competition 
between the two co-chaperones for PfHsp90.  
  




















































Figure 7.8 Residue N108 in PfAha1 is essential for interaction with PfHsp90 
A. SDS-PAGE analysis showed that mutation at residue N108 in PfHsp90 resulted in 
diminished binding to PfHsp90 as compared to PfAha1-WT. The interaction was almost 
abolished when substitution N108A was combined with E91A in the PfAha1 double mutant. 
On the other hand, mutations F98A, E110A, R111A and R119A when introduced singly or in 
combination, did not affect PfAha1 binding to PfHsp90, indicating that they are not 
important for PfHsp90 interaction. B. Densitometric analysis of PfAha1-WT and mutants 
bound to PfHsp90. The percentage of PfHsp90 and PfAha1 bound were calculated with 
respect to the sample with PfAha1-WT. Statistical analysis was carried out using the 
Student’s t-test (* indicates p<0.05). Result shown is representative of three independent 
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7.3.7 PfAha1 competes with Pfp23 to interact with PfHsp90 
In the previous Chapter, the interaction between the co-chaperone Pfp23 and 
PfHsp90 was demonstrated to be dependent on MgCl2 and ATP (Chapter 6, Section 6.3.4). 
Since the binding conditions were similar to that required for the formation of PfAha1-
PfHsp90 complex as shown in this Chapter, the interaction between PfHsp90 and PfAha1 
was further examined in the presence of Pfp23. In the experiment, the immobilized PfHsp90 
was first incubated with PfAha1 (2 uM) for complex formation, followed by the addition of 
Pfp23 in increasing concentrations (0.5 to 4 uM). SDS-PAGE analyses of the complexes pulled 
down by PfHsp90 revealed that Pfp23, when introduced in increasing concentrations, 
gradually displaced PfAha1 from PfHsp90 (Figure 7.9A). Repeating the experiment with an 
initial incubation of PfHsp90 with Pfp23 (2 uM) and a subsequent addition of PfAha1 in 
increasing concentrations (0.5 to 4 uM) yielded a similar interaction trend whereby the co-
chaperone that was added at a higher concentration (i.e. PfAha1) would displace the other 
co-chaperone that was of lower concentration (i.e. Pfp23) from PfHsp90 (Figure 7.9B). Hence, 
the results indicated competition between PfAha1 and Pfp23 for binding to PfHsp90.  
 
7.3.8 PfAha1 stimulates the ATPase activity of PfHsp90 
Following PfAha1 and PfHsp90 interaction study, the binding effect of PfAha1 on the 
ATPase activity of PfHsp90 was subsequently investigated. The ATPase activity of PfHsp90 (2 
uM) was measured in the absence or presence of increasing concentrations of PfAha1 (0.1 to 
2 uM). PfAha1 was observed to stimulate the ATPase activity of PfHsp90 to approximately 
300% of its original activity when added in equimolar concentration (Figure 7.10). However, 
when incubated with equimolar concentration of PfAha1 double mutant E91A/N108A with 
defective binding to PfHsp90, no significant stimulation of PfHsp90’s ATPase activity was 
detected. The results indicated that PfAha1 interaction with PfHsp90 is essential for the co-
chaperone to exert its stimulatory effect on the ATPase activity of PfHsp90.    
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Figure 7.9 PfAha1 competes with Pfp23 to interact with PfHsp90  
A. (Top) In each 500-ul reaction, 2 ug PfHsp90 was immobilized on 50-ul glutathione 
sepharose beads and incubated with 2 uM Pfp23 for 30 min. Following that, PfAha1 was 
added in increasing concentrations (0.1 uM to 4 uM) into the respective reactions and 
incubated for an additional 30 min. SDS-PAGE analysis of the eluted PfHsp90 complex 
showed that the level of Pfp23 bound to PfHsp90 was progressively reduced in the presence 
of increasing concentrations of PfAha1. (Bottom) Densitometric analysis of Pfp23 bound to 
PfHsp90 in increasing concentrations of PfAha1. Percentage of PfHsp90 bound was 
calculated with respect to the sample with PfHsp90 only; Pfp23 with respect to the Pfp23 
bound to PfHsp90 in the absence of PfAha1; PfAha1 with respect to the PfAha1 bound to 
PfHsp90 in the presence of 4 uM PfAha1. B. (Top) The experiment was repeated using a 
similar protocol but a fixed concentration of PfAha1 (2 uM) and increasing concentrations of 
Pfp23 (0.1 uM to 4 uM). Results from the SDS-PAGE analysis revealed reduced level of 
PfAha1 bound to PfHsp90 in the presence of increasing concentrations of Pfp23. (Bottom) 
Densitometric analysis of PfAha1 bound to PfHsp90 in increasing concentrations of Pfp23. 
Percentage of PfHsp90 bound was calculated with respect to the sample with PfHsp90 only; 
PfAha1 with respect to the PfAha1 bound to PfHsp90 in the absence of Pfp23; Pfp23 with 
respect to the Pfp23 bound to PfHsp90 in the presence of 4 uM Pfp23. Collectively, the 
results indicated that PfAha1 competes with Pfp23 for binding to PfHsp90. Statistical analysis 
was carried out using the Student’s t-test (* indicates p<0.05). Results shown are 
representative of three independent experiments.     
  

























Figure 7.10 PfAha1 stimulates the ATPase activity of PfHsp90  
PfAha1 was added in increasing concentrations (0.1 uM to 2 uM) to a fixed amount of 
PfHsp90 (2 uM) to investigate its effect on the ATPase activity of PfHsp90. The ATPase 
activity of PfHsp90 was stimulated in the presence of PfAha1. At equimolar concentration, 
PfAha1 enhanced the ATPase activity of PfHsp90 to approximately 300% of its original 
activity. On the contrary, when PfAha1 double mutant E91A/N108A that exhibited defective 
binding to PfHsp90 was added in equimolar concentration, no significant stimulation of 
PfHsp90’s ATPase activity was detected. The relative activity was calculated with respect to 
the ATPase activity of PfHsp90 in the absence of PfAha1. Statistical analysis was carried out 
using the Student’s t-test (* indicates p<0.05). Result shown is representative of three 
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7.4 Discussion  
In P. falciparum, several putative homologues of Hsp90’s co-chaperones have been 
identified in the genome sequence of the malaria parasite. The co-chaperones found include 
Pfp23 (PF14_0510), PfAha1 (putative, PFC0270w and PFC0360w), PfHop (putative, 
PF14_0324), PfFKBP35 (PFL2275c), PfCyp19 (PFC0975c) and PfPP5 (PF13_0294). Many of 
these putative co-chaperones have not been characterized for their functionality and 
regulation on PfHsp90. Generally, they share low sequence homology with the human and 
yeast homologues (Kumar et al., 2007) and thus, inevitably raised questions as to whether 
they interact and regulate PfHsp90 in a manner similar to that of the human/yeast Hsp90 
system. Considering that Aha1 is one of the only two co-chaperones (Cpr6 is the other co-
chaperone) known to be capable of stimulating the ATPase activity of Hsp90 that is essential 
for promoting the activation of Hsp90’s client proteins, the putative Aha1 in P. falciparum 
was characterized in this study to investigate its putative role as a co-chaperone of PfHsp90.      
PfAha1 was expressed as a soluble 44 kDa recombinant protein and was shown to 
interact with PfHsp90 in the presence of MgCl2 and ATP. Although recent studies indicated 
that the human Aha1 could interact with Hsp90 in the absence of nucleotide (Hessling et al., 
2009; Koulov et al., 2010), this was not observed between PfAha1 and PfHsp90. This may 
reflect differences in the binding preference of the plasmodial homologue or could be due to 
low concentrations of PfHsp90-PfAha1 nucleotide-free complexes that are difficult to detect.  
Since PfAha1 shares similar Hsp90-binding requirements with Pfp23 (Chapter 6, 
Section 6.3.4), the influence of Pfp23 on PfHsp90-PfAha1 interaction was investigated. Using 
similar binding assay, PfAha1 was shown to compete with Pfp23 to interact with PfHsp90. 
The experimental observation was supported by in silico modelled PfHsp90-PfAha1-Pfp23 
tertiary complex which revealed overlapping PfAha1 and Pfp23 binding sites on PfHsp90 
(Figure 7.7). Probing into the interaction between PfAha1 and PfHsp90, primary sequence 
and tertiary structure analyses further revealed several conserved charged residues in 
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PfAha1 (i.e. E15, R58, E67, D94 and K127) that could be essential for PfHsp90 interaction. 
These residues in PfAha1 were substituted by site-directed mutagenesis and subsequently 
tested for their respective ability to interact with PfHsp90. Contrary to expectations, these 
PfAha1 mutants with substitution at the charged residue to a non-charged alanine or an 
oppositely charged amino acid residue, displayed no significant defects in their interaction 
with PfHsp90 when compared to PfAha1-WT. Further mutational studies revealed the 
residue N108 in PfAha1 to be essential for PfHsp90 interaction instead. Based on the 
modelled structure, the amino acid residue N108 presumably interacts with the residues 
N472 and T476 in PfHsp90 through polar-polar interaction. The observation is surprising as 
the interaction between yeast Hsp82 and Aha1 are known to be contributed by multiple 
binding interfaces and that single amino acid substitution is unlikely to destabilize their 
association (Meyer et al., 2004b). Nevertheless, in the case of PfAha1, a single mutation at 
residue N108 significantly diminished its binding to PfHsp90, indicating that PfAha1’s 
interaction with PfHsp90 may depend primarily on certain strategic amino acid residues 
instead of interfaces for stable association. Similar analyses of putative Aha1s in other 
Plasmodium sp. i.e. P. vivax (PVX_119435), P. chabaudi (PCHAS_040550) and P. berghei 
(PBANKA_040460) showed that the asparagine residue is identically conserved in all the 
plasmodial Aha1s, suggesting that they may play similar importance for interaction with the 
respective Hsp90s in the various species. 
The functional significance of PfAha1’s binding to PfHsp90 was subsequently 
examined and PfAha1 was found to stimulate the ATPase activity of PfHsp90 to 
approximately 300% of the original activity when added in equimolar concentration. The 
ATPase stimulatory effect is consistent with that of the human/yeast Aha1 binding effect on 
Hsp90 where the increased ATP hydrolysis has been reported to be essential for the 
activation of Hsp90’s client proteins e.g. glucocorticoid receptors, v-Src and c-Raf (Harst et 
al., 2005; Holmes et al., 2008; Panaretou et al., 2002). In addition, a recent study in yeast 
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demonstrated that Aha1 is capable of restoring the functionality of Hsp90 mutants with 
defective ATPase activity (Mollapour et al., 2011b). This may highlight the importance of 
Aha1 in maintaining the functional integrity of Hsp90, where its ATPase stimulatory effect 
can compensate for the diminished activity in compromised Hsp90.    
Taken together, PfHsp90 has been shown to interact with the co-chaperones PfAha1 
and Pfp23 (Chapter 6). The binding of PfAha1 and Pfp23 to PfHsp90 are mutually exclusive as 
demonstrated in the competitive binding assay and well-supported by the modelled tertiary 
structure of the PfHsp90-PfAha1-Pfp23 complex. The ATPase stimulatory and inhibitory 
effects exerted by PfAha1 and Pfp23 respectively on PfHsp90, would further indicate 
potential in vivo regulation of PfHsp90’s chaperone activity by the co-chaperones in the 
malaria parasite. Most importantly, results from the interaction studies and ATPase assays 
have provided evidence on the presence of an active Hsp90 and a competent set of co-
chaperones in P. falciparum which would dispel previously held doubts on the existence of a 
conserved functional Hsp90 system in the malaria parasite. This would provide the necessary 
support for subsequent investigation and identification of the proteins that PfHsp90 
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8.1 Introduction  
Following investigations on PfHsp90’s interaction and regulation by its co-
chaperones Pfp23 and PfAha1 in the previous Chapters, the project subsequently focused on 
identifying potential client proteins of PfHsp90. In general, Hsp90s in human and yeast are 
known to chaperone an extensive number of cellular proteins, many of which are kinases 
and transcription factors that are involved in signal transduction and developmental 
regulation (Taipale et al., 2010). In the case of PfHsp90, the current literature information on 
its client proteins in P. falciparum remains limited (Chapter 4, Section 4.2). As knowledge on 
the client proteins of PfHsp90 can provide significant insights to the biological roles of the 
chaperone in P. falciparum, through examining the biochemical pathways with their 
involvement, it is essential to expand the current list of PfHsp90’s client proteins. Therefore, 
in an attempt to identify novel client proteins of PfHsp90, this study has adopted the use of 
the split-ubiquitin assay, a library-based protein-protein interaction method, to screen for 
PfHsp90-interacting proteins in P. falciparum.  
Principle of the split-ubiquitin assay. The split-ubiquitin system is an alternative yeast 
two-hybrid assay that exploits the principle of conditional proteolysis which occurs when a 
ubiquitin molecule is fused to a protein (Figure 8.1) (Lehming, 2002). In this system, the 
ubiquitin molecule is split into an N-terminal half (Nub) and a C-terminal half (Cub) where 
neither half is capable of inducing proteolytic cleavage. A modified Ura3p with an arginine at 
the first position (RUra3p) fused to the C-terminal end of Cub is used as a reporter gene. 
Yeast cells expressing protein X-Cub-RUra3p fusion proteins are uracil prototrophs and 
sensitive to 5-fluoroorotic acid (5-FOA), as Ura3p, orotidine-5’-phosphate decarboxylase, is 
required for the biosynthesis of uracil and also converts 5-FOA into toxic fluorouracil. In the 
event that protein X interacts with protein Y fused to Nub, the Cub and Nub halves are brought 
to proximity and reconstituted into a native-like ubiquitin. This is recognized by the 
ubiquitin-specific protease and results in the cleavage of RUra3p. The free RUra3p is rapidly 




degraded due to the inclusion of the arginine that is a destabilizing residue in the N-end rule 
pathway (Varshavsky, 1996). Hence protein interaction is inferred from the degradation of 
RUra3p in yeast cells, indicated by the lack of growth in media lacking uracil and resistance 
to 5-FOA. Some of the advantages of the split-ubiquitin assay include: (1) detection of in vivo 
protein-protein interaction in situ, without a need to localize to the nucleus to initiate a 
transcriptional readout and (2) allows analysis of transient protein-protein interaction 
(Johnsson and Varshavsky, 1994; Lehming, 2002). The assay is useful for the identification of 
interacting transcription factors that would interfere with the transcriptional readout used in 
conventional yeast two-hybrid studies (Fields and Song, 1989; Wellhausen and Lehming, 
1999). As Hsp90 is generally known to chaperone numerous transcription factors, the split-
ubiquitin assay was thus employed to screen for PfHsp90 interaction partners from a 
prepared P. falciparum cDNA library. 
 
  
























Figure 8.1 Schematic illustration of the principle of split-ubiquitin assay 
A. The RUra3p with a ubiquitin molecule fused to it is recognized and cleaved by ubiquitin-
specific protease. The free RUra3p is rapidly degraded by the N-end rule protein degradation 
pathway. As RUra3p is required for uracil synthesis and can convert 5-FOA to toxic 
fluorouracil, the degradation of RUra3p in yeast cells would result in the lack of growth in 
uracil-lacking media and resistance to 5-FOA. B. RUra3p fused to the C-terminal half of 
ubiquitin, the Cub, is not recognized by the ubiquitin-specific protease and hence, it is not 
cleaved and remains functional. C. When Protein X fused to Cub-RUra3p interacts with 
Protein Y fused to Nub, the Cub and Nub are brought to proximity and reconstituted into a 
native-like ubiquitin molecule. This results in the recognition by ubiquitin-specific protease 
and leads to the degradation of RUra3p. Protein-protein interaction in the split-ubiquitin 
assay is thus inferred from the conditional degradation of RUra3p. The figure is adapted 
from Lehming, 2002.   
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8.2 Materials and Methods 
8.2.1 Construction of P. falciparum cDNA library 
The P. falciparum cDNA was constructed using the mRNA extracted from P. 
falciparum 3D7 (Chapter 5, Section 5.2.1). Reverse transcription of the mRNA was 
performed using the SuperScript® II kit (Invitrogen) and a reverse poly-T primer designed 
with a NotI restriction enzyme site (Table 8.1). The thymine nucleotides in the poly-T primer 
would recognize and hybridize on the poly-A tail of the mRNA and initiate the synthesis of 
the first-strand cDNA. Following that, PCR was performed using a forward random hexamer 
primer design with a BglII restriction enzyme site to obtain the double-stranded cDNA.  
The double-stranded cDNA was subsequently double-digested with restriction 
enzymes BglII and NotI. The restriction digested product was purified using MinEluteTM Gel 
Extraction Kit (Qiagen) and ligated into Nub vector (Laser et al., 2000) that has been treated 
with the same set of restriction enzymes. The ligation mixture was then transformed into 
Escherichia coli DH5α and plated onto Luria Bertani agar plate containing 40 ug/ml of 
ampicillin. Twenty random individual transformants that grew on the plates were picked and 
their plasmids were extracted using Wizard® Plus SV Minipreps DNA Purification System 
(Promega). The Nub recombinant plasmids were subsequently double-digested with 
restriction enzymes BglII and NotI, and subjected to gel electrophoresis to determine the 
number of clones with a DNA insert. Upon ascertaining 95% of the recombinant Nub plasmids 
extracted from the randomly selected transformants possessed an insert, the 
transformation of the ligation mixture into E. coli DH5α was repeated and up-scaled. 
Approximately 25,000 independent transformant colonies that grew on the Luria Bertani 
agar plate containing 40 ug/ml of ampicillin were pooled and plasmid extraction was carried 
out. The pool of recombinant Nub plasmids obtained constituted the P. falciparum cDNA 
library. 
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8.2.2 Generation of PfHsp90 and PfAha1 constructs for split-ubiquitin assay 
PfHsp90 (PF07_0029) and PfAha1 (PFC0270w) were reverse-transcribed and 
amplified from the mRNA of P. falciparum 3D7 using appropriate forward and reverse 
primers (Table 8.1). The PfHsp90 was to be cloned into the Cub-RUra3p vector  (Wittke et al., 
1999) whereas PfAha1 into the Nub vector  (Laser et al., 2000). The amplified PfHsp90 gene 
was double-digested with restriction enzymes EcoRI and SalI and ligated into the Cub-RUra3p 
vector. As for PfAha1, the amplified gene was double-digested with BglII and SalI and ligated 
into the Nub vector. The recombinant plasmids were transformed into E. coli DH5α cells and 
plated onto Luria Bertani agar plate containing 40 ug/ml of ampicillin. Subsequently the 
recombinant plasmids in the transformants that grew were extracted and the authenticities 
of the PfHsp90 and PfAha1 gene inserts were verified by DNA sequencing. 
 
8.2.3 Validation of the expression of PfHsp90 and PfAha1 constructs in yeast 
The recombinant plasmids PfHsp90-Cub-RUra3p and Nub-PfAha1 were respectively 
transformed into the Saccharomyces cerevisiae JD52. The yeast cells transformed with 
PfHsp90-Cub-RUra3p recombinant plasmid were plated onto media plates lacking tryptophan 
and uracil. The absence of tryptophan selects for yeast cells carrying the Cub-RUra3p plasmid 
whereas the lack of uracil selects for a functional PfHsp90-Cub-RUra3p fusion protein. The 
growth of transformants would indicate the expression of a functional PfHsp90-Cub-RUra3p 
fusion protein.  As for yeast cells transformed with Nub-PfAha1, they were plated onto media 
lacking in leucine. The lack of leucine selects for the Nub plasmid. As the Nub-PfAha1 construct 
is constitutively expressed with an HA-tag, the transformant was lysed and the cell lysate 
was subjected to Western blot analysis using anti-HA antibody to validate the expression of 
Nub-PfAha1 fusion protein in the yeast cells.  
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8.2.4 Split-ubiquitin interaction assay 
Protein interaction study using split-ubiquitin was carried out according to protocols 
that have been described (Laser et al., 2000; Lehming, 2002). Briefly, to investigate the 
interaction between PfHsp90-Cub-RUra3p and Nub fusion constructs (Nub-PfAha1 or the P. 
falciparum Nub cDNA library), both the Cub and Nub constructs were co-transformed into the S. 
cerevisiae JD52 and plated onto media plates lacking leucine and tryptophan to select for 
transformants that carried both constructs. For directed split-ubiquitin assay (PfHsp90 Cub-
RUra3p and Nub PfAha1 constructs), the yeast cells that contained both the recombinant Cub-
RUra3p and Nub fusion constructs were tenfold serial-diluted and dropped onto plates 
lacking leucine and tryptophan, onto plates additionally lacking uracil and onto plates 
additionally containing 5-fluoroorotic acid (5-FOA). In the case of the split-ubiquitin screen 
(PfHsp90 Cub-RUra3p fusion construct and P. falciparum Nub cDNA library), approximately 
25,000 independent colonies were obtained and pooled, to ensure the complexity of the 
original library (25,000 constructs) was retained. The pooled clones were subsequently 
plated onto media plates lacking leucine and tryptophan but containing 5-FOA. A total of 
100 transformants that grew were picked and inoculated into liquid broth lacking in leucine 
to select for the Nub recombinant plasmid. Following that, the Nub recombinant plasmids 
were extracted from the yeast cells. However, due to the low quantity of plasmids obtained 
that were not sufficient for restriction enzyme analysis, the extracted Nub recombinant 
plasmids were transformed into E. coli DH5α cells and the plasmids were subsequently re-
extracted. Thereafter, the recombinant Nub plasmids were double-digested with restriction 
enzymes BglII and NotI to determine the presence of DNA insert. The Nub recombinant 
plasmids that contained unique insert size were selected, co-transformed with PfHsp90 Cub-
RUra3p fusion construct into the S. cerevisiae JD52 and plated onto media plates lacking 
leucine and tryptophan. Subsequently, the yeast cells that contained both the recombinant 
Cub-RUra3p and Nub fusion constructs were tenfold serial-diluted and dropped onto plates 
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lacking leucine and tryptophan, onto plates additionally lacking uracil and onto plates 
additionally containing 5-FOA. The recombinant Nub constructs that demonstrated 
interaction with the PfHsp90 Cub-RUra3p fusion protein were subsequently analyzed by DNA 
sequencing to determine the peptide/protein encoded in the DNA insert that led to the 
observed interaction (Figure 8.2). 
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Table 8.1 Primers Designed for Split-Ubiquitin Assay 
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Figure 8.2 Overview of the experimental flow for the identification of PfHsp90-interacting 
proteins in P. falciparum using the split-ubiquitin assay  
-Tryp indicates media lacking tryptophan; -Leu indicates media lacking leucine; -Ura indicates 
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8.3 Results  
8.3.1 Evaluation of the split-ubiquitin system for identifying PfHsp90 interaction partners 
To determine whether the split-ubiquitin assay is feasible for the identification of 
PfHsp90 interaction partners, the system was tested using PfAha1 which has been shown to 
interact with PfHsp90 in previous GST pull-down assay. The full-length and the respective 
domains of PfHsp90 (full-length, PfHsp90FL; N-terminal domain, PfHsp90N; middle domain, 
PfHsp90M; C-terminal domain, PfHsp90C) were cloned into the Cub-RUra3p vector and 
PfAha1 into the Nub vector (Figure 8.3). All the PfHsp90 Cub-RUra3p fusion constructs when 
transformed into yeast cells respectively conferred growth on plates lacking uracil (Figure 
8.4). This indicated that the various PfHsp90 constructs were expressed as functional Cub-
RUra3p fusion proteins. The expression of the PfAha1 constructs in yeast was verified by 
Western blotting against the HA-tag found on the Nub fusion proteins (Figure 8.4). 
Subsequently, the PfHsp90 Cub-RUra3p and Nub PfAha1 constructs were co-transformed into 
yeast cells and titrated onto plates lacking tryptophan and leucine (as a control to detect for 
yeast cells carrying both Cub-RUra3p and Nub recombinant plasmids), lacking tryptophan, 
leucine and uracil (reduced growth indicates degradation of RUra3p and hence interaction 
between PfAha1 and PfHsp90) and lacking tryptophan, leucine but containing 5-FOA 
(increased growth indicates PfAha1-PfHsp90 interaction). 
Initial split-ubiquitin assay performed using full-length PfHsp90 Cub-RUra3p 
(PfHsp90FL-Cub-RUra3p) did not reveal any significant interaction with the full-length Nub 
PfAha1 (Nub-PfAha1FL; Figure 8.5) fusion protein. As the interaction is inferred from the 
degradation of RUra3p that occurs when the Cub and Nub halves are brought in close 
proximity, the lack of interaction observed between PfHsp90FL-Cub-RUra3p and Nub-
PfAha1FL could possibly be due to the large protein size of PfHsp90 that hinders the 
proximity required for the reconstitution of the Cub and Nub halves. Thus, if two proteins 
interact but the Nub and Cub fused to them respectively are not brought sufficiently close 
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enough (e.g. due to steric hindrance, size, orientation etc.) to be reconstituted as a native-
like ubiquitin molecule, their interaction would not be reflected in the assay. Hence, PfHsp90 
was subsequently dissected into its respective smaller domains and tested for their 
interaction with PfAha1.  
When Nub-PfAha1FL was co-transformed with the respective PfHsp90 Cub-RUra3p 
domain constructs (i.e. PfHsp90N-Cub-RUra3p, PfHsp90M-Cub-RUra3p, and PfHsp90C-Cub-
RUra3p), a slight growth reduction on the uracil-lacking plate was observed for yeast cells 
harboring the Nub-PfAha1FL and PfHsp90M-Cub-RUra3p constructs (Figure 8.5). This was 
complemented by an increased growth on the 5-FOA plate. Hence, the result suggested that 
PfAha1 interacted with the middle domain of PfHsp90. To further analyze the interaction, 
PfAha1 was dissected into two parts, the N- and C-terminal domains (PfAha1N and PfAha1C, 
respectively; Figure 8.4), based on sequence alignment to the yeast Aha1 and Hch1 to 
investigate the domain that is interacting with PfHsp90. The PfAha1 domains were cloned 
into the Nub vector (i.e. Nub-PfAha1N and Nub-PfAha1C) and they were each co-transformed 
with the respective PfHsp90 Cub-RUra3p constructs. Significant growth reduction on the 
uracil-lacking plate and growth increment on the 5-FOA plate were observed for yeast cells 
harboring Nub-Aha1N/Aha1C and PfHsp90M-Cub-RUra3p constructs (Figure 8.5). The results 
indicated that both the N- and C-terminal domains of Aha1 interacted with the middle 
domain of PfHsp90. 
Based on the results, although PfHsp90FL-Cub-RUra3p was expressed, the fusion 
protein was unable to exhibit interaction with PfAha1. Interaction with PfAha1 was only 
observed when the smaller individual domain of PfHsp90, PfHsp90M-Cub-RUra3p, was used. 
This highlighted the potential difficulty in using the PfHsp90FL-Cub-RUra3p construct to 
screen for PfHsp90 interaction partners from the prepared P. falciparum cDNA library. 
Instead, the smaller PfHsp90 Cub-RUra3p constructs that encode the respective individual 
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domains may be more useful for identifying PfHsp90-interacting proteins in the split-
ubiquitin assay.   
 
  


























Figure 8.3 Cloning of PfHsp90 and PfAha1 for split-ubiquitin assay 
The full-length PfHsp90 (PfHsp90FL) and PfAha1 (PfAha1FL) were reverse transcribed and 
amplified from the mRNA of P. falciparum and cloned into the Cub-RUra3p and Nub vectors 
respectively. In addition, Cub-RUra3p constructs carrying the individual domains of PfHsp90 
(N-terminal domain, PfHsp90N; middle domain, PfHsp90M; C-terminal domain, PfHsp90C) 
and Nub constructs harboring the individual domains of PfAha1 (N-terminal domain, PfAha1N; 
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Legend: 
 
1. Restriction digested PfHsp90FL-Cub-RUra3p 
recombinant plasmid (EcoR1/Sal1) 
2. Restriction digested PfHsp90N-Cub-RUra3p 
recombinant plasmid (EcoR1/Sal1) 
3. Restriction digested PfHsp90M-Cub-RUra3p 
recombinant plasmid (EcoR1/Sal1) 
4. Restriction digested PfHsp90C-Cub-RUra3p 





5. Restriction digested Nub-PfAha1FL 
recombinant plasmid (BglII/Sal1) 
6. Restriction digested Nub-PfAha1N 
recombinant plasmid (BglII/Sal1) 
7. Restriction digested Nub-PfAha1C 
recombinant plasmid (BglII/Sal1) 
 
L    :  1 kb DNA ladder (Promega) 







































Figure 8.4 Analyses of the expression of PfHsp90 Cub-RUra3p and Nub PfAha1 fusion 
proteins 
A. Schematic representation of the various PfHsp90 and PfAha1 constructs generated for the 
split-ubiquitin assay. B. The various PfHsp90 Cub-RUra3p constructs were transformed into S. 
cerevisiae JD52 and plated onto media lacking in tryptophan and uracil. Growth was 
observed for yeast cells transformed with all the various PfHsp90 Cub-RUra3p constructs. 
This indicated that all the PfHsp90 constructs were expressed in the yeast as fusion proteins 
with a functional RUra3p. C. Western blot analysis of Nub-PfAha1 fusion proteins. All the Nub 
PfAha1 fusion proteins contained a HA-tag respectively and were probed using anti-HA 
antibody. The Nub-PfAha1N and Nub-PfAha1C fusion proteins were expressed at a 
significantly higher level than Nub-PfAha1FL. For each lane, 10 ug of lysate from yeast cells 
carrying the respective Nub PfAha1 constructs were loaded. Results shown are representative 













1. Nub-PfAha1FL yeast cell lysate 
2. Nub-PfAha1N yeast cell lysate 
3. Nub-PfAha1C yeast cell lysate 
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Figure 8.5 Analysis of PfHsp90 interaction with PfAha1 by split-ubiquitin assay 
The Nub Aha1 constructs (Nub-PfAha1FL, Nub-PfAha1N and Nub-PfAha1C) were respectively 
co-transformed with each of the PfHsp90 Cub-RUra3p constructs (PfHsp90FL-Cub-RUra3p, 
PfHsp90N-Cub-RUra3p, PfHsp90M-Cub-RUra3p and PfHsp90C-Cub-RUra3p) into yeast cells and 
plated onto media plates lacking leucine and tryptophan (-LW), onto media plates 
additionally lacking uracil (-LWU) and onto media plates additionally containing 5-FOA. 
Growth on –LW plate served as a control to ensure the transformed yeast cells carried both 
the Cub-RUra3p and Nub recombinant plasmids. A protein-protein interaction is indicated by 
reduced growth on the –LWU plate and complementary increased growth on the 5-FOA 
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8.3.2 Construction of the P. falciparum cDNA library 
The mRNA extracted from P. falciparum 3D7 was reversed transcribed and amplified 
using a poly-T reverse primer and a random hexamer forward primer to yield double-
stranded cDNA (Figure 8.6). The cDNA was subsequently restriction digested, ligated into the 
Nub vector and transformed into E. coli DH5α cells. Analyses of 20 randomly selected 
transformants revealed that 95% (19 out of 20) of the transformants carried recombinant 
Nub plasmids with a DNA insert respectively (Figure 8.6). Approximately 25,000 individual 
transformant colonies were pooled and grown at 37˚C for 2 hr to amplify the number of 
transformant cells. Subsequently, plasmid extraction was carried out and the pool of 
plasmids obtained constituted the P. falciparum Nub cDNA library (Figure 8.6).  
 
8.3.3 Screening of PfHsp90 interaction partners by split-ubiquitin assay 
The PfHsp90M-Cub-RUra3p construct that encodes the middle domain of PfHsp90 
was used as a bait to screen for interacting proteins from the P. falciparum Nub cDNA library. 
As the middle domain has been proposed to be the client protein binding site in the human 
and yeast Hsp90s, it was hoped that the PfHsp90M-Cub-RUra3p construct could uncover 
potential PfHsp90’s client proteins in the split-ubiquitin assay. The PfHsp90FL-Cub-RUra3p 
construct was not used following evaluation on its inability to interact with PfAha1 as 
described earlier. The PfHsp90M-Cub-RUra3p was co-transformed with the P. falciparum Nub 
cDNA library into yeast cells and plated onto media plates lacking tryptophan and leucine 
but containing 5-FOA (growth indicates interaction between PfHsp90M-Cub-RUra3p and the 
Nub fusion protein). Subsequently, 100 individual transformants were picked, grown in liquid 
media lacking in leucine, subjected to plasmid extraction followed by restriction analysis to 
identify recombinant Nub plasmids with a DNA insert (Figure 8.7).  
A total of 56 recombinant Nub plasmids that contained a DNA insert respectively 
were selected for validation of their interaction with the PfHsp90M-Cub-RUra3p construct. 
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These recombinant Nub plasmids were respectively co-transformed with the PfHsp90M-Cub-
RUra3p construct into yeast cells and titrated onto plates lacking tryptophan and leucine (as 
a control to detect for yeast cells carrying both Cub-RUra3p and recombinant Nub plasmids), 
lacking tryptophan, leucine and uracil (reduced growth indicates degradation of RUra3p and 
hence interaction between PfHsp90M and the Nub fusion protein) and lacking tryptophan, 
leucine but containing 5-FOA (increased growth indicates interaction between PfHsp90M 
and the Nub fusion protein). Among the 56 recombinant Nub plasmids, 51 encoded Nub fusion 
proteins that showed substantial interaction with PfHsp90M-Cub-RUra3p (Figure 8.8). Hence, 
these 51 recombinant Nub plasmids were selected for DNA sequencing to determine the 
peptide/protein sequence encoded by the DNA insert that contributed to the observed 
interaction with PfHsp90M-Cub-RUra3p. 
Analysis of the DNA sequence revealed that 7 of the recombinant Nub plasmids 
encoded peptide fragments of a conserved Plasmodium protein with unknown function, 
PF13_0165 (Table 8.2). In addition, 41 of the recombinant Nub plasmids were found to 
encode short peptide fragments of length between 5 to 10 amino acid residues. However, 
due to the short amino acid sequence, no significant match on plasmodial protein was 
retrieved from the BLASTP result performed in the PlasmoDB. 
  





















Figure 8.6 Construction of P. falciparum cDNA library for split-ubiquitin assay 
The cDNA of P. falciparum was obtained by RT-PCR using extracted mRNA and appropriate 
primers. The amplified cDNA was subsequently restriction digested, ligated into Nub vector 
and transformed into E. coli DH5α. Analyses of 20 randomly selected transformants showed 
that 19 of them carried an insert (except 2.14). Approximately 25,000 independent colonies 
obtained from the transformation were pooled, subjected to plasmid extraction, to obtain 
the Nub recombinant plasmids that would constitute the P. falciparum Nub cDNA library. The 
P. falciparum Nub cDNA library was verified by the appearance of a DNA smear following 















































1. RT-PCR amplified P. falciparum cDNA 
2. Restriction digestion analysis of 20 
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P. falciparum cDNA (2.01 to 2.20) 
3. Restriction digestion analysis of P. 
falciparum cDNA Nub plasmid library 
 












































Figure 8.7 Screening of 5-FOA plated transformants carrying recombinant Nub plasmids 
with DNA insert 
A total of 100 independent yeast colonies that grew on 5-FOA plates, following co-
transformation of PfHsp90M-Cub-RUra3p and the Nub cDNA library, were picked and grew in 
liquid media lacking in leucine to select for the Nub recombinant plasmids. The Nub 
recombinant plasmids that were subsequently isolated were subjected to restriction 
analyses using BglII and NotI to identify those that harbor a DNA insert. A total of 56 
recombinant Nub plasmids with DNA insert were selected for verification of their interaction 
with PfHsp90M-Cub-RUra3p.  L: 1kb DNA ladder (Promega) 
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Figure 8.8 Analysis of PfHsp90 interaction with selected recombinant Nub constructs from 
the cDNA library 
PfHsp90M-Cub-RUra3p was co-transformed with each of the 56 selected Nub recombinant 
constructs into yeast cells and plated onto media plates lacking leucine and tryptophan (-
LW), onto media plates additionally lacking uracil (-LWU) and onto media plates additionally 
containing 5-FOA. A protein-protein interaction is indicated by reduced growth on the –LWU 
plate and complementary increased growth on the 5-FOA plate. The Nub plasmid that does 
not carry any DNA insert was used as a negative control for PfHsp90 interaction. The Nub 
recombinant constructs that demonstrated interaction with PfHsp90M-Cub-RUra3p were 
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Table 8.2 Summary of Recombinant Nub Constructs that Interacted with PfHsp90M-Cub-
RUra3p in the Split-Ubiquitin Screen 
1The numbering used for the recombinant Nub constructs is with reference to Figure 8.8. 
2Amino acid residues encoded by the restriction enzyme site (BglII: CAG ATC TNN) are underlined. 
Amino acid residues that gave an identical match to the BLASTP results are in bold and highlighted in 
red. 





Peptide sequence encoded 
by the DNA insert2 
PlasmoDB BLASTP 
results 
27, 93 2 Q I S S K V S E K K K T K K N E 
D K K K K K K K K S G R R G L F 








2 Q I S S K V S E K K K T K K N E 
D K K K K K K K D D T S E S S D 
S S S D S D D D S E E D N K I E 
I K N E N K K E N K K E N K N E 
N K N E N K N E N K N E S K K 
E K K K K S G R R G L F G Q L E F T 








1 Q I S S K V S E K K K T K K N E 
D K K K K K K K D D T S E S S D 
S S S D S D D D S E E D N K I E 
I K N E N K K E N K K E N K N E 
N K N E N K N E N K N E S K K 
E N K K E V K K D D S S S D S D 
S S S D S D D S D D S D S D E V 
E K K K K K K K K S G R R G L F G 
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90 1 Q I S S K V S E K K K T K K N E 
D K K K K K K K D D T S E S S D 
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I K K K K K K K K S G R R G L F G Q 






2, 5, 13, 14, 18, 19, 
21, 24, 26, 28, 33, 34, 
35, 39, 46, 48, 52, 56, 
57, 61, 64, 69, 72, 74, 
79, 83, 87, 88, 91, 94 
 
30 Q I L K N G M K K Stop - 
1, 11, 98 3 Q I S M T N K F Stop 
 
- 
4,25, 38, 43 4 Q I S R A R G R R Stop 
 
- 
96 1 Q I F K N I I H K K C K Stop 
 
- 
29, 47, 82 3 Q I F G K I S S H N K P N Stop 
 
- 
41, 51, 60 3 Missing restriction enzyme site 
 
- 




The split-ubiquitin assay was adopted in this study to identify potential client 
proteins of PfHsp90. Initial evaluation of the feasibility of the assay to detect for PfHsp90-
interacting protein, indicated that the smaller constructs made up of the respective 
PfHsp90’s domains were more suitable for detecting interacting proteins as compared to the 
full-length PfHsp90 construct. When the full-length PfHsp90 (PfHsp90FL-Cub-RUra3p 
construct) was tested for its interaction with PfAha1 (Nub-PfAha1FL construct), no interaction 
was detected in the split-ubiquitin assay despite having shown that PfHsp90 interacted with 
PfAha1 in the GST pull-down assay. Nevertheless, when a smaller construct consisting of the 
middle domain of PfHsp90 was used (PfHsp90M-Cub-RUra3p), significant interaction was 
observed between PfHsp90 and PfAha1. The lack of interaction observed in the full-length 
PfHsp90 could possibly be due to the large protein size of PfHsp90 that may have hindered 
the proximity required for the reconstitution of Cub and Nub important for reflecting protein 
interaction in the assay. Hence, subsequent attempt to identify potential client proteins of 
PfHsp90 was carried out using a smaller PfHsp90 domain construct. The PfHsp90M-Cub-
RUra3p was selected as the middle domain has been proposed to be the client protein 
binding site in the human and yeast Hsp90s.    
Using the PfHsp90M-Cub-RUra3p construct, the split-ubiquitin assay was carried out 
to screen for PfHsp90-interacting proteins from the prepared P. falciparum Nub cDNA library. 
Analysis of the interaction results revealed a candidate protein that was repeatedly detected 
in the screen, PF13_0165. The PF13_0165 encodes a 596 amino acid protein that is currently 
annotated as a conserved Plasmodium protein with unknown function. To further 
investigate the potential function of PF13_0165, the protein was subjected to sequence 
analyses in PROSITE and Pfam. Both the bio-computational protein scans detected the 
presence of a RNA recognition motif (RRM) in PF13_0165 between amino acid residues 432 
and 503. 
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The RRM, also known as the ribonucleoprotein (RNP) domain or the RNA binding 
domain, is commonly found in eukaryotic proteins that are involved in post-transcriptional 
gene expression regulation (Glisovic et al., 2008; Lunde et al., 2007). The regulatory activities 
include processing of mRNA and rRNA, export of RNA and maintenance of RNA stability. 
Indeed, a review on the current Hsp90 literature revealed the involvement of the molecular 
chaperone in RNA processing. Recent studies showed that Hsp90 regulates the biogenesis of 
small nucleolar RNP (snoRNP) complexes that have essential roles in ribosomal RNA 
maturation (Boulon et al., 2008; Zhao et al., 2008). In general, each snoRNP complex consists 
of a small nucleolar RNA (snoRNA) and a set of snoRNP proteins i.e. box C/D set (i.e. 
15.5K/Snu13, Nop56, Nop58, and Nop1) or Box H/ACA set (i.e. hNHP2, Gar1, Nop10, and 
Cbf5). The snoRNA acts as a guide to the snoRNP complex in targeting specific RNA for 
modifications. For a snoRNP complex to achieve its functional state, the snoRNP proteins 
would have to be assembled with the snoRNA in a series of intricate steps that require 
constant folding and remodelling of both the RNA and protein components. Studies on 
human and yeast demonstrated that Hsp90 is essential in the assembly process and its 
inhibition by geldanamycin hindered the accumulation of the snoRNP complex (Boulon et al., 
2008; Zhao et al., 2008). In addition, studies on the transcription factor TonEBP/OREBP that 
is involved in osmoregulation revealed its interaction with Hsp90β as well as heterogeneous 
nuclear RNP- (hnRNP) F and M (Chen et al., 2007). Both the hnRNP-F and hnRNP-M possess 
the RRM and have been implicated in the splicing and processing of pre-mRNA. However, so 
far there is no direct evidence on the interaction between Hsp90 and the hnRNPs. 
Nevertheless, considering that PF13_0165 possesses a RRM and has been shown to interact 
with PfHsp90 in the split-ubiquitin assay, it is plausible that PF13_0165 may have a role in 
the processing of RNA in the malaria parasite. BLASTP analysis of PF13_0165 further 
revealed that the homologue of this protein is absent in other organisms apart from the 
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Plasmodium genus. This indicated that PF13_0165 is not only conserved in Plasmodium sp. 
but also unique to the malaria parasite.  
Apart from PF13_0165 that was identified from the split-ubiquitin screen, most of 
the constructs detected were peptide sequences ranging from 5 to 10 amino acid residues. 
Due to their short peptide length, no significant protein match was detected when they 
were subjected to standard BLASTP analysis (standard PlasmoDB BLASTP parameters setting). 
Nevertheless, it is intriguing that the presence of these short peptide sequences would 
result in a strong interaction with PfHsp90 as observed in the split-ubiquitin assay. This 
prompted further analysis of these peptides and BLASTP was again performed but with the 
exclusion of the low complexity filter. This was done with the intention of surveying and 
identifying plasmodial proteins with these short peptides in their protein sequences. Results 
from BLASTP with the low complexity filter removed revealed an interesting finding for the 
“K N G M K K” peptide sequence. The sequence GMKK appears to be present only in 12 P. 
falciparum proteins and one of which is a putative FKBP-like peptidyl-prolyl cis-trans 
isomerase (MAL13P1.68). FKBP peptidyl-prolyl cis-trans isomerases are well-known co-
chaperones of the human and yeast Hsp90s and they are essential in promoting the 
maturation of steroid receptor client proteins (Riggs et al., 2007; Riggs et al., 2003). Hence, it 
would be of interest to investigate the interaction between the putative FKBP-like peptidyl-
prolyl cis-trans isomerase and PfHsp90 using full-length recombinant proteins, and explore 
its potential role as a co-chaperone of PfHsp90 in future studies. 
Taken together, the split-ubiquitin screen in this study has identified two PfHsp90 
interaction partners that would be of interest for further study. Nevertheless, based on the 
results of the screen, it is clear that the spectrum of constructs detected with PfHsp90 
interaction is narrow and could be improved to identify more PfHsp90-interacting proteins. 
Although the repeated detection of the same peptide/protein sequence provided support 
on the authenticity of the interaction observed, it could also signal that some of these 
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sequences are present in high abundance in the mRNA that was used to construct the P. 
falciparum cDNA library. The presence of high abundant transcripts encoding 
proteins/peptides that interact with the protein of interest would greatly hinder the 
detection of interacting-proteins encoded by low abundant transcripts. Hence, one of the 
possible improvements to the current screen is through the reconstruction of a normalized 
cDNA library. Methods for normalization of cDNA library have been described (Zhulidov et 
al., 2004) and they are useful in decreasing the prevalence of highly abundant transcripts in 
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9.1 Introduction  
In Chapter 8, the split-ubiquitin assay was carried out to screen for interaction 
partners of PfHsp90, in the attempt to identify novel client proteins of PfHsp90. The split-
ubiquitin assay uncovered two PfHsp90-interacting proteins (PF13_0165 and MAL13P1.68) 
that are of much interest, one of which could be a potential client protein involved in RNA 
processing. However, the protein-protein interaction screen was unable to detect any 
interacting kinases or transcription factors as anticipated, in view that they are the major 
client proteins of Hsp90s in human and yeast. To further broaden the search for potential 
PfHsp90’s client protein, literature and bio-computational analyses were concurrently 
carried out and these have led to the identification of two plasmodial proteins that may 
associate with PfHsp90; PF11_0147, the mitogen-activated protein kinase 2 (PfMap2) and 
PF11_0161, the cysteine protease falcipain 2B (PfFP2B).   
The mitogen-activated protein kinase (MAPK) cascade is an essential signal 
transduction pathway that regulates cellular growth and differentiation in the eukaryotes 
(Pearson et al., 2001). The modular MAPK cascade is composed of three components; a 
MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K) and a MAPK. The MAPK signaling 
cascade progresses with an activated MAP3K that would phosphorylate and activate a 
MAP2K, which would in turn phosphorylate and activate the downstream MAPK. In human 
and yeast, Hsp90 has been reported to regulate each of the three components of the MAPK 
pathway. Hsp90’s functionality was shown to be essential in maintaining the stability of Raf-
1 (a MAP3K) (Schulte et al., 1995; Schulte et al., 1996), MEK (a MAP2K) (Stancato et al., 1997) 
and the activation of ERK-5 (a MAPK) kinase activity (Truman et al., 2006). Abrogation of 
Hsp90’s activity through the use of specific inhibitors (e.g. geldanamycin) resulted in the 
rapid degradation of Raf-1 and MEK and the loss of activity in ERK-5. In P. falciparum, 
genomic analysis revealed that the classical three-component MAPK pathway is not 
conserved in the malaria parasite (Ward et al., 2004). Efforts to map the homologous MAPK 
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pathway in P. falciparum could only identify two plasmodial MAPK, PfMap1 and PfMap2 
(Doerig et al., 1996; Dorin et al., 1999; Graeser et al., 1997). So far, homologues of MAP3K 
and MAP2K appear to be absent in the genome. This has certainly raised doubts on the 
existence of a MAPK pathway in P. falciparum. Nevertheless, recent studies have identified a 
kinase from the NIMA-like family, PfNek3, which could phosphorylate and activate the 
activity of PfMap2, similar to that expected of a MAP2K (Low et al., 2007; Lye et al., 2006). 
Hence, the current evidence suggests that P. falciparum is likely to possess a functional 
MAPK pathway, albeit an atypical one where the MAP2K- and MAP3K-like activities are 
elicited by non-MAPK pathway kinases. In addition, gene knock-out studies have highlighted 
the essentiality of the MAPK pathway for the survival of P. falciparum, where the deletion of 
PfMap2 resulted in intra-erythrocytic stage developmental arrest (Dorin-Semblat et al., 
2007). In view of the importance of PfMap2 in P. falciparum and Hsp90’s general 
involvement with kinases in the MAPK pathway, the association between PfMap2 and 
PfHsp90 was pursued in this study.    
In the case of PfFP2B, its association with PfHsp90 was predicted in a bio-
computational study on P. falciparum chaperone network (Pavithra et al., 2007). PfFP2B was 
postulated to interact with PfHop (PF14_0324), a putative co-chaperone of PfHsp90. The 
interaction between PfHop and PfHsp90 was only recently demonstrated by co-
immunoprecipitation using recombinant proteins (Gitau et al., 2011). As the co-chaperone 
Hop is generally known to be involved in the transfer of client proteins from Hsp70 to Hsp90 
in the human and yeast, the predicted interaction between PfHop and PfFP2B would suggest 
the latter being a potential client protein of PfHsp90. The cysteine protease PfFP2B is known 
to be involved in the degradation of hemoglobin where together with a cohort of aspartic 
proteases (i.e. plasmepsins) and other cysteine proteases (i.e. PfFP2A and PfPF3), PfFP2B 
metabolizes hemoglobin in the food vacuole of P. falciparum and releases free amino acids 
for the parasite’s protein synthesis (Liu et al., 2006; Rosenthal, 2004). The potential 
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involvement of PfHsp90 in hemoglobin degradation is also supported by another 
independent study which reported the association of PfHsp90 with ferriprotoporphyrin IX, a 
toxic product from hemoglobin metabolism (Famin and Ginsburg, 2003). Hence, to further 
investigate PfHsp90’s potential involvement in the hemoglobin degradation pathway, 
PfHsp90 interaction with PfFP2B was analyzed in this study.  
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9.2 Materials and Methods 
9.2.1 Recombinant clones of PfMap2, PfNek3 and PfFP2B 
Recombinant plasmids containing P. falciparum 3D7 PfMap2 (PlasmoDB ID: 
PF11_0147) and PfNek3 (PlasmoDB ID: PFL0080c) were available in the laboratory (Low et al., 
2009). The PfMap2 obtained was encoded in the pET24a (Novagen) expression vector and 
would be expressed as a fusion protein with a C-terminal His6-tag. As for PfNek3, the gene 
had been cloned into the pGEX-6P-1 (GE Healthcare) expression vector and would be 
expressed as a fusion protein with an N-terminal GST-tag.  
The recombinant plasmid of PfFP2B (PlasmoDB ID: PF11_0161) from P. falciparum 
3D7 was previously cloned in the laboratory (Goh et al., 2003). The recombinant plasmid 
carried the mature domain of PfFP2B (amino acid residues 242 to 482) in the pMAL-c2X 
(New England Biolabs) expression vector. The full-length PfFP2B was not used as the 
inclusion of the pro-domain (amino acid residues 1 to 241) impaired recombinant protein 
expression (Goh et al., 2003). Hence, only the mature domain of PfFP2B that contained the 
substrate-binding and catalytic sites was cloned. PfFP2B would be expressed as a fusion 
protein with an N-terminal maltose binding protein (MBP)-tag. The PfMap2, PfNek3 and 
PfFP2B recombinant plasmids were provided as E. coli BL21 (DE3) recombinant clones.  
 
9.2.2 Expression and purification of PfMap2, PfNek3 and PfFP2B recombinant proteins 
The expression and purification of recombinant PfMap2 from the pET24a expression 
vector were carried out using an identical protocol described for PfHsp90, which was also 
cloned into the same expression vector (Chapter 5, Section 5.2.3). As for PfNek3 and PfFP2B, 
the bacterial clones were grown at 37°C in Luria Bertani broth, supplemented with 40 ug/ml 
kanamycin (Sigma) and 40 ug/ml ampicillin (Sigma) respectively until an OD600 of 0.8 was 
reached. Protein expression was induced by the addition of 1 mM isopropyl-β-D-1-
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thiogalactopyranoside (Sigma) followed by incubation at 24°C with shaking at 250 rpm for 16 
hr. 
Subsequently, bacterial cells were harvested, lysed by sonication and PfFP2B 
recombinant protein was purified from the cell lysate. Affinity purification was performed 
using amylose resins (New England Biolabs) followed by gel filtration separation on a 
Superdex 200 column (GE Healthcare) to obtained purified PfFP2B recombinant proteins. 
The concentration of the purified fusion proteins were determined by Bradford Assay 
(Biorad) using bovine serum albumin (Sigma) as a standard. As for PfNek3, the cell lysate was 
subjected to glutathione sepharose beads, washed to remove the unbound proteins and 
subsequently used for kinase assay reaction.  
 
9.2.3 GST pull-down assay to investigate the PfHsp90’s interaction with PfMap2 and 
PfFP2B 
The GST pull-down assay was carried out using an identical protocol described for 
Pfp23 (Chapter 6, Section 6.2.5). 
 
9.2.4 PfMap2 kinase assay 
PfMap2 was subjected to kinase assay in the presence of PfNek3 to obtain 
phosphorylated PfMap2 (termed PfNek3-phosphorylated PfMap2 hereafter). To carry out 
the assay, 100 ul of bacterial cell lysate containing approximately 10 ug of GST-tagged 
PfNek3 was subjected to 50 ul of glutathione sepharose beads to immobilize the 
recombinant PfNek3. The unbound proteins were removed by washing and the glutathione 
sepharose beads containing PfNek3 were reconstituted in 250 ul of kinase assay buffer (50 
mM Tris-HCl, pH7.5, 10 mM MgCl2, 0.5 mM ATP). Subsequently, 25 ug of PfMap2 was added 
into the reaction mixture and incubated at 30°C for 30 min. Following that, the reaction 
mixture was centrifuged and the supernatant containing the PfNek3-phosphorylated 
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PfMap2 was collected. The unphosphorylated PfMap2 was also subjected to similar kinase 
assay reaction condition, except in the absence of PfNek3. The supernatants containing 
PfNek3-phosphorylated PfMap2 and the unphosphorylated PfMap2 respectively were added 
directly to PfHsp90 that has already been immobilized on the glutathione sepharose beads 
for the GST pull-down assay (Figure 9.1).   
  




























Figure 9.1 Schematic illustration of the strategy employed to compare PfNek3-phosphorylated 
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9.3 Results  
9.3.1 PfMap2 interacts with PfHsp90 in the presence of MgCl2 and ATP 
The GST pull-down assay was employed to investigate the interaction between 
PfMap2 and PfHsp90. To carry out the assay, 2 ug of the dual-tagged PfHsp90 (with an N-
terminal GST-tag and a C-terminal His6-tag) was immobilized on glutathione sepharose 
beads and incubated with PfMap2 (with a C-terminal His6-tag) that was added in an excess 
of 25 ug. The binding reaction was performed either in the presence or absence of 5 mM 
MgCl2, 5 mM ADP and 5 mM ATP. Under the different conditions tested, PfMap2 was 
observed to interact with PfHsp90 only in the presence of MgCl2 and ATP (Figure 9.2). No 
interaction was detected between PfMap2 and GST in the controls performed under similar 
experimental conditions.      
 
9.3.2 PfHsp90 interacts with PfNek3-phosphorylated PfMap2 and unphosphorylated 
PfMap2  
A study in yeast revealed that the association of the MAPK ERK-5 with Hsp82 was 
enhanced when the TEY motif in the kinase activation loop of ERK-5 was phosphorylated 
(Truman et al., 2006). In P. falciparum, PfMap2 was found to possess a slightly modified 
motif of TSH in the corresponding kinase activation loop (Dorin et al., 1999). Recent study 
has shown that PfNek3 phosphorylates the threonine residue at the TSH motif and 
consequently stimulates the kinase activity of PfMap2 (Low et al., 2007). Hence, to 
investigate whether the phosphorylated PfMap2 would also exhibit increased binding to 
PfHsp90 similar to that observed between the phosphorylated ERK-5 and Hsp82 in yeast, 
PfHsp90’s respective interaction with PfNek3-phosphorylated PfMap2 and the 
unphosphorylated PfMap2 were compared. The binding assays were carried out in the 
presence of MgCl2 and ATP, and subsequently analyzed by Western blotting using anti-His6 
and anti-phosphothreonine antibodies. The anti-His6 antibody detects for PfHsp90, PfNek3-
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phosphorylated PfMap2 and unphosphorylated PfMap2, whereas the anti-
phosphothreonine antibody detects only proteins that have been phosphorylated at their 
threonine residues (i.e. PfNek3-phosphorylated PfMap2).             
Western blot analysis performed using anti-His6 antibody revealed a band that 
corresponded to that of PfMap2 in PfHsp90 reactions incubated with PfNek3-
phosphorylated PfMap2 and the unphosphorylated PfMap2 respectively (Figure 9.3A). Using 
the anti-phosphothreonine antibody, a faint band was observed at an identical position to 
that of PfMap2 detected in the anti-His6 analysis, in the PfHsp90 reaction incubated with 
PfNek3-phosphorylated PfMap2 (Figure 9.3B). The results indicated that PfHsp90 interacts 
with both the PfNek3-phosphorylated PfMap2 and the unphosphorylated PfMap2 
respectively. The PfNek3-phosphorylated PfMap2 was not observed to have increased 
binding to PfHsp90 as compared to the unphosphorylated PfMap2 based on the anti-His6 
analysis. 
 
9.3.3 PfNek3-phosphorylated PfMap2 increases the level of threonine phosphorylation in 
PfHsp90 
Although the PfNek3-phosphorylated PfMap2 did not exhibit increased binding to 
PfHsp90 as compared to the unphosphorylated PfMap2, the PfHsp90 incubated with 
PfNek3-phosphorylated PfMap2 was observed to have a higher level of threonine 
phosphorylation as compared to that incubated with unphosphorylated PfMap2. The anti-
His6 analysis showed that the levels of PfHsp90 present in the reactions with PfNek3-
phosphorylated PfMap2 or unphosphorylated PfMap2 were comparable (Figure 9.3A). 
However, when probed with anti-phosphothreonine antibody, the PfHsp90 signal was 
observed to be higher in the reaction incubated with PfNek3-phosphorylated PfMap2 than 
that of unphosphorylated PfMap2 (Figure 9.3B). The results indicated that PfNek3-
phosphorylated PfMap2 is likely to phosphorylate PfHsp90 on threonine residue(s).    






































Figure 9.2 SDS-PAGE analysis of the interaction between PfMap2 and PfHsp90 
A. The interaction between PfMap2 and PfHsp90 was investigated by GST pull-down assay 
using purified recombinant proteins. In each 500-ul reaction, 2 ug PfHsp90 was immobilized 
on 50-ul glutathione sepharose beads and used to pull-down PfMap2 that was added in an 
excess of 25 ug. The assay was performed either in the presence or absence of 5 mM MgCl2, 
5 mM ADP and 5 mM ATP. PfMap2 was observed to interact with PfHsp90 only in the 
presence of MgCl2 and ATP. B. No interaction was observed between PfMap2 and GST in the 
control experiments performed under similar reaction conditions. Results shown are 








MgCl2 - +  + + - 
ADP - -  + - - 
ATP - -  - + - 
MgCl2 - +  + + - 
ADP - -  + - - 
ATP - -  - + - 
A. 
B. 














































Figure 9.3 Western blot analyses of PfHsp90 interaction with PfNek3-phosphorylated 
PfMap2 and unphosphorylated PfMap2 
A. PfHsp90 was tested for its interaction with both PfNek3-phosphorylated and 
unphosphorylated PfMap2 using GST pull-down assay in the presence of MgCl2 and ATP. 
PfNek3-phosphorylated PfMap2 was prepared by incubating PfMap2 with PfNek3 in kinase 
assay reaction as described in the Materials and Methods. Unphosphorylated PfMap2 used 
was also subjected to similar kinase assay reaction condition but without the presence of 
PfNek3. Western Blot analysis using anti-His6 antibody revealed an approximately 60 kDa 
band (*) that corresponded to that of PfMap2 in lane 2 and 3, indicative of the respective 
interaction of the unphosphorylated PfMap2 and PfNek3-phosphorylated PfMap2 with 
PfHsp90. B. As PfNek3 is known to phosphorylate PfMap2 at the threonine 290 amino acid 
residue, the blot was further analyzed by anti-phosphothreonine (anti-pThr) antibody. The 
blot was stripped to remove anti-His6 antibody and reprobed with anti-Thr antibody. As 
shown in lane 4 and 5, the unphosphorylated PfMap2 exhibited little threonine 
phosphorylation whereas upon incubation with PfNek3, a high threonine phosphorylation 
signal was detected.  A faint band of approximately 60 kDa (**) that was observed in lane 3 
but absent in lane 2 is likely to be the PfMap2 that has been phosphorylated by PfNek3. 
Surprisingly, the PfHsp90 incubated with PfNek3-phosphorylated PfMap2 (lane 3) 
demonstrated a higher threonine phosphorylation signal as compared to the PfHsp90 
incubated with or without the unphosphorylated PfMap2 (lane2 and 1 respectively). The 
result indicated that PfNek3-phosphorylated PfMap2 may phosphorylate PfHsp90 on 
threonine residue(s). Results shown are representative of two independent experiments. 
 
 
Legend (A. & B.): 
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9.3.4 PfNek3 does not increase the level of threonine phosphorylation in PfHsp90 
As PfNek3-phosphorylated PfMap2 was pre-incubated in kinase reaction with 
PfNek3 prior to use in PfHsp90 interaction study, it was necessary to investigate whether the 
increased level of threonine phosphorylation detected in PfHsp90 earlier could be due to 
contaminating PfNek3 in the PfNek3-phosphorylated PfMap2 protein preparation. Using 
similar experimental procedures, PfNek3 was incubated in kinase reaction and subsequently 
mixed with PfHsp90 in the binding assay buffer. It is important to note that PfNek3 and 
PfHsp90 were both GST-tagged and hence, their simultaneous presence in the Western blot 
analysis is not indicative of interaction between the two proteins. Using anti-GST antibody, 
both PfHsp90 and PfNek3 were detected in the reactions (Figure 9.4A). When probed with 
anti-phosphothreonine antibody, the PfHsp90 incubated with PfNek3 showed comparable 
threonine phosphorylation level as compared to the PfHsp90 that was not incubated with 
PfNek3 (Figure 9.4B). Hence, the results indicated that PfNek3 does not phosphorylate 
PfHsp90 on threonine residue, and the increased threonine phosphorylation observed in 
PfHsp90 earlier is likely to be due to the activity of PfNek3-phosphorylated PfMap2.    
 
9.3.5 PfFP2B interaction with PfHsp90 requires MgCl2 and ADP or ATP 
PfFP2B was investigated for its interaction with PfHsp90 using GST pull-down assay 
either in the presence or absence of 5 mM MgCl2, 5 mM ADP and 5 mM ATP. SDS-PAGE 
analysis revealed that PfFP2B interacts with PfHsp90 in the presence of MgCl2 and ADP or 
ATP (Figure 9.5). No interaction was detected between PfFP2B and GST in the controls 
performed under similar experimental conditions.    
  

































Figure 9.4 PfNek3 does not enhance the threonine phosphorylation signal in PfHsp90 
A. PfNek3 was investigated for its ability to phosphorylate PfHsp90 under the binding 
conditions used for investigating PfHsp90-PfMap2 interaction. Similar to the treatment of 
PfNek3-phosphorylated PfMap2, PfNek3 was subjected to kinase reaction prior to 
incubation with PfHsp90 in the GST pull-down assay conditions. Western Blot analysis using 
anti-GST antibody revealed the presence of PfHsp90 and PfNek3 in the reaction mixture. B. 
Upon further analysis with anti-phosphothreonine (anti-pThr) antibody, no significant 
increase in PfHsp90 phosphorylation was detected in the presence of PfNek3. The results 
indicated that PfHsp90 is not phosphorylated by PfNek3. Results shown are representative 
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Figure 9.5 SDS-PAGE analysis of the interaction between PfFP2B and PfHsp90  
A. GST pull-down assay was performed to investigate the interaction between PfFP2B and 
PfHsp90 using purified recombinant proteins. In each 500-ul reaction, 2 ug PfHsp90 was 
immobilized on 50-ul glutathione sepharose beads and used to pull-down MBP-
PfFP2B/PfFP2B that was added in an excess of 25 ug. The assay was performed either in the 
presence or absence of 5 mM MgCl2, 5 mM ADP and 5 mM ATP. MBP-PfFP2B/PfFP2B was 
observed to interact with PfHsp90 in the presence of MgCl2/ATP and MgCl2/ADP. B. As a 
control, MBP-PfFP2B/PfFP2B was investigated for its interaction with GST in a similar 
experimental set up. Under the conditions tested, no interaction was observed between 
MBP-PfFP2B/PfFP2B and GST. This indicated that the binding observed between PfHsp90 
and MBP-PfFP2B/PfFP2B is a result of PfHsp90’s interaction with PfFP2B. Results shown are 
representative of two independent experiments. 
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Initial literature review on Hsp90’s association with kinases in the MAPK pathway in 
human and yeast suggested that PfHsp90 may potentially regulate the atypical MAPK 
pathway in P. falciparum through PfMap2. A study on yeast has demonstrated the 
association between Hsp82 and the MAPK ERK-5, and their interaction was also shown to be 
stronger when the latter was phosphorylated (Truman et al., 2006). Using recombinant 
proteins and GST pull-down assay, PfHsp90 was shown in this study to interact with PfMap2. 
However, unlike the yeast homologues, a stronger interaction was not observed between 
PfHsp90 and the PfMap2 that has been phosphorylated by PfNek3. Surprisingly, PfNek3-
phosphorylated PfMap2 was observed to enhance the level of threonine phosphorylation in 
PfHsp90 instead. This unexpected increased threonine phosphorylation was only observed in 
PfHsp90 that was incubated with PfNek3-phosphorylated PfMap2 and not in the reaction 
containing unphosphorylated PfMap2. This indicated that the increased threonine 
phosphorylation in PfHsp90 is effected by PfMap2 upon phosphorylation by PfNek3.  
PfMap2 has been characterized as a serine/threonine kinase and its deletion in P. 
falciparum demonstrated to be lethal (Doerig et al., 1996; Dorin-Semblat et al., 2007; Dorin 
et al., 1999). Although shown to be functional and important for the malaria parasite, the 
native substrates of PfMap2 in P. falciparum remain largely unknown. Kinase 
characterization studies have previously identified PfNek3 to be an upstream regulator of 
PfMap2 (Lye et al., 2006). PfNek3 phosphorylates PfMap2 on the threonine residue at 
position 290, as attested by mass spectrometric analysis, and consequently stimulates the 
kinase activity of PfMap2 (Low et al., 2007). Together with the results from this study, it 
appears that the stimulated PfNek3-phosphorylated PfMap2 would act on and 
phosphorylate threonine residue(s) in PfHsp90.  
Recent studies on yeast Hsp82 revealed that the molecular chaperone is regulated 
by casein kinase 2, which is also a serine/threonine kinase (Mollapour et al., 2011a; 
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Mollapour et al., 2011b). Casein kinase 2 phosphorylates Hsp82 on the threonine residue at 
position 22 (T22) and influences its chaperone function and sensitivity to Hsp90-specific 
inhibitors. Using a combination of site-directed mutagenesis and phosphomimetic 
substitutions, phosphorylation at residue T22 was indirectly shown to diminish the ATPase 
activity of Hsp82. Nevertheless, the T22 phosphorylation effect on the chaperone activity of 
Hsp82 is less clear, as the phosphomimetic Hsp82 mutant would activate some of its known 
clients more effectively than the others. For example, the T22E mutant that was supposed to 
mimic an Hsp82 with phosphorylation at residue T22, displayed enhanced activity in the 
activation of glucocorticoid receptor but diminished ability to chaperone some of its known 
kinase clients such as v-Src, Ste11, and Mpk1/Slt2. A recent study has also reported that 
yeast expressing the Hsp82 phosphomimetic T22E mutant as the sole Hsp90 species, was 
observed to be more sensitive to Hsp90-specific inhibitors as compared to yeast strains 
carrying wild-type Hsp82 or the non-phosphomimetic T22A mutant (Mollapour et al., 2011a). 
Hence, although the effects of phosphorylation on Hsp90 has yet to be clearly established, 
there is a general consensus that this post-translational modification has important 
influences and implications on the functioning of Hsp90 as a molecular chaperone. As 
phosphorylation is emerging to be an important mode of regulation on Hsp90, studying the 
types of phosphorylation (i.e. serine-, threonine- and tyrosine-residue specific) present in 
PfHsp90 and their effects on its chaperone function would be an important aspect to further 
the understanding on the modulation of the molecular chaperone in the malaria parasite. To 
this end, it would be of interest to determine the threonine phosphorylation site(s) of 
PfMap2 on PfHsp90 and investigate the influence of the phosphorylation on the chaperone 
function of PfHsp90, particularly in the aspects of its ATPase activity, co-chaperones 
interaction and sensitivity to Hsp90-specific inhibitors in future studies. 
In addition, this study has also demonstrated the interaction between PfHsp90 and 
PfFP2B, the cysteine protease that is involved in the essential hemoglobin degradation 
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pathway in P. falciparum. This has provided the necessary experimental evidence to support 
the association between PfHsp90 and PfFP2B as first detected in a bio-computational study 
(Pavithra et al., 2007). As the hemoglobin degradation pathway is known to be mediated by 
several other cysteine proteases apart from PfFP2B, namely falcipain 2A (PfFP2A) and 
falcipain 3 (PfFP3) (Rosenthal, 2004), it would be of interest to investigate whether PfHsp90 
also interacts with PfFP2A and PfFP3 respectively. Furthermore, PfFP2B shares high amino 
acid sequence similarities and overlapping functional roles with PfFP2A and PfFP3 (Sijwali 
and Rosenthal, 2004).     
In summary, this part of the study has identified PfMap2 as a potential regulator of 
PfHsp90. The observed increased threonine phosphorylation in PfHsp90 attributed to 
PfNek3-phosphorylated PfMap2 provides an interesting lead to study the effects of 
phosphorylation in PfHsp90. Similarly, the demonstration of PfHsp90’s interaction with 
PfFP2B may indicate the falcipain(s) to be client proteins of PfHsp90. Nevertheless, further 
research is required to investigate whether the activity of PfFP2B is directly influenced by 
the functionality of PfHsp90. If so, this would open up new research interests on the role and 
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10.1 Summary and Future Directions 
Hsp90 is a well-known molecular chaperone in eukaryotes that folds and activates 
many proteins key to biochemical pathways essential for cellular growth and development 
(Taipale et al., 2010). This project has focused on the characterization of Hsp90 from P. 
falciparum, the parasite that causes the most lethal form of malaria in human. Prior to this 
study, PfHsp90 has been reported to be essential for the intra-erythrocytic development of P. 
falciparum (Banumathy et al., 2003). Treatment of in vitro P. falciparum culture with Hsp90-
specific inhibitor resulted in developmental arrest in the intra-erythrocytic stage progression, 
mainly from the ring to the trophozoite stage, and subsequently led to parasitic death. The 
importance of PfHsp90 for the survival of P. falciparum has consequently highlighted its 
potential development as a drug target for malaria inhibition. However, apart from the 
recognition of its potential as an anti-malarial drug target, very little is known on the 
molecular function and biology of PfHsp90 in the malaria parasite. Hence, this project was 
initiated to characterize PfHsp90’s functionality, regulation and interaction partners in the 



























Figure 10.1 A summary of the findings in this study. In Chapter 5, the functionality of 
PfHsp90 was investigated using heterologously expressed and purified recombinant proteins. 
Chapters 6 and 7 present the interaction of PfHsp90 with Pfp23 and PfAha1 respectively, and 
the influences of their interactions on the regulation of PfHsp90’s ATPase activity. 
Subsequent Chapters 8 and 9 explore the interaction partners of PfHsp90 in the attempt to 
better understand the biological roles of PfHsp90 in the malaria parasite P. falciparum.    
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10.1.1 P. falciparum encodes an Hsp90 with active ATPase activity 
This study has provided the first evidence on the ATPase activity of PfHsp90. The 
ATPase activity is known to be crucial in driving conformational changes in human and yeast 
Hsp90s for client protein interaction and activation (Panaretou et al., 1998; Prodromou and 
Pearl, 2003). Hence, having an active ATPase activity is central to the functionality of Hsp90. 
In the previous P. falciparum inhibition studies where the essentiality of PfHsp90 was 
demonstrated using Hsp90-specific inhibitor, PfHsp90 was assumed to possess a functional 
ATPase activity which when inactivated, would lead to the death of the malaria parasite. 
Although the interaction between the Hsp90-specific inhibitor (i.e. geldanamycin) and 
PfHsp90 was demonstrated, evidence for the ATPase activity of PfHsp90 was neglected. 
Hence, one of the early objectives of this project was to investigate whether PfHsp90 
possesses an active ATPase activity, which forms the basis of its inhibition in P. falciparum.  
Using recombinant proteins, PfHsp90 was shown to have an ATPase activity 
comparable to that of yeast Hsp82 and approximately ten times lower than that of human 
Hsp90 (Chua et al., 2010). The measured ATPase activity of PfHsp90 was found to be 
sensitive to inhibition by radicicol, another Hsp90-specific inhibitor, and is also consistent 
with that published subsequently by Pallavi et al. (2010). This study is also the first to 
describe a methodology for the heterologous expression and purification of PfHsp90 
recombinant protein. The availability of a reliable procedure to obtain a constant supply of 
active PfHsp90 recombinant protein is an imperative requirement for subsequent 
biochemical and protein interaction studies. In addition, the introduction of a dual-tagged 
PfHsp90 in this study was demonstrated to be useful and feasible for GST pull-down assay in 
studying the interaction partners of PfHsp90. Collectively, these methods would facilitate 
the procurement of PfHsp90 recombinant proteins for biochemical, structural and protein 
interaction studies in the future. 
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10.1.2 Regulation of PfHsp90 by co-chaperones Pfp23 and PfAha1 
Co-chaperones are well-known regulators of Hsp90’s chaperone function. In human 
and yeast, certain co-chaperones have been demonstrated to modulate the ATPase activity 
of Hsp90 and promote the activation of its client proteins. In the case of P. falciparum, 
earlier studies conducted prior to this project were unable to detect PfHsp90’s interaction 
with the putative co-chaperones (i.e. Pfp23 and PfAha1) identified from the malaria 
parasite’s genome (Kumar et al., 2007). Coupled with the low sequence conservation 
between the plasmodial and the human/yeast co-chaperones, this has raised doubts on 
whether the regulation and modus operandi of the Hsp90 system is conserved in P. 
falciparum. Hence, following the demonstration of the functionality of PfHsp90’s ATPase 
activity, PfHsp90 was subsequently investigated for its interaction with the two putative co-
chaperones, Pfp23 and PfAha1.  
PfHsp90 was shown to interact with Pfp23 and PfAha1 respectively using GST pull-
down assays. The binding of Pfp23 was further demonstrated to exert an inhibitory effect on 
the ATPase activity of PfHsp90. On the contrary, the association of PfAha1 stimulated the 
ATPase activity of PfHsp90. The binding of Pfp23 and PfAha1 to PfHsp90 were observed to 
be mutually exclusive, plausibly due to overlapping binding sites on PfHsp90 as supported by 
the analysis of their computationally modelled tertiary structure complex. The influences 
that Pfp23 and PfAha1 exert on the ATPase activity of PfHsp90 upon interaction are also 
indicative of their potential regulatory roles in modulating the in vivo chaperone activity of 
PfHsp90 in P. falciparum. To this end, this study has provided evidence on the interaction 
and regulation of PfHsp90 by the plasmodial co-chaperones and the results support the 
presence of an Hsp90 chaperone system in P. falciparum.       
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10.1.3 Emerging insights to co-chaperones’ influence on Hsp90’s affinity for inhibitors 
Apart from regulating Hsp90’s chaperone function, recent studies have 
demonstrated that certain co-chaperones interaction can confer protection against the 
lethal cellular effects caused by Hsp90-specific inhibitors. Genetic studies in yeast revealed 
that strains with co-chaperone genes Sti1 and Sba1 deleted respectively, displayed 
phenotypes that are hypersensitive to Hsp90-specific inhibitors. These observations 
indicated that the presence of Hop/Sti1 and p23/Sba1 would interfere with the biological 
effects of the inhibitors (Piper et al., 2003). Subsequent in vitro binding assays demonstrated 
that this could be due to Hsp90’s diminished affinity for the inhibitors when the molecular 
chaperone interacts and complexes with Hop/Sti1 and p23/Sba1, respectively. The binding 
of Hop/Sti1 resulted in an Hsp90 conformation with low affinity for the inhibitors 
(Prodromou et al., 1999), whereas p23/Sba1 trapped Hsp90 in the ATP-bound state, thereby 
preventing the inhibitor that shares the same binding site as ATP from interacting with 
Hsp90 (Forafonov et al., 2008). Similar protective effects against Hsp90-specific inhibitors 
have also been described for Aha1 (Zurawska et al., 2010). It was observed that Hsp90 
mutants that bind Aha1 tightly were able to suppress the lethal cellular effects exerted by 
Hsp90-specific inhibitors. As isothermal titration calorimetric analysis indicated that Aha1 
interaction did not significantly affect the affinity of Hsp90 for the inhibitors, the protective 
effects observed were attributed to improved Hsp90’s chaperone function (by having a 
higher ATPase activity) upon Aha1’s association. Conceivably, the activation of Hsp90’s 
activity would negate the loss of function in a subset of Hsp90 with the inhibitors bound 
which normally would have caused a collapse in the cellular activities.  
Collectively, these studies indicated that the abrogation of Hsp90’s interaction with 
certain co-chaperones could potentially enhance the lethal cellular effects of Hsp90-specific 
inhibitors. Hence, with increasing understanding on the roles of co-chaperones in the 
regulation of Hsp90’s function and their influence on the biological effects exerted by 
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Hsp90-specific inhibitor, it is imperative to (1) uncover and validate Hsp90-co-chaperone 
interactions with regards to the Plasmodium parasite and (2) assess the influence of these 
co-chaperone associations on PfHsp90’s affinity for the inhibitors to facilitate considerations 
on the use of Hsp90-specific inhibitors as anti-malarial drugs. This study has demonstrated 
the interaction between PfHsp90 and the co-chaperones, Pfp23 and PfAha1 respectively, 
and it would be interesting to investigate whether their binding alters PfHsp90’s affinity for 
the inhibitors in future studies. Also, mutagenesis studies conducted on Pfp23 and PfAha1 
have revealed amino acid residues in these co-chaperones that are crucial for mediating 
interaction with PfHsp90. The information may be useful in designing inhibitors in future for 
selective disruption of the co-chaperone’s interaction with PfHsp90, should the abrogation 
of their association proved to be useful in crippling the malaria parasite. Taken together, 
knowledge on the factors that regulate and influence PfHsp90’s affinity for the inhibitors are 
necessary and crucial for exploitation of PfHsp90 as an anti-malarial drug target. Such 
knowledge may also provide a mechanistic understanding on plausible drug resistance that 
may arise through modulation of PfHsp90’s sensitivity to the inhibitors.  
 
10.1.4 Uncovering the biological roles of PfHsp90 through its protein partners 
One of the conventional strategies to uncover the biological role of a protein is to 
identify its protein partners and relate to their cellular functions. In a parallel conception, 
knowledge on the interaction partners of PfHsp90 and their biochemical pathways 
involvement would shed light on the cellular roles of PfHsp90 in P. falciparum. Hence, to 
expand the current knowledge on the interaction partners of PfHsp90, the split-ubiquitin 
assay was carried out to screen for interacting proteins from a prepared P. falciparum cDNA 
library. Results from the split-ubiquitin screen revealed PF13_0165 to be an interacting 
potential client protein of PfHsp90. PF13_0165 is currently annotated as a conserved 
Plasmodium protein with unknown function. Nevertheless, computational analysis revealed 
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the presence of a RNA recognition motif in PF13_0165 that may suggest its involvement in 
RNA processing, considering that Hsp90s in the human and yeast chaperone client proteins 
that have been implicated in RNA modification pathways (Boulon et al., 2008; Chen et al., 
2007; Zhao et al., 2008). In addition, literature review has also indicated PfHsp90’s potential 
involvement in the hemoglobin degradation pathway in P. falciparum (Pavithra et al., 2007). 
The hemoglobin degradation pathway is an important process that supplies the malaria 
parasite with the necessary amino acids for protein synthesis (Liu et al., 2006). Using the GST 
pull-down approach, PfHsp90 was demonstrated to interact with one of the major cysteine 
proteases, PfFP2B, crucial for the degradation of hemoglobin. The implications of PfHsp90-
PfFP2B interaction would be an interesting research subject for investigation, as hemoglobin 
degradation is one of the essential pathways in the malaria parasite for survival.  
So far, the inhibition of PfHsp90 has been demonstrated to be lethal to P. falciparum 
although the precise mechanism on how the abrogation of PfHsp90 could lead to parasitic 
death remains unclear. As PfHsp90 is likely to assume a chaperone function in P. falciparum, 
with the assistance of co-chaperones whose interaction have been demonstrated in this 
study, it is plausible that the parasitic death observed could be a result of the inactivation of 
certain PfHsp90’s client proteins (due to PfHsp90’s inhibition) that are involved in crucial 
biochemical pathways responsible for cellular growth and differentiation. Hence, expanding 
the knowledge of PfHsp90’s clientele would not only aid in deciphering the cellular roles and 
functions of PfHsp90, in the aspect of the biochemical pathways that it regulates in P. 
falciparum, but also reveal client proteins that have essential roles in the development of 
the parasite. These client proteins may in turn be valuable molecular targets that could be 
inactivated singly for malaria inhibition. This highlights the value in uncovering the 
interaction partners of PfHsp90 and the continual need to do so, albeit the inherent 
difficulties in handling plasmodial proteins and studying their interaction using the 
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conventional protein-protein interaction methods i.e. co-immunoprecipitation, pull-down 
and yeast two-hybrid or similar systems. 
 
10.1.5 Regulation of PfHsp90’s activity through phosphorylation? 
Phosphorylation is one of the post-translational modifications that have emerged to 
be important in regulating the chaperone function of Hsp90. In yeast, casein kinase 2 was 
recently elucidated to phosphorylate Hsp82 on the threonine residue at amino acid position 
22 (T22) (Mollapour et al., 2011b). The phosphorylation at T22 reportedly led to diminished 
ATPase activity, affected Hsp82’s interaction with the co-chaperones Aha1 and Cdc37, 
resulted in varying client protein activation efficiencies and sensitized yeast cells expressing 
the mutant Hsp82 to Hsp90-specific inhibitors. Although how the phosphorylation at T22 
leads to the observed functional changes in Hsp82 is still not fully understood at the 
mechanistic level, it is likely to be attributed to structural changes in Hsp82 induced by the 
introduction of a phosphate group at that particular amino acid residue. In the course of 
identifying potential novel client proteins of PfHsp90 through protein-protein interaction in 
this study, the plasmodial MAPK PfMap2 was unexpectedly observed to enhance the level of 
threonine phosphorylation in PfHsp90. The enhancement was further revealed to be 
mediated only by PfMap2 that has already been activated through phosphorylation by 
PfNek3. PfNek3 was previously shown to be an upstream regulator that phosphorylates and 
stimulates the kinase activity of PfMap2 (Low et al., 2009; Low et al., 2007). In the absence 
of PfNek3, the unphosphorylated PfMap2 was unable to increase the level of threonine 
phosphorylation in PfHsp90. Hence, considering the major influence that phosphorylation 
can exert on the chaperone function of Hsp90 as demonstrated in yeast, it would be of 
interest to investigate the effects of PfMap2’s phosphorylation on the chaperone function of 
PfHsp90. The PfMap2 phosphorylation site(s) on PfHsp90 can be identified by mass 
spectrometric analysis (through comparing peptide fragments of PfHsp90 incubated with 
Chapter 10: Conclusion 
218 
 
unphosphorylated PfMap2 and PfNek3-phosphorylated PfMap2 respectively) and the effects 
of phosphorylation on PfHsp90 can be assessed subsequently by ATPase assays and co-
chaperone interaction studies. This would certainly provide a good lead in uncovering new 
factors that can regulate the activity of the plasmodial Hsp90, apart from the already known 
co-chaperones. 
  




Perspectives on Hsp90 research 
It has been almost 20 years since Hsp90 first entered the limelight of biological 
research. The landmark discovery by Whitesell et al. (1994) on the association between 
geldanamycin, a cancer-inhibitory compound, and Hsp90 had instantly illuminated scientists 
on the possibility of targeting Hsp90 for cancer treatment. Since then, Hsp90 has been 
intensely studied from its basic structure and functions, to its biology in phenotypic 
evolution and human diseases. Research investigation over the past decade has revealed 
Hsp90 to be quite a challenging molecule to study. The dynamicity of its protein structure 
and the complexity of its protein interaction network are slowly beginning to be appreciated 
with the advent of technology and omics-based (i.e. genomics, proteomics etc.) research. 
Although structural studies have provided a wealth of information on the various tertiary 
conformations assumed by Hsp90 (mostly constrained to static positions/images), how 
Hsp90 chaperones its diverse spectrum of client proteins is still not well-understood as it is 
highly challenging to capture the dynamic motion of Hsp90 at work. Nevertheless, the 
structural information has facilitated studies on Hsp90’s association with inhibitors and the 
latter’s potential application in the treatment of cancers and other human diseases. 
Currently, there are more than 10 Hsp90 inhibitors that are being evaluated in clinical trials 
for cancer therapy (Chapter 3, Table 3.4).  
In all likelihood, the next 10 years will be one of the most exciting decades in the 
study of Hsp90 as important findings from various Hsp90 research facets will begin to 
emerge. Basic research: Biophysical techniques such as isothermal titration calorimetry, 
fluorescence resonance energy transfer and advanced protein imaging are rapidly adopted 
and becoming gold-standards in the study of Hsp90’s interaction and structural 
conformations. These techniques are sensitive and some provide access to capturing the 
dynamic motion of Hsp90 as it transits between the various structural configurations. Hence, 
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it may not be long before the precise mechanism on how Hsp90 activates its client proteins 
will be deconvoluted. Clinical research: Many clinical trial reports on the safety and efficacy 
of Hsp90 inhibitors for cancer treatment will be published over the next few years. This will 
provide important data on the safety and therapeutic profiles of these Hsp90 inhibitors and 
a clear outlook on their use as anti-cancer drugs in future. Some of these inhibitors are likely 
to be explored as anti-infectives for the treatment of other human diseases, and the already 
available safety data would greatly benefit the economy of drug testing.  
Plasmodium research: In the case of malaria, PfHsp90 has been recognized as a drug 
target and correspondingly, Hsp90-specific inhibitors as potential anti-malarial drugs. A 
recent study has demonstrated the anti-malarial activities of geldanamycin derivatives as 
they were used to treat P. yoelii infected mice (Mout et al., 2012). However unlike 
conventional anti-malarial drugs that kill the parasite rapidly, the geldanamycin derivatives 
appeared to render the parasite into an attenuated state. This prolonged the residing time 
of the parasite in the host and apparently, facilitated the generation of an immune response 
against the malaria parasite. Interestingly, the treatment outcome of geldanamycin 
derivatives seems to bear close resemblance to that expected of a malaria vaccine in that 
the cured mice exhibited robust protection against subsequent malaria infection. The study 
has provided a proof-of-concept on targeting the plasmodial Hsp90 for malaria inhibition. 
Nevertheless, scientists and clinicians recognized the need to identify Hsp90-specific 
inhibitors that are highly selective against the plasmodial Hsp90 (with little/no effect on the 
human Hsp90), if any Hsp90-specific inhibitor is to be used as an anti-malarial drug. This is 
crucial considering that off-target effects on human Hsp90 is toxic. Hence, it is likely that 
much effort will be invested (i.e. compound/drug libraries screening) to identify small 
molecule that selectively inhibit the plasmodial Hsp90 in near future for anti-malarial drug 
development. As for the basic research aspect of malaria, perhaps the real excitement lies in 
unveiling the cellular functions of the mysterious pool of hypothetical proteins with 
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unknown functions that are encoded by approximately 50% of P. falciparum genome 
(Aurrecoechea et al., 2009). These proteins do not exhibit homology to proteins in other 
eukaryotic organisms and thus, are likely to be unique to the Plasmodium parasite. It would 
not be surprising if a subset of these proteins is essential for the cellular functioning of P. 
falciparum. Hence, these hypothetical proteins represent untapped potential that if 
uncovered, could potentially be targeted for anti-malarial purposes. With the recognition 
and decorations that Hsp90 received in chaperoning many proteins crucial to cellular growth 
and development, perhaps the plasmodial Hsp90 is the key to baiting the cellularly essential 
proteins from this current large pool of unknown macromolecules in P. falciparum.   
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Appendix II 
Protein Standard Curve Used in this Study 
All protein concentrations measured in this study by Bradford assay were calculated with 
respect to the bovine serum albumin (BSA, Sigma Chemicals) protein standard curve. The 
protein standard curve was prepared using concentrations of BSA ranging from 0.1 to 0.8 
mg/ml. The figure below shows a representative BSA protein standard curve. Protein 
samples were subjected to Bradford assay and their absorbance at wavelength of 595 nm 
were measured. The concentrations of the protein samples were subsequently determined 
by extrapolating against the BSA protein standard curve. Duplicates were performed for 
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a  b  s  t  r  a  c  t
The  recent  recognition  of Plasmodium  falciparum  Hsp90  (PfHsp90)  as  a promising  anti-malaria  drug  target
has  sparked  interest  in  identifying  factors  that  regulate  its  function  and  drug-interaction.  Co-chaperones
are  well-known  regulators  of  Hsp90’s  chaperone  function,  and  certain  members  have been  implicated  in
conferring  protection  against  lethal  cellular  effects  of  Hsp90-speciﬁc  inhibitors.  In this  context,  studies
on PfHsp90’s  co-chaperones  are  imperative  to gain  insight  into  the  regulation  of the  chaperone  in  the
malaria  parasite.  In this  study,  a  putative  co-chaperone  P. falciparum  Aha1  (PfAha1)  was  identiﬁed  and
investigated  for its interaction  and  regulation  of  PfHsp90.  A previous  genome-wide  yeast  two-hybrid
study  failed  to identify  PfAha1’s  association  with  PfHsp90,  which  prompted  us  to  use  a  directed  assay  to
investigate  their  interaction.  PfAha1  was  shown  to interact  with  PfHsp90  via the  in  vivo  split-ubiquitin
assay  and  the  association  was  conﬁrmed  in  vitro  by GST  pull-down  experiments.  The  GST  pull-down  assay
further revealed  PfAha1’s  interaction  with  PfHsp90  to  be dependent  on  MgCl2 and  ATP, and  was  competed
by  co-chaperone  Pfp23  that  binds  PfHsp90  under  the same  condition.  In  addition,  the PfHsp90–PfAha1
complex  was  found  to be sensitive  to disruption  by high  salt,  indicating  a polar  interaction  between
them.  Using  bio-computational  modelling  coupled  with  site-directed  mutagenesis,  the polar  residue
N108  in PfAha1  was found  to be strategically  located  and essential  for PfHsp90  interaction.  The  functional
signiﬁcance  of  PfAha1’s  interaction  was clearly  that of  exerting  a  stimulatory  effect on the ATPase  activity
of PfHsp90,  likely  to  be essential  for  promoting  the activation  of  PfHsp90’s  client  proteins.. Introduction
Protein folding and activation mediated by the molecular chap-
rone Hsp90 (Heat shock protein 90) is a complex ATP-driven
rocess that is regulated by a cohort of accessory proteins termed
o-chaperones (reviewed in Pearl and Prodromou, 2006; Neckers
t al., 2009; Taipale et al., 2010). A subset of these co-chaperones
e.g. Hop, p23, and Aha1) coordinates the progression of Hsp90’s
haperone cycle by modulating the ATPase activity of Hsp90 that
s tightly coupled to its conformational states (Wandinger et al.,
008; Hessling et al., 2009; Li et al., 2011). The co-chaperone Aha1
Activator of Hsp90 ATPase) is known to associate with Hsp90 and
Abbreviations: 5-FOA, 5-ﬂuoroorotic acid; ADP, adenosine diphosphate; Aha1,
ctivator of Hsp90 ATPase 1; ATP, adenosine triphosphate; Cub, C-terminal half
f  ubiquitin; DNA, deoxyribonucleic acid; GST, glutathione S-transferase; His6,
exa-histidine; Hsp90, Heat shock protein 90; Ni-NTA, nickel-nitrilotriacetic acid;
MR, nuclear magnetic resonance; Nub, N-terminal half of ubiquitin; PCR, poly-
erase chain reaction; PDB, Protein Data Bank; SDS–PAGE, sodium dodecyl
ulfate–polyacrylamide gel electrophoresis; WT,  wild-type.
∗ Corresponding author. Tel.: +65 65163280; fax: +65 67766872.
E-mail address: micsimts@nus.edu.sg (T.S. Sim).
357-2725/$ – see front matter ©  2011 Elsevier Ltd. All rights reserved.
oi:10.1016/j.biocel.2011.10.021© 2011 Elsevier Ltd. All rights reserved.
activate its ATPase activity to promote the activation of Hsp90’s
client protein.
Aha1 was  initially discovered as a homologue of Saccha-
romyces cerevisiae Hch1, a suppressor of growth defect observed
in temperature sensitive yeast strain carrying mutant Hsp82
(Hsp90 in yeast) with E381K substitution (Nathan et al., 1999;
Panaretou et al., 2002). Gene deletion studies in yeast indicated
that both Aha1 and Hch1 are non-essential for viability, although
temperature sensitive phenotypes were observed in the single
and double deletion-strains constructed i.e. AHA1, HCH1 and
AHA1–HCH1 (Panaretou et al., 2002; Lotz et al., 2003). Never-
theless, the deletion of Aha1 signiﬁcantly impaired the activation
of glucocorticoid receptor and v-Src kinase in yeast, suggesting that
the presence of the co-chaperone is essential for functional matu-
ration of these Hsp82 client proteins (Lotz et al., 2003; Meyer et al.,
2003). Similar observation has been made in an siRNA study con-
ducted on mammalian cell culture where downregulation of Aha1
led to drastically reduced level of activated glucocorticoid receptors
(Harst et al., 2005). Together with the observed role in activat-
ing Hsp90’s ATPase activity, Aha1 has been proposed as a positive
regulator of Hsp90’s chaperone function, whose association with
Hsp90 is important in driving certain client proteins towards their
activated states.



























































Primers designed for gene cloning and mutations.
































































a Restriction enzyme sites are in lowercase; F represents forward primer; R rep-34 C.S. Chua et al. / The International Journal o
In Plasmodium falciparum,  a putative Aha1 (PfAha1; PlasmoDB
ccession number: PFC0270w) that shares approximately 20%
mino acid sequence identity with that of the yeast homologue
as been described in a computational study (Kumar et al., 2007).
s the putative PfAha1 has not been characterized prior to this
tudy, its role as a co-chaperone of P. falciparum Hsp90 (PfHsp90)
emains elusive. PfHsp90 has recently emerged as a promising drug
arget for malaria inhibition (Pesce et al., 2010; Shonhai, 2010) as
ts speciﬁc inhibitors have been shown to cause growth arrests in
. falciparum intra-erythrocytic stage cultures (Banumathy et al.,
003; Kumar et al., 2003). This indicates PfHsp90’s involvement
n crucial biological pathways in P. falciparum and thereafter its
nhibition, an attractive avenue to abrogate the cellular activities
f the parasite. Despite recognizing the importance of PfHsp90 for
he survival of the parasite, knowledge on the chaperone function
nd regulation of PfHsp90 remains limited, partly due to difﬁcul-
ies in genetic manipulation of the Plasmodium parasite. So far,
o-immunoprecipitation and yeast two-hybrid experiments were
nable to provide evidence on the association between PfHsp90
nd many putative co-chaperones (e.g. Aha1, Hop, and p23) that
re known to play essential roles in the yeast and human Hsp90
haperone cycle (Banumathy et al., 2003; LaCount et al., 2005). The
nteraction between P. falciparum p23 (Pfp23) and PfHsp90 was
nly recently elucidated using recombinant proteins and GST pull-
own approach, whereby Pfp23 reportedly exerts an inhibitory
ffect on the ATPase activity of PfHsp90 (Chua et al., 2010). In view
f the importance of Aha1 in the yeast and human Hsp90 chap-
rone system for client protein activation, the putative PfAha1 is
nvestigated in this study with the intention of characterizing its
nteraction and regulation of PfHsp90.
. Materials and methods
.1. Split-ubiquitin assay
The use of the split-ubiquitin system for investigating protein
nteraction in yeast has been described previously (Lehming, 2002;
aser et al., 2000). PfHsp90 (PF07 0029) and PfAha1 (PFC0270w)
ere reverse transcribed and ampliﬁed from the mRNA extracted
rom P. falciparum 3D7 (MRA-102, MR4, ATCC Manassas, VA) and
ubsequently used as a template to clone the respective PfHsp90
PfHsp90N, PfHsp90M and PfHsp90C) and PfAha1 (PfAha1N and
fAha1C) domains using appropriate forward and reverse primers
Table 1). PfHsp90N, PfHsp90M and PfHsp90C DNA products were
igested with EcoRI and SalI and ligated into the Cub-RUra3p vector
Wittke et al., 1999), whereas PfAha1, PfAha1N and PfAha1C were
igested with BglII and SalI  and subsequently cloned into the Nub
ector (Laser et al., 2000). The recombinant plasmids were trans-
ormed into Escherichia coli DH5 cells and their authenticity were
eriﬁed by DNA sequencing.
To investigate the interaction between PfHsp90 and PfAha1,
he appropriate PfHsp90-Cub-RUra3p and Nub-PfAha1 fusion con-
tructs were co-transformed into the S. cerevisiae strain JD52 and
lated onto media lacking leucine and tryptophan to select for
ransformants that carried both constructs. Subsequently, the yeast
ells that contained both the recombinant PfHsp90-Cub-RUra3p
nd Nub-PfAha1 fusion constructs were tenfold serial-diluted and
ropped onto plates lacking leucine and tryptophan, onto plates
dditionally lacking uracil and onto plates additionally containing
-ﬂuoroorotic acid (5-FOA).
.2. Construction of PfHsp90 and PfAha1 plasmids for
ecombinant protein expression
The molecular cloning of PfHsp90 into expression vectors pGK
nd pET24a (Novagen) has been reported (Chua et al., 2010). Forresents reverse primer.
b Codons mutated in PfAha1 are in bold and underlined.
cloning of PfAha1 into bacterial expression vector, PfAha1 was  re-
ampliﬁed by PCR from the Nub-PfAha1 recombinant plasmid using
appropriate forward and reverse primers (Table 1), digested with
BamHI and XhoI, and ligated into the expression vector pET24a.
The ligated recombinant plasmid was  transformed into E. coli BL21
(DE3) cells that contained a RIG plasmid (Baca and Hol, 2000) for
recombinant protein expression. DNA sequencing was  performed
to authenticate the recombinant clone that carries PfAha1.
2.3. Expression and puriﬁcation of PfHsp90, Pfp23 and PfAha1
recombinant proteinsThe expression and puriﬁcation of PfHsp90 and Pfp23 recom-
binant proteins have been described (Chua et al., 2010). An
identical protocol used for the expression and puriﬁcation of Pfp23
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xpression vector, pET24a (Novagen). The concentration of the
uriﬁed fusion proteins were determined by Bradford Assay (Bio-
ad) using bovine serum albumin (Sigma) as a standard.
.4. In vitro interaction assay between PfHsp90 and PfAha1
The puriﬁed dual-tagged PfHsp90 fusion protein (GST-tag at the
-terminus and His6-tag at the C-terminus of PfHsp90) expressed
rom the pGK vector was used as bait to capture interacting PfAha1
ecombinant protein. In each 500-l reaction, 2 g PfHsp90 fusion
rotein was incubated with 50 l of glutathione Sepharose beads
GE Healthcare) at 4 ◦C for 15 min. The bound PfHsp90 fusion pro-
eins were washed thrice with 50 mM Tris–HCl, pH 7.5 buffer, to
emove unbound proteins. Subsequently, the beads were reconsti-
uted in 500 l of binding buffer (50 mM Tris–HCl, pH 7.5, 25 mM
Cl, 2 mM dithiothreitol, 0.01% (v/v) Triton X-100). The binding
ssay was carried out in the presence of 5 mM  MgCl2, 5 mM ATP and
 M PfAha1, unless stated otherwise. Samples were incubated at
0 ◦C for 30 min  to allow any formation of PfHsp90–PfAha1 com-
lex. In the case of competitive binding assays between PfAha1
nd Pfp23, this was followed by the addition of 0.1–4 M Pfp23 and
ncubated for an additional 30 min  at 30 ◦C. Thereafter, the samples
ere washed thrice with 500 l of binding buffer prior to elution
n 150 l of reduced glutathione buffer. 50 l of the eluted sample
as analyzed by SDS–PAGE. Gel image analyses and densitometric
easurements were performed using Bio-Rad Molecular Imager
el Doc XR system equipped with the Quantity One® Software.
.5. Construction of PfAha1 single, double and quadruple mutants
QuikChangeTM Site-directed Mutagenesis Kit from Stratagene
as employed for the construction of PfAha1 single mutants, using
he recombinant pET24a plasmid that contains PfAha1 as a tem-
late. Appropriate primers were designed (Table 1) and the desired
utations were introduced using the following PCR cycling param-
ters: (1) 95 ◦C for 1 min, (2) 95 ◦C for 30 s, (3) 55 ◦C for 30 s,
4) 72 ◦C for 14 min, (5) 28 cycles of steps 2–4 and (6) 72 ◦C for
 min. DNA sequencing was carried out to verify the substitution
f the nucleotide sequences, followed by transformation into E. coli
L21 (DE3) with the RIG plasmid for recombinant fusion protein
xpression. PfAha1 double and triple mutants were respectively
onstructed from veriﬁed PfAha1-containing plasmids with single
nd double mutations, using the appropriate mutagenic primers.
.6. ATPase assay
The ATPase activity of PfHsp90 was measured using the
yruvate kinase/lactate dehydrogenase-coupled assay described
reviously with some modiﬁcations (Chua et al., 2010). In this
xperiment, recombinant PfHsp90 with a single His6-tag at the
-terminus, expressed from the pET24a vector was used. As
fHsp90–PfAha1 interaction is salt-sensitive, a low KCl concentra-
ion was used to promote their association. Brieﬂy, the assay was
arried out in a 200-l reaction containing 2 M PfHsp90, 25 mM
ris–HCl pH 7.5, 4 mM KCl, 1.2 mM MgCl2, 0.8 mM ATP, 2 mM
hosphoenolpyruvate, 0.2 mM NADH, 50 g/ml lactate dehydro-
enase and 0.2 mg/ml  pyruvate kinase. Radicicol, a Hsp90-speciﬁc
nhibitor, was used at a ﬁnal concentration of 200 M to speciﬁcally
nhibit the ATPase activity of PfHsp90 for accurate determination
f its ATP turnover rate.
.7. Bio-computational analyses of PfHsp90 interaction with
fAha1 and Pfp23
A modelled PfHsp90–PfAha1 complex was  constructed using
he crystal structure of PfAha1 (PDB accession number: 3N72) and aemistry & Cell Biology 44 (2012) 233– 245 235
computationally predicted structure of PfHsp90 (Chua et al., 2010).
To model the PfHsp90–PfAha1 complex, the yeast Hsp82–Aha1
crystal structure complex (PDB accession number: 1USV) was used
as a template for superimposition. Similarly, Pfp23 was modelled
and superimposed against the yeast Hsp82–Sba1 crystal struc-
ture (PDB accession number: 2CG9) and compared with that of
the modelled PfHsp90–PfAha1 complex. The superimposition and
visualization of the tertiary structures were performed using the
Swiss-PdbViewer (SPdbV) program (Guex et al., 1999).
3. Results
3.1. P. falciparum genome encodes two putative Aha1
Homology search revealed two  putative copies of Aha1 in
the genome of P. falciparum,  namely PFC0270w and PFC0360w.
PFC0270w encodes a 349 amino acid protein that shares approx-
imately 20% amino acid identity with the human and yeast Aha1.
On the other hand, PFC0360w is relatively shorter with 140 amino
acid residues and displayed only approximately 13% amino acid
identity with the human and yeast Aha1. The proteins of both puta-
tive homologues of Aha1 were detected in the intra-erythrocytic
stages of P. falciparum (Le Roch et al., 2003). Multiple sequence
analysis further revealed that the shorter PFC0360w is aligned to
the C-terminal portion of the human and yeast Aha1 (Fig. 1) with
no homologous N-terminal domain. As the N-terminal domain of
Aha1 has been shown to be important for interaction and induc-
ing structural rearrangement in Hsp90 to promote ATP hydrolysis
(Meyer et al., 2003, 2004), the lack of a homologous N-terminal
domain in PFC0360w has prompted the study to focus on the char-
acterization of PFC0270w, the longer putative copy of Aha1 in P.
falciparum (PfAha1 refers to PFC0270w hereafter). Moreover, the
crystal structure of the N-terminal domain of PFC0270w (PDB:
3N72) was  recently resolved, and thus warrants investigation on
its functionality as a co-chaperone of PfHsp90.
3.2. Detection of the PfAha1–PfHsp90 interaction by the
split-ubiquitin assay
To characterize the putative co-chaperone, the putative PfAha1
was ﬁrst investigated for its ability to interact with PfHsp90
using the split-ubiquitin system. The split-ubiquitin system is an
alternative yeast two-hybrid assay that exploits the principle of
conditional proteolysis which occurs when a ubiquitin molecule is
fused to a protein. In this system, the ubiquitin molecule is split
into an N-terminal half (Nub) and a C-terminal half (Cub) where
neither half is capable of inducing proteolytic cleavage. A modiﬁed
Ura3p with an arginine at the ﬁrst position (RUra3p) fused to the C-
terminal end of Cub is used as a reporter gene. Yeast cells expressing
protein X-Cub-RUra3p fusion proteins are uracil prototrophs and
sensitive to 5-FOA, as Ura3p, orotidine-5′-phosphate decarboxy-
lase, is required for the biosynthesis of uracil and also converts
5-FOA into toxic ﬂuorouracil. In the event that protein X interacts
with protein Y fused to Nub, the Cub and Nub halves are brought into
close proximity and reconstitute into a native-like ubiquitin. This
is recognized by the ubiquitin-speciﬁc proteases and results in the
cleavage of RUra3p. The free RUra3p is rapidly degraded due to the
inclusion of the arginine that is a destabilizing residue in the N-
end rule pathway (Varshavsky, 1996). Hence protein interaction is
inferred from the degradation of RUra3p in yeast cells, indicated by
the lack of growth in media lacking uracil and resistance to 5-FOA.To test whether the putative PfAha1 interacts with PfHsp90,
the full-length and respective domains of PfHsp90 (PfHsp90N,
PfHsp90M and PfHsp90C; Fig. 2) were cloned into the Cub-RUra3p
vector and PfAha1 into the Nub vector. All the PfHsp90Cub-RUra3p







aig. 1. Protein sequence alignment of human, yeast and putative P. falciparum Aha1. P
ith  the human Aha1 (NP 036243.1) and yeast Aha1 (NP 010500.1). (A) PFC0270w
B)  PFC0360w mapped to the C-terminal domain.usion constructs when transformed into yeast cells respectively
onferred growth on plates lacking uracil (results not shown).
his indicated that the various PfHsp90 constructs were expressed
s functional Cub-RUra3p fusion proteins. The expression of thearum genome encodes two  putative Aha1, PFC0270w and PFC0360w. When aligned
yed high homology to the N-terminal domain whereas the shorter homologue andPfAha1 constructs in yeast was veriﬁed by Western blotting against
the HA-tag found at the Nub fusion proteins (Fig. 2). Subsequently,
the PfHsp90-Cub-RUra3p and Nub-PfAha1 fusion constructs were
co-transformed into yeast cells and titrated onto plates lacking
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Fig. 2. Analysis of the PfAha1–PfHsp90 interaction by the split-ubiquitin assay. (A) Schematic representation of the various PfHsp90 and PfAha1 constructs generated for
the  split-ubiquitin assay. (B) Western blot analysis of Nub-PfAha1 fusion proteins. All the Nub-PfAha1 fusion proteins contain a HA-tag respectively and were probed using
anti-HA antibody. The Nub-PfAha1N and Nub-PfAha1C fusion proteins were expressed at a signiﬁcantly higher level than Nub-PfAha1FL. For each lane, 10 g of lysate from
yeast  cells carrying the respective Nub-PfAha1 constructs were loaded. (C) PfAha1FL, PfAha1N and PfAha1CNub fusion constructs were respectively co-transformed with each








gdditionally lacking uracil (-LWU) and onto plates additionally containing 5-ﬂuoro
LWU  plate with complementary increased growth on the 5-FOA plate.
ryptophan and leucine (as a control to detect for yeast cells car-
ying both Cub-RUra3p and Nub recombinant plasmids), lacking
ryptophan, leucine and uracil (reduced growth indicates degrada-
ion of RUra3p and hence interaction between PfAha1 and PfHsp90)
nd lacking tryptophan, leucine but containing 5-FOA (increased
rowth indicates PfAha1–PfHsp90 interaction). acid (5-FOA). A protein–protein interaction is indicated by reduced growth on the
Initial split-ubiquitin assay performed using full-length
PfHsp90-Cub-RUra3p did not reveal any signiﬁcant interaction
with Nub-PfAha1 (data not shown). As the interaction is inferred
from the degradation of RUra3p that occurs when the Cub and
Nub halves are brought in close proximity, the lack of interac-
tion observed between the full-length PfHsp90-Cub-RUra3p and
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Fig. 3. Expression of PfHsp90 and PfAha1 recombinant proteins. PfHsp90 and
PfAha1 were solubly expressed as recombinant tagged fusion proteins; PfHsp90 has




































Fig. 4. SDS–PAGE analysis of the interaction between PfAha1 and PfHsp90 deter-
mined by GST pull-down assay. GST pull-down assay was employed to investigate
the interaction between PfAha1 and PfHsp90. In each 500-l reaction, 2 g PfHsp90
was immobilized on 50-l glutathione Sepharose beads and used to pull-down
PfAha1 that was added in an excess of 2 M (44 g). The assay was performed either
PfAha1 on PfHsp90 interactionis6-tag. M:  protein marker (Biorad).
ub-PfAha1 could possibly be due to the large protein size of
fHsp90 that hinders the proximity required for the reconstitution
f the Cub and Nub halves. Thus, if two proteins interact but the
ub and Cub fused to them respectively are not brought sufﬁciently
lose enough (e.g. due to steric hindrance, size, orientation, etc.)
o be reconstituted as a native-like ubiquitin molecule, their
nteraction will not be reﬂected in this assay. Hence, PfHsp90 was
ubsequently dissected into its respective smaller domains and
ested for their interaction with PfAha1.
When Nub-PfAha1 was  co-transformed with the respective
fHsp90-Cub-RUra3p domain constructs, a slight growth reduction
n the uracil-lacking plate was observed for yeast cells harboring
he Nub-PfAha1 and PfHsp90M-Cub-RUra3p constructs (Fig. 2). This
as complemented by an increased growth on the 5-FOA plate.
ence, the result suggested that PfAha1 interacts with the middle
omain of PfHsp90. To further analyze the interaction, PfAha1 was
issected into two parts, the N- and C-terminal domains (PfAha1N
nd PfAha1C, respectively; Fig. 2), based on sequence alignment to
he yeast Aha1 and Hch1 to investigate the domain that is inter-
cting with PfHsp90. The PfAha1 domains were cloned into the
ub vector and they were each co-transformed with the respective
fHsp90-Cub-RUra3p fusion constructs. Signiﬁcant growth reduc-
ion on the uracil-lacking plate and growth increment on the 5-FOA
late were observed for yeast cells harboring Nub-Aha1N/Aha1C
nd PfHsp90M-Cub-RUra3p (Fig. 2). The results indicated that both
he N- and C-terminal domains of Aha1 interact with the middle
omain of PfHsp90.
.3. Expression and puriﬁcation of recombinant PfAha1 and
fHsp90
To verify the interaction observed between PfAha1 and PfHsp90
n the split-ubiquitin assay, recombinant proteins were prepared
or in vitro interaction assay. PfAha1 was expressed and puriﬁed as
 recombinant fusion protein with a C-terminal His6-tag of approx-
mately 44 kDa whereas PfHsp90 as a 114 kDa dual-tagged fusion
rotein with an N-terminal GST and a C-terminal His6-tag (Chua
t al., 2010) (Fig. 3).in  the presence or in the absence of 5 mM MgCl2, 5 mM ADP or/and 5 mM ATP. The
interaction between PfAha1 and PfHsp90 was only observed in the presence of MgCl2
and ATP. Result shown is representative of three independent experiments.
3.4. PfAha1 interacts with PfHsp90 in the presence of MgCl2 and
ATP
The interaction between the PfAha1 and PfHsp90 was probed
using GST pull-down assay where 2 g of PfHsp90 was  immobi-
lized on glutathione Sepharose beads and used to pull-down PfAha1
that was  added in excess. PfHsp90’s association with the putative
PfAha1 was  tested in various conditions, either in the presence
or absence of 5 mM MgCl2, ADP and/or ATP. Consistent with the
results from the split-ubiquitin assay, PfAha1 was found to inter-
act with PfHsp90. In addition, based on the different conditions
tested, the interaction between PfHsp90 and PfAha1 was observed
to require MgCl2 and ATP (Fig. 4). No interaction was  detected
between PfAha1 and GST in the controls performed under similar
experimental conditions (data not shown).
3.5. PfAha1 and PfHsp90 interaction is disrupted under high salt
condition
Previous study on yeast indicated that the interaction between
Aha1 and Hsp82 to be sensitive to high salt concentration
(Panaretou et al., 2002). To test whether the binding of PfAha1
to PfHsp90 is also affected by high salt content, their association
was investigated using buffers with increasing salt concentra-
tions i.e. 10 mM,  25 mM,  50 mM,  75 mM,  100 mM,  125 mM and
150 mM KCl. High salt concentration is known to disrupt ion-
pair and polar–polar interaction by ‘insulating’ the charges on the
protein through the salt ions, and hence preventing effective inter-
action between the two  proteins. At a low concentration of KCl
(i.e. 10 mM),  PfAha1 binds PfHsp90 as expected. However, in the
presence of increasing concentrations of KCl (25–100 mM KCl),
the association between PfAha1 and PfHsp90 was progressively
reduced (Fig. 5). At 150 mM KCl, the interaction between PfAha1
and PfHsp90 was  almost completely disrupted. The observed
results indicated that the association between PfAha1 and PfHsp90
may  be dependent on ion-pair and/or polar–polar interaction medi-
ated by charged and/or polar amino acid residues in the two
proteins.
3.6. Mutational effects of residues E15, R58, E67, D94 and K127 inThe crystal structure of yeast Aha1 complexed with Hsp82
(PDB accession number: 1USV) revealed two interacting interfaces
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Fig. 5. Interaction between PfAha1 and PfHsp90 is sensitive to disruption by high salt concentration. (A) To investigate whether the association between PfAha1 and PfHsp90
is  dependent on polar–polar and ion-pair interaction, the PfAha1–PfHsp90 binding assay was carried out in the presence of 5 mM MgCl2, 5 mM ATP and with increasing
concentrations of KCl (10–150 mM).  SDS–PAGE analysis revealed a gradual reduction in the level of PfAha1 bound to PfHsp90 when KCl was introduced in increasing
concentrations. (B) The effect of KCl on PfAha1 binding to PfHsp90 was  analyzed by densitometry. The percentage of PfHsp90 bound was calculated with respect to the
























tample  with PfHsp90 only; PfAha1 with respect to the PfAha1 bound to PfHsp90 at
isrupted. Result shown is representative of three independent experiments.
nvolving polar amino acid residues in Aha1 that are important for
inding Hsp82 i.e. (1) residues D53, D68, E97, and D101 (inter-
ct with residues K387, K390, K394, and K398 in Hsp82) and
2) residues E122, D110 and R128 (interact with residues K469,
514, and E515 in Hsp82). Of these residues, three were found
o be conserved in PfAha1 by sequence alignment, namely, E67
D68 in yeast Aha1), D94 (E97 in yeast Aha1) and K127 (R128 in
east Aha1) (Fig. 1). In addition, analyses of the modelled com-
lex of PfHsp90–PfAha1 structure revealed two additional charged
esidues in PfAha1, E15 and R58, that could potentially interact with
fHsp90. Hence, to investigate whether these conserved charged
mino acid residues in PfAha1 are essential in forming ion-pair
nteraction with PfHsp90, site-directed mutagenesis was  carried
ut where alanine substitutions were introduced to replace the
ighlighted residues. The PfAha1 single mutants E15A, R58A, E67A,
94A and K127A were solubly expressed, puriﬁed and their ability
o interact with PfHsp90 was tested and compared to that of PfAha1
ild-type (PfAha1-WT).
Results from the GST pull-down assay showed that these
fAha1 single mutants had comparable PfHsp90 binding capacity
s PfAha1-WT (Fig. 6), indicating that single amino acid mutation
t these residues did not affect PfAha1’s interaction with PfHsp90.
o further evaluate the effect of these substitutions, the muta-
ions were combined and the resulting PfAha1 mutants were tested KCl. At 150 mM KCl, the interaction between PfAha1 and PfHsp90 is signiﬁcantly
for their ability to interact with PfHsp90. Similar to that of the
single mutants, PfAha1 double (E15A/R58A and E67A/D94A) and
quadruple (E15A/R58A/E67A/D94A) mutants were able to bind
PfHsp90 at levels comparable to that of PfAha1-WT. Likewise,
substituting these single, double and quadruple PfAha1 mutants
to an amino acid residue with oppositely charged side chain
(i.e. E15K, R58D, E67K, D94K, K127D, E15K/R58D, E67K/D94K
and E15K/R58D/E67K/D94K) did not signiﬁcantly affect PfAha1’s
interaction with PfHsp90 (results not shown). Hence, the results
indicated that residues E15, R58, E67, D94 and K127 in PfAha1 are
not important for interaction with PfHsp90. All the PfAha1 mutants
were solubly expressed and no interaction was observed between
these mutants and GST in the controls performed under similar
experimental conditions (results not shown).
3.7. Amino acid residue N108 in PfAha1 is essential for PfHsp90
interaction
As the proposed conserved charged residues in PfAha1 were
found to be non-essential for PfHsp90 interaction, other residues
that were observed in the modelled PfHsp90–PfAha1 complex
to be potentially involved in binding PfHsp90 were investi-
gated i.e. E91, F98, N108, E110, R111 and R119 (Fig. 7). As
residues in proximity may  potentially form interfaces that are
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Fig. 6. Amino acid substitutions at residues E15, R58, E67, D94 and K127 in PfAha1 did not affect interaction with PfHsp90. (A) Amino acid residues in PfAha1 that were
postulated to be important for forming ion-pair interaction with PfHsp90 were mutated to investigate their importance for PfHsp90 interaction. SDS–PAGE analysis revealed
that  the respective PfAha1 single mutants (i.e. E15A, R58A, E67A, D94A and K127A) possessed comparable PfHsp90 binding capacity to that of PfAha1-WT. Combination
of  these substitutions in PfAha1 double (E15A/R58A and E67A/D94A) and quadruple (E15A/R58A/E67A/D94A) mutants also did not compromise their binding to PfHsp90.


























sutants bound to PfHsp90. The percentage of PfHsp90 and PfAha1 bound are calcul
ndependent experiments.
mportant for interaction, these residues were mutated singly and
ubsequently combined into double, triple or quadruple PfAha1
utants to investigate their involvement in PfHsp90 interac-
ion. Similarly, these residues were substituted to an alanine
nd the PfAha1 mutants were tested for their ability to interact
ith PfHsp90 using the GST pull-down assay. Seven additional
ha1 mutants were constructed; 3 single mutants (E91A, F98A
nd N108A), a double mutant (E91A/N108A), 2 triple mutants
E67A/D94A/F98A and E110A/R111A/R119A) and a quadruple
utant (E110A/R111A/R119A/K127A). SDS–PAGE analysis of the
ulled down complexes revealed that PfAha1 single mutant N108A
ad signiﬁcantly diminished binding to PfHsp90, retaining only
pproximately 20% of PfAha1-WT binding (Fig. 8). When further
ombined with the E91A mutation, the resulting PfAha1 double
utant E91A/N108A displayed almost no observable binding to
fHsp90. Hence, the results indicated that the residue N108 in
fAha1 is essential for interaction with PfHsp90. On the other
and, alanine substitutions at residues F98, E110, R111 and R119
n PfAha1 had negligible effects on PfHsp90 interaction, suggest-
ng that these residues are not important for binding PfHsp90.
ll the PfAha1 mutants were solubly expressed and no interac-
ion was observed between these mutants and GST in the controls
erformed under similar experimental conditions (results not
hown).ith respect to the sample with PfAha1-WT. Result shown is representative of three
3.8. PfAha1 competes with Pfp23 to interact with PfHsp90
Previous study on the interaction between the co-chaperone
Pfp23 and PfHsp90 demonstrated the requirement of MgCl2 and
ATP for effective association (Chua et al., 2010). Since the bind-
ing conditions were similar to that required for the formation of
PfAha1–PfHsp90 complex as shown in this study, the interaction
between PfHsp90 and PfAha1 was  further examined in the pres-
ence of Pfp23. In the experiment, the immobilized PfHsp90 was
ﬁrst incubated with PfAha1 (2 M)  for complex formation, followed
by the addition of Pfp23 in increasing concentrations (0.5–4 M).
SDS–PAGE analyses of the complexes pulled down by PfHsp90
revealed that Pfp23, when introduced in increasing concentrations,
gradually displaced PfAha1 from PfHsp90 (Fig. 9A). Repeating the
experiment with an initial incubation of PfHsp90 with Pfp23 (2 M)
and a subsequent addition of PfAha1 in increasing concentrations
(0.5–4 M)  yielded a similar interaction trend whereby the co-
chaperone that is added at a higher concentration (i.e. PfAha1)
would displace the other co-chaperone that is of lower concentra-
tion (i.e. Pfp23) from PfHsp90 (Fig. 9B). Hence, the results indicated
competition between PfAha1 and Pfp23 for binding to PfHsp90.
No interaction was observed between PfAha1 and Pfp23 under
the experimental condition used for the competitive binding assay
(data not shown).
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Fig. 7. Analysis of PfAha1 and PfHsp90 tertiary structures. (A) The tertiary structures of PfHsp90 (modelled) and PfAha1 (PDB: 3N72) were superimposed against the
yeast  Hsp82–Aha1 complex (PDB: 1USV). Residues in PfAha1 that were investigated for their importance in PfHsp90 interaction by site-directed mutagenesis are highlighted.















AfAha1’s residue N108 was  observed to be in proximity with residues N472 and T476
PDB:  1USV) and Hsp82–Sba1 (PDB: 2CG9) crystal structures, the PfHsp90–PfAha1–
verlapping PfHsp90-interaction interfaces (boxed), supporting the experimentally
.9. PfAha1 stimulates the ATPase activity of PfHsp90
Following PfAha1 and PfHsp90 interaction study, the binding
ffect of PfAha1 on the ATPase activity of PfHsp90 was subse-
uently investigated. The ATPase activity of PfHsp90 (2 M)  was
easured in the absence or presence of increasing concentrations
f PfAha1 (0.1–2 M).  PfAha1 was observed to stimulate the ATPase
ctivity of PfHsp90 to approximately 300% of its original activ-
ty when added in equimolar concentration (Fig. 10).  However,
hen incubated with equimolar concentration of PfAha1 single
utant N108A with reduced binding to PfHsp90, the ATPase stimu-ation was diminished to approximately 150% of its original activity.
sing the PfAha1 double mutant E91A/N108A that displayed fur-
her reduced binding to PfHsp90, the stimulation of PfHsp90’s
TPase activity was almost abolished. The results indicated thatsp90, presumably forming polar–polar interaction. (B) Using the yeast Hsp82–Aha1
 complex was  modelled and constructed. PfAha1 and Pfp23 were observed to have
ved binding competition between the two co-chaperones for PfHsp90.
PfAha1 interaction with PfHsp90 is essential for the co-chaperone
to exert its stimulatory effect on the ATPase activity of PfHsp90.
4. Discussion
In P. falciparum,  several putative homologues of Hsp90’s co-
chaperones have been identiﬁed in the genome sequence of
the malaria parasite. The co-chaperones found include Pfp23
(PF14 0510), PfAha1 (putative, PFC0270w and PFC0360w), PfHop
(putative, PF14 0324), FKBP35 (PFL2275c), Cyp19 (PFC0975c) and
PP5 (PF13 0294). Many of these putative co-chaperones have
not been characterized for their functionality and regulation on
PfHsp90. Generally, they share low sequence homology with
the human and yeast homologues (Kumar et al., 2007) and
thus, inevitably raises questions as to whether they interact and
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Fig. 8. Residue N108 in PfAha1 is essential for interaction with PfHsp90. (A) SDS–PAGE analysis showed that mutation at residue N108 in PfHsp90 resulted in diminished
binding  to PfHsp90 as compared to PfAha1-WT. The interaction was  almost abolished when substitution N108A was combined with E91A in the PfAha1 double mutant. On


























Kmportant for PfHsp90 interaction. (B) Densitometric analysis of PfAha1-WT and m
ith  respect to the sample with PfAha1-WT. Result shown is representative of thre
egulate PfHsp90 in a manner similar to that of the human/yeast
sp90 system. Considering that Aha1 is one of the only two  co-
haperones (Cpr6 is the other co-chaperone) known to be capable
f stimulating the ATPase activity of Hsp90 that is essential for
romoting the activation of Hsp90’s client proteins, the putative
ha1 in P. falciparum is characterized in this study to investigate its
utative role as a co-chaperone of PfHsp90.
As previous genome wide yeast two-hybrid study on plas-
odial proteins (LaCount et al., 2005) and co-immunoprecipitation
xperiments on PfHsp90 (Banumathy et al., 2003) were unable
o establish the interaction between PfHsp90 and the putative
fAha1, a directed protein–protein interaction approach using
he yeast split-ubiquitin assay was employed to investigate the
ssociation between PfAha1 and PfHsp90. Results from the split-
biquitin assay indicated that there is interaction between PfAha1
nd PfHsp90, and the binding site for PfAha1 is likely to be at
he middle domain of PfHsp90. This was further conﬁrmed using
ecombinant proteins and the in vitro GST pull-down assay that
as been established and used previously to investigate the inter-
ction between PfHsp90 and Pfp23 (Chua et al., 2010). PfAha1
as expressed as a soluble 44 kDa recombinant protein and was
hown to interact with PfHsp90 in the presence of MgCl2 and ATP.
lthough recent studies indicated that the human Aha1 could inter-
ct with Hsp90 in the absence of nucleotide (Hessling et al., 2009;
oulov et al., 2010), this was not observed between PfAha1 andts bound to PfHsp90. The percentage of PfHsp90 and PfAha1 bound are calculated
pendent experiments.
PfHsp90. This may  reﬂect differences in the binding preference of
the plasmodial homologue or could be due to low concentrations
of PfHsp90–PfAha1 nucleotide-free complexes that are difﬁcult to
detect.
Since PfAha1 shares similar Hsp90-binding requirements with
Pfp23 that has been reported previously (Chua et al., 2010), the
inﬂuence of Pfp23 on PfHsp90–PfAha1 interaction was investi-
gated. Using similar binding assay, PfAha1 was shown to compete
with Pfp23 to interact with PfHsp90. The experimental observa-
tion was  supported by in silico modelled PfHsp90–PfAha1–Pfp23
tertiary complex which revealed overlapping PfAha1 and Pfp23
binding sites on PfHsp90 (Fig. 7).
Probing into the interaction between PfAha1 and PfHsp90, pri-
mary sequence and tertiary structure analyses further revealed
several conserved charged residues in PfAha1 (i.e. E15, R58, E67,
D94 and K127) that could be essential for PfHsp90 interaction.
These residues in PfAha1 were substituted by site-directed muta-
genesis and subsequently tested for their ability to interact with
PfHsp90. Contrary to expectations, these PfAha1 mutants with
substitution at the charged residue to a non-charged alanine or
an oppositely charged amino acid residue, displayed no signiﬁ-
cant defects in their interaction with PfHsp90 when compared
to PfAha1-WT. Further mutational studies revealed the residue
N108 in PfAha1 to be essential for PfHsp90 interaction instead.
Based on the modelled structure, the amino acid residue N108
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Fig. 9. PfAha1 competes with Pfp23 to interact with PfHsp90. (A) (Top) In each 500-l reaction, 2 g PfHsp90 was immobilized on 50-l glutathione Sepharose beads
and  incubated with 2 M Pfp23 for 30 min. Following that, PfAha1 was  added in increasing concentrations (0.1–4 M) into the respective reactions and incubated for an
additional 30 min. SDS–PAGE analysis of the eluted PfHsp90 complex showed that the level of Pfp23 bound to PfHsp90 was progressively reduced in the presence of increasing
concentrations of PfAha1. (Bottom) Densitometric analysis of Pfp23 bound to PfHsp90 in increasing concentrations of PfAha1. Percentage of PfHsp90 bound is calculated with
respect to the sample with PfHsp90 only; Pfp23 with respect to the Pfp23 bound to PfHsp90 in the absence of PfAha1; PfAha1 with respect to the PfAha1 bound to PfHsp90
in  the presence of 4 M PfAha1. (B) (Top) The experiment was repeated using a similar protocol but a ﬁxed concentration of PfAha1 (2 M)  and increasing concentrations of
Pfp23  (0.1–4 M).  Results from the SDS–PAGE analysis revealed reduced level of PfAha1 bound to PfHsp90 in the presence of increasing concentrations of Pfp23. (Bottom)
D fp23. Percentage of PfHsp90 bound is calculated with respect to the sample with PfHsp90
o 23; Pfp23 with respect to the Pfp23 bound to PfHsp90 in the presence of 4 M Pfp23.









































































 PfHsp90 + Pf Aha1
Fig. 10. PfAha1 stimulates the ATPase activity of PfHsp90. PfAha1 was added in
increasing concentrations (0.1–2 M)  to a ﬁxed amount of PfHsp90 (2 M) to inves-
tigate its effect on the ATPase activity of PfHsp90. The ATPase activity of PfHsp90 was
stimulated in the presence of PfAha1. At equimolar concentration, PfAha1 enhanced
the  ATPase activity of PfHsp90 to approximately 300% of its original activity. On
the contrary, when PfAha1 single mutant N108A that exhibited reduced binding to
PfHsp90 was  added in equimolar concentration, the stimulation of PfHsp90’s ATPase
activity was signiﬁcantly reduced to approximately 150% of its original activity. The
PfAha1 double mutant E91A/N108A that had defective binding to PfHsp90 displayed
negligible stimulation of the ATPase activity of PfHsp90. The relative activity is cal-ensitometric analysis of PfAha1 bound to PfHsp90 in increasing concentrations of P
nly;  PfAha1 with respect to the PfAha1 bound to PfHsp90 in the absence of Pfp
ollectively, the results indicated that PfAha1 competes with Pfp23 for binding to P
resumably interacts with the residues N472 and T476 in PfHsp90
hrough polar–polar interaction. The observation is surprising as
he interaction between yeast Hsp82 and Aha1 are known to
e contributed by multiple binding interfaces and that single
mino acid substitution are unlikely to destabilize their association
Meyer et al., 2004). Nevertheless, in the case of PfAha1, a single
utation at residue N108 signiﬁcantly diminished its binding to
fHsp90, indicating that PfAha1’s interaction with PfHsp90 may
epend primarily on certain strategic amino acid residues instead
f interfaces for stable association. Similar analyses of putative
ha1s in other Plasmodium sp. i.e. Plasmodium vivax (PVX 119435),
lasmodium chabaudi (PCHAS 040550) and Plasmodium berghei
PBANKA 040460) showed that the asparagine residue is iden-
ically conserved in all the plasmodial Aha1s (data not shown),
uggesting that they may  play similar importance for interaction
ith the respective Hsp90s in the various species.
The functional signiﬁcance of PfAha1’s binding to PfHsp90 was
ubsequently examined and PfAha1 was found to stimulate the
TPase activity of PfHsp90 to approximately 300% of the origi-
al activity when added in equimolar concentration. The ATPase
timulatory effect is consistent with that of the human/yeast Aha1
inding effect on Hsp90 where the increased ATP hydrolysis has
een reported to be essential for the activation of Hsp90’s client
roteins e.g. glucocorticoid receptors, v-Src and c-Raf (Panaretou
t al., 2002; Harst et al., 2005; Holmes et al., 2008). In addition, a
ecent study in yeast demonstrated that Aha1 is capable of restoring
he functionality of Hsp90 mutants with defective ATPase activity
Mollapour et al., 2011). This may  highlight the importance of Aha1
n maintaining the functional integrity of Hsp90, where its ATPaseculated with respect to the ATPase activity of PfHsp90 in the absence of PfAha1.
Result shown is representative of three independent experiments.
stimulatory effect can compensate for the diminished activity in
compromised Hsp90.
In the battle against P. falciparum that is increasingly resis-
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t al., 2009)), PfHsp90 has emerged as a promising new drug-
arget for malaria therapy (Neckers and Tatu, 2008; Pesce et al.,
010; Shonhai, 2010). The recognition stemmed from the obser-
ation that Hsp90-speciﬁc inhibitors are capable of inhibiting the
rowth and development of P. falciparum at the intra-erythrocytic
tages (Banumathy et al., 2003; Kumar et al., 2003). The struc-
ure of PfHsp90’s N-terminal domain that was resolved recently
evealed subtle differences between the ATP/inhibitor-binding
ockets of PfHsp90 and the human Hsp90, prompting exploitation
f the disparity to engineer inhibitors that are selective towards
fHsp90 (Corbett and Berger, 2010). A recent high-throughput
mall molecule screening study has also reportedly identiﬁed
nhibitors that can selectively inhibit the ATPase activity of PfHsp90
ithout incurring signiﬁcant effects on the function of human
sp90 (Shahinas et al., 2010), further supporting the possibility of
esigning inhibitors that are highly speciﬁc and selective against
fHsp90.
While the search for PfHsp90-speciﬁc inhibitors is essential,
nowledge on the factors that regulate the function of PfHsp90
nd its afﬁnity for the inhibitors are similarly crucial for effec-
ive anti-malaria therapeutic intervention. Genetic studies have
emonstrated that certain co-chaperones, apart from regulating
sp90’s chaperone function, can inﬂuence the sensitivity of cells
o the biological effects of Hsp90-speciﬁc inhibitors (Piper et al.,
003). Co-chaperones Hop/Sti1, p23/Sba1 and Aha1 have respec-
ively been shown to confer protection against lethal cellular effects
f Hsp90-speciﬁc inhibitor, albeit through different mechanisms
Prodromou et al., 1999; Forafonov et al., 2008; Zurawska et al.,
010). In the case of Aha1, the protective effect observed was
ttributed to improved Hsp90’s chaperone function (by having
 higher ATPase activity) upon Aha1’s association, that would
egate the loss of function in a subset of Hsp90 with the inhibitors
ound which would normally lead to the collapse of cellular
ctivities. Hence, with increasing understanding on the roles of
o-chaperones in the regulation of Hsp90’s function and their inﬂu-
nce on the biological effects exerted by Hsp90-speciﬁc inhibitor, it
s imperative to uncover and validate Hsp90-co-chaperone inter-
ctions with regards to the Plasmodium parasite. This is crucial
o facilitate assessment on the potential use of Hsp90-speciﬁc
nhibitors as anti-malarials, as well as to provide a mechanis-
ic understanding on plausible drug resistance that may  arise
hrough modulation of PfHsp90’s sensitivity to the inhibitors. Taken
ogether, the ﬁndings in this study would contribute to the knowl-
dge of PfHsp90’s co-chaperones and may  serve as a useful platform
or future studies on the regulation of PfHsp90, with regards to its
n vivo function and sensitivity to the inhibitors.
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Abstract Despite the absence of classical tyrosine kinases
encrypted in the kinome of Plasmodium falciparum, bio-
chemical analyses have detected significant tyrosine
phosphorylation in its cell lysates. Supporting such phos-
phorylation is critical for parasite development. These
observations have thus raised queries regarding the plasmo-
dial enzymes accountable for tyrosine kinase activities in
vivo. In the current investigation, immunoblot analysis
intriguingly demonstrated that Pfnek3, a plasmodial mitogen-
activated protein kinase kinase (MAPKK), displayed both
serine/threonine and tyrosine kinase activities in autophos-
phorylation reactions as well as in phosphorylation of the
exogenous myelin basic protein substrate. The results
obtained strongly support Pfnek3 as a novel dual-specificity
kinase of the malarial parasite, even though it displays a
HGDLKSTN motif in the catalytic loop that resembles the
consensus HRDLKxxN signature found in the serine/threo-
nine kinases. Notably, its serine/threonine and tyrosine kinase
activities were found to be distinctly influenced by Mg2? and
Mn2? cofactors. Further probing into the regulatory mecha-
nism of Pfnek3 also revealed tyrosine phosphorylation to be a
crucial factor that stimulates its kinase activity. Through
biocomputational analyses and functional assays, tyrosine
residues Y117, Y122, Y172, and Y238 were proposed as
phosphorylation sites essential for mediating the catalytic
activities of Pfnek3. The discovery of Pfnek3’s dual role in
phosphorylation marks its importance in closing the loop for
cellular regulation in P. falciparum, which remains elusive to
date.
Keywords Malaria  Plasmodium falciparum 
MAPKK  Dual-specificity kinase  Phosphorylation
Abbreviations
BSA Bovine serum albumin
GST Glutathione S-transferase
MAPK Mitogen-activated protein kinase
MAPKK Mitogen-activated protein kinase kinase
MAPKKK Mitogen-activated protein kinase kinase
kinase
MBP Myelin basic protein
PTP1B Protein tyrosine phosphatase 1B
PVDF Polyvinylidene fluoride
SDS-PAGE Sodium dodecyl sulphate–polyacrylamide
gel electrophoresis
TBS Tris buffered saline
Introduction
In the eukaryotes, modification of proteins through
reversible phosphorylation is an essential mechanism for
regulation of cellular processes. This post-translational
event is catalyzed by enzymes belonging to the protein
kinase superfamily that constitutes approximately 2–3% of
the eukaryotic proteome [1, 2]. Eukaryotic protein kinases
share extensive sequence and structural homologies within
their catalytic domains [1, 3]. Depending on their speci-
ficities for the target hydroxyl amino acids, protein kinases
are traditionally classified into two major classes: the
serine/threonine kinases and the tyrosine kinases [1]. In
addition, a smaller class of protein kinases, termed as the
dual-specificity kinases, is subsequently discovered with
specificity for both the serine/threonine and the tyrosine
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residues [4]. Through the phosphorylation of specific tar-
gets on serine, threonine and/or tyrosine residues, protein
kinases play integral roles in a diverse array of cellular
events. Thus, their activities have to be tightly regulated.
Abnormal functioning of protein kinases has been impli-
cated in a number of major human diseases such as cancer,
arthritis, and Alzheimer’s condition [5–7]. Therefore, they
have emerged as prime molecular targets for the develop-
ment of therapeutic intervention against these diseases. In
2001, the Food and Drug Administration approved the first
kinase inhibitor, imatinib (GleevecTM), for the treatment of
chronic myelogenous leukemia [8]. Its clinical success
provided compelling evidence for the effectiveness of
kinase-specific inhibitors in the treatment of human
diseases.
The growing number of kinase inhibitors for clinical use
has raised the interest in whether kinase-targeted therapy
can be extended to the treatment of malaria, a parasitic
disease that currently causes 800,000 deaths annually
[9, 10]. Current efforts to control this disease have been
marred by the propensity of Plasmodium falciparum, the
most lethal causative agent, to rapidly develop resistance
against the front-line artemisinin combination therapies
[11]. Therefore, in the context where producing efficacious
malarial vaccines remains a great challenge, continued
efforts to develop novel antimalarial chemotherapeutics is
imperative. One widely adopted strategy for discovering
new antimalarial agents is the target-based approach,
through which novel targets are first identified followed by
the design of parasite-specific inhibitors that act on these
targets [12]. The search for promising drug targets from the
P. falciparum kinome is relevant, since plasmodial kinases
are reportedly divergent in terms of their primary sequen-
ces and biochemical properties as compared to their
mammalian counterparts [13–15]. More importantly, a
number of plasmodial protein kinases have been demon-
strated to be essential in the life cycle of P. falciparum,
further supporting their potential as ‘‘druggable’’ targets
(summarized in [16]).
One of the plasmodial kinases under intense investiga-
tion is Pfmap2, a mitogen-activated protein kinase
(MAPK) homologue of P. falciparum [17, 18]. It is rec-
ognized as an antimalarial drug target following a knock-
out study that validated its essentiality in the asexual
propagation of P. falciparum [18]. To further probe into the
molecular mechanisms by which Pfmap2 is engaged for
mediating P. falciparum development, identifying its
upstream activating kinases is fundamental. Unfortunately,
the P. falciparum kinome lacks clear homologues of the
MAPK kinase (MAPKK) and MAPKK kinase (MAP-
KKK), both of which are components of the conserved
MAPK signaling pathway that lead to the activation of
MAPKs. On hindsight, this indicates that P. falciparum
may possess a MAPK pathway that is distinctively differ-
ent from the other eukaryotes, including its human host.
Hence, other than gaining insights into the mechanistic
basis leading to the activation of Pfmap2, identification of
its upstream kinases is critical for deciphering the elusive
P. falciparum MAPK pathway where novel kinase targets
suitable for antimalarial drug discovery can be discerned.
In the absence of traditional MAPKK homologues,
distinguishing upstream kinases of Pfmap2 is reliant on the
detection and biochemical characterization of plasmodial
kinases capable of phosphorylating and activating it. A
potential Pfmap2 regulator was first illustrated by Dorin
et al. [19], whereby Pfnek1, a kinase belonging to the
NIMA-like kinase family, demonstrated the competency to
catalyze Pfmap2 phosphorylation in vitro. However, the
relevance of this phosphorylation event on the activity of
Pfmap2 was not clarified. Contrary to Pfnek1, a second
plasmodial NIMA-like kinase, Pfnek3, was subsequently
reported to display both the ability to phosphorylate and
stimulate Pfmap2 activity [20]. The molecular mechanism
by which Pfnek3 activates Pfmap2 was further verified to
involve phosphorylation within the latter’s activation motif
[21]. As this mode of activation mechanism is highly
conserved among the eukaryotes, where the MAPKKs
phosphorylate their downstream MAPKs within the
activation motif to stimulate them [22], Pfnek3 was con-
sequently recognized as a MAPKK-like enzyme of
P. falciparum.
In the current study, further characterization of this
unusual MAPK activator is pursued to assess whether it
possesses additional properties of a typical MAPKK.
Results obtained via Western-blot analysis had intrigu-
ingly unveiled the ability of Pfnek3 to autophosphorylate
and phosphorylate an exogenous substrate at tyrosine-
specific sites, in addition to the serine/threonine residues.
Like the serine and threonine phosphorylation illustrated
earlier [23], tyrosine phosphorylation was demonstrated
to play a crucial role in regulating the kinase activity of
Pfnek3. Collectively, the findings of this study indicate
that Pfnek3 is a novel dual-specificity kinase of P. fal-
ciparum and further highlight the similarities between
Pfnek3 and the MAPKKs, which also exert both threo-
nine and tyrosine kinase activities on their MAPK
substrates.
Materials and methods
Heterologous expression and purification
of recombinant proteins
Escherichia coli BL21-CodonPlusTM cells expressing the
glutathione S-transferase (GST)-tagged wild-type Pfnek3,
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the DPfnek3 and DPfmap2 mutants were obtained previously
[20, 21]. They were cultured in 100 ml of Luria–Bertani
broth supplemented with ampicillin and chloramphenicol
(100 and 40 lg/ml, respectively) at 37C with continuous
agitation until an OD600 of 0.6–0.8 was obtained. They
were afterwards induced with 1 mM isopropyl-beta-D-
thiogalactopyranoside (Sigma) and incubated at room tem-
perature overnight with shaking. Subsequently, the cells
were harvested and lysed by sonication as previously
reported [21]. Fusion proteins were purified from soluble
cell-free extracts by affinity chromatography using the Mi-
crospin GST Purification Module (GE Healthcare) according
to the manufacturer’s instructions. Protein concentrations of
the purified samples were determined by the Bio-Rad protein
assay, using bovine serum albumin (BSA, Sigma) as
the reference protein standard. New Pfnek3 site-directed
mutants generated in the current study were similarly
expressed and purified using the same protocol.
Western blot
Protein samples were routinely boiled for 5 min and sepa-
rated by either 8 or 15% sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE). Resolved
proteins were transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore), which were then blocked with 2%
(w/v) BSA in Tris buffered saline (TBS), following which,
the membranes were probed with either the anti-phospho-
serine (1:1,000 dilution, Millipore), anti-phosphotyrosine
(1:2,000 dilution, Millipore) or anti-phosphothreonine
(1:1,000 dilution, Cell Signaling Technology) primary
antibodies. A peroxidase-conjugated secondary antibody
(1:3,500 dilution, Thermo Fisher Scientific) was then incu-
bated with the membranes. The blots were developed using
either the Advance Western Blotting Detection Kit (GE
Healthcare) or the ECL Plus Western Blotting Substrate
(Thermo Fisher Scientific) and exposed to the CL-XPosure
film (Thermo Fisher Scientific). Densitometric quantifica-
tion of the Western-blot results was performed using ImageJ
software [24]. To serve as controls for protein loading,
duplicated SDS-PAGE gels were run and stained with
Coomassie Blue. Stained gels were visualized using the Bio-
Rad Molecular Imager Gel Doc XR system equipped with
the Quantity One software.
Phospho-protein staining
Following in vitro kinase assays, reaction mixtures were
subjected to SDS-PAGE using 8% polyacrylamide gels. The
gels were stained with Pro-Q Diamond phosphoprotein gel
stain (Invitrogen) according to the manufacturer’s protocol
and visualized on a UV transilluminator. Densitometric
quantification of the result was performed using ImageJ
software [24]. To ensure uniform loading of protein samples
for each lane, the gels were subsequently stained with
Coomassie Blue.
Tyrosine dephosphorylation of Pfnek3 using protein
tyrosine phosphatase 1B
For tyrosine dephosphorylation reactions, a 24 ll assay
mixture contained 10 lg of wild-type Pfnek3 and 5 U of
protein tyrosine phosphatase 1B (PTP1B, Millipore) in a
reaction buffer provided by the manufacturer. The phos-
phatase was omitted in samples that served as negative
controls. Incubations were carried out for 1 h at 30C
before 6 ll of 100 mM sodium orthovanadate was added to
the reaction mixture to inhibit the activity of PTP1B (final
concentration: 20 mM, NEB). A 12-ll aliquot of the
resultant mixture was thereafter subjected to both Western
blot and ELISA-based kinase assay for verifying the
dephosphorylated status and the kinase activity of the
PTP1B-treated Pfnek3.
Generation of Pfnek3 mutants through site-directed
mutagenesis
The truncated Pfnek3 gene, encoding a catalytically active
form of Pfnek3, was earlier cloned into the GST-encoding
pGEX-6P-1 vector [20]. The resultant recombinant
expression plasmid was used as the template for site-
directed mutagenesis reactions. All GST-tagged Pfnek3
mutants were constructed according to the QuikChangeTM
site-directed mutagenesis protocol (Stratagene), using
mutagenic primers listed in Table 1. The authenticity of the
respective Pfnek3 mutants was verified through DNA
sequencing to ensure that no spontaneous nucleotide sub-
stitution was introduced during the PCR amplification
process.
Protein kinase assays
Kinase assay mixtures of 40 ll aliquots prepared for
Western blot comprised of 4 lg of wild-type or mutant
Pfnek3 proteins, 500 lM ATP, 10 mM MgCl2/MnCl2 and
50 mM Tris–HCl (pH 7.2). The samples were incubated at
30C for 30 min before they were boiled for SDS-PAGE
and Western-blot analysis. When required, the assay mix-
tures were supplemented with 10 lg of dephosphorylated
myelin basic protein (MBP, Millipore) substrate or the cata-
lytically inactive Pfmap2 mutants [DPfmap2 or DPfmap2
(T290A)].
To quantify the kinase activities of the tyrosine
dephosphorylated Pfnek3 or its site-directed mutants, an
ELISA-based kinase assay was adopted as described in [23].
P. falciparum possesses a unique dual-specificity serine/threonine and tyrosine kinase, Pfnek3 1525
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Briefly, the assays were performed using 96-well microtiter
plates (Costar) coated with dephosphorylated MBP. Kinase
reaction mix (60 ll) added into each well comprised of
4 lg of recombinant protein, 500 lM ATP, 10 mM MgCl2
and 50 mM Tris–HCl (pH 7.2). The assays were allowed to
proceed at 30C for 30 min. Following which, the serine/
threonine and the tyrosine kinase activities of the enzymes
were independently assessed, based on the levels of MBP
phosphorylation detected using the mixed anti-phospho-
serine/threonine (1:500 dilution, Millipore) and the anti-
phosphotyrosine (1:1,000 dilution) antibodies, respectively.
Biocomputational analysis
The NetPhos server (http://www.cbs.dtu.dk/services/NetPhos/)
was utilized for predicting potential tyrosine phosphoryla-
tion sites in Pfnek3 [25]. Using the Swiss-PdbViewer [26],
the locality of the predicted phospho-tyrosine sites was
determined in the Pfnek3 three-dimensional model gener-
ated previously [23].
Results
Recombinant Pfnek3 autophosphorylates on serine,
threonine as well as tyrosine residues
Using a generic phosphostain, it was earlier shown that the
heterologously expressed Pfnek3 purified from bacterial
cells exhibited detectable autophosphorylation [23]. To
further examine the autophosphorylation specificity of
Pfnek3, Western-blot analysis was performed on the purified
fusion kinase using antibodies specific against phospho-
serine, phospho-threonine as well as phospho-tyrosine resi-
dues. As illustrated in Fig. 1a, the wild-type Pfnek3 was
immunoreactive with all three phospho-specific antibodies,
indicating that the kinase was autophosphorylated on serine,
threonine and tyrosine residues following its expression in
bacterial cells. The absence of detectable signals by its cat-
alytically inactive counterpart (DPfnek3) supports that
phosphorylation of these hydroxyl residues is indeed due to
the intrinsic activity of Pfnek3, and not the result of any
bacterial kinase phosphorylation.
When the wild-type Pfnek3 was incubated in a kinase
assay mix consisting of the ATP phosphate donor and the
Mn2?/Mg2? cofactor prior to Western blotting, a signifi-
cant increase in its phospho-tyrosine signals was observed
(Fig. 1b). Notably, the rise in signal was more evident in
the presence of Mn2? as compared to Mg2? [294 vs. 211%
of untreated Pfnek3 tyrosine autophosphorylation based on
densitometric quantification of the Western-blot data
(Fig. 1c)]. This indicates that Pfnek3 could undergo further
tyrosine autophosphorylation in vitro, with Mn2? as the
preferred metal cofactor. On the other hand, no significant
increment was detected for both its phospho-serine and
phospho-threonine signals. One plausible explanation
could be that the heterologously expressed Pfnek3 has
already been substantially autophosphorylated on serine
and threonine residues in the bacterial cells. Hence, any
further enhancement in the autophosphorylation of serine
and threonine residues would not be significantly detected
through in vitro experiments.
The ability of Pfnek3 to autophosphorylate on both the
serine/threonine and the tyrosine residues suggests its
potential as a dual-specificity kinase in P. falciparum. This
is intriguing since Pfnek3 is predicted to exert only serine/
threonine kinase activity based on its primary sequence
homology to the classical serine/threonine-type kinases and
thus is not expected to phosphorylate tyrosine residues.
Table 1 Primers used for generating Pfnek3 site-directed mutants





























The designations F and R denote the forward and reverse primers,
respectively, with the sites of mutagenesis underlined
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Recombinant Pfnek3 exhibits dual-specificity activity
on the exogenous MBP substrate, but phosphorylates
its potential in vivo Pfmap2 substrate largely
on threonine 290
To provide additional support for Pfnek3 as a dual-speci-
ficity kinase, further investigations were pursued to
determine if the kinase could likewise phosphorylate sub-
strates on both tyrosine and serine/threonine residues. The
in vitro serine/threonine kinase activity of recombinant
Pfnek3 has been previously assessed using a panel of
generic kinase substrates consisting of MBP, histone H1,
casein kinase I and casein kinase II peptide substrates [20].
However, Pfnek3 was found to be competent in phos-
phorylating only the MBP substrate. In view of this, the
MBP substrate is used in the present study to evaluate the
tyrosine phosphorylation capacity of Pfnek3. The recom-
binant kinase was co-incubated with MBP in the presence
of ATP and Mg2?/Mn2? before Western blot was per-
formed to detect for the presence of phospho-tyrosines in
the MBP substrate. As observed in Fig. 2a, incubation with
Pfnek3 considerably increased the level of phospho-tyro-
sine signal detected in MBP, providing evidence that
Pfnek3 does exert a tyrosine kinase activity towards the
exogenous MBP substrate. Furthermore, similar to the
phenomenon observed for tyrosine autophosphorylation in
Fig. 1b, densitometric analysis of the immunoblot revealed
that the MBP phospho-tyrosine signal was 61% higher when
the assay mix was supplemented with Mn2? as compared to
Mg2? (Fig. 2b). This offers additional support that the in vitro
tyrosine kinase activity of Pfnek3 is triggered to a greater
extent in the presence of the Mn2? cofactor.
As the serine/threonine kinase activity of Pfnek3 was
previously examined using mixed antibodies specific
against both phospho-serines and phospho-threonines, it
was unable to clearly distinguish whether phosphorylation
had occurred on serine and/or threonine residues. In view
of this, Western blot was performed using antibodies spe-
cific against either the phospho-serines or the phospho-
threonines to further delineate the Pfnek3 phosphorylation
specificity on MBP. The results shown in Fig. 2a indicate
that Pfnek3 phosphorylates MBP on threonine, but not
serine residues. Additionally, in contrast to the trend seen
for tyrosine phosphorylation, a stronger phospho-threonine
signal was observed when the kinase assay was performed
in the presence of Mg2? instead [141% higher compared to
that in the presence of Mn2? following densitometric
quantification of the Western-blot data (Fig. 2b)]. With the
competency of Pfnek3 to similarly phosphorylate the
exogenous MBP substrate on both the threonine and tyro-
sine residues, the functionality of Pfnek3 as a dual-
specificity kinase is strengthened. In addition, it appears
that the dual-specificity activity of the kinase is distinctly
influenced by the type of divalent cation present.
Of the two MAPKs (Pfmap1 and Pfmap2) found in the
P. falciparum kinome, Pfnek3 was earlier demonstrated to
phosphorylate only Pfmap2 in vitro [20]. Hence, other than the
exogenous MBP substrate, the dual-specificity kinase activity
of Pfnek3 was also evaluated using its plasmodial Pfmap2
substrate in an attempt to gain insights into the functional
relevance of its dual-specificity activity in vivo. A catalyti-
cally inactive mutant of Pfmap2 (denoted as DPfmap2) was
used as the substrate to rule out the effect of its autophos-
phorylation. In Fig. 2c, Western-blot analysis illustrated that
Pfnek3 phosphorylated DPfmap2 at threonine residues. Fur-
ther densitometric quantification of the immunoblot indicates
(a) (b)
(c)
Fig. 1 Autophosphorylation characteristics of recombinant Pfnek3.
a Recombinant Pfnek3 and its kinase-dead mutant (DPfnek3) were
transferred to PVDF membrane and probed with antibodies specific
against phospho-tyrosine, serine, or threonine (denoted by Anti P-Tyr,
Anti P-Ser, and Anti P-Thr, respectively). Coomassie staining of
duplicated SDS-PAGE gels indicates similar protein loading for each
lane. Representative blots/gel from three independent experiments is
shown. b Following protein expression and purification, Pfnek3 was
incubated in a kinase assay mix comprising ATP and Mn2?/Mg2? as
shown in the top panel. The mixtures were then subjected to
immunoblotting using the specified antibodies. Coomassie staining of
duplicated SDS-PAGE gels indicates similar protein loading for each
lane. The result shown is representative of three independent
experiments. c Densitometric analysis of the results obtained in
b. Data is expressed as a percentage of Pfnek3 autophosphorylation in
the absence of ATP/Mn2?/Mg2?, with each bar representing the
mean autophosphorylation level ± standard deviation from the three
independent assays
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that the phospho-threonine signal detected in the presence of
Mg2? was 154% more intense as compared to that in Mn2?
(Fig. 2d). This observation coincides with the result obtained
from an earlier mass spectrometry study where Pfnek3 was
validated to phosphorylate Pfmap2 at the threonine residue,
T290 [21]. Apart from threonine residues, Pfnek3 was not
observed to phosphorylate DPfmap2 at serine or tyrosine
residues. The basal DPfmap2 phosphorylation detected in the
phospho-serine blot could be an effect of bacterial kinase
phosphorylation when it was heterologously expressed in
E. coli. It is believed that Pfnek3 phosphorylates Pfmap2
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was diminished by 89% based on densitometric quantification
when the threonine was mutated to a non-phosphorylatable
alanine (Fig. 2e, f).
Tyrosine phosphorylation is involved in regulation
of the serine/threonine and tyrosine kinase activities
of Pfnek3
The detection of Pfnek3 tyrosine autophosphorylation in
Fig. 1a has prompted the evaluation of its importance in
regulating the catalytic activity of Pfnek3. With this in mind,
recombinant Pfnek3 was treated with a tyrosine-specific
phosphatase, PTP1B, before its activity was tested in an
ELISA-based kinase assay using MBP as the exogenous
substrate. In comparison to the untreated Pfnek3, the phos-
phatase-treated recombinant kinase showed a reduction in its
serine/threonine kinase activity by 34%, while its tyrosine
kinase activity was lowered by 73% (Fig. 3a). Since prior
treatment of Pfnek3 with PTP1B resulted only in the removal
of phosphorylation from tyrosine, but not from serine and
threonine residues (Fig. 3b), it indicates that the decrease in
the activities of Pfnek3 is mainly attributed to the deficiency in
tyrosine phosphorylation. Hence, this supports that tyrosine
phosphorylation is crucial for the serine/threonine and tyro-
sine kinase activities of Pfnek3.
Probing for potential tyrosine phosphorylation sites
involved in mediating Pfnek3 kinase activity
Regulation of protein kinase activities can be generally
achieved through several mechanisms including phos-
phorylation by upstream kinases or through autocatalytic
events, and/or interaction with regulatory domains or
subunits [27, 28]. Among these, phosphorylation within the
activation loop, a segment located between the DFG and
APE motifs of kinase subdomains VII and VIII, respec-
tively, is a widespread mechanism that controls the
function of a wide range of protein kinases [29]. This mode
of regulation is similarly adopted by Pfnek3, where pre-
vious site-directed mutagenesis and phosphorylation
analyses supported S221 and S226 within the activation
segment as phospho-activating sites [23]. Other than this,
Pfnek3 activity was also demonstrated to rely on phos-
phorylation of residue T82, located at the N-terminal of the
catalytic domain [23]. With the additional observations that
Pfnek3 is autophosphorylated on tyrosines residues and
that the phosphorylation is essential for its kinase activities
(Figs. 1, 3a), determining the specific phospho-tyrosine
sites is fundamental to further comprehend the enzymatic
regulation of Pfnek3.
However, due to the nature of its amino acid sequence,
delineating Pfnek3 phosphorylation sites via mass spec-
trometry is technically difficult. Despite substantial
optimization and troubleshooting, limited protein sequence
coverage was constantly obtained, which greatly deterred
phospho-site detection [23]. Moreover, as no tyrosine
residue is present within the activation loop of Pfnek3,
mapping of potential tyrosine phosphorylation sites is
further impeded. Hence, a biocomputational approach was
undertaken in this study to screen for potential tyrosine
phosphorylation sites in Pfnek3. Using the online NetPhos
software [25], a total of six candidate phospho-tyrosine
sites at Y99, Y117, Y122, Y172, Y238, and Y286 were
identified in Pfnek3 (Table 2). With reference to the 3D
model of Pfnek3 generated earlier [23], these residues were
found to be located on the surface of the protein structure
with their hydroxyl side chains projecting outwards
(Fig. 4a).
Mutation of residues Y117, Y122, Y172, and Y238 led
to drastic reductions in both Pfnek3 tyrosine
phosphorylation and catalytic activities
Based on the hypothesis that phosphorylation occurs at
positions Y99, Y117, Y122, Y172, Y238, and Y286, which
is in turn essential for stimulating the kinase activity of
Pfnek3, site-directed mutagenesis was performed to replace
each tyrosine with a non-phosphorylatable phenylalanine.
In the event that these tyrosines function as critical phos-
pho-regulatory sites, the mutation would result in the
reduction of both the tyrosine phosphorylation of Pfnek3 as
well as its catalytic activity.
The GST-tagged mutants (hereafter referred to as Y99F,
Y117F, Y122F, Y172F, Y238F, and Y286F) were similarly
expressed in E. coli cells as the wild-type kinase and
Fig. 2 Recombinant Pfnek3 exhibits dual-specificity kinase activity
on the exogenous MBP substrate but not Pfmap2. In vitro Pfnek3
kinase assays were performed in the presence of ATP and Mn2?/
Mg2? using a MBP or c DPfmap2 as substrates. The mixtures were
resolved by SDS-PAGE and phosphorylation status of the respective
substrates was analyzed by Western blot using the indicated phospho-
specific antibodies. Coomassie staining of duplicated SDS-PAGE gels
indicates similar loading of the respective proteins. Results depicted
are representative of three independent experiments. b, d Densitomet-
ric quantification of the results obtained in a and c, respectively. For
referencing purposes, phosphorylation levels are expressed as
percentages of MBP/DPfmap2 phosphorylation in the presence of
Pfnek3/ATP/Mn2?. Each bar depicts the mean phosphorylation
level ± standard deviation from the three independent experiments.
e In vitro kinase assays for Pfnek3 were repeated in reaction buffers
supplemented with ATP, Mg2? and either the DPfmap2 or the
DPfmap2/T290A substrates. Phosphorylation status of the substrates
was subsequently assessed using the Pro-Q Diamond phosphopro-
tein gel stain. Coomassie staining of the same gel at the lower panel
demonstrates comparable protein loading. A representative result of
three independent experiments is illustrated. f Graphical representa-
tion of the densitometric analyses for e. Result is expressed as a
percentage of DPfmap2 phosphorylation, with each bar representing
the mean phosphorylation level ± standard deviation from the three
independent assays. ND denotes kinase activity not detected
b
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affinity-purified using the glutathione agarose beads. To
detect for possible decrease in the tyrosine autophospho-
rylation of these purified mutants, Western blot was
performed using the anti-phosphotyrosine antibody. As
illustrated in Fig. 5a, b, both the Y99F and Y286F mutants
displayed a comparable level of tyrosine phosphorylation as
seen in wild-type kinase. On the contrary, the phospho-
tyrosine levels of Y117F, Y122F, Y172F, and Y238F were
significantly reduced (29, 51, 27, and 34%, respectively, of
wild-type Pfnek3 tyrosine autophosphorylation level based
on densitometric analysis of the immunoblot). This supports
that tyrosine phosphorylation could originate from residues
Y117, Y122, Y172, and Y238, and not from residues Y99
and Y286.
The ELISA-based kinase assays were subsequently
conducted to examine the effects of the respective muta-
tions on the serine/threonine and tyrosine kinase activities
of Pfnek3. Interestingly, the profile displayed by the
mutants for the serine/threonine kinase activity coincided
with that for the tyrosine kinase activity (Fig. 5c). It was
observed that the Y99F mutant exhibited serine/threonine
and tyrosine kinase activities that were similar to the wild-
type Pfnek3. On the other hand, the Y117F, Y122F, and
Y172F mutants demonstrated significant decrease in both
their serine/threonine (5, 26, and 2%, respectively, of wild-
type Pfnek3 serine/threonine kinase activity) and tyrosine
(13, 26, and 7%, respectively, of wild-type Pfnek3 tyrosine
kinase activity) kinase activities. For both the Y238F and
Y286F mutants, no significant activity was detected. As the
Fig. 3 Effects of tyrosine dephosphorylation on the serine/threonine
and tyrosine kinase activities of Pfnek3. Recombinant Pfnek3 was
treated with PTP1B as described in the Materials and methods
section. In control experiments, PTP1B was omitted. a Aliquots of the
mixtures were subjected to ELISA-based kinase assays using MBP as
substrate to determine the serine/threonine and tyrosine kinase
activities of the PTP1B-treated Pfnek3. Results are expressed as
percentage of untreated Pfnek3 activity, with each bar representing
the mean activity ± standard deviation from two independent assays.
b Phosphorylation status of the PTP1B-treated and control Pfnek3
were verified by Western blot using the indicated antibodies.
Coomassie staining of duplicated SDS-PAGE gel illustrates similar
loading of the proteins. The results illustrated are representative of
two independent experiments
Table 2 Potential Pfnek3 tyrosine phosphorylation sites predicted by











The score represents the probability for each tyrosine residue to
undergo phosphorylation. The locality of the residues in the 3D model
of Pfnek3 is also indicated
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reduction in tyrosine autophosphorylation was concomitant
with the decrease in kinase activities for the Y117F, Y122F,
Y172F, and Y238F mutants, it supports the notion that
phosphorylation does occur at these tyrosine residues and is
critical for regulating the catalytic activity of Pfnek3.
Nevertheless, structural analyses of the Pfnek3 model
revealed that residues Y117 and Y122 each form a hydro-
gen bond with their neighboring amino acids (Fig. 4b).
Therefore, it remains a possibility that the reduction in
kinase activity observed for the Y117F and Y122F mutants
might be due to the loss of hydrogen bond that could be
important for maintaining the structural integrity of the
protein.
Based on the results obtained for the Y286F mutant, it is
interesting to note that although Y286 is unlikely to be a
phosphorylation site, the tyrosine residue was found to be
critical for Pfnek3 to phosphorylate the MBP substrate.
Considering that autophosphorylation of the Y286F mutant
was comparable to that of the wild-type Pfnek3, it suggests
that the mutation did not drastically alter the catalytic
activity of the kinase. However, the mutant did not exhibit
detectable kinase activity using the MBP substrate. A
plausible explanation is that the residue Y286 in Pfnek3 is
an important binding site residue required for the interaction
with the MBP substrate. Therefore, removal of the tyrosine
residue via site-directed mutagenesis could have led to a
loss of the Pfnek3-MBP interaction and thereby resulted in a
lack of phosphorylation in the MBP substrate.
In an attempt to constitutively mimic the effects of
phosphorylation at residues Y117, Y122, Y172, and Y238,
the tyrosine at these sites were each altered to the negatively
charged aspartate or glutamate. The resultant mutants were
then assayed for their kinase activities. As depicted in
Fig. 6, no significant serine/threonine or tyrosine kinase
Fig. 4 Positions of predicted
phospho-tyrosine sites in the
tertiary model of Pfnek3. a The
3D model of Pfnek3 was
generated in an earlier study
[23] and viewed using the
Swiss-PdbViewer. Location of
the predicted phospho-tyrosines
are shown and highlighted in
red. b Neighboring residues that
fall within 4 A˚ of the predicted
phospho-tyrosines were
identified and are shown in
white. Only residues that form
hydrogen bonds (indicated by
dotted green lines) with the
respective tyrosines are labeled
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activity was detected for the Y117D, Y117E, Y172D,
Y172E, Y238D, and Y238E phospho-mimetic mutants. In
addition, the kinase activities of the Y122D and Y122E
mutants did not surpass that of the non-phosphorylatable
Y122F mutant. Collectively, it appears that these phospho-
mimetic mutations were unable to restore the wild-type
activity of Pfnek3. However, it is noteworthy to mention
that although aspartate and glutamate are negatively
charged amino acids, they may not efficiently mimic the
effect of phospho-tyrosines due to the lack of an aromatic
ring in their side chains.
Discussion
The majority of eukaryotic protein kinases are categorized
into two broad classes based on whether they phosphorylate
serine/threonine or the tyrosine residues. Although the pre-
cise basis for conferring amino acid specificity is not entirely
clear, serine/threonine and tyrosine kinases can generally be
distinguished based on consensus signatures located within
the catalytic loop of the kinase domain. The serine/threonine
kinases typically contain a HRDLKxxN motif while the
tyrosine kinases possess either a HRDLAARN or a
HRDLRAAN sequence [1]. However, identification of the
third group of protein kinases, the dual-specificity kinases, is
less straightforward, as no unique consensus motif has been
identified in these kinases. In fact, many of the dual-speci-
ficity kinases were initially isolated through phospho-tyrosine
antibody screening of cDNA expression libraries designed
for detecting novel tyrosine kinases [4]. However, instead of
possessing a catalytic domain that was expected to resemble
the typical tyrosine kinases, these kinases displayed extensive
primary sequence homology to the serine/threonine kinases.
Subsequent biochemical analysis revealed their abilities to
phosphorylate both the serine/threonine and the tyrosine
residues, thus identifying them as dual-specificity kinases.
Hence, kinases that are originally predicted as serine/threo-
nine kinases by virtue of their catalytic loop sequences could
potentially emerge as dual-specificity kinases.
In the current study, the P. falciparum Pfnek3 was dem-
onstrated via Western-blot analysis to undergo
Fig. 5 Tyrosine phosphorylation levels and catalytic activities of
Pfnek3 phenylalanine-substituted mutants. a Purified wild-type
Pfnek3 and the indicated site-directed mutants were subjected to
Western blot using the phospho-tyrosine antibody. Coomassie
staining of duplicated SDS-PAGE gel demonstrates similar protein
loading for each lane. The result illustrated is representative of three
independent experiments. b Densitometric analysis of the result
obtained in a. Data is expressed as a percentage of wild-type Pfnek3
tyrosine autophosphorylation, with each bar representing the mean
autophosphorylation level ± standard deviation from the three inde-
pendent assays. c Via the ELISA-based kinase assay, the in vitro
serine/threonine (upper panel) and tyrosine (lower panel) kinase
activities of the respective Pfnek3 mutants were determined by their
ability to phosphorylate the MBP substrates. Results are presented as
a percentage of wild-type Pfnek3 activity, with each bar representing
the mean activity ± standard deviation from two independent assays.
ND denotes kinase activity not detected
b
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autophosphorylation at not only the serine/threonine but also
the tyrosine residues (Fig. 1). Additionally, the kinase could
also catalyze phospho-transfer to both groups of hydroxyl
amino acids in the exogenous MBP substrate (Fig. 2a, b).
These intriguing observations thus point towards a novel
dual-specificity kinase activity in Pfnek3. Prior to this study,
Pfnek3 was anticipated to phosphorylate merely on serines
and/or threonines, since it possesses a catalytic loop
(HGDLKSTN) that coincides with the HRDLKxxN con-
sensus element of serine/threonine kinases. Hence, without a
more in-depth biochemical examination, the dual-specificity
property of Pfnek3 would inevitably be overlooked. These
findings thus shed light on another biochemical similarity
between Pfnek3 and the classical MAPKK. The latter rep-
resents an important dual-specificity kinase in the MAPK
signaling pathway essential for activating the downstream
MAPK through the concomitant phosphorylation of both
threonine and tyrosine residues within the TXY activation
site [22].
To assess whether Pfnek3 could exert a similar dual-
specificity kinase activity on its Pfmap2 MAPK substrate,
its ability to phosphorylate both the serine/threonine and
tyrosine residues in Pfmap2 was also investigated. Via
mass spectrometry, Pfnek3 was previously verified to
phosphorylate Pfmap2 at the threonine residue, T290,
within its conserved TSH activation site [21]. This was
reflected in the current work where immunoblot analysis
demonstrated threonine phosphorylation of Pfmap2 by
Pfnek3 (Fig. 2c, d). Other than threonine phosphorylation,
no serine or tyrosine phosphorylation was detected. It
therefore appears that Pfnek3 exhibits only threonine
kinase activity on Pfmap2, and this could occur mainly on
residue T290 as phosphorylation of Pfmap2 was largely
abrogated when the threonine residue was substituted to an
alanine (Fig. 2e, f).
It was also noted that the threonine and tyrosine kinase
activities of Pfnek3 were distinctly influenced by the Mg2?
and Mn2? cofactors (Figs. 1, 2). In the presence of Mn2?,
the recombinant Pfnek3 displayed a stronger tyrosine
kinase activity in vitro. On the other hand, phosphorylation
of threonine residues was more evident in the presence of
Mg2?. These findings is in line with the metal cofactor
preferences of classical serine/threonine kinases and tyro-
sine kinases, where Mg2? and Mn2? cofactors are favored,
respectively [30, 31]. It is plausible that binding of dif-
ferent metal cofactors may induce Pfnek3 to adopt distinct
conformations at its active site for promoting the phos-
phorylation of either serine/threonine or the tyrosine
residues.
The catalytic activity of recombinant Pfnek3 has earlier
been validated to be influenced by both threonine and serine
phosphorylation [23]. In particular, it was demonstrated that
phosphorylation of residues T82, S221, and S226 was
critical for enhancing the kinase activity of Pfnek3. To
complement this finding, results highlighted in Fig. 3 fur-
ther indicate that tyrosine phosphorylation is also a crucial
factor for mediating the kinase activity of Pfnek3. Collec-
tively, the regulatory mechanism involved in controlling
Pfnek3 activity seems to become increasingly evident with
both serine/threonine and tyrosine phosphorylation playing
a pivotal role. Phosphorylation is a major post-translational
modification that can modulate protein activity, protein–
protein interaction, and protein translocation. Hence, other
than acting as molecular switches to regulate its activity, it
would be interesting to pursue whether phosphorylation of
Pfnek3 can play additional roles in terms of substrate
interaction and cellular localization. Efforts have also been
made in this study to identify the tyrosine phosphorylation
sites that are crucial for modulating Pfnek3 kinase activity.
However, as mass spectrometric identification of Pfnek3
Fig. 6 Catalytic activities of Pfnek3 tyrosine phospho-mimetic
mutants. Residues Y117, Y122, Y172, and Y238 were each replaced
with either an aspartate or a glutamate to mimic phosphorylation at
these residues. Serine/threonine (upper panel) and tyrosine (lower
panel) kinase activities of these mutants were analyzed using the
ELISA-based kinase assay. Results are presented as a percentage of
wild-type Pfnek3 activity, with each bar representing the mean
activity ± standard deviation from two independent assays.
ND denotes kinase activity not detected
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tyrosine phosphorylation sites is technically challenging,
the current investigation adopted an alternative biocompu-
tational approach for identifying potential tyrosine
phosphorylation sites. The NetPhos program predicted a
total of six tyrosines that could potentially be phosphory-
lated (Table 2). The combined data obtained following site-
directed mutagenesis and biochemical assays support resi-
dues Y117, Y122, Y172, and Y238 as phosphorylation sites
crucial for mediating the catalytic activity of Pfnek3
(Fig. 5). Although these tyrosines were phosphorylated
based on the autocatalytic activity of recombinant Pfnek3,
there remains a possibility for them to be phosphorylated by
regulatory kinases in vivo. This would ultimately aid in
mapping protein kinase signaling pathways of P. falciparum,
which still remains elusive to date. A similar phenomenon has
been previously documented for the mammalian ERK2,
where bacterially expressed ERK2 was shown to undergo
autophosphorylation at the threonine and tyrosine residues
within its consensus TEY activation site [32, 33]. However, in
vivo, these residues require phosphorylation by the upstream
MEK activator to enable ERK2 to achieve its fully activated
state [22]. Other than tyrosine phospho-regulatory sites,
results obtained from Fig. 5 also suggest that the residue Y286
of Pfnek3 could be an important binding site residue for the
interaction with the MBP substrate. This notion, however,
requires further investigation and the ability to obtain a crystal
structure of the Pfnek3-MBP complex would be advantageous
in evaluating the hypothesis.
To summarize, this investigation has provided evidence
to support Pfnek3 as a novel dual-specificity kinase of
P. falciparum and illustrates an additional biochemical
similarity with the MAPKKs. Its serine/threonine and
tyrosine kinase activities were also found to be indepen-
dently stimulated through the binding of distinct metal
cofactors. Among all the P. falciparum kinases investigated
thus far, Pfmap1, another MAPK homologue, is the only
other kinase that reportedly phosphorylates at both the
serine/threonine and the tyrosine residues [34]. However, in
contrast to Pfnek3, its dual-specificity kinase activity was
only restricted to autophosphorylation reactions and whe-
ther it exhibits a corresponding activity on its substrates is
unclear [34]. An interesting observation highlighted from
the study of P. falciparum kinome is that members
belonging to the tyrosine kinase family are absent [13].
Despite this, tyrosine phosphorylation was evident
throughout the intra-erythrocytic maturation of P. falcipa-
rum, and was demonstrated to be essential for parasite
survival [35, 36]. This has therefore raised queries regard-
ing the kinases involved in undertaking the role of tyrosine
phosphorylation in vivo. The discovery of dual-specificity
kinases such as Pfnek3 and Pfmap1 is thus of great bio-
logical significance as they could be exploited as key
players to perform crucial tyrosine phosphorylation in vivo.
More specifically, these kinases may play critical roles in
modulating the functions of cellular proteins that require
activation by both the serine/threonine and tyrosine phos-
phorylation. It is also noteworthy to mention that tyrosine-
specific phosphatases have been identified in the parasite
[37, 38]. Therefore, cellular tyrosine phosphorylation in P.
falciparum may be modulated through the cooperative
function of these phosphatases and the dual-specificity
kinases. Finally, as the dual-specificity property of kinases
is difficult to be predicted based on amino acid sequence
analysis alone, it is highly likely that additional members of
such kinases in P. falciparum could be unveiled through
assessment of plasmodial kinases for their tyrosine kinase
activities by the biochemical characterization approach.
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Abstract It is well known that the co-chaperone p23
regulates Hsp90 chaperone activity in protein folding. In
Plasmodium falciparum, a putative p23 (Pfp23) has been
identified through genome analysis, but its authenticity
has remained unconfirmed since co-immunoprecipitation
experiments failed to show its interaction with P. falcipa-
rum Hsp90 (PfHsp90). Thus, recombinant Pfp23 and
PfHsp90 proteins purified from expressed clones were used
in this study. It was clear that Pfp23 exhibited chaperone
activity by virtue of its ability to suppress citrate synthase
aggregation at 45C. Pfp23 was also shown to interact with
PfHsp90 and to suppress its ATPase activity. Analyses of
modeled Pfp23-PfHsp90 protein complex and site-directed
mutagenesis further revealed strategically placed amino
acid residues, K91, H93, W94 and K96, in Pfp23 to be
crucial for binding PfHsp90. Collectively, this study has
provided experimental evidence for the inherent chaperone
function of Pfp23 and its interaction with PfHsp90, a
sequel widely required for client protein activation.
Keywords Heat shock protein 90  p23 
Plasmodium falciparum  Chaperone 
Site-directed mutagenesis
Introduction
The co-chaperone, p23, is a small protein involved in the
cascade of Hsp90 chaperone activity [1, 2]. It is well
documented that Hsp90 folds and activates proteins essen-
tial in cellular signaling and development (e.g., kinases and
transcription factors) by undergoing a cycle of conforma-
tional changes driven by the binding and hydrolysis of ATP
at its N-terminal domain [3–6]. The interaction between p23
and Hsp90 occurs at the late stage of the chaperone cycle
and is ATP-dependent [7–9]. Reportedly, the binding of p23
reduces the rate of ATP hydrolysis and traps Hsp90 in the
ATP-bound conformation [10]. It was also proposed that
p23 binding prolongs the interaction between Hsp90 and its
client proteins, thereby securing their maturation. Subse-
quently, the hydrolysis of ATP leads to the release of
activated client proteins [11]. This latter feature was dem-
onstrated using an in vitro reconstituted Hsp90 chaperone
system, whereby the incorporation of p23 significantly
increased the competence of mature progesterone and glu-
cocorticoid receptors in binding steroid hormones [12, 13],
as such attesting to p23’s importance in driving the Hsp90
functional repertoire.
In the recently resolved crystal structure complex of
Hsp82 and SbaI, homologues of Hsp90 and p23 in yeast,
respectively, the two proteins were shown to interact
through their N-terminal domains [14]. Hsp82 was crys-
tallized in the ATP-bound conformation and possessed a
closed ‘lid’ segment positioned over the ATP-binding
pocket, which would otherwise remain open in the absence
of ATP. In the case of SbaI, the N-terminal domain was
found to bind over the ATP-binding pocket of Hsp82, with
the closed ‘lid’ forming one of the interaction interfaces.
The requirement for this ATP-induced closed ‘lid’ con-
formation in Hsp82 to interact with SbaI is circumstantially
supported by experiments showing the preferential binding
of p23 to ATP-bound Hsp90 [7–9].
Apart from regulating Hsp90 chaperone functions, p23
is also capable of binding partially folded proteins and
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suppressing protein aggregation in vitro [15, 16]. This has
led to the suggestion that p23 may itself function as a
chaperone, independent of Hsp90. When the C-terminal
tail of p23 was truncated, its chaperone activity was
abolished, suggesting that the acidic amino acid-rich tail
may be instrumental for its function [17]. This intrinsic
chaperone activity of p23 has been demonstrated to be
essential for the recycling of steroid receptors and telo-
merase [18, 19].
In Plasmodium falciparum, the species that causes the
most severe form of human malaria, a putative homologue
of p23 (Pfp23) has been reported [20]. Pfp23 was initially
identified as a 36-kDa major phosphoprotein associated
with the kinase activity of an unknown protein in P. fal-
ciparum [21, 22]. Subsequent procurement of its protein
sequence revealed its homology to the co-chaperone p23
[20]. However, validation of its role as a co-chaperone of
P. falciparum Hsp90 (PfHsp90) has been unsuccessful so
far [20, 23]. Co-immunoprecipitation experiments per-
formed using either antibodies specific to Pfp23 or
PfHsp90 did not detect complexes containing both the
proteins. However, as alluded to earlier, p23 has important
roles in the activation of a plethora of Hsp90 client pro-
teins, many of which are crucial in signal transduction and
regulating cell growth. Thus, it would be unusual to
exclude its role in P. falciparum, as implicated in reports so
far. Therefore, in this study, the putative Pfp23 was probed
for its intrinsic chaperone activity and interaction with
PfHsp90.
Materials and methods
Cloning of Pfp23 and PfHsp90
The DNA sequences of Pfp23 (PF14_0510) and PfHsp90
(PF07_0029) were retrieved from PlasmoDB, and primers
were designed to clone these genes (Table 1). The genes
were cloned from the mRNA of P. falciparum 3D7. The
mRNA extraction and reverse transcription procedures
were carried out as previously described [24].
Briefly, the PCR-amplified gene products were sepa-
rated by agarose gel electrophoresis using 0.8% (w/v)
agarose gel, and the bands that corresponded to the
expected size of the genes were excised and purified using
the MinEluteTM Gel Extraction Kit (Qiagen). Subse-
quently, the purified fragments were ligated into pCR-
BluntII-TOPO Vector using the Zero BluntTM TOPOTM
PCR Cloning Kit (Invitrogen). The plasmids of the
recombinant clones were extracted using the Wizard Plus
SV Minipreps DNA Purification System from Promega.
Full sequencing was carried out using the ABI PRISMTM
BigDyeTM Terminator Cycle Sequencing Ready Reaction
Kit from Perkin Elmer and analyzed using the ABI PRISM
3100 DNA sequencer to identify recombinant clones that
contained the genes of interest.
Subsequently, the recombinant clones that contained
Pfp23 and PfHsp90 were double-digested with BamHI/SalI
and BamHI/XhoI, respectively. Pfp23 was subcloned into
the expression vector, pET24a (Novagen), whereas
PfHsp90 was ligated to pET24a and pGK [25] expression
vectors. PfHsp90 expressed using the pGK vector con-
tained a GST- and a His6 tag and would be used for the
GST pull-down assay. However, the more highly expressed
PfHsp90 from the recombinant pET24a vector possessed
only a His6 tag. This fusion protein would be used for the
ATPase assay. The ligated recombinant vectors were
transformed into Escherichia coli BL21 (DE3) cells that
contained a RIG plasmid [26] for expression of the
recombinant fusion proteins. DNA sequencing was per-
formed to authenticate the recombinant clones carrying the
genes of interest.
Construction of Pfp23-truncated and single mutants
The recombinant pET24a plasmid that contained Pfp23
was used as a template for the construction of Pfp23-
truncated mutants. Pfp23-truncated mutants T1, T2, T3, T4
and T5 were PCR-amplified using appropriate forward
primers and a common reverse primer used for Pfp23 wild-
type (Pfp23-WT) previously. On the other hand, amplifi-
cations of Pfp23-truncated mutants, Pfp23-(D135–275) and
Pfp23-(D220–275) were carried out using appropriate
designed reverse primers and a common forward primer
from Pfp23-WT (Table 1). Similar cloning procedures
described earlier were adopted for the subsequent steps.
The QuikChangeTM Site-directed Mutagenesis Kit from
Stratagene was used for the construction of Pfp23 single
mutants [27]. Primers were designed to introduce the
desired mutations using PCR protocols described previ-
ously [28]. DNA sequencing was performed subsequently
to verify the changes in the nucleotide sequences prior to
transformation into E. coli BL21 (DE3) with the RIG
plasmid for recombinant fusion protein expression.
Expression and purification of Pfp23 and PfHsp90
Bacterial cultures carrying the PfHsp90 and Pfp23
recombinant plasmids were grown in 100 ml Luria-Bertani
broth with 50 lg/ml kanamycin (Sigma) and 40 lg/ml
chloramphenicol (Sigma) for protein expression. The cul-
tures were grown at 37C with agitation at 250 rpm until an
OD600 of 0.8 was reached. Protein expression was induced
by the addition of 1 mM isopropyl-b-D-1-thiogalactopyr-
anoside (Sigma) followed by incubation at 16C with
shaking at 250 rpm for 16 h.
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Following induction, the cultures were harvested by
centrifugation at 6,000 rpm for 5 min at 4C. The super-
natant was discarded, and the pelleted cells were
resuspended in cold 50 mM Tris-HCl, pH 7.5 buffer. The
cells were lysed via sonication with a 1/8-inch probe at an
intensity of 10 lm for eight cycles with 10-s pulse and 10-s
rest in each cycle. Cell lysates were subsequently centri-
fuged at 12,000 rpm for 20 min, and the soluble protein
fractions that contained the fusion proteins of interest were
subjected to purification.
The PfHsp90 and Pfp23 recombinant proteins, both
carrying a C-terminal His6 tag, were purified by affinity
chromatography using nickel-nitrilotriacetic acid (Ni-
NTA) beads (Qiagen). For each purification, an aliquot of
1 ml of the soluble protein fraction was incubated with
50 ll of Ni-NTA beads for 15 min at 4C. Unbound pro-
teins were removed by washing thrice with 250 ll of
50 mM Tris-HCl, pH 7.5, 20 mM imidazole buffer. The
recombinant proteins were eluted in 50 ll of 50 mM Tris-
HCl, pH 7.5, 300 mM imidazole buffer.
To remove co-purified contaminating proteins, the eluted
proteins were further purified by gel filtration chromatog-
raphy on a Superdex 200 column (GE Healthcare). The
recombinant proteins were separated at a flow rate of
0.5 ml/min in buffer containing 50 mM Tris-HCl, pH 7.5.
The eluted samples were analyzed by SDS-PAGE to
determine the fractions that contained the recombinant
proteins of interest. These fractions were pooled and con-
centrated using Amicon Ultra-4 Centrifugal Filter Units
with appropriate molecular weight cutoff and stored at 4C
for subsequent assays. The concentrations of the purified
fusion proteins were determined by Bradford assay (Biorad)
using bovine serum albumin (Sigma) as a standard.
Expression and purification of the recombinant proteins
were upscaled proportionately when necessary to obtain a
sufficient amount of recombinant proteins for the sub-
sequent assays.
Citrate synthase aggregation assay
The intrinsic Hsp90-independent chaperone activity of
Pfp23 was assayed based on the aggregation of citrate
synthase [29] using a slightly modified protocol. Porcine
citrate synthase (Sigma) was dialyzed with 40 mM
HEPES, pH 7.5 buffer, overnight and concentrated to an
8.5-lM stock solution. Aggregation was induced by the
Table 1 Primers designed for
gene cloning and mutations
a Restriction enzyme sites are
in lower case, F represents
forward primer, R represents
reverse primer
b Codons mutated in Pfp23 are
bold and underlined
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incubation of citrate synthase (0.15 lM) in 40 mM
HEPES, pH 7.5 buffer, at 45C. The assays were performed
in the presence or absence of five-fold excess (0.75 lM) of
Pfp23-WT and Pfp23-(D220–275). The extent of aggre-
gation was measured by the increase in absorbance due to
light scattering and monitored at 334 nm using the Tecan
Safire spectrophotometer. The absorbance was recorded
every 2.5 min for 20 min.
In vitro interaction between Pfp23 and PfHsp90
The in vitro interaction of Pfp23 and PfHsp90 was inves-
tigated using GST pull-down assay. Nickel affinity purified
dual-tagged PfHsp90 fusion protein expressed from the
pGK vector was used as a bait. For each experiment, 2 lg
of PfHsp90 fusion protein was incubated with 50 ll of
glutathione Sepharose beads (GE Healthcare) at 4C for
15 min. The bound fusion proteins were washed thrice with
50 mM of Tris-HCl, pH 7.5, buffer to remove unbound
proteins. Subsequently, the beads were reconstituted in
500 ll of binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM
KCl, 2 mM dithiothreitol, 0.01% (v/v) Triton X-100). The
binding assays were carried out in the presence of 5 mM
MgCl2, 5 mM ATP and 10 lg of Pfp23, unless stated
otherwise. Samples were incubated at 30C for 30 min for
PfHsp90-Pfp23 complex formation. Thereafter, the sam-
ples were washed thrice with 500 ll of binding buffer prior
to elution in 150 ll of reduced glutathione buffer. Fifty
microliters of the eluted sample was analyzed by SDS-
PAGE. Gel image analyses and densitometric measure-
ments were performed using Bio-Rad Molecular Imager
Gel Doc XR system equipped with the Quantity One
Software.
ATPase assay
The ATPase activity of PfHsp90 was measured using the
pyruvate kinase/lactate dehydrogenase-coupled assay [6,
30]. The assay was carried out in a 200-ll reaction con-
taining 2 lM PfHsp90 incubated in 100 mM Tris-HCl, pH
7.5, 6 mM MgCl2, 20 mM KCl, 0.8 mM ATP, 2 mM
phosphoenolpyruvate, 0.2 mM NADH, 50 lg/ml lactate
dehydrogenase and 0.2 mg/ml pyruvate kinase at 37C.
The decrease in NADH level, which is in direct stoichi-
ometry to the amount of ATP hydrolysed, was determined
spectrophotometrically at 340 nm. The authenticity of
PfHsp90 ATPase activity was verified by its sensitivity to
inhibition by radicicol (100 lM), a specific Hsp90 ATPase
inhibitor. To determine the effect of Pfp23 interaction on
PfHsp90 ATPase activity, Pfp23 was added to the assay
reactions in increasing concentrations (2–30 lM). In
addition, Pfp23 single mutants with differential binding
capacity to PfHsp90 were also tested for their influence on
PfHsp90 ATPase activity. The Pfp23 single mutants were
added in ten-fold molar excess (20 lM), and their effects
on the ATPase activity of PfHsp90 were compared to that
of Pfp23-WT. All measurements were made using the
Tecan Safire spectrophotometer. The ATPase activity
reported is expressed as micromole of ATP hydrolysed per
micromole of PfHsp90 in 1 min at 37C.
Bio-computational analyses of Pfp23 and PfHsp90
Protein sequence alignment was performed using the
CLUSTAL W Multiple Alignment Program [31], and the
percentage identities were determined by MatGAT 2.02
[32]. Tertiary structures of Pfp23 and PfHsp90 were
modeled by the SWISS-MODEL program [33] using the
‘‘First Approach Mode’’. The Hsp82-SbaI crystal structure
complex (PDB accession number: 2cg9) was used as a
template for protein modeling. The modeled protein
structures were subsequently visualized using the Swiss-
PdbViewer (SPdbV) program [34].
Results
Bio-computational analyses of the putative Pfp23
P. falciparum 3D7 genome encodes a putative p23
homologue of 275 amino acid residues. The Pfp23 pos-
sesses the characteristic ‘‘Hsp20-like chaperone super-
family’’ domain (residues 2-106) and a C-terminal tail rich
in acidic residues. The ‘‘Hsp20-like chaperone superfam-
ily’’ domain, which is also present in the yeast SbaI,
is known to be important for Hsp82 interaction [14].
Sequence homology analyses indicated that Pfp23 shared
44% sequence identity with Schizosaccharomyces pombe
p23 homologue [20], but exhibited only 19.6 and 23.6%
sequence identities in common with the human p23 and
Saccharomyces cerevisiae SbaI, respectively. In addition,
the putative Pfp23 (275 residues) has a longer protein
sequence than the human p23 (160 residues) and S. cere-
visiae SbaI (216 residues). Multiple sequence alignment
further revealed the difference in protein length of Pfp23
lies in the presence of the unique tandem repeats,
GNMGGLx7 (between amino acid residues 135–176) and
a longer C-terminal tail (Fig. 1). Similar glycine-rich
tandem repeats were also found in p23 of other Plasmo-
dium species, namely P. chabaudi, P. berghei, P. yeolii
and P. knowlesi [20]. In comparison, the human p23 only
possessed a GGD sequence, whereas the yeast SbaI has
two repeats of GGAGGA and a single GGAGGM sequence.
So far, the significance of these glycine-rich sequences
has yet to be reported and as such its functionality remains
enigmatic.
C.-S. Chua et al.
Cloning, expression and purification of Pfp23
and PfHsp90
To clone the putative Pfp23 and PfHsp90, reverse tran-
scription and PCR amplifications were carried out using
appropriate primers and mRNA from P. falciparum 3D7.
The resultant ORF of Pfp23 was inserted into the pET24a
expression vector, whereas that of PfHsp90 was ligated
into pET24a and pGK expression vectors. Subsequently,
DNA sequencing was performed to verify their authentic-
ities. The recombinant plasmids were transformed into
E. coli BL21 (DE3) already harboring the RIG plasmid.
The RIG plasmid encodes tRNAs that recognize rare
codons present in the AT-rich plasmodial genes [26].
Hence, it was included in anticipation of improving the
expression of the recombinant proteins.
Pfp23 and PfHsp90 were solubly expressed as recom-
binant proteins. The PfHsp90 fusion protein expressed
from the pGK vector contained an N-terminal GST tag and
a C-terminal His6 tag. The inclusion of a dual tag allowed
an initial purification of PfHsp90 fusion protein using Ni2?
affinity chromatography and gel filtration separation, prior
to immobilization on the glutathione Sepharose for the
GST pull-down assays. As the subsequent ATPase assay
requires large quantities of highly purified proteins, the
recombinant PfHsp90 was expressed using the pET24a
vector. The recombinant pET24a vector provided signifi-
cantly higher quantities of PfHsp90 fusion proteins
compared to the recombinant pGK vector. Pfp23 was also
recombinantly expressed using the pET24a vector, and
similar Ni2? affinity chromatography and gel filtration
separation techniques were utilized to purify these fusion
proteins. After electrophoretic separation, the recombinant
Pfp23 was found to be approximately 36 kDa, whereas
PfHsp90 expressed from recombinant pGK and pET24a
vectors were 114 kDa and 88 kDa, respectively (Fig. 2).
The recombinant Pfp23 possesses chaperone activity
Prior to this study, the functionality of the putative Pfp23
had not been demonstrated. In view of this, Pfp23 was
examined for its intrinsic chaperone activity in preventing
the aggregation of citrate synthase [29]. Pfp23 was added
to citrate synthase in a 5:1 M ratio and incubated at 45C.
Aggregation of citrate synthase was detected by the
increase in absorbance at 334 nm over a 20-min interaction
time.
In the absence of Pfp23, citrate synthase aggregated
spontaneously at 45C (Fig. 3). The addition of Pfp23
suppressed the aggregation of citrate synthase, as reflected
by the decrease in absorbance reading. Similar anti-
aggregation activity was observed in human p23, but was
abolished when its acidic C-terminal tail was truncated by
30 amino acid residues [17]. To investigate whether the
C-terminal tail of Pfp23 also contributes to anti-aggrega-
tion activity, a mutant clone of Pfp23 that lacks the
C-terminal acidic residues was constructed. Deletion of the
C-terminal tail in Pfp23-(D220–275) resulted in a total loss
of the anti-aggregation activity observed in Pfp23-WT,
implying the requirement of the C-terminal tail for its full
chaperone activity. No self-aggregation of Pfp23-WT and
Pfp23-(D220–275) was observed at 45C in the control
Fig. 1 Protein sequence alignment of p23 and related sequences.
Protein sequences of Homo sapiens p23 (NP_006592.3) and Saccha-
romyces cerevisiae SbaI (NP_012805.1) were obtained from
GenBank, whereas that of Pfp23 (PF14_0510) was retrieved from
PlasmoDB. The P. falciparum genome encodes a longer putative p23
homologue that shares only 19.6 and 23.6% amino acid sequence
identities with the human p23 and S. cerevisiae SbaI, respectively.
The glycine-rich GNMGGLx7 sequence repeats in Pfp23 are bold
and underlined. Asterisk identical amino acid residues in all the
sequences, colon indicates conserved amino acid substitutions, dot
indicates semi-conserved amino acid substitutions
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experiments performed without citrate synthase (data not
shown).
Pfp23 interaction with PfHsp90 is dependent
on MgCl2 and ATP
The role of Pfp23 as a co-chaperone of PfHsp90 in
P. falciparum has remained debatable as previous attempts
to identify their interaction via co-immunoprecipitation
techniques were unsuccessful [20, 23]. As such, their
interaction was probed in this study using recombinant
proteins and GST pull-down assays. Purified Pfp23
recombinant protein was added to PfHsp90 immobilized on
glutathione Sepharose in a 5:1 ratio and incubated either in
the presence or absence of 5 mM MgCl2, 5 mM ADP or
5 mM ATP. Under the different conditions tested, the
binding of Pfp23 to PfHsp90 was only observed in the
presence of MgCl2 and ATP (Fig. 4). Recombinant GST-
His6 fusion protein without PfHsp90 was used as a control
to ensure that the recombinant tags do not contribute to the
interaction observed. Pfp23 binding was absent in the
control experiments performed under similar conditions
(data not shown).
Sequential N-terminal truncation of Pfp23 affects
interaction with PfHsp90
As Pfp23 shares low amino acid sequence identities with
the human p23 and yeast SbaI, its interaction with PfHsp90
may potentially differ from that of their homologues.
Hence, the interaction between Pfp23 and PfHsp90 was
further analyzed. Pfp23 was sequentially truncated by 25
amino acid residues from the N-terminal end to identify
regions that are essential for binding PfHsp90 (Fig. 5a).
A total of five Pfp23-truncated mutants (T1 to T5) were
constructed, cloned, expressed and purified under similar
conditions to those described for Pfp23-WT. All the trun-
cated mutants were solubly expressed in E. coli BL21
(DE3) (data not shown). Pfp23-truncated mutants T1, T2
and T3 retained their binding to PfHsp90, whereas further
truncations in T4 and T5 abolished interaction with
PfHsp90 (Fig. 5b). The results indicated that certain amino
acid residues located between the 75th to 100th positions in
Fig. 2 SDS-PAGE analyses of purified Pfp23 and PfHsp90 recom-
binant proteins. PfHsp90 was expressed from recombinant pGK and
pET24a vectors separately. PfHsp90 expressed from the pGK vector
contained an N-terminal GST tag and a C-terminal His6 tag, whereas
PfHsp90 from the pET24a vector possessed only the C-terminal His6
tag. Similarly, Pfp23 expressed from the recombinant pET24a vector
harbored a C-terminal His6 tag. The molecular weights of the
recombinant proteins are approximately 114 kDa (PfHsp90 from
pGK), 88 kDa (PfHsp90 from pET24a) and 36 kDa (Pfp23). M protein
marker (Biorad)
Fig. 3 The Pfp23 recombinant protein exhibited intrinsic chaperone
activity. The intrinsic chaperone activity of Pfp23 was determined by
citrate synthase aggregation assay. Spontaneous aggregation of citrate
synthase was monitored continuously over 20 min at 45C by the
increase in absorbance. Addition of Pfp23-WT suppressed the
aggregation of citrate synthase. The anti-aggregation activity was
abolished when Pfp23-WT was substituted with Pfp23-(D220–275),
which has a truncated C-terminal tail. Results shown are represen-
tative of three independent experiments. CS citrate synthase
Fig. 4 SDS–PAGE analyses of Pfp23 interaction with PfHsp90. The
interaction between Pfp23 and PfHsp90 was tested in the presence or
absence of 5 mM MgCl2, 5 mM ADP and 5 mM ATP as indicated.
Pfp23 was bound to PfHsp90 only in the presence of MgCl2 and ATP.
Results shown are representative of three independent experiments
C.-S. Chua et al.
Pfp23 are crucial for binding PfHsp90. To identify these
amino acid residues, the corresponding region in yeast SbaI
was determined by primary sequence alignment and
examined for the presence of Hsp82-interacting residues.
Inspection of the region using the yeast Hsp82-SbaI crystal
structure complex revealed an interface in SbaI (K113,
Y114, P115, Y116, I117 and K118) that interacts with the
closed ‘lid’ segment of Hsp82 (Fig. 6a) [14]. This interface
corresponded to the amino acid residues K91, K92, H93,
W94, V95 and K96 in Pfp23 and was observed to be in
proximity to PfHsp90 in the modeled complex (Fig. 6b).
Hence, these residues may potentially be essential for
PfHsp90 interaction, such that when deleted (in Pfp23-
truncated mutants T4), Pfp23’s competency in binding
PfHsp90 is undermined.
Residues K91, H93, W94 and K96 in Pfp23
are essential for PfHsp90 interaction
To investigate the importance of the amino acid residues
K91, K92, H93, W94, V95 and K96 in Pfp23 for PfHsp90
interaction, single mutants were generated. Firstly, Pfp23
residues K91, K92 and K96 were each mutated to an ala-
nine to examine the importance of the lysine side chains for
binding PfHsp90. As for residues H93 and W94, mutation
to a polar serine residue was proposed to disrupt any
hydrophobic interaction formed between Pfp23 and
PfHsp90. Similarly, the hydrophobic amino acid residue,
V95, was mutated to a polar asparagine residue as a pre-
vious study showed that substitution at the corresponding
position in SbaI (I117N) abolished interaction with Hsp82
[35]. All the Pfp23 mutant proteins were solubly expressed,
purified and tested for PfHsp90 interaction under similar
binding conditions to those described for Pfp23-WT. Pfp23
mutants K91A, H93S, W94S and K96A displayed signifi-
cant reduction in their binding to PfHsp90, retaining less
than 25% of Pfp23-WT’s binding (Fig. 7). However, Pfp23
mutants K92A and V95 N retained more than 85% of
Fig. 5 Interaction between Pfp23-WT and truncated mutants with
PfHsp90. a Schematic representation of the Pfp23-truncated mutants
constructed in this study. A 25-amino acid serial truncation was
performed from the N-terminal end of Pfp23 (T1 to T5) to identify the
region that is essential for binding PfHsp90. Pfp23-(D220–275) was
constructed to investigate the intrinsic chaperone activity of Pfp23.
On the other hand, Pfp23-(D135–275) was generated to determine
whether the GNMGGLx7 sequence repeats are essential for PfHsp90
interaction. b Purified Pfp23-WT and the respective truncated mutants
were incubated with PfHsp90 in the presence of 5 mM MgCl2 and
5 mM ATP. Truncated mutants T4 and T5 were unable to bind
PfHsp90, as shown in the SDS-PAGE analysis. Results presented are
representative of three independent experiments
Fig. 6 Analyses of the modeled structures of Pfp23 and PfHsp90.
a PfHsp90 (orange) and Pfp23 (green) were modeled against the yeast
Hsp82 (gold)-SbaI (brown) crystal structure complex (PDB accession
number: 2cg9). The modeled Pfp23 shares similar structural features
with SbaI and possesses an extended loop (highlighted in grey) that is
projected towards the closed ‘lid’ segment of PfHsp90. Only the
N-terminal domains of PfHsp90 and Hsp82 were shown in the graphical
presentation. b Amino acid residues K91, K92, H93, W94, V95 and
K96, located at the extended loop of Pfp23, were observed to be in
proximity to the closed ‘lid’ segment of PfHsp90. Pfp23 residue H93
was observed to be in close contact with the hydrophobic residues F104
and I114 in PfHsp90 (top right). Similarly, the residue W94 in Pfp23 is
directed towards residues I108 and M105 in PfHsp90 (bottom right).
AMP-PNP a non-hydrolysable analogue of ATP
Plasmodium falciparum co-chaperone p23
Pfp23-WT’s binding to PfHsp90. Recombinant GST-His6
fusion protein without PfHsp90 was used as a control, and
no interaction with Pfp23 mutants was observed when
tested under similar conditions (data not shown).
The GNMGGLx7 sequence repeats in Pfp23
are not essential for PfHsp90 interaction
The protein sequence of Pfp23 contains GNMGGLx7
sequence repeats, which have yet to be functionally char-
acterized. To determine if the sequence repeats are
important for PfHsp90 interaction, two additional truncated
mutants, Pfp23-(D220–275) and Pfp23-(D135–275), were
constructed. The Pfp23-(D220–275) mutant contained the
GNMGGLx7 sequence repeats but lacked the C-terminal
tail, whereas Pfp23-(D135–275) had both the sequence
repeats and the C-terminal tail deleted (Fig. 8). SDS-PAGE
analysis showed that Pfp23-(D220–275) retained interac-
tion with PfHsp90. Similarly, further removal of the
GNMGGLx7 sequence repeats in Pfp23-(D135–275) did
not affect the mutant’s competency in binding PfHsp90.
Hence, the results indicated that the GNMGGLx7
sequence repeats are not essential for PfHsp90 interaction.
Pfp23 inhibits the ATPase activity of PfHsp90
The binding and hydrolysis of ATP are known to induce
conformational changes in Hsp90, essential for the chap-
eroning of its client proteins [3–5]. To determine whether
the binding of Pfp23 affects the hydrolysis of ATP in
PfHsp90, and henceforth, the regulation of its chaperone
function, ATPase assay was carried out.
Using a sensitive enzyme-coupled assay, PfHsp90 was
shown to have an ATPase activity of 0.504 ± 0.044
lmolATP/min/lmolPfHsp90 at 37C. The activity measured
was sensitive to inhibition by radicicol, a specific Hsp90
ATPase inhibitor, and thus ensured that the activity
detected was not attributed to other co-purified ATPase
contaminants. The activity observed is approximately ten
times more than the human Hsp90 ATPase activity (0.034–
0.089 lmolATP/min/lmolHsp90) [10, 36], but comparable to
that reported for yeast Hsp82 (0.40–1.05 lmolATP/min/
lmolHsp82) [5, 6, 37, 38].
The effect of Pfp23 interaction on PfHsp90 ATPase
activity was subsequently investigated by the addition of
Pfp23 in increasing concentrations to the assay reactions
(Fig. 9a). Introduction of an equimolar concentration of
Pfp23 had a negligible effect on the ATPase activity of
Fig. 7 Effects of Pfp23 mutations on PfHsp90 interaction. a Pfp23-
WT and mutants were incubated with PfHsp90 in the presence of
5 mM MgCl2 and 5 mM ATP. The complexes formed were analyzed
by SDS-PAGE. b The binding of Pfp23 mutants to PfHsp90 was
analyzed by densitometry. The percentage of PfHsp90 bound was
calculated with respect to the PfHsp90 control (single asterisk),
whereas Pfp23 mutants binding to PfHsp90 was determined with
respect to Pfp23-WT (double asterisk). Pfp23 single mutants K91A,
H93S, W94S and K96A displayed drastically reduced binding to
PfHsp90, whereas single mutants K92A and V95 N retained binding
comparable to Pfp23-WT to PfHsp90. Results shown are represen-
tative of three independent experiments
Fig. 8 SDS-PAGE analyses of Pfp23-(D220–275) and Pfp23-(D135–
275) interactions with PfHsp90. To investigate the importance of the
GNMGGLx7 sequence repeats in Pfp23 for PfHsp90 interaction,
Pfp23-(D135–275) was constructed. Using Pfp23-(D220–275)
mutant, the C-terminal tail of Pfp23 was shown to be dispensable
for PfHsp90 interaction. Further deletion of the GNMGGLx7
sequence repeats in Pfp23-(D135-275) did not affect its binding to
PfHsp90, indicating that the sequence repeats are not essential for
PfHsp90 interaction
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PfHsp90. However, when added in ten-fold molar excess,
Pfp23 reduced the ATPase activity of PfHsp90 to
approximately 20% of its original activity.
To further verify whether the ATPase inhibitory effect
was due to the interaction of Pfp23 with PfHsp90, Pfp23
single mutants with differential PfHsp90 binding levels
were used. As expected, Pfp23 single mutants (K91A,
H93S, W94S and K96A), which displayed drastically
reduced PfHsp90 binding, had little inhibitory effect on the
ATPase activity of PfHsp90 (Fig. 9b). PfHsp90 retained
approximately 90% of its ATPase activity in the presence
of Pfp23 single mutants K91A, H93S and W94S, respec-
tively. Nevertheless, Pfp23 single mutant K96A was able to
suppress the ATPase activity of PfHsp90 to approximately
65% of its original activity. On the contrary, Pfp23 single
mutants (K92A and V95 N) that have a binding capacity to
PfHsp90 similar to Pfp23-WT significantly inhibited the
ATPase activity of PfHsp90 to approximately 35% of its
original activity. The results clearly demonstrated the
inhibitory effect that Pfp23 binding has on the ATPase
activity of PfHsp90, and this may have significance in the
regulation of PfHsp90 chaperone function in vivo.
Discussion
Treatment of malaria is increasingly challenging with the
emergence of new strains that are resistant to conventional
anti-malaria drugs such as chloroquine and pyrimethamine-
sulfadoxine [39, 40]. Coupled with the lack of efficacious
vaccines, there is a need to search for new anti-malarials
and drug targets. Recent studies have recognized the
potential of targeting PfHsp90 for malaria therapy as its
inhibition effectively arrests the intra-erythrocytic devel-
opment of P. falciparum [23, 41, 42]. Nevertheless, there
are some considerations on the use of Hsp90-specific inhibi-
tors as anti-malarials. How selective inhibition of PfHsp90
can be achieved in humans remains a concern since the
Hsp90s in the two organisms are fairly conserved, with 63%
amino acid identity [43]. Furthermore, the paucity of knowl-
edge on the Hsp90 chaperone system in P. falciparum hinders
the understanding of its function in the malaria parasite.
Hence, identifying factors that regulate the function of
PfHsp90 and its affinity for the inhibitors is imperative to
facilitate the assessment of its relevance as a drug target.
One of the factors that influences Hsp90 activity and
sensitivity to the inhibitors is the binding of co-chaperones
[44–48]. However, thus far, PfHsp90 has only been dem-
onstrated to form complexes with P. falciparum Hsp70,
PP5, PKBP35 and a-tubulin [23, 49, 50]. It is surprising
that homologues of co-chaperones (e.g., p23, Hop), which
are known to be essential in regulating the chaperone
function of Hsp90 in human and yeast [2], were not
detected in those PfHsp90 complexes isolated. Inevitably,
this has raised doubts about the functional conservation of
these putative co-chaperones in P. falciparum. As the
interaction between p23 and Hsp90 is essential for client
protein activation, and recently has been shown to influ-
ence the sensitivity of yeast to Hsp90-specfic inhibitors
[44], the interaction status of their homologues in P. fal-
ciparum may have implications on the modus operandi of
PfHsp90 and its affinity for the drugs. Hence, in this study,
the putative co-chaperone Pfp23 was investigated for its
functionality and interaction with PfHsp90.
The purified Pfp23 recombinant protein was shown to
possess intrinsic chaperone activity by virtue of its ability
to suppress the aggregation of citrate synthase at 45C.
However, removal of the C-terminal tail of Pfp23 resulted
in the loss of this anti-aggregation activity and attests to the
need to have a full-fledged Pfp23 protein to elicit the
Fig. 9 Effects of Pfp23-WT and mutants on PfHsp90 ATPase
activity. a Pfp23 was added in increasing concentrations to the
ATPase assay reactions containing a fixed amount of PfHsp90
(2 lM). The ATPase activity of PfHsp90 was inhibited by Pfp23 in a
concentration-dependent manner. At ten-fold molar excess, Pfp23
inhibited the ATPase activity of PfHsp90 to approximately 20% of its
original activity. b Pfp23 single mutants were tested for their ability
to inhibit the ATPase activity of PfHsp90. Pfp23 single mutants
known to have reduced binding to PfHsp90 (K91A, H93S, W94S and
K96A) displayed a negligible inhibitory effect on its ATPase activity.
However, Pfp23 single mutants (K92A and V95 N) that exhibited
comparable binding to PfHsp90 as Pfp23-WT inhibited PfHsp90
ATPase activity to approximately 35% of its original activity. Pfp23-
WT and mutants were added in ten-fold molar excess to PfHsp90 in
all the assay reactions. Results shown are representative of two
independent experiments
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chaperone activity. Pfp23 was subsequently probed for its
interaction with PfHsp90 to assess its potential role as a co-
chaperone in P. falciparum. Using GST pull-down assays,
Pfp23 was observed to bind PfHsp90 in the presence of
MgCl2 and ATP. The conditions conducive for binding
were similar to that of the human and yeast homologues [7,
8], where the Mg2? ion is essential as a cofactor for ATP
binding in Hsp90 [51]. Truncation experiments indicated
that the unique GNMGGLx7 sequence repeats in Pfp23
are dispensable for PfHsp90 interaction. Instead, when
coupled to computational analyses, the results from the
truncation study suggested that the 91st to 96th amino acid
residues in Pfp23 may form an essential interface for
binding PfHsp90. This interface (consisting of amino acid
residues K91, K92, H93, W94, V95 and K96) is located at
an extended loop of Pfp23 and was observed to be in
proximity to the closed ‘lid’ segment of PfHsp90 (Fig. 6a).
Site-directed mutagenesis experiments affirmed the impor-
tance of residues K91, H93, W94 and K96 for PfHsp90
interaction. Their respective single amino acid substitutions,
K91A, H93S, W94S and K96A, resulted in drastically
reduced binding to PfHsp90. However, Pfp23 mutants with
K92A or V95 N substitution displayed PfHsp90 binding
levels comparable to Pfp23-WT. The effects of these muta-
tions were analyzed by computationally modeled structures
to further comprehend the molecular forces that are involved
in their interaction.
With the aid of modeled tertiary structures, the side
chains of K91, H93, W94 and K96 in Pfp23 were observed
to be projected towards the closed ‘lid’ segment of
PfHsp90 (Fig. 6b). Under the in vitro binding conditions
used (at pH 7.5), the side chain of the histidine residue
(H93) would be uncharged, suggesting that the main force
of interaction is hydrophobic in nature. This was supported
by the observation that its side chain is located close to the
hydrophobic residues F104 and I114, of PfHsp90 (Fig. 6b).
Similar hydrophobic interaction would be expected of
Pfp23 residue W94, which was visualized to be in proximity to
I108 and the aliphatic side chain of M105 in PfHsp90. Con-
ceivably, substitutions of H93 and W94 to a polar serine
residue, respectively, would disrupt the hydrophobic interac-
tion and result in the diminished binding to PfHsp90, as
observed in this study.
Apart from that, in silico analyses of the Pfp23 residues,
K91 and K96, did not reveal any electrostatic interaction
between the charged group in the lysine side chains with
PfHsp90 residues. This is consistent with the observation
that the interaction between Pfp23 and PfHsp90 was stable
at high salt concentrations of up to 300 mM KCl (data not
shown), suggesting that electrostatic force plays a minor
role in their interaction. Instead, results from the mutation
study suggest that the long aliphatic side chains of the
lysine residues may be important in contributing to the
hydrophobic interaction between the Pfp23 residues, H93
and W94, with PfHsp90. Substitution to an alanine with
a much shorter side chain would greatly diminish the
hydrophobicity and proximity required for binding
PfHsp90, and this may account for the lack of PfHsp90
interaction as observed.
On the contrary, the Pfp23 mutant K92A retained a
similar PfHsp90 binding capacity to that of the Pfp23-WT.
This implies that the residue K92 is not essential for
PfHsp90 interaction. Likewise, replacing V95 with an
asparagine resulted in a mutant that retained comparable
binding to PfHsp90 as the Pfp23-WT. This result is sur-
prising as the corresponding mutation in yeast SbaI
(I117N) had rendered it defective in binding Hsp82 [35].
However, using the modeled structures, the side chain of
V95 was observed to be projected away from PfHsp90.
In view of this, Pfp23 mutant V95N’s ability to retain
its binding to PfHsp90 is likely to be attributed to the lack
of interaction between the amino acid residue V95 and
PfHsp90.
The results of the truncation study have also highlighted
that a large segment of Pfp23’s N-terminal domain (1st to
74th amino acid residues) can be deleted without affecting
its interaction with PfHsp90. This segment corresponds to
the region in SbaI (1st to 93rd amino acid residues) where
three other Hsp82-interacting interfaces (amino acid resi-
dues 13–16, 31–37, 85–91) were found [14]. It is difficult
to postulate whether the deletion of these interfaces in SbaI
(similar to that of Pfp23-truncated mutants T4) would
affect Hsp82 interaction, as only a few amino acid residues
located at these interfaces were conserved at the corre-
sponding positions in Pfp23.
Probing the significance of Pfp23 binding on PfHsp90
function, results from the ATPase assays revealed that
Pfp23 is capable of suppressing the hydrolysis of ATP by
PfHsp90. The ATPase inhibitory effect of Pfp23 is posi-
tively correlated with its binding capacity to PfHsp90.
Pfp23 single mutants (K91A, H93S, W94S and K96A) that
were defective in binding PfHsp90 were unable to inhibit
PfHsp90 ATPase activity as effectively as Pfp23-WT. The
observation is consistent with that reported for the human
and yeast homologues [10, 11, 52], and it was suggested
that the binding of p23 traps Hsp90 in the ATP-bound
state and prolongs its interaction with the client proteins.
Nevertheless, it is noteworthy that the ATPase inhibitory
effect was only observed when Pfp23 was added in large
molar excess. While this may indicate limitations of the
in vitro environment for stable binding of Pfp23 to
PfHsp90, it may also highlight the transient interaction
between the two proteins. Coupled with semi-quantitative
mass spectrometry data that suggested that Pfp23 is
present at a low physiological concentration in P. falci-
parum [53, 54], these observations could explain why
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previous studies were unsuccessful in identifying the
PfHsp90-Pfp23 complex through co-immunoprecipitation
techniques [20, 23].
With the recognition of PfHsp90 as a potential drug
target against malaria, there is increasing interest in the
development of assays for testing Hsp90-specific
inhibitors as anti-malarials. In a recent study, PfHsp90
was shown to be capable of supporting the survival of a
yeast strain with both Hsp90 genes (Hsc82 and Hsp82)
deleted, which is otherwise lethal [42]. This has led to
the proposal of exploiting the viable yeast strain com-
plemented with PfHsp90 to screen for inhibitors that are
selective against the parasite Hsp90. While this method
offers the advantage of an in vivo setting for drug
screening, the slower growth profile reported may
reflect non-optimal heterologous interaction between
PfHsp90 and the yeast co-chaperones and client pro-
teins. Since the binding of co-chaperones has a major
influence on the affinity of Hsp90 for the inhibitors
[44–48], it alerts us to the need to assess the sensitivity
of PfHsp90 to the inhibitors in the presence of native
P. falciparum co-chaperones, using a priori an in vitro
assay system. Providing an experimentally endorsed
PfHsp90 chaperone complex is important to set the
stage correctly for testing inhibitors against this protein
consortium in P. falciparum. To this end, it is thus
essential to determine and validate experimentally the
interaction between PfHsp90 and its putative co-chap-
erones, particularly that of p23 with its underscored
regulatory function and influence on Hsp90’s affinity
for the inhibitors [44, 55].
Taken together, this study demonstrated that the
P. falciparum genome encodes a functional p23 homo-
logue and has provided valuable evidence concerning its
in vitro interaction with PfHsp90. The inhibitory effect
that Pfp23 exerts on the ATPase activity of PfHsp90
further highlighted its potential regulatory role on the
chaperone function of PfHsp90 in vivo. In addition,
truncation experiments and site-directed mutagenesis
demonstrated significant roles played by certain amino
acid residues in Pfp23, i.e., K91, H93, W94 and K96 in
PfHsp90 interaction. Analyses of the modeled structures
further revealed these residues to be strategically located
at an extended loop of Pfp23 that presumably interacts
with the closed ‘lid’ segment of PfHsp90 via hydrophobic
forces. As the interaction between Pfp23 and PfHsp90
was not observed in previous studies [20, 23], this may
underline the technical difficulties in using co-immuno-
precipitation to identify PfHsp90 complexes. In view of
this, a similar GST pull-down approach would be useful
and may be adopted to investigate the interactions
between PfHsp90 and other putative co-chaperones (e.g.,
Hop), which were also not detected in previous studies.
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Abstract A mitogen-activated protein kinase (MAPK),
Pfmap2, has been identified in Plasmodium falciparum.
However, its bona fide activator remains elusive as no
MAPK kinase (MAPKK) homologues have been found so
far. Instead, Pfnek3, a NIMA (never in mitosis, Aspergil-
lus)-related kinase, was earlier reported to display a
MAPKK-like activity due to its activating effect on
Pfmap2. In this study, the regulatory mechanism of Pfnek3
was investigated. Pfnek3 was found to possess a SSEQSS
motif within its activation loop that fulfills the consensus
SXXXS/T phospho-activating sequence of MAPKKs.
Functional analyses of the SSEQSS motif by site-directed
mutagenesis revealed that phosphorylation of residues
S221 and S226 is essential for mediating Pfnek3 activity.
Moreover, via tandem mass-spectrometry, residue T82 was
uncovered as an additional phosphorylation site involved in
Pfnek3 activation. Collectively, these results provide
valuable insights into the potential in vivo regulation of
Pfnek3, with residues T82, S221 and S226 functioning as
phospho-activating sites.
Keywords Activation loop  MAPK  Phosphorylation 
Plasmodium falciparum  Site-directed mutagenesis
Introduction
Malaria remains a leading cause of morbidity and mortality
in many tropical countries despite continuous efforts to
eradicate it or control its spread. Each year, this disease
affects 350–500 million people worldwide and accounts
for over 1 million deaths [1]. The most lethal form of
human malaria is caused by infection with Plasmodium
falciparum. These parasitic protozoa undergo complex
physiological and morphological changes as they develop
through their life cycles within the mosquito and human
hosts [2]. Although various stages of the P. falciparum life
cycle have been defined, little is known about the mecha-
nisms regulating the growth and differentiation of these
parasites. With the emergence of P. falciparum resistance
against many of the existing anti-malarial drugs, elucidat-
ing these mechanisms would enhance our knowledge of the
parasite pathogenesis and facilitate the design of novel
treatments against malaria.
The mitogen-activated protein kinase (MAPK) signaling
pathways are among the most widespread mechanisms
involved in cell regulation. They are highly conserved
throughout eukaryotic evolution and mediate crucial bio-
logical processes including cell proliferation, differentiation,
migration, and apoptosis [3]. A distinctive feature of MAPK
pathways is the presence of a three-kinase phosphorelay
module which includes a MAPK, a MAPK kinase
(MAPKK), and a MAPKK kinase (MAPKKK). In response
to various stimuli, such as growth factors and inflammatory
cytokines, MAPKKKs activate MAPKKs via phosphoryla-
tion of the serine and serine/threonine residues within the
SXXXS/T activation site [4]. The dual-specificity MAPKKs
in turn phosphorylate the MAPKs on both threonine and
tyrosine residues within the TXY motif to activate them.
Upon activation, MAPKs exert their influences on different
physiological processes through phosphorylation of appro-
priate downstream substrates [5].
As MAPK signaling pathways play pivotal roles in the
cellular processes of many eukaryotes, it is plausible that
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similar mechanisms might be adopted by P. falciparum to
regulate its complex life cycle. To date, only two MAPK
homologues (Pfmap1 and Pfmap2) have been identified in
these parasites [6–8]. In a previous gene knock-out study,
Pfmap2, but not Pfmap1, was found to be essential for
P. falciparum to complete its intraerythrocytic develop-
ment [9]. This study thus shed light on the importance of a
MAPK in mediating the growth and proliferation of these
parasites. Prior biochemical characterizations of Pfmap2
revealed that it possesses a TSH motif in place of the
consensus TXY activation site found in most MAPKs [8].
As such, activation of Pfmap2 in vivo may require phos-
phorylation within the TSH motif by upstream kinases.
However, analyses of the P. falciparum kinome did not
uncover sequences that are obvious homologues of typical
MAPKKs. In view of this, the identity of a MAPK activator
and the existence of a complete MAPK signaling pathway
in P. falciparum remain to be established [10, 11].
Nevertheless, attempts to isolate plasmodial MAPKK-
related genes using a degenerate oligonucleotide-based
PCR method and BLAST analyses of the Plasmodium
genome have led to the identification of Pfnek1 (P. falci-
parum NIMA-like kinase 1) and PfPK7 (P. falciparum
protein kinase 7) [12, 13]. Although Pfnek1 shares low-
protein sequence identity (10%) with the mammalian
MAPKKs, it possesses an activation motif reminiscent of
those found in the MAPKKs [12]. On the other hand, the
similarity between PfPK7 and MAPKKs is restricted to the
C-terminal lobe of the kinase domain [13]. Of these two
kinases, only Pfnek1 was capable of phosphorylating
Pfmap2 in vitro [12]. Moreover, Pfnek1 and Pfmap2 act
synergistically in exogenous substrate phosphorylation
[12]. Typically, NIMA-like kinases function as important
cell cycle regulators in eukaryotic cells [14]. The ability of
Pfnek1 to phosphorylate Pfmap2 suggests the possibility of
Pfnek1 as a MAPK regulator, and that NIMA-like kinases
may adopt unique functions in the malarial parasite.
Interestingly, a second plasmodial NIMA-like kinase,
Pfnek3, was subsequently found to be competent in phos-
phorylating and activating Pfmap2 [15]. The mechanism by
which Pfnek3 activates Pfmap2 was further validated to
involve phosphorylation of the conserved threonine residue,
T290, within the latter’s TSH activation motif [16]. Despite
sharing only 17–19% amino acid sequence identity with the
mammalian and yeast MAPKKs, these observations support
Pfnek3 as a plasmodial kinase displaying a MAPKK-like
activity. Hence, in the absence of a typical MAPKK, Pfnek3
could potentially function as a MAPK regulator in P. fal-
ciparum, similar to that of Pfnek1. Currently, the regulatory
mechanism of Pfnek3 remains enigmatic. As such, this
study aimed to examine the regulation of Pfnek3 activity
and assess if it possesses additional biochemical properties
that are similar to the MAPKKs.
Materials and methods
Homology modeling of Pfnek3
Tertiary structure of Pfnek3 was predicted using the
SWISS-MODEL program (http://www.swissmodel.expasy.
org//SWISS-MODEL.html) [17], based on templates which
share at least 25% primary sequence similarity. The Pfnek3
amino acid sequence submitted for modeling process was
retrieved from the Plasmodium genome database (Plas-
moDB; http://www.PlasmoDB.org). The Pfnek3 tertiary
model, together with the crystal structure of human
MAPKK1 (1S9J) [18], were analyzed and compared using
the Swiss-PdbViewer (http://expasy.org/spdbv/) [19].
Construction of Pfnek3 mutants via site-directed
mutagenesis
The truncated Pfnek3 gene, encoding a catalytically active
form of Pfnek3, was expressed by the GST-encoding pGEX-
6P-1 vector [15]. The resultant recombinant expression
plasmid was used as the template for site-directed muta-
genesis reactions. All GST-Pfnek3 mutants were generated
according to the QuikChangeTM site-directed mutagenesis
protocol (Stratagene), using mutagenic primers summarized
in Table 1. Following which, DNA sequencing was
performed to verify the authenticity of the respective
GST-Pfnek3 mutants and to ensure that no spontaneous
nucleotide substitution was introduced during the PCR
amplification process. The catalytically inactive recombi-
nant Pfnek3 (GST-DPfnek3) harboring a K102M mutation
at the ATP binding site was previously constructed and used
as a negative control in kinase assays [15].
Heterologous expression and purification
of recombinant proteins
Recombinant pGEX plasmids expressing GST-Pfnek3,
GST-Pfnek3 mutants, and GST-Pfmap2 (a gift from
C. Doerig) were independently electro-transformed into
Escherichia coli BL21-CodonPlusTM cells (Stratagene).
Transformants obtained were inoculated into 100 ml Luria
Bertani broth supplemented with ampicillin and chloram-
phenicol (100 and 40 lg/ml, respectively) for vector
propagation. The cultures were grown at 37C with con-
tinuous agitation at 220 rpm until an OD600 of 0.6–0.8 was
reached, after which they were induced with 1 mM
isopropyl-beta-D-thiogalactopyranoside (Sigma) and incu-
bated at room temperature overnight with shaking at
220 rpm. Following this, the cells were harvested and lysed
by sonication as previously described [16]. Fusion proteins
were purified from soluble cell free extracts by affinity
chromatography using the Microspin GST Purification
3082 H. Low et al.
Module (GE Healthcare) according to manufacturer’s
instructions. The eluted proteins were subsequently ana-
lyzed by 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). Gel images of separated
proteins were captured using the Bio-Rad Molecular Ima-
ger Gel Doc XR system equipped with the Quantity One
software. Protein concentration of the purified samples was
determined by the Bio-Rad protein assay, using bovine
serum albumin (BSA; Sigma) as the reference protein
standard. In experiments that required cleavage of the GST
fusion partner, purified proteins were incubated overnight
at 4C with the PreScission Protease (GE Healthcare).
Protein phosphorylation analysis of GST-Pfnek3
and its mutants
Following bacterial expression and purification, wild-type
and mutant GST-Pfnek3 proteins were separated by
SDS-PAGE using 10% polyacrylamide gels. After electro-
phoresis, the gels were stained with Pro-Q Diamond
phosphoprotein gel stain (Invitrogen) according to manu-
facturer’s protocol and visualized on a UV transilluminator.
The gels were subsequently stained with Coomassie Blue to
ensure uniform loading of protein samples for each lane.
Dephosphorylation of GST-Pfnek3 by lambda
phosphatase
For dephosphorylation reactions, 10 lg of wild-type GST-
Pfnek3 was treated with 500 U of lambda phosphatase
(Millipore) in 40 ll of reaction buffer supplied by the
manufacturer. The phosphatase was omitted from mock-
treated samples which served as negative controls. Incu-
bations were carried out for 30 min at 30C before the
reaction mixture was supplemented with a 109 phospha-
tase inhibitor cocktail (Thermo Fisher Scientific) to
terminate the phosphatase activity. One-half of the reaction
mixture was thereafter subjected to phosphorylation anal-
ysis to ensure dephosphorylation of the protein had
occurred. The remaining half was used in kinase assays to
examine the activity of dephosphorylated GST-Pfnek3.
ELISA-based protein kinase assay
Kinase assays were performed using 96-well microtiter
plates (Costar) coated with dephosphorylated myelin basic
protein (MBP; Millipore). Each kinase assay reaction mix
of 60 ll comprised of 10 lg of wild-type or mutant GST-
Pfnek3 enzymes, 500 lM ATP, 40 mM MgCl2 and 50 mM
Tris–HCl (pH 7.2). The assay was initiated upon addition
of the kinase reaction mix to each well. The microplates
were then incubated at 30C for 30 min before the reac-
tions were quenched by repeated washing with phosphate-
buffered saline (PBS). Mixed monoclonal anti-phospho-
serine/threonine antibodies (1:500 dilution; Millipore) were
subsequently added to each well and incubated at room
temperature for 1 h. During this period, any phosphoryla-
tion of MBP that arose from the activities of the kinases
would be detected by these antibodies. After another round
of extensive washing with PBS, the wells were incubated
with a peroxidase-conjugated secondary antibody (1:2,000
dilution; Thermo Fisher Scientific) for 45 min. The wells
Table 1 Mutagenic primers
used for the construction of
GST-Pfnek3 mutants
The designations F and R
denote the forward and reverse
primers, respectively, with the
sites of mutagenesis underlined
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were again rinsed, followed by addition of the SuperSignal
West Femto peroxidase substrate (Thermo Fisher Scien-
tific). The resulting chemiluminescent signal arising from
the presence of phosphorylated serine and/or threonine
residues was measured using the GeniosTM microplate
reader (Tecan).
For co-incubation kinase assays, the same protocol was
adopted except that each MBP-coated well was incubated
for 15 min with a kinase reaction mix that contained 5 ng
of wild-type or mutant GST-Pfnek3 and 3 lg of GST-
Pfmap2.
Liquid chromatography-tandem mass spectrometric
(LC-MS/MS) analysis
To determine the phosphorylation sites present in Pfnek3,
10 lg of wild-type GST-Pfnek3 was gel-purified by 10%
SDS-PAGE and the coomassie-stained band containing the
protein of interest was excised. In-gel digestion with
trypsin and the subsequent LC-MS/MS analysis were per-
formed by A*STAR Experimental Therapeutics Centre
using API QSTAR Pulsar (Applied Biosystems). The
experiment was repeated with the catalytically inactive
GST-DPfnek3 to ascertain that any phospho-sites detected
in the wild-type kinase were indeed due to autophospho-
rylation and not attributed to the kinase activities of any
contaminating bacterial kinases.
All MS/MS samples were analyzed using Mascot (ver-
sion 2.2.0; Matrix Science, London, UK). Mascot was set
up to search the NCBInr_20070223 database, specifying
trypsin as the digestion enzyme. Mascot was searched
with a fragment ion mass tolerance of 0.80 Da and a parent
ion tolerance of 500 ppm. Scaffold (version Scaffold-
01_07_00; Proteome Software, Portland, OR, USA) was
used to validate MS/MS-based peptide and protein identi-
fications. Peptide identifications were accepted if they
could be established at greater than 95.0% probability as
specified by the Peptide Prophet algorithm [20]. Protein
identifications were accepted if they could be established at
greater than 95.0% probability and contained at least 2
identified peptides. Protein probabilities were assigned by
the Protein Prophet algorithm [21].
Results
The activity of Pfnek3 was abrogated in the absence
of phosphorylation
From an earlier study, recombinant wild-type GST-Pfnek3
was observed to display a significant level of phosphory-
lation [15]. As its kinase inactive counterpart (GST-
DPfnek3) lacks detectable phosphorylation, Pfnek3 was
proposed to exhibit an autophosphorylation property [15].
To exclude the possibility that phosphorylation had occur-
red solely on the GST moiety, GST-Pfnek3 was subjected to
PreScission protease cleavage and the resultant untagged
Pfnek3 was examined for its phosphorylation status. As
shown in Fig. 1a, the untagged kinase retained a level of
phosphorylation that was comparable to GST-Pfnek3, hence
confirming the autophosphorylation ability of Pfnek3.
To determine whether phosphorylation of Pfnek3 plays
a crucial role in regulating its kinase activity, wild-type
GST-Pfnek3 was treated with lambda phosphatase to
eliminate phosphoryl groups on serine, threonine, and
tyrosine residues. Upon incubation with lambda phospha-
tase, a significant reduction in the phosphorylation level of
GST-Pfnek3 was observed (Fig. 1b, lane 2), validating the
dephosphorylated status of the kinase. In addition, phos-
phatase-treated GST-Pfnek3 exhibited a complete loss of
kinase activity using MBP as the exogenous substrate
(Fig. 1c, lane 2). On the contrary, preincubation of lambda
phosphatase with the phosphatase inhibitor cocktail
blocked both dephosphorylation and inactivation of GST-
Pfnek3 (Fig. 1b, c, lane 3). These results indicate that the
loss of kinase activity observed earlier was indeed associ-
ated with the absence of phosphorylation and therefore
highlight the importance of phosphorylation in the activa-
tion of Pfnek3.
Pfnek3 possesses a SSEQSS motif that is analogous
to the activation sites of MAPKKs
Several classes of eukaryotic protein kinases, including the
MAPKKs, are regulated via phosphorylation at the acti-
vation loop [22]. This segment is commonly defined as the
region that spans the DFG and APE motifs within kinase
subdomains VII and VIII, respectively [23]. In Pfnek3, the
APE motif has been altered to a SYE, and the region that
represents its putative activation loop is highlighted in
Fig. 2. Interestingly, a SSEQSS motif within this loop
fulfills the conserved SXXXS/T phospho-activating
sequence found in the MAPKKs. To further assess whether
this motif is analogous to the activation sites of MAPKKs
in terms of its tertiary structure, the three-dimensional
model of Pfnek3 was generated using the SWISS-MODEL
program. When the Pfnek3 model was compared with the
crystal structure of human MEK1 (PDB identifier: 1S9J), a
well-characterized MAPKK, it was observed that the
SSEQSS motif of Pfnek3 coincides with the SMANS
activation site of MEK1 (Fig. 2). It has been established
that phosphorylation of the two serine residues within the
SMANS motif is critical for the activation of MEK1 [22].
Hence, these observations provide a strong indication that
the SSEQSS motif could adopt a similar function as the
SMANS motif in mediating the activation of Pfnek3.
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Mutations of residues S221 and S226 in the SSEQSS
motif affect autophosphorylation and kinase activity
of Pfnek3
To investigate whether any of the serine residues in the
SSEQSS motif could serve as phospho-regulatory sites,
they were independently substituted with a non-phospho-
rylatable alanine via site-directed mutagenesis. Each of
these GST-tagged mutants (hereafter known as S221A,
S222A, S225A, and S226A) was similarly expressed in
E. coli cells and assayed to determine their relative auto-
phosphorylation levels. While both S222A and S225A
mutants exhibited a level of autophosphorylation that was
similar to the wild-type enzyme, significant reductions in
autophosphorylation levels were observed for the S221A
and S226A mutants (Fig. 3a). A double mutant (S221A/
S226A) was thereafter constructed, and it displayed a much
lower autophosphorylation signal as compared to either of
the individual single mutants.
The effect of these mutations on Pfnek3 activity was
then analyzed using the microtiter plate kinase assay.
Consistent with the phenomenon observed in Fig. 3a, the
kinase activities of both S221A and S226A mutants were
lower than that of the wild-type kinase (Fig. 3b). Likewise,
the activity of the S221A/S226A double mutant was sig-
nificantly lower as compared to its respective single
mutants. The concomitant reductions in autophosphoryla-
tion levels and kinase activities of the S221A and S226A
mutants indicate the potential of these serine residues to
function as crucial phospho-activating sites in Pfnek3.
Phospho-mimic mutants (S221D/E and S226D/E) were
subsequently constructed in an effort to further examine the
above postulation. Aspartates and glutamates are utilized,
with varying competency, to simulate the effects of phos-
phorylation and maintain kinases in the activated states
[24]. Replacing S221 with either aspartate or glutamate
Fig. 1 Activation of Pfnek3 is correlated with its phosphorylation
status. a To authenticate the autophosphorylation ability of Pfnek3,
GST-Pfnek3 was subjected to PreScission protease cleavage to
remove the GST moiety. The phosphorylation level of the untagged
recombinant kinase was subsequently analyzed using the Pro-Q
Diamond phosphoprotein gel stain. The untagged Pfnek3 displayed a
similar level of phosphorylation as its GST-fused counterpart. Lane M
denotes the protein standard marker (Fermentas) used for estimating
the protein sizes. b Purified GST-Pfnek3 was treated with lambda
phosphatase in the presence (lane 3) or absence (lane 2) of the
phosphatase inhibitor cocktail. In the mock-treated sample (lane 1),
lambda phosphatase was omitted. c Following lambda phosphatase
treatment in (b), an aliquot of the respective reaction mixture was
transferred to MBP-coated microtiter plates to assay for the activity of
dephosphorylated GST-Pfnek3. ND Kinase activity not detected
Fig. 2 Pfnek3 possesses a MAPKK-like activation site within its
activation loop. Top The Pfnek3 amino acid sequence corresponding
to the putative activation loop is illustrated. The underlined SSEQSS
motif bears a resemblance to the SXXXS/T activation sites of
MAPKKs. Bottom The Pfnek3 model was generated using SWISS-
MODEL and subsequently compared with the crystal structure of
human MEK1 (1S9J). The putative activation loop of Pfnek3 is
highlighted in yellow. The SSEQSS motif was observed to locate at
the surface of this loop and reside in a position analogous to the
SMANS activation site of human MEK1 (both boxed up in blue)
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residues resulted in a loss of Pfnek3 activity (Fig. 4).
Conversely, the activity of the S226D mutant was
approximately half of the wild-type kinase activity. When
S226 was altered to a glutamate residue, the activity of the
mutant was increased by approximately 50% as compared
to wild-type Pfnek3. This finding supported our speculation
that S226 is an activating phospho-acceptor site, whose
functionality could be substituted by the negatively
charged glutamate. At this point, however, it is difficult to
unequivocally rule out the possibility of S221 as a phos-
phorylation site. Since the catalytic activity of Pfnek3 was
completely abrogated upon mutation of S221 to either an
aspartate or a glutamate, these mutations may have led to
unfavorable conformational changes resulting in the loss of
kinase activity.
LC-MS/MS analyses revealed amino acid T82
as a crucial phosphorylation site in Pfnek3
The low level of autophosphorylation and kinase activity
retained by the S221A/S226A double mutant implies that
additional phosphorylation sites are present in Pfnek3,
which could potentially be involved in regulating its kinase
activity. As such, LC-MS/MS was employed to verify this
speculation. In total, seven tryptic peptides were identified
which made up 30% of the Pfnek3 amino acid sequence. A
single phosphorylation site was detected in the 74FET-
VLDFMTSDSEIHLIR91 peptide, and amino acid residue
T82 was validated as the site of phosphorylation (Fig. 5a).
The loss of 80 Da detected on this residue corresponds to
the neutral loss of a phosphate group. When LC-MS/MS
was repeated using the catalytically inactive GST-DPfnek3,
no phosphorylation was detected on the same site (Fig. 5b).
These observations thus validate that residue T82 is an
autophosphorylation site. To elucidate whether phosphor-
ylation of T82 serves as a mechanism to regulate the kinase
activity of Pfnek3, the amino acid residue was similarly
replaced with an alanine to prevent phosphorylation from
occurring at this site. Absence of the T82 phosphorylation
site provoked a loss of wild-type activity by over 80%
(Fig. 3b), suggesting its importance in modulating the
catalytic activity of Pfnek3. A significant drop in auto-
phosphorylation level was also observed for the T82A
mutant (Fig. 3a). This finding was somewhat expected
since removal of this phospho-site is likely to reduce the
overall phosphorylation content of the kinase.
As both the S221A and S226A mutations were earlier
found to reduce autophosphorylation level and kinase
activity of Pfnek3, T82A/S221A, T82A/S226A, and T82A/
S221A/S226A mutants were also constructed to investigate
their combined effects on the autophosphorylation status
and catalytic activity of Pfnek3. The T82A/S221A mutant
displayed a slightly lower catalytic activity as compared to
the single T82A mutant (Fig. 3b). On the other hand,
activities of both the T82A/S226A and T82/S221A/S226A
mutants were nearly eliminated completely (Fig. 3b). It
was also found that all these mutants exhibited drastic
reductions in autophosphorylation levels as compared to
Fig. 3 Autophosphorylation levels and kinase activities of GST-
Pfnek3 alanine-substituted mutants. a Purified wild-type GST-Pfnek3
and the indicated mutants were resolved by SDS-PAGE and stained
with the phosphoprotein gel stain to assess their autophosphorylation
levels. In the protein standard marker (M), the 70-kDa protein band
corresponds to a phosphoprotein that could be detected using the
phosphostain. Following phosphostaining, the gel was stained with
Coomassie Blue to ensure that relatively equal amounts of proteins
were loaded. b The in vitro kinase activities of the respective GST-
Pfnek3 mutants were subsequently determined by their ability to
phosphorylate the MBP substrates. ND Kinase activity not detected
Fig. 4 Kinase activities of phospho-mimic GST-Pfnek3 mutants.
Residues S221 and S226 were each replaced with either aspartate or
glutamate to mimic phosphorylation at these residues. Activities of
these mutants were analyzed using the ELISA-based kinase assay as
described in ‘‘Materials and methods’’. ND Kinase activity not
detected
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the wild-type kinase (Fig. 3a). Collectively, these data
strongly suggest the importance of T82, S221 and S226 in
regulating the activity of Pfnek3.
Amino acid residues T82 and S226 are crucial
for Pfnek3 to activate Pfmap2 in vitro
Since Pfnek3 was reported to function as a Pfmap2 acti-
vator in vitro [15], we postulate that any alteration in
Pfnek3 activity could affect its ability to phosphorylate and
trigger Pfmap2 activation. As the S221A, S226A, and
T82A mutants displayed reduced activities towards the
exogenous MBP substrate, their influence on GST-Pfmap2
activation was also assessed via a co-incubation kinase
assay. In this assay format, GST-Pfmap2 was mixed with
GST-Pfnek3 or its mutants in the MBP-coated microtiter
wells. It was previously noted that, when GST-Pfnek3
activates GST-Pfmap2, a synergistic increase in the phos-
phorylation of MBP would be observed [15].
GST-Pfmap2 alone, or when mixed with the kinase-dead
GST-DPfnek3, displayed a modest level of kinase activity
(Fig. 6a). The co-incubation of GST-Pfnek3 and GST-
Pfmap2 led to the activation of GST-Pfmap2 by approxi-
mately 70-fold (Fig. 6a). When residue T82 or S226 was
replaced with an alanine, the ability of GST-Pfnek3 to
activate GST-Pfmap2 was reduced by at least 50%
(Fig. 6a). Surprisingly, the S221A mutant was able to
stimulate GST-Pfmap2 to a similar extent as the wild-type
GST-Pfnek3. One possible explanation for this outcome
could be that S221 is not fundamental for Pfnek3 to
phosphorylate and activate Pfmap2. To examine this
notion, the phosphorylation status of GST-Pfmap2 was
analyzed following incubation with the various GST-
Pfnek3 proteins. Indeed, the S221A mutant retained the
ability to phosphorylate the GST-Pfmap2 substrate
(Fig. 6b). On the other hand, both the S226A and T82A
mutants phosphorylated GST-Pfmap2 to a lower extent.
These data thus indicate that residues T82 and S226 are
essential for Pfnek3 to stimulate the activity of Pfmap2,
and we propose phosphorylation at these residues might be
responsible for this phenomenon.
Discussion
Pfnek3 was previously validated to exhibit a MAPKK-like
activity due to its activating effect on Pfmap2 via phos-
phorylation at the signature TSH activation motif. This
triggered our interest in investigating the regulation of
Pfnek3 activity to elucidate additional properties that might
be common between Pfnek3 and the MAPKKs. Kinase
activities are commonly modulated by several strategies
including changes in cellular localization, binding of reg-
ulatory subunits and phosphorylation by upstream kinases
or via autophosphorylation [25]. The authentication of
Pfnek3 autophosphorylation (Fig. 1a) led us to hypothesize
that phosphorylation of the kinase plays a crucial role in
regulating its activity. This notion was further supported
when GST-Pfnek3 activity was abrogated upon dephos-
phorylation with lambda phosphatase (Fig. 1c).
For a number of kinases, phosphorylation within specific
motifs found in the kinase activation loop is essential for
enzyme activation [26]. In NIMA-like kinases, for instance,
stimulation of kinase activity requires phosphorylation of
Fig. 5 Pfnek3 autophosphorylates at residue T82. a After bacterial
expression and purification, GST-Pfnek3 was subjected to SDS-
PAGE. The desired protein band was in-gel digested with trypsin
before analysis by LC-MS/MS. Amino acid T82, which resides within
the tryptic peptide 74FETVLDFMTSDSEIHLIR91, was identified as a
phosphorylation site. The neutral loss of 80 Da corresponded to the
mass of a phosphate group. b LC-MS/MS analysis was repeated with
the catalytically inactive GST-DPfnek3. The same peptide was devoid
of phosphorylation at residue T82, confirming the phosphoryl-group
detected in (a) was a result of autophosphorylation reaction
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the threonine residue within the consensus FXXT motif [27].
However, this motif is absent in Pfnek3. Instead, Pfnek3 was
found to possess a SSEQSS motif which resembles the
characteristic SXXXS/T activation site of MAPKKs. Simi-
lar MAPKK-like activation motif has also been reported in
Pfnek1 [12].
A comparison of the Pfnek3 tertiary model with the
human MEK1 crystal structure revealed that the SSEQSS
motif resides in a position that is analogous to the SMANS
activation motif of MEK1 (Fig. 2). Phosphorylation of
both serines within the SMANS motif has been validated
to be a prerequisite for MEK1 activation [22]. Thus, the
co-location of SSEQSS motif with the known activation
site of MEK1 highlights its potential to serve as a phospho-
regulatory site in Pfnek3. In support of this, our results
showed that the S221A and S226A mutants displayed
significant reductions in kinase activities that were
accompanied by decreases in autophosphorylation levels
(Fig. 3). Therefore, out of the four serines within the
SSEQSS motif, phosphorylation of S221 and S226 is likely
to induce the activation of Pfnek3.
We also attempted to replace S221 and S226 with either
an aspartate or a glutamate to mimic phosphorylation at
these residues. Among these mutants, only S226E exhibited
a considerably higher activity than the wild-type Pfnek3
(Fig. 4), suggesting that phosphorylation of S226 indeed
occurs. Additionally, this observation may signify that the
phosphorylation state of S226 could only be efficiently
mimicked by glutamate, and not aspartate, to maintain
Pfnek3 in an active conformation. On the other hand, the
inability of the S221D and S221E mutants to activate
Pfnek3 cannot completely revoke the potential of S221 as a
phospho-activating site. This is because, in certain kinases,
negatively charged amino acids may be incompetent in
emulating the function of experimentally verified phospho-
sites. For instance, although the second serine within the
SMANS activation site of human MEK1 has been validated
as an important phosphorylation site for kinase activation,
its mutation to either glutamate or aspartate did not con-
stitutively activate the kinase [24]. It was suggested that the
phospho-mimic mutations may have led to conformational
changes in the kinase structure that prevented them from
simulating the effect of serine phosphorylation [24]. Like-
wise, the S221D and S221E mutations may also have led to
undesirable conformational changes in the Pfnek3 structure,
rendering their inability to simulate the effect of the nega-
tive charges arising from phosphorylation at this position.
Given that phosphorylation at the activation loop is a
widespread mechanism in mediating kinase activation, we
are in favor of the proposal that both S221 and S226 serve as
phospho-activating residues in Pfnek3.
In this study, amino acid residue T82 is a novel phos-
phorylation site authenticated via LC-MS/MS analysis
(Fig. 5). To evaluate the implication of T82 phosphoryla-
tion in regulating the kinase activity of Pfnek3, the
threonine residue was mutated to a non-phosphorylatable
alanine. The T82A mutant displayed a more drastic reduc-
tion in autophosphorylation and kinase activity as compared
to the S221A and S226A mutants, suggesting that phos-
phorylation at this residue plays a more crucial role in
stimulating Pfnek3 activity (Fig. 3). Interestingly, residue
T82 is located within a unique FMTSDS motif which was
earlier reported to replace the highly conserved glycine
triad (GXGXXG) in kinase subdomain I [15]. In general,
this glycine triad is essential for modulating the activity of
eukaryotic protein kinases due to its involvement in
anchoring ATP during the phospho-transfer reaction [23].
In the absence of this motif, ATP binding in Pfnek3 might
involve an unusual mechanism that potentially requires the
phosphorylation of residue T82. Hence, the huge decrease
Fig. 6 Effect of T82A, S221A, and S226A mutations on the ability
of GST-Pfnek3 to activate GST-Pfmap2. a Adopting the co-incuba-
tion kinase assay, 5 ng of wild-type GST-Pfnek3 or the respective
mutants were mixed with 3 lg of GST-Pfmap2 in MBP-coated wells.
When existing alone, or mixed with the kinase-dead GST-DPfnek3
mutant, GST-Pfmap2 displayed a low level of kinase activity (lanes 1
and 3). In the presence of wild-type GST-Pfnek3, the activity of GST-
Pfmap2 was stimulated by approximately 70-fold. Only the S221A,
but not the S226A or T82A mutants, retained the ability to activate
GST-Pfmap2. b After GST-Pfmap2 was incubated with the indicated
GST-Pfnek3 proteins in a kinase assay mix, the kinases were resolved
by SDS-PAGE and subjected to phosphorylation analysis to deter-
mine the phosphorylation status of GST-Pfmap2. The Coomassie
staining of the same gel is shown in lower panel. M Protein standard
marker
3088 H. Low et al.
in Pfnek3 activity upon mutation of T82 could be attributed
to its importance in triggering efficient ATP binding during
phosphorylation reactions. However, the amino acid resi-
dues flanking T82 were not visible in the modeled Pfnek3
structure, conceivably due to the low sequence homology
between Pfnek3 and the modeling templates at this region.
As such, until the structure of Pfnek3 in both the unphos-
phorylated and phosphorylated state is made available, the
bona fide role of T82 phosphorylation in regulating Pfnek3
activity remains debatable.
Since Pfnek3 was earlier reported to modulate the
activity of Pfmap2, it was also of interest to examine
whether phosphorylation of S221, S226, and T82 was
crucial for Pfnek3 to activate Pfmap2. From the results
illustrated (Fig. 6), only residues T82 and S226 were found
to be essential for Pfnek3 to phosphorylate and trigger
GST-Pfmap2 activation. The outcome was unexpected
since the absence of these three residues has rendered
Pfnek3 less capable of phosphorylating the exogenous
MBP substrate. Consequently, this may imply that phos-
phorylation of T82 and S226 is more crucial for Pfnek3 to
recognize the Pfmap2 substrate.
The results of this study have strengthened the notion
that Pfnek3 is a MAPKK-like kinase in P. falciparum with
an activation mechanism similar to the well-known MAP-
KKs. On top of this, Pfnek3 activation further requires
phosphorylation at residue T82, suggesting the regulation of
Pfnek3 activity might involve a more complex mechanism
as compared to the MAPKKs. Moreover, since the T82A/
S221A/S226A triple mutant retained a low, but observable,
level of phosphorylation, it is plausible that additional
phosphorylation sites are present that may contribute to the
regulation of Pfnek3 activation. It is also noteworthy to
mention that, although phosphorylation of T82, S221 and
S226 in vitro is a result of Pfnek3 autophosphorylation, the
possibility remains that phosphorylation of these residues in
vivo may be performed by upstream kinases and/or require
binding with regulatory subunits. In view of this, it is
imperative to identify interacting partners of Pfnek3 so as to
fully understand its regulation in the malarial parasite.
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